<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>re: The Consensus Conference On NET-Liver-Metastases - London Dec 13th 2012</title>
	<pubDate>2012-12-28T14:42:40+01:00</pubDate>
	<wp:post_id>3598</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The Consensus Conference On NET-Liver-Metastases - London Dec 13th 2012</span>&nbsp;<br><span style="font-size: 12px;">Comment: Last week’s meeting provided a useful insight into the positioning pros and cons of NET treatments beyond the targeted and biological therapies e.<wbr>g.<wbr> radio-frequncy ablation, liver directed embolization therapies, PRRT, priomary surgical resection and transplantation.<wbr> These therapeis are already quite widely deployed but the need for more definitive comparative controlled trials was underlined as was such data for adjuvant and neoadjuvant therapeutic approaches.<wbr>.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7198">...</a><br></div><div style="margin-bottom: 10px;"><STRONG>6%&ndash;93% of patients with NETs will find Liver metastases (LMs) involved at the time of diagnosis and LMs significantly worsen the prognosis of patients with NET.<wbr> </STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Nevertheless, there is considerable controversy regarding the optimal management of GEP-NET metastases.<wbr> Surgical interventions for LMs have consistently been shown to have superior outcomes to non-operative therapies, but they are limited to only 10% of these patients, due to excessive metastatic tumor burden in difficult locations.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Among treatment options for patients that are not surgical, it looks that SSAs and PRRT are considered as methods of choice in selected conditions based on already sufficient level of evidence and with expectations for promising results from forthcoming investigations.<wbr></STRONG> </div><div style="margin-bottom: 10px;">In order to document briefly the above sentences, please find the following figures: </div><div style="margin-bottom: 10px;">- The 5-year survival of NET patients with LMs on supportive care is 0%&ndash;20%.<wbr> (as a comparison, The median survival probabilities in patients with G1/<wbr>G2 NETs who had localized, regional, and distant disease are 82%, 38% &amp; 25 %, respectively.<wbr> </div><div style="margin-bottom: 10px;">- Also 50% of all patients with reported disease stage have either regional or distant metastases at diagnosis (please refer to Yao JC et al.<wbr>, 2008 J Clin Oncol 26:3063-3072 for wider information).<wbr> </div><div style="margin-bottom: 10px;">- Grades of recommendation for alternative treatment options in neuroendocrine liver metastases are available in , with ( as a reminder) &ldquo;Standard medical therapies prescribed for distant or recurrent neuroendocrine tumors include long-acting somatostatin analogues (octreotide and lanreotide) for both palliation of hormonal symptoms and for the control of tumor growth.<wbr> Grade of recommendation A&rdquo; (highest level of evidence).<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px Arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; text-align: justify; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">As explained on the E-AHPBA website of the organization of the Consensus Conference (NET-Liver-Mets), 300 worldwide experts from key societies were expected to attend this meeting whereas the hot topics are extensively discussed and reviewed well in advance by working groups of key people, named expert panels.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Thanks to CI-Digest and Jacquelyne Cantle who reported this event, we understand that </div><div style="margin-bottom: 10px;">- Liver metastases not only render the resection of primary tumor or local regional surgical treatments limited and questionable, but their benefit on long-term survival and patient quality of life has been poorly investigated.<wbr> (NB: postoperative mortality is high and surgery could lead to disabling and chronic complications such as short bowel syndrome.<wbr> </div><div style="margin-bottom: 10px;">- Also, although liver transplantation is uncommonly performed in NET, it appears for the attending experts that </div><div style="margin-bottom: 10px;"><UL><LI>Liver transplantation is a reasonable option for NET patients with LM, according that disease is well-differentiated with a moderate tumor burden;
</LI>
<LI>A worldwide transplant registry of NET patients with liver metastases is needed.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">- Rate of recurrence post liver resection is high (50-80%) and highlights the need for adjuvant strategies (with an expected role of SSAs ? please refer to Chung MH et al.<wbr> Surgery 2011; 130: 954-962 ).<wbr> </div><div style="margin-bottom: 10px;">- Of course, therapeutical methods are the same as currently investigated in the whole scope of NETs, including chemotherapy, MTT, SSA, PRRT, Intra-Arterial &hellip; </div><div style="margin-bottom: 10px;"><UL><LI>From Van Gulik&rsquo;s communication (unpublished trial data) it is indicating a 30% response with PRRT in terms of downsizing after 6 months;
</LI>
<LI>Still on PRRT, -as reported by Jacquie-, D Kweekboon noted that the maximum effect of therapy is generally seen at 6 months post treatment and even can be later
</LI>
<LI>D Kweekboon&rsquo;s slide seems to show that globally PRRT results from CT in NETs are the same with Lu vs Gamma-DOTATOC with respective disease response ranges of [17%-31%] and [4%-33%]&hellip;to be confirmed indeed.<wbr>
</LI>
<LI>Other information on PRRT &ldquo;picked-up&rdquo; among Jacquie&rsquo;s one :
<UL><LI>PFS is the outcome parameter to be used ++
</LI>
<LI>Patients with stable disease and progression have the same response (on PFS) to PRRT.<wbr>
</LI>
<LI>PNET responds to PRRT shorter than Midgut NET
</LI>
</UL>

</LI>
<LI>Extensive liver involvement is a negative predictive factor for response to PRRT
</LI>
</UL> </div><div style="margin-bottom: 10px;">- Finally, concerning neo-adjuvant and adjuvant therapies, there is no clear evidence to date that an effect on Overall Survival and PFS can be expected in patients after LM resection.<wbr> However, there is considerable disagreement about what type of trial would be best and which patients should be included, some arguing that there was more of case to be made for pNET downsizing than for carcinoid.<wbr> </div><div>To conclude, it must be mentioned that all topics treated during the meeting are listed and available at page and it must be opportunistically noted that <STRONG>conference outputs can be followed up as a summary is expected to be published in a high impact factor journal.<wbr></STRONG> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7207">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7198">View thread  Endocrinology7198: The Consensus Conference On NET-Liver-Metastases - London Dec 13th 2012</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-28T14:42:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-28T14:42:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>2012 in emerging markets growth and investment</title>
	<pubDate>2012-12-27T11:59:53+01:00</pubDate>
	<wp:post_id>3599</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : 2012 growth rates in emerging markets have continued to outstrip those in the developed markets by a notable margin for Big Pharma.<wbr> </div><div style="margin-bottom: 10px;">Despite a global economic slowdown, increased government focus on drug prices in some key emerging markets, and the realisation that not all of these territories are immune to the impact of patent expiries, emerging markets will remain a key focus in 2013 and beyond by virtue of their likely sustainable growth opportunity.<wbr> </div><div style="margin-bottom: 10px;"><IMG height="219" src="http://media.firstwordpharma.com/Emerging_market_sales.jpg" width="550"> </div><div>Source : Firstword, <EM>Annual Reviews Desk, </EM>December 20th, 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10268">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-27T11:59:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-27T11:59:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Court rules Medivation has no rights to ARN-509</title>
	<pubDate>2012-12-27T11:20:18+01:00</pubDate>
	<wp:post_id>3600</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">Comment : a California state court ruled that <A href="http://www.biocentury.com/companies/medivation_inc" target="_blank" title="Medivation company profile and pipeline intelligence from BCIQ"><SPAN style="COLOR: #000000">Medivation Inc.<wbr></SPAN></A> does not have rights to <A href="http://www.biocentury.com/products/arn-509" target="_blank" title="ARN-509 product news and analysis from BCIQ"><SPAN style="COLOR: #000000">ARN-509</SPAN></A>, a second-generation androgen receptor antagonist from <SPAN style="COLOR: #000000">Aragon Pharmaceuticals Inc</SPAN>.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">In February 2011, Medivation filed suit against the University of California and Aragon alleging that the university breached a 2005 deal with Medivation when it granted Aragon rights to ARN-509, which Medivation said is based on technology similar to its prostate cancer drug <A href="http://www.biocentury.com/products/xtandi" target="_blank" title="Xtandi product news and analysis from BCIQ"><SPAN style="COLOR: #000000">Xtandi</SPAN></A> enzalutamide.<wbr> Under the 2005 deal, Medivation has rights to the university's small molecule androgen receptor antagonists, including Xtandi.<wbr> The court ruled Medivation has exclusive rights to a specific series of compounds identified by a chemical structure that does not include ARN-509, which is in Phase II testing for castration-resistant prostate cancer (CRPC).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">The court has not yet ruled on Medivation's claim that the university improperly disclosed information to Aragon about the compounds covered in the 2005 deal.<wbr> The companies could not be reached for comment.<wbr></SPAN> </div><div><SPAN style="COLOR: #000000">Source : BioCentury Extra for Wednesday, December 26, 2012</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8686">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-27T11:20:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-27T11:20:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novel medicines approved in 2012</title>
	<pubDate>2012-12-26T14:58:14+01:00</pubDate>
	<wp:post_id>3601</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : in a recent report issued by the Food and Drug Administration (FDA) &ldquo;<A href="http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM330859.pdf">Fiscal Year 2012 Innovative Drug Approvals</A>,&rdquo; the agency highlighted 35 new drug approvals.<wbr>  This marks the second year in a row where FDA has issued 35 approvals and continues the trend of more annual approvals than in years past.<wbr> </div><div style="margin-bottom: 10px;">In addition, FDA approved 77 percent of these drugs on the first review cycle without the need for additional information.<wbr>  Of the 35 drugs, 32 were also approved in other countries, and in these cases, FDA was the first to approve 75 percent of the time.<wbr> The list includes a total of 10 drugs to treat cancer, as well as important new therapies for HIV and macular degeneration.<wbr> The proportion of these drugs from small biopharmaceutical companies is also significant.<wbr> Many are the companies&rsquo; first-approved products.<wbr> Notable drugs from small companies include Eylea for macular degeneration, Kalydeco for cystic fibrosis, Jakafi and Xtandi for cancer, and Elelyso for Gaucher disease.<wbr> </div><div style="margin-bottom: 10px;">Approximately one-third of the NMEs approved in the  last five years have been drugs for rare diseases.<wbr> In FY 2012, FDA approved 9 NMEs for rare diseases.<wbr> Two of the drugs represent advances in personalized medicine (Perjeta (pertuzumab) for late-stage breast cancer and Kalydeco (ivacaftor) to treat a form of cystic fibrosis).<wbr><STRONG> </STRONG>These approvals also include nine new drugs for orphan diseases, continuing FDA&rsquo;s commitment to approving drugs for patients with rare conditions.<wbr> </div><div style="margin-bottom: 10px;">In 2013, the European Medicines Agency expects a stable total number of applications for human medicines, with 100 applications in 2013.<wbr> These include some 54 applications for new medicinal products (excluding designated orphan medicines), 20 new orphan medicines and 20 generic applications (2012: 52, 13 and 39 respectively) </div><div style="margin-bottom: 10px;">Sources : </div><div style="margin-bottom: 10px;"><A href="http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM330859.pdf">http:/<wbr>/<wbr>www.<wbr>fda.<wbr>gov/<wbr>downloads/<wbr>AboutFDA/<wbr>ReportsManualsForms/<wbr>Reports/<wbr>UCM330859.<wbr>pdf</A> </div><div><A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/12/news_detail_001680.jsp&amp;mid=WC0b01ac058004d5c1">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>news_and_events/<wbr>news/<wbr>2012/<wbr>12/<wbr>news_detail_001680.<wbr>jsp&amp;mid=WC0b01ac058004d5c1</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10269c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">I just put a focus in Oncology.<wbr> FDA uses a range of tools to expedite the development, review, and approval of the most promising new therapies.<wbr> These tools include Fast Track, Priority Review, and Accelerated Approval.<wbr> For 2012, in oncology, 8 drugs (listed below) were approved as Fast Track drugs.<wbr> </div><div><OL start="1"><LI>Erivedge (vismodegib)for late-stage skin cancer            Hedgehog inhibitor
</LI>
<LI>Xtandi (enzalutamide) for late-stage prostate cancer   Androgen inhibitor
</LI>
<LI>Jakafi (ruxolitinib) for myelofibrosis                                      Janus Associated Kinase (JAK) inhibitor
</LI>
<LI>Voraxaze (glucarpidase) to lower toxic levels of the chemotherapy drug methotrexate
</LI>
<LI>Erwinaze (asparaginase erwinia chrysthemi) for acute leukemia
</LI>
<LI>Stivarga (reborafenib) for late-stage colorectal cancer A multi-kinase inhibitor
</LI>
<LI>Perjeta (pertuzumab) for late-stage breast cancer        Anti HER2 inhibitor
</LI>
<LI>Bosulif (bosutinib) for chronic leukemia
</LI>
</OL> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10267">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-26T14:58:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-26T14:58:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Scientists find new marker to measure LRRK2 activity implicated in Parkinson’s disease</title>
	<pubDate>2012-12-26T12:25:07+01:00</pubDate>
	<wp:post_id>3602</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : the biotech company Genentech recently published a paper in Science Translational Medicine suggesting that they may have in fact found such a laboratory tool to both measure abnormal LRRK2 activity that might lead to disease, and how drugs are affecting this abnormal activity.<wbr> </div><div style="margin-bottom: 10px;">Mutations in the LRRK2 gene are the most common cause of familial Parkinson's disease accounting for 1-2% of all cases.<wbr> The protein is viewed as a promising drug target to treat Parkinson&rsquo;s, but it is not possible to track LRRK2 activity in the brain, making the search for targeted therapies against the disease challenging.<wbr> In this paper, researchers now provide evidence for a way to measure LRRK2 activity.<wbr> </div><div style="margin-bottom: 10px;">The scientists also developed a molecular screening approach to test hundreds of potential LRRK2 inhibitors.<wbr> In the end, they identified one such compound, G1023, which that can block the damaging effects of the protein in rodent neurons.<wbr> G1023 protected embryonic neurons taken from mice with the LRRK2 mutation, returning the growth rate of these cells to the same level as that seen in cells taken from healthy mice.<wbr> </div><div>Sources : <BR>Nature.<wbr>com blogs; <BR>see preclinical results published on Decembrer 12 in Science Translational Medicine<BR><A href="http://stm.sciencemag.org/content/4/164/164ra161.full">http:/<wbr>/<wbr>stm.<wbr>sciencemag.<wbr>org/<wbr>content/<wbr>4/<wbr>164/<wbr>164ra161.<wbr>full</A><BR>see basic patent WO 2011151360 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6722">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-26T12:25:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-26T12:25:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Allergan Receives European Approval For iOAB Indication</title>
	<pubDate>2012-12-26T10:20:59+01:00</pubDate>
	<wp:post_id>3603</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Receives European Approval For iOAB Indication</span>&nbsp;<br><span style="font-size: 12px;">Comment: Allergan has announced today that it has received a positive opinion from the Irish Medicines Board for the treatment of idiopathic overactive bladder (iOAB) with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to or are intolerant to anticholinergic medications.<wbr> This is an important step towards securing national licenses in all 14 European countries involved in the MRP.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6711">...</a><br></div><div>Ireland acted as reference member state.<wbr> Austria, Belgium, Denmark, Finland, Germany, Greece, Iceland, Italy, Luxembourg, Norway, Portugal, Spain and Sweden are concerned member states of the Mutual Recognition Procedure.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6721">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6711">View thread  Neurology6711: Allergan Receives European Approval For iOAB Indication</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-26T10:20:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-26T10:20:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>USA: Unapproved Botox</title>
	<pubDate>2012-12-24T11:20:55+01:00</pubDate>
	<wp:post_id>3604</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA has warned 350 medical practices that they may have purchased unapproved&mdash;and potentially counterfeit&mdash;versions of Botox from a network of wholesalers controlled by Canada Drugs.<wbr> </div><div style="margin-bottom: 10px;">Canada Drugs, a 10-year-old Internet pharmacy based in Winnipeg,sells cheaper, foreign versions of medicines from price-controlled markets such as the U.<wbr>K.<wbr> and Turkey to American customers and doctors.<wbr> The FDA considers the activity illegal, even when the drugs are authentic medicines, because those drugs aren't approved by the agency.<wbr> </div><div style="margin-bottom: 10px;">A spokeswoman for Allergan said the company learned of the suspect Botox vials from the FDA last week.<wbr> In a statement, the company said, "[w]e cannot confirm the safety or authenticity of products that are imported from unauthorized distributors.<wbr>" </div><div>Source: Wall Street Journal 23 December 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6718">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-24T11:20:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-24T11:20:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: FDA Advisory Committee Recommends Approval of Gattex For Short Bowel Syndrome</title>
	<pubDate>2012-12-24T10:53:02+01:00</pubDate>
	<wp:post_id>3605</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Source: <a href="http://www.npsp.com" class="defaultlink" title="http://www.npsp.com">npsp.com</a></span>&nbsp;<br></div><div style="margin-bottom: 10px;">The FDA approved Gattex on 21 December 2012.<wbr> NPS said it plans to launch it in the U.<wbr>S.<wbr> in 1Q13 and will disclose details on the drug's pricing during a 2 January early evening conference call with investors and analysts.<wbr> </div><div style="margin-bottom: 10px;">The approval comes with a REMS that includes a communication plan and training for prescribers.<wbr> NPS is also required to conduct a postmarketing study in SBS patients to evaluate the drug's potential increased risk of causing colorectal cancer and other conditions.<wbr> </div><div><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333171.htm" class="defaultlink" title="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333171.htm">fda.gov/<wbr>NewsEvent&hellip;</a> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7205">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7126">View thread  Endocrinology7126: FDA Advisory Committee Recommends Approval of Gattex For Short Bowel Syndrome</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-24T10:53:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-24T10:53:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis to Position in the "Activated Cellular Immunotherapy" Area</title>
	<pubDate>2012-12-21T12:49:34+01:00</pubDate>
	<wp:post_id>3606</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis is to buy Dendreon's immunotherapy manufacturing facility (IMF)based in New Jersey (USA) for $43M in cash.<wbr> ACI offers the potential to treat a variety of diseases </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The transaction is to bring value for the company's shareholders, and will accelerate path to profitability.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">To take the opportunity to work with the 100 existing employees to build out immunotherapy operations and dedevelop new treatments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>173,100 square foot sate-of-the art IMF.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10266">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-21T12:49:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-21T12:49:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Combination of BMS' Ipilimumab and Anti-KIR MAb for CRPC</title>
	<pubDate>2012-12-21T11:28:01+01:00</pubDate>
	<wp:post_id>3607</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: FIM trial is anticipated to recruit approx.<wbr> 150 participants with selected advanced tumors (NSCLC; CRPC; melanoma).<wbr> Primary endpoint will assess rate of AEs and serious AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01750580?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F05%2F2012&amp;rank=72"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Official Title: A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors </div><div style="margin-bottom: 10px;">Start date: Dec 2012 - Completion: July 2015 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8685">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-21T11:28:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-21T11:28:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>POC Study to Assess Abiraterone and Degarelix 1M Together</title>
	<pubDate>2012-12-20T17:27:22+01:00</pubDate>
	<wp:post_id>3608</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Comment: Sponsored by the Memorial Sloan-Kettering Cancer Center and ten collaborators among which J&amp;J, this randomized, 3-arm trial will assess both drugs in combinaison as possible treatment for PSA recurrent prostate cancer, following definitive radical prostatectomy, as compared to abiraterone and degarelix alone.<wbr> Primary endpoint will measure PFS.<wbr></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"><U>Background</U></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">The FDA recently approved abiraterone acetate (Zytiga ®) in combination with prednisone to treat patients with mCRPC in the post docetaxel setting.<wbr></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Degarelix (Firmagon ®), is FDA approved for the treatment of patients with advanced prostate cancer.<wbr> </P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"><U>Objective</U></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">- to evaluate abiraterone acetate and prednisone in combination with degarelix as a possible treatment for PSA recurrent prostate cancer as compared to abiraterone acetate alone and degarelix alone.<wbr> </P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"></P> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01751451?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F04%2F2012&amp;rank=90"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Recruitment: approx.<wbr> 120</P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Start date: Dec 2012 - Completion: Oct 2014</P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Location: USA (10 sites)</P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">PI: Howard I Scher, MD @ the Memorial Sloan-Kettering Cancer Center</P> </div><div><P dir="ltr" style="MARGIN-RIGHT: 0px">Source: clinicaltrials.<wbr>gov</P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10660c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Interestingly, the trial end date was initially postponed in March 2014 from Oct 2014 to Oct 2015.<wbr> Again, the trial completion has now been postponed to Oct 2016 mainly due to opening of additional clinical sites in the US.<wbr> This is still a proof of concept trial as the target patient remains quite small (n=120) for a 3 arm study.<wbr> At this stage, the primary focus for J&amp;J likely remains to ensure its ARN509 market entry.<wbr> (Source: clinicaltrial.<wbr>gov) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8682">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-20T17:27:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-20T17:27:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant Cuts Medicis Staff</title>
	<pubDate>2012-12-20T12:33:31+01:00</pubDate>
	<wp:post_id>3609</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Following the takeover of Medicis, and according to the Phoenix Business Journal, 319 Medicis employees lost their jobs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Valeant is consolidating workforce in Arizona and New Jersey.<wbr> </div><div style="margin-bottom: 10px;">Commercial dermatology operations will remain in Scottsdale.<wbr> </div><div>Valeant also is removing some of the functions currently in New Jersey to Arizona.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6717">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-20T12:33:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-20T12:33:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recordati Enters Into Asset Purchase Agreement To Strengthen US Business</title>
	<pubDate>2012-12-20T11:27:44+01:00</pubDate>
	<wp:post_id>3610</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Recordati has acquired a portfolio of non-core products from Lundbeck, aimed at strengthen its US operations and its rare disease portfolio.<wbr> Lundbeck, meanwhile, wishes to exit these areas to focus on its core CNS business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">As part of the transaction Recordati has acquired rights to 8 products with annual revenues of approximately $45m in 2011.<wbr> </div><div style="margin-bottom: 10px;">The total cost of the purchase will be $100m with $80m paid uprfront upon closing during the Q113 and the further $20m subject to product registration transfers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature Of The Product Portfolio</STRONG> </div><div style="margin-bottom: 10px;">The acquired portfolio will be marketed in the U.<wbr>S.<wbr> by Recordati Rare Diseases, a wholly-owned U.<wbr>S.<wbr> corporation.<wbr> The main product in the portfolio is Panhematin® (haemin for injection) for the amelioration of recurrent attacks of acute intermittent porphyria.<wbr> Other important drugs acquired are NeoProfen® (ibuprofen lysine injection) and Indocin® I.<wbr>V.<wbr> (indomethacin injection), indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, and Cosmegen® (dactinomycin for injection) used mainly in the treatment of three rare cancers: Wilms’ tumor, childhood rhabdomyosarcoma and choriocarcinoma.<wbr> The portfolio also includes Chemet® (succimer) indicated for the treatment of lead poisoning in pediatric patients, Desoxyn® (methamphetamine hydrochloride) indicated for the treatment of attention deficit/<wbr>hyperactivity disorder (ADHD) in children over 6 years of age and for the short-term treatment of exogenous obesity, and other minor products.<wbr> </div><div style="margin-bottom: 10px;">The acquisition of this portfolio of products is a confirmation of Recordati’s intention to become a leading player in rare diseases worldwide and it will reinforce Recordati’s entry into the Hematology and Oncology fields </div><div style="margin-bottom: 10px;">Yesterday Lundbeck announced a downward revision of its financial forecasts based on the need to invest signficantly in product launches and development.<wbr> </div><div>Source: <A href="http://www.recordati.it/">www.<wbr>recordati.<wbr>it</A> and <A href="http://www.lundbeck.xom/">www.<wbr>lundbeck.<wbr>xom</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10303c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Recordati has completed its acquisition of a portfolio of H.<wbr> Lundbeck&rsquo;s non-core products.<wbr> Recordati paid Lundbeck $80 million at closing.<wbr> Recordati said it expects 2013 revenues for the acquired portfolio to be about $40 million.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10260">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-20T11:27:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-20T11:27:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New US Reimbursement Codes For Botox Procedures In Chronic Migraine and OAB</title>
	<pubDate>2012-12-20T09:50:22+01:00</pubDate>
	<wp:post_id>3611</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Leerink and Swann analysts have noted in a reported issued on 
Tuesday that starting January 2013, the official US CPT code for migraine will 
reduce physician's estimated reimbursement by 40-50%, whilst the new CPT code 
for OAB is positive for the forthcoming approval and launch of the iOAB 
indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Migraine Situation</STRONG> </div><div style="margin-bottom: 10px;">With the official code, the estimated procedure reimbursement for chronic 
migraine is expected to decrease from $350 and$300 to $200 and $150 for 
commercial and Medicare respectively.<wbr> </div><div style="margin-bottom: 10px;">Lerrink's small survey of neurologists seems to indicate that a cut was 
expected  and thit was not expected to impact their prescribing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>OAB situation</STRONG> </div><div>Currently urologists are reimbursed $400 per Botox procedure (both commercial 
and Medicare).<wbr> With the new CPT code the commercial rate will remain the 
same whilst the Medicare rate will reduce to $300.<wbr> Notably the CPT code 
will cover all overactive bladder indications, a clear positive for 
Allergan in terms of hitting the ground running once the iOAB indication is 
approved.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6716">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-20T09:50:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-20T09:50:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Portugal to Revise Basket of Reference Countries</title>
	<pubDate>2012-12-20T09:40:52+01:00</pubDate>
	<wp:post_id>3612</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Portugal to Revise Basket of Reference Countries</span>&nbsp;<br><span style="font-size: 12px;">Comment: Slovenia and Spain are expected to remain on the list, and France to be replaced by Italy.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10256">...</a><br></div><div style="margin-bottom: 10px;">Correction: According to the new law and with confirmation of the Portuguese team, the previous reference basket was Spain Italy and Slovenia.<wbr> And now the current reference basket in Portugal is France, Spain and Slovakia as from January 2013.<wbr> </div><div>Contact initiated with the provider of the initial information.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10259">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10256">View thread  PharmaWorld10256: Portugal to Revise Basket of Reference Countries</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-20T09:40:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-20T09:40:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Fast Track Status for Lexicon's LX1033 (IBS-d)</title>
	<pubDate>2012-12-19T12:46:50+01:00</pubDate>
	<wp:post_id>3613</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: LX1033, an inhibitor of tryptophan hydroxylase (TPH) that acts locally in the gastrointestinal tract, is currently being evaluated in Ph2 (results expected Q1:13).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Lexicon also has FDA Fast Track status for telotristat etiprate, or LX1032, an oral, systemic TPH inhibitor currently in Ph3 for carcinoid syndrome.<wbr> </div><div>Source: <A href="http://www.lexicon-genetics.com/news/press-releases/2255-lexicon-s-drug-candidate-for-irritable-bowel-syndrome-receives-fast-track-status-from-the-fda.html">Lexicon</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1868">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-19T12:46:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-19T12:46:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Portugal to Revise Basket of Reference Countries</title>
	<pubDate>2012-12-19T12:26:24+01:00</pubDate>
	<wp:post_id>3614</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Slovenia and Spain are expected to remain on the list, and France to be replaced by Italy.<wbr> </div><div style="margin-bottom: 10px;">According to <I>Diário Económico</I> – which has seen an internal document of the Government on the sixth review of a troika of the European Commission, IMF, and European Central Bank – Portugal's drug regulator, Infarmed will be responsible for introducing the second price change in the 2013.<wbr> According to the source, under the law, the retail price of drugs is defined on the basis of prices prevailing for the same drug in the reference countries.<wbr> However, if the comparison will result in higher prices than the current price, the current price will remain.<wbr> Thus, comparison with the reference countries should not result in an increase in drug prices.<wbr> According to <I>Diário Económico,</I> the prices of drugs are expected to reduce further in 2013, with an average variation in price expected to be 8% in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">As part of Portugal's agreement with the troika signed in 2011, several policies were introduced that were aimed at reducing the budget deficit in return for a financial bailout.<wbr> In the health sector, these included reducing expenditure on drugs through introducing a new basket of reference countries – Spain, Italy, and Slovenia, as well as restricting the price of generics to no more than 50% of the branded product with the same active ingredient.<wbr> </div><div style="margin-bottom: 10px;">It is noteworthy that in the fifth review of the Memorandum of Understanding between Portugal and the troika, it was agreed that the government was to implement an annual revision of medicines, as well as that of the reference countries, aimed at attaining further savings in costs.<wbr> The potential change in reference countries aimed at further price reductions therefore reflects the government's continuing cost-containment policies with the aim of reducing the overall spend on pharmaceuticals 1 % of GDP in 2013.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10259c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Correction: According to the new law and with confirmation of the Portuguese team, the previous reference basket was Spain Italy and Slovenia.<wbr> And now the current reference basket in Portugal is France, Spain and Slovakia as from January 2013.<wbr> </div><div>Contact initiated with the provider of the initial information.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10256">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-19T12:26:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-19T12:26:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Drug Sales in Brazil Increased 7.6% m/m in October</title>
	<pubDate>2012-12-19T12:23:46+01:00</pubDate>
	<wp:post_id>3615</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The growth in sales experienced by the Brazilian pharmaceutical industry in the branded and generics sectors is linked to the expansion of the domestic industry as more money is being invested into the sector by the government and international brands operating in the country.<wbr> The Brazilian pharmaceutical sector is expected to double its sales volume in the next five years, with more investment in the sector.<wbr> Generics account for a consistent part of this outcome, with patients increasingly gaining more confidence in the generics sector and the market growing accordingly.<wbr>
According to Geraldo Monteiro, executive director of the Brazilian Association of National Pharmaceutical Laboratories (ABRADILAN), cited by Investimentos e Noticias, the expansion of the Brazilian domestic industry in terms of sales and volume is sizeable, especially in the generics segment.<wbr> </div><div style="margin-bottom: 10px;">Monteiro said that the Brazilian population has increasingly gained confidence in using generics drugs as a more affordable alternative to branded drugs, with generics accounting for 26.<wbr>5% of total units sold in Brazil.<wbr> According to the source, the national laboratories associated to ABRADILAN represent 22% of the country's laboratories that produce generics, distributing their generic products to 82% of Brazilian cities and 77% of the 71,000 pharmacies in the country; specifically 82% of the pharmacies in the Southeast, 75% in the South, 80% in the Northeast, 83% in the Central East, and 34% in the North regions of the country.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">The growth in sales experienced by the Brazilian pharmaceutical industry in the branded and generics sectors is linked with the expansion of the domestic industry as more money is being invested into the sector by the government.<wbr> Brands operating in the country are also focusing on upgrading investments in Brazil, which is one of the top Latin American markets, hence the increase in branded sales.<wbr> </div><div style="margin-bottom: 10px;">In terms of generics, the increase in sales and revenues volumes is a consequence of the strong pro-generics policy of President Dilma Rousseff, which is leading to a strengthening of the domestic industry and encouraging domestic production of drugs, taking advantage of the many branded products that are going off patent.<wbr> The Brazilian generic industry is forecast to flourish in the short-to-medium term, placing itself as one of the strongest generics markets in the Americas.<wbr> Current price-control policies being implemented on branded drugs in the country are also another element in favour of generics, as the wide use of generics in the public sector would help the government to cut the national healthcare budget significantly.<wbr> </div><div style="margin-bottom: 10px;">The Brazilian pharmaceutical sector is expected to double its sales volume in the next five years, with more investment in the sector from the government and international brands operating in the country.<wbr> The new pro-generics era envisaged by Rousseff's government is likely to further boost the domestic generic sector in the country – the most profitable in Latin America – with major international generics giants eyeing opportunities to invest in the country.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10255">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-19T12:23:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-19T12:23:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>South Korean Pricing Pressures See GSK and Pfizer to Reduce Staff Numbers</title>
	<pubDate>2012-12-19T12:09:05+01:00</pubDate>
	<wp:post_id>3616</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to a report in the <I>Korea Herald, </I>GSK has offered early retirement packages to up to 100 employees, out of a total of 750 in the country, expected to take effect before the end of this year.<wbr> Although Pfizer has not issued details regarding the exact nature of its plans, a similar downsizing in staff is also expected to take place, the first restructuring since the company first entered South Korea in 1969.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">GSK and Pfizer are joining a number of multinational pharma firms in downsizing their workforce numbers in South Korea; the source reports that the local subsidiaries of Bayer (Germany), Janssen Korea (subsidiary of Johnson &amp; Johnson, US), Sanofi (France), and AstraZeneca (UK) have all undergone similar restructuring in recent months.<wbr> </div><div style="margin-bottom: 10px;">Such moves reflect the South Korean government's increasing desire to suppress drug prices as the country's population continues to age: in April 2012, 13,800 medicines, including 6,500 types of prescription medicines, saw their prices slashed by 14%.<wbr> </div><div style="margin-bottom: 10px;">The South Korean market is generally becoming more competitive for innovative firms, with the government targeting ingrained corrupt practices in the pharma industry, and generic competition increasing, as Pfizer has experienced with generic competition against Viagra (sildenafil) earlier this year.<wbr> </div><div>Sorce: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10254">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-19T12:09:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-19T12:09:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Receives European Approval For iOAB Indication</title>
	<pubDate>2012-12-19T12:00:10+01:00</pubDate>
	<wp:post_id>3617</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has announced today that it has received a positive opinion from the Irish Medicines Board for the treatment of idiopathic overactive bladder (iOAB) with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to or are intolerant to anticholinergic medications.<wbr> This is an important step towards securing national licenses in all 14 European countries involved in the MRP.<wbr> </div><div style="margin-bottom: 10px;">The positive opinion which is specfic to Botox is based on Allergan's successful global phIII programme which was reported earlier this year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6332" class="defaultlink">Neurology6332: Allergan's R&D Day Highlights New Therapeutic Opportunities For Botox & Its Novel TEM Programme</a>).<wbr> Regulatory filings were made in March with first approvals at that time anticipated in Q1:13.<wbr> </div><div style="margin-bottom: 10px;">Allergan's European President Douglas Ingram notes in the press release that "this is a critical milestone for the company extending its commitment to urology beyond neurogenic detrusor overactivity and building on a long-term commitment to innovation in botulinum toxin research".<wbr> </div><div style="margin-bottom: 10px;">The positive opinion is based on the results of two randomised placebo-controlled phIII studies involving over 1,100 patients.<wbr> In these studies patients ecperienced a significant and clinically relevant response to treatment compared to placebo in the reduction of urinary incontinence, including more patients becoming dry ( no urinary leakage at 12 weeks).<wbr> Patients also reporeted an improvement in their QOL.<wbr> </div><div style="margin-bottom: 10px;">The most common adverse events reported were urinary tract infection and dysuria (painful urination).<wbr> </div><div>Source: <a href="http://www.allergan.com" class="defaultlink" title="http://www.allergan.com">allergan.com</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6721c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Ireland acted as reference member state.<wbr> Austria, Belgium, Denmark, Finland, Germany, Greece, Iceland, Italy, Luxembourg, Norway, Portugal, Spain and Sweden are concerned member states of the Mutual Recognition Procedure.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6711">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-19T12:00:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-19T12:00:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva Creates Business Ventue in South Korea</title>
	<pubDate>2012-12-19T11:14:02+01:00</pubDate>
	<wp:post_id>3618</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The venture with Handok Pharm.<wbr>, expected to begin operations in the next few months, is a strategic fit for Teva and the first commercial deal in East Asian territory outside Japan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Teva's plans in S-Korea include selling Copaxone (for MS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Teva will contribute for manufacturing and supplying a wide range of "affordable and innovative medicines".<wbr> </div><div style="margin-bottom: 10px;">Handok will assume responsibility for sales and marketing, distribution and regulatory affairs.<wbr> </div><div style="margin-bottom: 10px;">Financial terms are not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.handok.co.kr/english/company/about.asp"><STRONG></STRONG></A><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Founded: 1954</LI>
<LI>Focus: prescription and OTC</LI>
<LI>The company has a strong tradition of partnerships.<wbr></LI>
<LI>Its vision is to be the top 3 Korean pharma companies by 2016.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10251_1_ScreenCapture1.jpg"> </div><div>Source: Teva; Handok </div><!-- Comment details --><a name="pharmaworld10251attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10251_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10251">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-19T11:14:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-19T11:14:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Development Candidate Moves In To Clinical Development For ALS</title>
	<pubDate>2012-12-18T17:43:05+01:00</pubDate>
	<wp:post_id>3619</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left">Comment: Phytopharm announced today plans for the clinical 
development of Cogane for ALS based on successful preclinical data.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">In collaboration with two leading grant bodies the ALS Association 
and the North-East ALS Consortium and the Masachusetts General Hospital, 
Phytopharm is to move forward with a clinical study.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">The company is also in discusion with leading regulatory agencies 
with regard to the design of a clinical development programme for Cogane in ALS.<wbr> 
The drug has been granted ODS  in both the US and Europe for ALS.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">In parallel Phytopharm has been completing a 400 patient phII 
trial of Cogane in early-stage Parkinson's disease (CONFIDENT-PD).<wbr> All patients 
have now completed the trial and the company is on track to receive the results 
from the trial in Feb 2013.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Whilst the progression of the ALS programme is not wholly 
dependent on the outcome of the PD trial its results may inform the design and 
conduct of future studies in ALS.<wbr></P> </div><div><P align="left">Source: <a href="http://www.phytopharm.com" class="defaultlink" title="www.phytopharm.com">phytopharm.com</a></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6709">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-18T17:43:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-18T17:43:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Otsuka Signs Cell Therapy Deal For Parkinson's Disease</title>
	<pubDate>2012-12-18T17:32:37+01:00</pubDate>
	<wp:post_id>3620</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Living Cell Technologies today announced an agreement with Otsuka pharmaceuticals to co-develop NTCELL a cell therapy for the treatment of Parkinson's disease and other neurological disorders.<wbr> </div><div style="margin-bottom: 10px;">What Type of Cell Therapy Is NTCELL? </div><div style="margin-bottom: 10px;">NTCELL is pig choroid plexus cells which have been encapsulated ith IMMUPEL, LTC's proprietary immune-protective capsule system which precents the immune system rejecting the pig cells as foreign.<wbr> </div><div style="margin-bottom: 10px;">Development Status </div><div style="margin-bottom: 10px;">LCT has received approval from Medsafem New Zealnad medicines regulator and ethics approval for the first clinical trial to comence in early 2013.<wbr> </div><div style="margin-bottom: 10px;">Key Terms Of The Agreement </div><div style="margin-bottom: 10px;">1.<wbr> Otsuka and LCT will form a co-development partnership to undertake the phI trial in PD during 2013 and 2014.<wbr> Otsuka will fund all costs.<wbr> </div><div style="margin-bottom: 10px;">2.<wbr> In consideration of the partnership Otsuka will make a $3m upfont payment to LC, plus an additional $2m milestone payment when the first patient in the trial has been safely implanted with NTCELL.<wbr> This milestone is expected to occur in Q213.<wbr> </div><div style="margin-bottom: 10px;">3.<wbr> Upon exercise of an option LCT will vest the NTCELL IP for use in developing treatments for neurological diseases and hearing loss into DIATRANZ OTSUKA Ltd a 50:50 JC formed between LCT and Otsuka in November 2011.<wbr> At the same time Otsuka will invest and additional $20m of capital into DOL to fund the clinical development of NTCELL in Parkinson's through to market approval.<wbr> Both companies will retain a 50% interest in DOL.<wbr> </div><div style="margin-bottom: 10px;">4.<wbr> LCT will retain the exclusive right to develop NTCELL for the treatment of other non-neurological diseases.<wbr> </div><div>Source: <a href="http://www" class="defaultlink" title="http://www">www</a>.<wbr> otsuka.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6705">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-18T17:32:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-18T17:32:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Consensus Conference On NET-Liver-Metastases - London Dec 13th 2012</title>
	<pubDate>2012-12-18T17:02:25+01:00</pubDate>
	<wp:post_id>3621</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last week’s meeting provided a useful insight into the positioning pros and cons of NET treatments beyond the targeted and biological therapies e.<wbr>g.<wbr> radio-frequncy ablation, liver directed embolization therapies, PRRT, priomary surgical resection and transplantation.<wbr> These therapeis are already quite widely deployed but the need for more definitive comparative controlled trials was underlined as was such data for adjuvant and neoadjuvant therapeutic approaches.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><OL style="MARGIN-TOP: 0cm" type="1"><LI style="MARGIN: 0cm 0cm 10pt; mso-list: l1 level1 lfo1"> </LI>
<LI style="MARGIN: 0cm 0cm 10pt; mso-list: l1 level1 lfo1"> </LI>
<LI style="MARGIN: 0cm 0cm 10pt; mso-list: l1 level1 lfo1"></LI>
<LI style="MARGIN: 0cm 0cm 10pt; mso-list: l1 level1 lfo1"> </LI>
<LI style="MARGIN: 0cm 0cm 10pt; mso-list: l1 level1 lfo1"></LI>
<LI style="MARGIN: 0cm 0cm 10pt; mso-list: l1 level1 lfo1"> </LI>
<LI style="MARGIN: 0cm 0cm 10pt; mso-list: l1 level1 lfo1"> </LI>
</OL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><BR> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><IMG height="368" name="C:\Users\jac89886\Documents\Traction Instant Publisher\Autosaved\12-18-2012\ScreenCapture9.jpg" src="file:///C:/Users/jac89886/Documents/Traction%20Instant%20Publisher/Autosaved/12-18-2012/ScreenCapture9.jpg" width="1022"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri"><SPAN style="mso-list: Ignore"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri"><SPAN style="mso-list: Ignore"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri"><SPAN style="mso-list: Ignore"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri"><SPAN style="mso-list: Ignore"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri"><SPAN style="mso-list: Ignore"> </SPAN></SPAN> </div><div><SPAN style="mso-bidi-font-family: Calibri"><SPAN style="mso-list: Ignore"> </SPAN></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7207c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><STRONG>6%&ndash;93% of patients with NETs will find Liver metastases (LMs) involved at the time of diagnosis and LMs significantly worsen the prognosis of patients with NET.<wbr> </STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Nevertheless, there is considerable controversy regarding the optimal management of GEP-NET metastases.<wbr> Surgical interventions for LMs have consistently been shown to have superior outcomes to non-operative therapies, but they are limited to only 10% of these patients, due to excessive metastatic tumor burden in difficult locations.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Among treatment options for patients that are not surgical, it looks that SSAs and PRRT are considered as methods of choice in selected conditions based on already sufficient level of evidence and with expectations for promising results from forthcoming investigations.<wbr></STRONG> </div><div style="margin-bottom: 10px;">In order to document briefly the above sentences, please find the following figures: </div><div style="margin-bottom: 10px;">- The 5-year survival of NET patients with LMs on supportive care is 0%&ndash;20%.<wbr> (as a comparison, The median survival probabilities in patients with G1/<wbr>G2 NETs who had localized, regional, and distant disease are 82%, 38% &amp; 25 %, respectively.<wbr> </div><div style="margin-bottom: 10px;">- Also 50% of all patients with reported disease stage have either regional or distant metastases at diagnosis (please refer to Yao JC et al.<wbr>, 2008 J Clin Oncol 26:3063-3072 for wider information).<wbr> </div><div style="margin-bottom: 10px;">- Grades of recommendation for alternative treatment options in neuroendocrine liver metastases are available in , with ( as a reminder) &ldquo;Standard medical therapies prescribed for distant or recurrent neuroendocrine tumors include long-acting somatostatin analogues (octreotide and lanreotide) for both palliation of hormonal symptoms and for the control of tumor growth.<wbr> Grade of recommendation A&rdquo; (highest level of evidence).<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px Arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; text-align: justify; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">As explained on the E-AHPBA website of the organization of the Consensus Conference (NET-Liver-Mets), 300 worldwide experts from key societies were expected to attend this meeting whereas the hot topics are extensively discussed and reviewed well in advance by working groups of key people, named expert panels.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Thanks to CI-Digest and Jacquelyne Cantle who reported this event, we understand that </div><div style="margin-bottom: 10px;">- Liver metastases not only render the resection of primary tumor or local regional surgical treatments limited and questionable, but their benefit on long-term survival and patient quality of life has been poorly investigated.<wbr> (NB: postoperative mortality is high and surgery could lead to disabling and chronic complications such as short bowel syndrome.<wbr> </div><div style="margin-bottom: 10px;">- Also, although liver transplantation is uncommonly performed in NET, it appears for the attending experts that </div><div style="margin-bottom: 10px;"><UL><LI>Liver transplantation is a reasonable option for NET patients with LM, according that disease is well-differentiated with a moderate tumor burden;
</LI>
<LI>A worldwide transplant registry of NET patients with liver metastases is needed.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">- Rate of recurrence post liver resection is high (50-80%) and highlights the need for adjuvant strategies (with an expected role of SSAs ? please refer to Chung MH et al.<wbr> Surgery 2011; 130: 954-962 ).<wbr> </div><div style="margin-bottom: 10px;">- Of course, therapeutical methods are the same as currently investigated in the whole scope of NETs, including chemotherapy, MTT, SSA, PRRT, Intra-Arterial &hellip; </div><div style="margin-bottom: 10px;"><UL><LI>From Van Gulik&rsquo;s communication (unpublished trial data) it is indicating a 30% response with PRRT in terms of downsizing after 6 months;
</LI>
<LI>Still on PRRT, -as reported by Jacquie-, D Kweekboon noted that the maximum effect of therapy is generally seen at 6 months post treatment and even can be later
</LI>
<LI>D Kweekboon&rsquo;s slide seems to show that globally PRRT results from CT in NETs are the same with Lu vs Gamma-DOTATOC with respective disease response ranges of [17%-31%] and [4%-33%]&hellip;to be confirmed indeed.<wbr>
</LI>
<LI>Other information on PRRT &ldquo;picked-up&rdquo; among Jacquie&rsquo;s one :
<UL><LI>PFS is the outcome parameter to be used ++
</LI>
<LI>Patients with stable disease and progression have the same response (on PFS) to PRRT.<wbr>
</LI>
<LI>PNET responds to PRRT shorter than Midgut NET
</LI>
</UL>

</LI>
<LI>Extensive liver involvement is a negative predictive factor for response to PRRT
</LI>
</UL> </div><div style="margin-bottom: 10px;">- Finally, concerning neo-adjuvant and adjuvant therapies, there is no clear evidence to date that an effect on Overall Survival and PFS can be expected in patients after LM resection.<wbr> However, there is considerable disagreement about what type of trial would be best and which patients should be included, some arguing that there was more of case to be made for pNET downsizing than for carcinoid.<wbr> </div><div>To conclude, it must be mentioned that all topics treated during the meeting are listed and available at page and it must be opportunistically noted that <STRONG>conference outputs can be followed up as a summary is expected to be published in a high impact factor journal.<wbr></STRONG> </div></div><a name="endocrinology7198attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(113,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(174,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(139 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(179,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(196,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(130,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(161,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(176,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(170,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(136,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(148,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(146,9 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(155,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(195,5 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(78 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(121,8 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(98,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(153,4 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(114,6 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(152,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(142,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(147,5 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(188,2 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(126,4 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(124,2 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(107,1 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(128,1 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(90,2 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_29_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(157,7 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_30_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(174,8 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_31_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(131,8 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_32_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(127,6 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_33_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(137,8 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_34_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(137,9 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_35_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(138,4 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_36_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(126,8 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_37_ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(143,5 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_38_ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(129,6 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_39_ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(129 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7198_40_ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(120,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7198">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-18T17:02:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-18T17:02:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Enzon To Review Asset Sales Or Sale Of The Company</title>
	<pubDate>2012-12-17T15:16:31+01:00</pubDate>
	<wp:post_id>3622</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment Enzon has announced that its Board of Directors has retained Lazard to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets, or a sale of the Company.<wbr> Its androgen receptor modulator programme is to be suspended.<wbr> </div><div style="margin-bottom: 10px;">Based on clinical data on the androgen receptor program, Enzon plans to suspend clinical development with a goal to conserve capital and maximize value returned to shareholders.<wbr> </div><div style="margin-bottom: 10px;">The press release notes that a special committee of Enzon's Board of Directors was established to oversee the review.<wbr> There can be no assurance that the review will result in the consummation of any transactions.<wbr> </div><div style="margin-bottom: 10px;">Alex Denner, Chairman of the Board, commented: "The Board of Directors, following a review of the Company's assets and strategic direction, has determined that it is in the best interest of Enzon's shareholders to pursue a sale, in whole or in part, of the Company.<wbr> In addition to a strong balance sheet and royalty revenues, Enzon's drug candidates and technologies offer the potential for a variety of transactions.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Enzon's Development Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8680_1_ScreenCapture1.jpg"> </div><div>Source: <a href="http://www.enzon.com" class="defaultlink" title="http://www.enzon.com">enzon.com</a> </div><!-- Comment details --><a name="oncology8680attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8680_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8680">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-17T15:16:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-17T15:16:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recruitment Now Well Underway In The Lutathera Trial</title>
	<pubDate>2012-12-17T14:51:16+01:00</pubDate>
	<wp:post_id>3623</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NETTAR-1 an international multi-centre open label study of PRRT against high dose Sandostatin LAR, in somatostatin receptor positive progressive mid-gut carcinoid patients, has now opened centres in the US.<wbr> </div><div style="margin-bottom: 10px;">This announcement was made on the Caring for Carcinoid website with the following comments made:- </div><div style="margin-bottom: 10px;">"This study will evaluate the safety and efficacy of Lutathera in neuroendocrine tumor patients.<wbr> This is a long awaited clinical trial that is anticipated to fill up quickly.<wbr> We encourage any patients that have been discussing peptide receptor radiotherapy with their physician to consider discussing this clinical trial.<wbr> The trial is anticipated to accrue patients quickly to the 14 centers in the United States".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In fact AAA, the company developing Lutathera was present at the NET- Liver Metastases meeting in London last week promoting this new study.<wbr></STRONG> </div><div style="margin-bottom: 10px;">To date, 3 patients have been treated, 4 randomised, 9 patients registered on CRFs and 18 patients are in screening.<wbr> Forty-two centres will participate in the trial of which 13 are active at the moment.<wbr> The trial was initiated in Europe in July 2012.<wbr> </div><div style="margin-bottom: 10px;">The clinical trial submission took place later in the US than elsewhere, hence the late opening of centres in this region.<wbr> The US participants are as follows:- </div><div style="margin-bottom: 10px;">Cedar Sinai Medical Center Not yet recruiting </div><div style="margin-bottom: 10px;">Los Angeles, California, United States, 90048 </div><div style="margin-bottom: 10px;">Contact: Edward Wolin, Dr.<wbr> 310-423-0709 edward.<wbr>wolin@cshs.<wbr>org </div><div style="margin-bottom: 10px;">Stanford University Medical Center Not yet recruiting </div><div style="margin-bottom: 10px;">Stanford, California, United States, 94305-5281 </div><div style="margin-bottom: 10px;">Contact: Erick Mittra, Dr.<wbr> 650-721-2024 emittra@stanford.<wbr>edu </div><div style="margin-bottom: 10px;">H Lee Moffitt <A class="glossary-term" href="glossary/term/26"><CITE title="Cancer is the general name for any disease in which cells in a part of the body begin to grow out of control. There are many different types of cancer but in all cancers cells divide without control and can invade nearby tissues.  
">Cancer</CITE></A> Center Not yet recruiting </div><div style="margin-bottom: 10px;">Tampa, Florida, United States, 33612 </div><div style="margin-bottom: 10px;">Contact: Jonathan Strosberg, Dr.<wbr> 813-745-7257 jonathan.<wbr>strosberg@moffitt.<wbr>org </div><div style="margin-bottom: 10px;">Robert H Lurie Comprehensive Cancer Center of Northwestern Univ </div><div style="margin-bottom: 10px;">Not yet recruiting </div><div style="margin-bottom: 10px;">Chicago, Illinois, United States, 60611-3015 </div><div style="margin-bottom: 10px;">Contact: Al B Benson, Dr.<wbr> 312-695-0990 abenson@nmff.<wbr>org </div><div style="margin-bottom: 10px;">University of Iowa Hospital Clinics Not yet recruiting </div><div style="margin-bottom: 10px;">Iowa City, Iowa, United States, 52242-1077 </div><div style="margin-bottom: 10px;">Contact: David Bushnell, Dr.<wbr> 319-338-0581 ext 5758 david-bushnell@uiowa.<wbr>edu </div><div style="margin-bottom: 10px;">United States, Louisiana </div><div style="margin-bottom: 10px;">Oshsner Medical Center Not yet recruiting </div><div style="margin-bottom: 10px;">Kenner, Louisiana, United States, 70065 </div><div style="margin-bottom: 10px;">Contact: Richard J Campeau, Dr.<wbr> 504-464-5000 rcampe@lsuhsc.<wbr>edu </div><div style="margin-bottom: 10px;">Dana Farber Cancer Center Not yet recruiting </div><div style="margin-bottom: 10px;">Boston, Massachusetts, United States, 02115-6084 </div><div style="margin-bottom: 10px;">Contact: Matthew H Kulke, Dr.<wbr> 617-632-5136 matthew_kulke@dfci.<wbr>harvard.<wbr>edu </div><div style="margin-bottom: 10px;">United States, Minnesota </div><div style="margin-bottom: 10px;">Mayo Clinic Not yet recruiting </div><div style="margin-bottom: 10px;">Rochester, Minnesota, United States, 55905 </div><div style="margin-bottom: 10px;">Contact: Anthony Hobday, Dr.<wbr> 507-284-8413 hobday.<wbr>timothy@mayo.<wbr>edu </div><div style="margin-bottom: 10px;">Principal Investigator: Anthony Hobday, Dr.<wbr> </div><div style="margin-bottom: 10px;">Weill-Cornell Medical College /<wbr> New York Prebyterian Not yet recruiting </div><div style="margin-bottom: 10px;">New York City, New York, United States, 10065 </div><div style="margin-bottom: 10px;">Contact: Stanley J Goldsmith, Dr.<wbr> </div><div style="margin-bottom: 10px;">212-746-4533 sjg2002@med.<wbr>cornell.<wbr>edu </div><div style="margin-bottom: 10px;">Duke University Not yet recruiting </div><div style="margin-bottom: 10px;">Durham, North Carolina, United States, 27710 </div><div style="margin-bottom: 10px;">Contact: R Edward Coleman, Dr.<wbr> 919-684-7244 r.<wbr>coleman@dm.<wbr>duke.<wbr>edu </div><div style="margin-bottom: 10px;">University of Pennsylvania Medical School Not yet recruiting </div><div style="margin-bottom: 10px;">Philadelphia, Pennsylvania, United States, 19104 </div><div style="margin-bottom: 10px;">Contact: David Metz 215-662-4279 david.<wbr>metz@uphs.<wbr>upenn.<wbr>edu </div><div style="margin-bottom: 10px;">Principal Investigator: David Metz </div><div style="margin-bottom: 10px;">Vanderbilt University Medical Center Not yet recruiting </div><div style="margin-bottom: 10px;">Nashville, Tennessee, United States, 37232 </div><div style="margin-bottom: 10px;">Contact: Eric H.<wbr> Liu, Dr.<wbr> 615-322-2391 eric.<wbr>liu@vanderbilt.<wbr>edu </div><div style="margin-bottom: 10px;">MD Anderson Cancer Center Not yet recruiting </div><div style="margin-bottom: 10px;">Houston, Texas, United States, 77030-4009 </div><div style="margin-bottom: 10px;">Contact: Alexandria T.<wbr> Phan, Dr 713-793-2300 atphan@mdanderson.<wbr>org </div><div style="margin-bottom: 10px;">Excel Diagnostics, Imaging Clinic Not yet recruiting </div><div style="margin-bottom: 10px;">Houston, Texas, United States, 77042 </div><div style="margin-bottom: 10px;">Contact: Ebrahim Delpassand, Dr.<wbr> 713-781-6200 edelpassand@exceldiagnostics.<wbr>com </div><div>Source: <A href="http://www.caringforcarcinoid.org/news/international-clinical-trial-peptide-receptor-radiotherapy-opens-among-centers-united-states">http:/<wbr>/<wbr>www.<wbr>caringforcarcinoid.<wbr>org/<wbr>news/<wbr>international-clinical-trial-peptide-receptor-radiotherapy-opens-among-centers-united-states</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7195">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-17T14:51:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-17T14:51:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves Signifor For Cushing's Disease</title>
	<pubDate>2012-12-17T11:47:20+01:00</pubDate>
	<wp:post_id>3624</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On friday the FDA approved the use of Signifor for the treatment 
of Cushing's disease in patients who cannot be helped through surgery.<wbr> 
Following a positive recommendation from EMDAC in early November this had been 
anticipated (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7165" class="defaultlink">Endocrinology7165: FDA EMDAC Unanimously Voted in Support for the Use of Pasireotide for Cushing's Disease</a>).<wbr> There are significant post-marketing 
commitments associated with the approval (see below).<wbr> </div><div style="margin-bottom: 10px;">The FDA is requiring three postmarketing studies for Signifor: a clinical 
trial to assess high blood sugar (hyperglycemia) management; a long-term 
prospective observational cohort study (registry) of patients with Cushing’s 
disease treated with Signifor; and focused safety monitoring for reports of 
serious hyperglycemia, acute liver injury, and adrenal insufficiency.<wbr> </div><div style="margin-bottom: 10px;">According to Signifor's US product website the drug is likely to be launched 
in March 2013.<wbr> Pricing information has yet to emerge.<wbr> </div><div style="margin-bottom: 10px;">Source.<wbr> <A href="http://www.signifor.us/index.jsp?usertrack.filter_applied=true&amp;NovaId=4029462041663896145">http:/<wbr>/<wbr>www.<wbr>signifor.<wbr>us/<wbr>index.<wbr>jsp?usertrack.<wbr>filter_applied=true&amp;NovaId=4029462041663896145</A> </div><div><A href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htm">http:/<wbr>/<wbr>www.<wbr>fda.<wbr>gov/<wbr>NewsEvents/<wbr>Newsroom/<wbr>PressAnnouncements/<wbr>ucm332351.<wbr>htm</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7194">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-17T11:47:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-17T11:47:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Adenosine A2A Receptor Antagonist Tozadenant Meets PhIIb Endpoints</title>
	<pubDate>2012-12-17T11:22:42+01:00</pubDate>
	<wp:post_id>3625</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left">Comment: Biotie has announced top-line data from its double-blind, international Phase IIb trial in 420 patients whose levodopa treatment was insufficient to control PD symptoms until their next dose demonstrating that twice-daily oral tozadenant met the primary endpoint of reducing mean daily &ldquo;off&rdquo; time.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Study Design &amp; Key Findings</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">In the phIIb study, patients received placebo or twice-daily 60, 120, 180 or 240 mg tozadenant for 12 weeks.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Biotie noted that tozadenant met several secondary endpoints, including increasing &ldquo;on&rdquo; time in which patients were symptom free, improving UPDRS Part III and Parts I-III combined scores and improving clinician and patient-assessed global impression scores.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">The study has helped Biotie to identify the minimally efficacious and maximum feasible dose.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Tozadenant was generally well tolerated.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Next Steps</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Biotie, which declined to provide further details about the study, said it plans to analyze the data with partner UCB and expects a decision from UCB regarding next steps in 1Q13.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">UCB, which has exclusive, worldwide rights to tozadenant will be responsible for Phase III testing and commercialization should it choose to proceed with development.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Competition</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Tozadenant is one of three A2A antagonists moving forward in development for the treatment of "off episodes" in Parkinson's disease.<wbr> The lead comound is Kyowa Hakko's Istradefylline (partnered with Valeant) which has a chequered history but has now been filed for approval in Japan.<wbr> Meanwhile, close to completing phIII development is Merck's preladenant.<wbr></P> </div><div><P align="left">Source: <A href="http://www.biotie.com">www.<wbr>biotie.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6702">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-17T11:22:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-17T11:22:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Gilead Adds YM Biosciences Drugs to its Growing Oncology Pipeline</title>
	<pubDate>2012-12-17T11:06:00+01:00</pubDate>
	<wp:post_id>3626</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Source: YM; Gilead</span>&nbsp;<br></div><div style="margin-bottom: 10px;">International Strategy &amp; Investment analyst Mark Schoenebaum suggests that current consensus estimates for CYT387 are around $300 million for 2020.<wbr> In terms of benchmark products, Novartis and Incyte's Jakafi &ndash; approved in November 2011 and indicated for myelofibrosis and myeloproliferative disorders &ndash; is the obvious reference point.<wbr> Sales of the product, to date, have been modest, although limited patient data in Phase I/<wbr>II trials suggest that CTY387 may be a more efficacious product.<wbr> </div><div style="margin-bottom: 10px;">With Big Pharma competition in the JAK inhibitor space high, commercial projections for CTY387 may remain fairly muted.<wbr> </div><div>Source: FirstWord 16 December 2012 </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8679">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8667">View thread  Oncology8667: Gilead Adds YM Biosciences Drugs to its Growing Oncology Pipeline</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-17T11:06:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-17T11:06:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New CRPC Study With Tokai's galeterone</title>
	<pubDate>2012-12-13T17:34:25+01:00</pubDate>
	<wp:post_id>3627</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New CRPC Study With Tokai's galeterone</span>&nbsp;<br><span style="font-size: 12px;">Comment: ClinicalTrials.<wbr>gov is listing a new Ph2 study with Tokai's androgen modulator galeterone.<wbr> The randomised 2 part trial will evaluate safety and efficacy in CRPC patients who have yet to receive TAK-700, ARN-509 , ketoconazole or enzalutamide as well as CRPC patients who have demonstrated progression on Zytiga.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8535">...</a><br></div><div style="margin-bottom: 10px;">Tokai has announced the treatment of the first patient in the ARMOR2 trial.<wbr> With its improved new tablet formulation, ARMOR2 will provide the company with additional important insights on the clinical utility of galeterone in several distinct CRPC patient populations.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Investigators</SPAN> </div><div>The study is being led by co-principal investigators Bruce Montgomery, M.<wbr>D.<wbr>, associate professor of medical oncology at the University of Washington School of Medicine and Mary-Ellen Taplin, M.<wbr>D.<wbr>, associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8674">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8535">View thread  Oncology8535: New CRPC Study With Tokai's galeterone</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-13T17:34:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-13T17:34:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Efficacy Data of Zytiga Published in the NEJM</title>
	<pubDate>2012-12-13T12:38:47+01:00</pubDate>
	<wp:post_id>3628</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Results from analyses of COU-AA-302 have been published online in the NEJM.<wbr> This PhIII study was the basis of the pre-chemo indication approved by the US FDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8611" class="defaultlink">Oncology8611: CHMP Recommends Approval of J&J's Zytiga</a>.<wbr> </div><div style="margin-bottom: 10px;">Since its first approval in the US in 2011, Zytiga has been approved in &gt;65 countries.<wbr> More than 40,000 WW have received the treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><H1></H1> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8672">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-13T12:38:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-13T12:38:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Astellas' Press Conference</title>
	<pubDate>2012-12-13T11:46:56+01:00</pubDate>
	<wp:post_id>3629</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas is progressing with the roll-out of Eligard, which was approved last month in Hong-Kong.<wbr> Gonax (degarelix 1M), launched enf of October, is expected to be a growth driver in Japan.<wbr> Management highlighted that sales in China and Russia increased by 13% and 18% respectively for FY2011.<wbr> Astellas Growth Strategy is to maximize OAB global sales, develop oncology franchise and improve R&amp;D productivity.<wbr> Of note, the strong initiatives of the company in the field of neglected tropical diseases (NTDs).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_7_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company has bet on 'precision medicine' and 'multi-track R&amp;D' approaches.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_5_ScreenCapture5.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="oncology8671attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(103,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(127,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(65,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_6_Astellas%255f121212%255fPress%20Conference.pdf">Astellas_121212_Press Conference.pdf</a>&nbsp;&nbsp;(5 MB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8671_7_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(85,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8671">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-13T11:46:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-13T11:46:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Scrip Interview with AZ's VP Strategic Partnering and Business Development</title>
	<pubDate>2012-12-12T18:44:56+01:00</pubDate>
	<wp:post_id>3630</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Three quarters of Az's Phase III pipeline comes  from business development activity.<wbr> </div><div style="margin-bottom: 10px;">During 2012 Shaun Grady has kept business development activities on track and  has also concluded some innovative deals.<wbr> He states that business development is at the centre of AZ's strategy and is key to how the company now discovers and develops drugs - 60% of the company's R&amp;D leaders are new to the organization and were recruited partially with business development and externalization in mind.<wbr> </div><div style="margin-bottom: 10px;">AZ has a '5Rs approach'  to both internal and external programmes - all need   to meet the 5R criteria of right target, right tissue/<wbr>exposure, right safety, right patients and right commercial.<wbr> </div><div style="margin-bottom: 10px;">The company does have  a New Opportunities team which looks at all areas, including those that are currently off-strategy.<wbr> </div><div style="margin-bottom: 10px;">Grady's focus currently is on good high quality Phase III programmes.<wbr> His team of about 130 look for assets via 3 routes: they look at and monitor all of the small- to mid-cap biotechs, .<wbr>they look  at others' pipelines and try to identify potential value that they may not have spotted and engage in late stage asset conventional licensing and collaborative deals.<wbr> The third route is peer to peer transactions - assessing peer pharma company pipelines and looking for overlaps in areas that might still be considered too high risk or expensive to pursue on their own.<wbr> </div><div>Source: Scrip 12 December 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10243">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T18:44:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T18:44:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer/Algeta's Alpharadin Submitted to the EMA for CRPC Patients with Bone Metastases</title>
	<pubDate>2012-12-12T17:43:37+01:00</pubDate>
	<wp:post_id>3631</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On August 20th, at last Bayer's Q2 financial results, management highlighted EU launch to occur in Q2/<wbr>Q3:13.<wbr> In Russia, the drug is expected to reach the market in the course of the next five years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Bayer expects to submit an NDA to FDA by year end.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8603" class="defaultlink">Oncology8603: Algeta Provides Additional Highlights on Alpharadin</a>.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8780c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Bayer has received notification from the FDA granting priority review of the NDA (filed in December 2012).<wbr> The application is under review for the treatment of CRPC patients with bone metastases.<wbr> </div><div style="margin-bottom: 10px;">FDA now has 8 months to complete its review (This suggests an estimated PDUFA action date of 13 August 2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Analysts with Deutsche Bank "believe Alpharadin has blockbuster potential in prostate cancer alone, supported by use as an alternative to Taxotere and potential for use in combination with new oral anti-hormonals.<wbr> </div><div>Benefits on bone palliation are particularly important given additional potential for repeat use in patients with bone pain at the end of life.<wbr> In addition, our discussions with physicians suggest Taxotere is often used more for its palliative benefits than for its improvement in survival.<wbr> The data suggests Alpharadin could be competitive in this regard and further adds to its benefits which include an improvement in overall survival (14.<wbr>9 vs 11.<wbr>3 mo; HR=0.<wbr>695) and delay in time to skeletalrelated events (15.<wbr>6 vs 9.<wbr>8 mo;P&lt; 0.<wbr>001; HR = 0.<wbr>66; 95% CI: 0.<wbr>52-0.<wbr>83).<wbr>" </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8669">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T17:43:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T17:43:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gilead Adds YM Biosciences Drugs to its Growing Oncology Pipeline</title>
	<pubDate>2012-12-12T16:54:59+01:00</pubDate>
	<wp:post_id>3632</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Gilead has acquired YM for a total of $510M, all paid with cash on hand.<wbr> YM's lead oncology candidate (CYT387) is a selective inhibitor of the Janus kinase family.<wbr> The transaction is expected to close 1Q:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to expand its R&amp;D expertise in the area of oncology beyond antivirals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- I<U>delalisib</U>, is a specific inhibitor of the phosphoinositide-3 kinase delta isoform.<wbr> Five PhIII studies in CLL and indolent NHL are progressing.<wbr> </div><div style="margin-bottom: 10px;">- <U>Simtuzumab</U> (PhII) mAB candidate targeting the human lysyl oxidase-like 2 protein for myelofibrosis, colorectal cancer pancreatic cancer, and certain fibrotic diseases.<wbr> </div><div>Source: YM; Gilead <a name="Oncology8679c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">International Strategy &amp; Investment analyst Mark Schoenebaum suggests that current consensus estimates for CYT387 are around $300 million for 2020.<wbr> In terms of benchmark products, Novartis and Incyte's Jakafi &ndash; approved in November 2011 and indicated for myelofibrosis and myeloproliferative disorders &ndash; is the obvious reference point.<wbr> Sales of the product, to date, have been modest, although limited patient data in Phase I/<wbr>II trials suggest that CTY387 may be a more efficacious product.<wbr> </div><div style="margin-bottom: 10px;">With Big Pharma competition in the JAK inhibitor space high, commercial projections for CTY387 may remain fairly muted.<wbr> </div><div>Source: FirstWord 16 December 2012 </div></div></div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8667">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T16:54:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T16:54:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galderma Joins Forces with Spirig Pharma AG</title>
	<pubDate>2012-12-12T15:59:22+01:00</pubDate>
	<wp:post_id>3633</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Galderma is to acquire Spirig Pharma, a leading company in the development, production and marketing of dermatics.<wbr> With 390 employees in total, Spirig generated sales of CHF98.<wbr>4M in 2011.<wbr> Transaction is expected to close in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Acquisition of Spirig gives Galderma a dermato leading position in Switzerland </div><div style="margin-bottom: 10px;">- Spirig's approach for protection, treatment, and prevention of dermatological conditions is closely aligned to that of Galderma.<wbr> </div><div style="margin-bottom: 10px;">- Galderma intends to utilize Spirig's Egerkingen location as HQs to its Swiss market operations, and as a center-of-excellence.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6695_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Focus: skin barrier function impairment; sun protection; solar damage </div><div style="margin-bottom: 10px;">Lead products: Excipia® for dry and sensitive skin, Daylong®, and Daylong Actinica® for sun protection </div><div style="margin-bottom: 10px;">Employees: 270 in Switzerland + 120 in international subsidiaries </div><div style="margin-bottom: 10px;">Network: dermatologists, GPs, drugstores, and pharmacies </div><div>Locations: <A href="http://www.spirig.ch/en/company/locations.html">http:/<wbr>/<wbr>www.<wbr>spirig.<wbr>ch/<wbr>en/<wbr>company/<wbr>locations.<wbr>html</A> </div><!-- Comment details --><a name="neurology6695attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6695_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6695">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T15:59:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T15:59:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva Unveils Its New Strategy At Yesterday's Analyst Meeting</title>
	<pubDate>2012-12-12T15:56:04+01:00</pubDate>
	<wp:post_id>3634</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: With Jeremy Levin now acting CEO, Teva's strategic focus is undergoing a transformation with a focus on execution, modernisation and extension of its global presence.<wbr> The newly established NTE platform will focus on a pipeline of differentiated medicies which will be re reasonbly priced, high vlaue and s uniquely meld together the company's generics and R&amp;D branded products capability.<wbr> Meanwhile, in terms of its specialty business, Teva will focus on its CNS (neurodegeneraton) and Respiratory pipelines with its business development activites focused upon these key areas.<wbr> Oncology has been clearly de-emphasized in the new structure although custirsen's launch for CRPC is still planned for 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The New R&amp;D Strategy </STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_13_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;">The New NTE Division </div><div style="margin-bottom: 10px;">The company intends to place renewed and special emphasis in the area of complex generics, improving compliance, improving convenience, improving efficacy and safety.<wbr> The focus will be on areas where the business is already quite strong such as oral delivery, modified release combinations, liposomal and long-acting release products but it will also look to grow these capabilities particularly in the area of injectables, nasal, patches and devices.<wbr> </div><div style="margin-bottom: 10px;">It acknowledged that it wasn't the first to develop NTES but just as it was the first to scale up industrialised paragraph IV submissions in the US it intends to be the first to scale up and trully industrialise NTEs.<wbr> The group's API business is central to the potential for NTEs something that needs to be closely watched in the context of Teva's capability to produce lanreotide.<wbr> </div><div style="margin-bottom: 10px;">In 2013 it will approve 10 to 15 NTEs, four have been approved thus far for development in 2013 and are scheduled for first launch in 2016.<wbr>.<wbr> No hint was given as to what might be amongst them besides three examples, possibly the ones approved so far a treatment for HIV another for schizophrenia.<wbr>and the third to treat Lupus.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_2_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_3_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Plans To Sustain &amp; Levarge CNS Business</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_5_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_6_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_7_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_9_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_10_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_11_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_14_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_12_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">For those interested in the full 238 slide presentation, please find a copy attached.<wbr> </div><div>source:www.<wbr>tevapharm.<wbr>com </div><!-- Comment details --><a name="pharmaworld10241attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_2_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(61,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(94 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(78,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(81,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(60,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(79,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(66,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(76 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(85,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(90 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_14_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(113,4 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10241_15_Investor%255fDay%255fpresentation%255fFINAL%255fnoAnimation%5b2%5d.pdf">Investor_Day_presentation_FINAL_noAnimation[2].pdf</a>&nbsp;&nbsp;(4,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10241">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T15:56:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T15:56:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Toxins 2012 Intelligence Update - Allergan and Other Insights of Note</title>
	<pubDate>2012-12-12T14:40:38+01:00</pubDate>
	<wp:post_id>3635</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan’s BPH trial data will read out by mid-2013 as well as the 2<SUP>nd</SUP> Urological indication being granted in iOAB by Q1 2013.<wbr> It has also come to our attention that Allergan is the only institution given permission by the US authorities to express toxin by recombinant methods at this time point.<wbr> </div><div style="margin-bottom: 10px;">Allergan presence was not as heavily felt as Merz, this probably had a lot to do with Merz ‘re-introducing’ itself off the back of the injunction which will be lifted on the 9<SUP>th</SUP> of January.<wbr> They only had six posters on display (See Allergan Poster Review) and did not sponsor any symposia.<wbr> </div><div style="margin-bottom: 10px;">The booth had various hand-outs in Spanish and English including the new injector checklist to schedule your training day for Chronic Migraine injections as well as post training (see attachment titled New Injector Checklist) and a leaflet on Chronic Migraine highlighting Botox as the first and only preventative treatment approved by the FDA for adults with chronic migraine.<wbr> </div><div style="margin-bottom: 10px;">I would like to thank Dominic Marchese, Brice Vignon, John Bruins, Eric Schultz and John Kramer for their intelligence scoops during the congress.<wbr> Their insights are contained within this report — this includes intell on Allergan, recombinant toxins, Myobloc and Purtox.<wbr> </div><div style="margin-bottom: 10px;">A very interesting talk on comparing toxins was presented by Dr.<wbr> Alberto Albanese (Milan, Italy) looking at efficacy safety and potency of the 3 marketed toxins </div><div style="margin-bottom: 10px;">Key questions addressed included: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Is one toxin more efficacious?</LI>
<LI>Are there differences in the therapeutic index?</LI>
<LI>Relative potency of different toxin brands</LI>
<LI>Does relative potency vary based on injection site or indication </LI>
</UL> </div><div style="margin-bottom: 10px;">Dr.<wbr> Albanese conducted a number of Medline searches (up to November 2012) of systematic reviews, clinical trials and observational studies on Dysort (abobotulinum), Botox (onabotulinum), Xeomin (incobotulinum) and Myobloc (rimabotulinum toxin B).<wbr> </div><div style="margin-bottom: 10px;">Results and summary below.<wbr> Full slide deck available upon request.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_4_ScreenCapture4.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Potential new product of note: Mark Hallet spoke of a BoNT A cream used for wrinkles which he is trialling for blepharospasm at his centre which will be moving into phase II at the beginning of next year.<wbr> The product is called AH8 and is produced by BCN Peptides.<wbr> He believes it will work on superficial muscles only.<wbr> Hence the trial in blepharospasm (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6672" class="defaultlink">Neurology6672: Hexapeptide-8 is Safe for Extending Duration of BoNT for Blepharospasm (BSP)</a>)<STRONG>.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><B>Allergan Poster Review</B> </div><div style="margin-bottom: 10px;"><B>Botulinum Neurotoxin Serotype — A Specific Cell Based Potency Assay To Replace The Mouse Bioassay</B> which has previously been posted on TRACTION.<wbr> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Although this is a cell based assay, mouse is still used.<wbr> </LI>
<LI>Patent was granted in July 2012</LI>
<LI>Full paper found at <A href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0049516">http:/<wbr>/<wbr>www.<wbr>plosone.<wbr>org/<wbr>article/<wbr>info%3Adoi%2F10.<wbr>1371%2Fjournal.<wbr>pone.<wbr>0049516</A></LI>
</UL> </div><div style="margin-bottom: 10px;"><B>Reconstituted BOTOX retains potency and safety under extended refrigerated storage</B> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The study presented evaluated the potency and microbial growth promotion of reconstituted BOTOX.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="circle"><LI>Microbal challenge study included</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>Staphylococcus</LI>
<LI>Pseudomonas aeruginosa</LI>
<LI>E.<wbr>Coli</LI>
<LI>Candida albicans</LI>
<LI>Aspergillius niger</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Results showed that equivalence in potency was established between the 0 hour and both the 24hr and 5 day (120hr) time points for three lots of BOTOX reconstituted</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Providing additional support in favour of a 24 hr reconstitution</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_9_ScreenCapture9.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><B>Efficacy and Treatment of Botox for the treatment of Crows Feet</B> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Multicentre double blind randomised placebo controlled, parallel group study</LI>
<LI>Single treatment cycle with 5 months follow up</LI>
</UL> </div><div style="margin-bottom: 10px;">Results </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Groups did not differ significantly in their demographics or CRL severity (which was moderate to mild)</LI>
<LI>There was no statistical significance between group differences in FLO-11 item scores, FLO -11 total score or perceived age of appearance on the SPA</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_11_ScreenCapture11.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><B>BOTOX Significantly Reduced Urinary Incontinence And Improved Quality Of Life In Patients With Idiopathic Overactive Bladder</B> </div><div style="margin-bottom: 10px;">Results: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Significantly greater reductions from baseline in UI episodes/<wbr>days occurred with BOTOX 100U compared with placebo (-2.<wbr>65vs-0.<wbr>87 at week 12 P5 episodes/<wbr>day) </LI>
<LI>A high proportion of BOTOX treated patients reported a positive response on the TBS (60.<wbr>8% vs 29.<wbr>2% for placebo)</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><B>CD PROBE Study: The use of Electomyogrpahy for BOTOX Treatment of CD — a sub-analysis of the CD patient Registry for the observation of BOTOX</B> </div><div style="margin-bottom: 10px;">Rationale: The usefulness of EMG for BoNT injections is controversial and utilisation has not been previously described from a large, prospectively ascertained treatment cohort.<wbr> </div><div style="margin-bottom: 10px;">Methods: CD PROBE is an on-going observational study of CD patients treated with BOTOX that includes physicians with prior injection experience.<wbr> Subjects were included if they had primary CD and were new to the treating physicians practice and who had not received toxin 16 weeks or were toxin naive.<wbr> This baseline was designed to describe the use of EMG by physicians at the baseline injection.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_16_ScreenCapture16.jpg"><STRONG> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_17_ScreenCapture17.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><B>The Percent of Chronic Migraine Patients who Responded to Botox Treatment per Treatment Cycle in the PREEMPT Clinical Programme</B> </div><div style="margin-bottom: 10px;">Patients were randomised (1:1) to BOTOX (155-195U) or placebo every 12 weeks, evaluating ≥50% responder rates for 3 treatments cycles across multiple efficacy variables.<wbr> This rate exceeds the previously suggested clinically meaningful response rate of ≥30% in patients with CM </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_18_ScreenCapture18.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><B>Intelligence gathered from Eric Shultz (BOTOX)</B> </div><div style="margin-bottom: 10px;">Source: Dr.<wbr> Bahroo off the back of Allergan’s speaker training meeting </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>They will be conducting DIP programs where the injector goes to the trainee (same as ours without the presentation)</LI>
<LI>Their CD and Bleph sales are flat and they are taking a renewed focus on these indications.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="circle"><LI>First time in several years they conducted training for these indications</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Allergan has 2-3 hospital reps per territory.<wbr> They are divided out by indication.<wbr> This is in addition to their office based sales force.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Intelligence gathered from John Bruins (Recombinant Toxin - Allergan)</STRONG> </div><div style="margin-bottom: 10px;">Source: Dr.<wbr> Singh (UMass Dartmouth) made the following statement: </div><div style="margin-bottom: 10px;">"Allergan in the only facility in the US that is permitted (by the government) to express toxin by recombinant methods".<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Singh is quite knowledgeable in this area and runs the Botulinum Research Facility in Dartmouth, Mass.<wbr> He is closely aligned with the DOD, DHS, and other government agencies </div><div style="margin-bottom: 10px;"><STRONG>Intelligence gathered from Brice Vignon (PurTox and RT001)</STRONG> </div><div style="margin-bottom: 10px;"><B>- Corey S MAAS : Clinical Botulinum neurotoxin protocols for the upper third of the face</B> </div><div style="margin-bottom: 10px;"><UL><LI>Purtox : PhII study demonstrated : Purtox has &gt; 30-60 days longer duration than Botox with the optimal dose Purtox 30U vs.<wbr> Botox 20U</LI>
</UL> </div><div style="margin-bottom: 10px;"><B>- Neil Sadick : Treatment of hyperhidrosis — What’s new in 2012?</B> </div><div style="margin-bottom: 10px;"><UL><LI>Topical gel BoNT : Transcutaneous delivery (Richard G Glogau 2012 publication)</LI>
<LI>Sub dermal laser treatment</LI>
<LI>Non Invasive Laser treatment</LI>
<LI>Microwave Glandular ablation</LI>
</UL> </div><div style="margin-bottom: 10px;">According to Neil Sadick, "Revance" is a topical BoNT type B (?), shows very good efficacy, is going to get FDA approval.<wbr> Onset of action= to injection, time of application : 5-7 mn and dose = to injection </div><div style="margin-bottom: 10px;"><B>Intelligence gathered from Dominic Marchese (Myobloc)</B> </div><div><UL type="disc"><LI>Medical Director at US Worldmeds said that they (Solstice Neurosciences/<wbr>Myobloc) have filed with the FDA an NDA for the treatment of sialorrhea.<wbr> </LI>
</UL> </div><!-- Comment details --><a name="neurology6693attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(75 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(96,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(97 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(127,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(67,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(81,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(74,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(50,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(83,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(50,6 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(22,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(74 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(97,1 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(36,8 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6693_21_New%20Injector%20Checklist.pdf">New Injector Checklist.pdf</a>&nbsp;&nbsp;(140,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6693">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T14:40:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T14:40:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Found in Breach of ABPI Code of Practice</title>
	<pubDate>2012-12-12T13:17:47+01:00</pubDate>
	<wp:post_id>3636</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The complaint against Merz was filled by Allergan, which said that 3 ads showed Bocouture and Botox standing alongside each other and used phrases such as "equipotent", "equal potency" and "1:1 clinical conversion ratio".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The overall message was the products were the same, and could be interchanged.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Prescription Medicines Code of Practice Authority (PMCPA) agreed with Allergan and found Merz in breach for making an "inaccurate, misleading and unsubstantiated claim".<wbr> </div><div style="margin-bottom: 10px;">In addition, Merz was found guilty of breaching Clause 2 of the code, bringing discredit upon and reducing confidence in the pharma industy, which is seen as the most serious breach.<wbr> </div><div>Details <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20121231&edate=20120901&rs=/link%20Neurology6701%401" class="defaultlink">@1</a> (attached document - from page 18) </div><!-- Comment details --><a name="neurology6688attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6688_1_Code%20of%20Practive%20Review%255f2012%20November%20Review.pdf">Code of Practive Review_2012 November Review.pdf</a>&nbsp;&nbsp;(725,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6688">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T13:17:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T13:17:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Toxins 2012 Intelligence Update - Merz Insights</title>
	<pubDate>2012-12-12T11:44:31+01:00</pubDate>
	<wp:post_id>3637</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz's main theme at the congress was pointed towards flexible dosing, with various data supporting this initiative including i) patient/<wbr>physician satisfaction surveys highlighting the wish for indivualised dosing/<wbr>injection intervals; ii) long term safety data of Xeomin in order to demonstrate the lack of antibody formation; and, iii) actual injection interval data.<wbr> </div><div style="margin-bottom: 10px;">The congress was the first INA (International Neurotoxins Association) meeting and had ~400 attendees compared to last years Toxin meeting which had around 700+ participants.<wbr> The INA meeting had a balance of clinical vs scientific events with the second half of most days focused on live patient cases(with injection demos) or patient videos.<wbr> </div><div style="margin-bottom: 10px;">Merz dominated the poster hall and had a total of 16 posters on display along with being the supporter of the opening symposia - Managing Patient Satisfaction, Safety And Therapeutic Efficacy In CD.<wbr> A copy of the slides can be found at <A href="&ldquo;,&rdquo;http:/www.jhasim.com/d&amp;s&ldquo;,&rdquo;">www.<wbr>jhasim.<wbr>com/<wbr>d&amp;s</A>.<wbr> </div><div style="margin-bottom: 10px;">In order to garner a label change with regards to flexible dosing, Merz has initiated the CD Flex Trial (see Poster Review).<wbr> This trial is US based and will not branch to EU sites in the near future.<wbr> It is understood that this data should be available by 2016.<wbr> </div><div style="margin-bottom: 10px;">Two previous trials looking at flexible dosing in CD and blepharospasm conducted by Merz (previously presented at MDS 2012) are believed to not have had sufficient data to file.<wbr> This could be due to the need for more immunogenicity data which is included in the CD Flex trial.<wbr> Previous trials were also US based only.<wbr> </div><div style="margin-bottom: 10px;">Speaking with Cynthia Comella regarding the CD Flex trial, &lsquo;<EM>recruitment is going at a snail&rsquo;s pace and the trial is slightly biased in that it only looks at patients who want/<wbr>request shorter injection intervals but the real goal of the trial is so we can wave the data in the face of Medicaid and not get sued for injecting prior to the guidelines&rsquo;</EM>.<wbr> When challenging her on increased cost, she replied &lsquo;<EM>it&rsquo;s what a good number of our patients want</EM>&rsquo;.<wbr> </div><div style="margin-bottom: 10px;">Note: Individualised dosing may turn into an actual advantage rather than just a point of differentiation.<wbr> The presumed increase of cost may not be as big of a concern when taking into account Merz&rsquo;s history of discounting.<wbr> </div><div style="margin-bottom: 10px;">During the opening symposia, Dr.<wbr> Steven Frucht&rsquo;s talk revolved around improving symptom control &mdash; a look at dosing/<wbr>frequency setting the scene to update the audience with data from the extension period of the "Xeomin Injected With Flexible Intervals Is a Well Tolerated Long Term Treatment of CD Trial" and the results of a "Satisfaction with BoNT A toxin treatment in CD" (see poster review below) </div><div style="margin-bottom: 10px;">Further supporting the theme, immunoresistance featured in the programme with Dr Dressler&rsquo;s overview of Immunological issues of BONT therapy.<wbr> His talk foucused on concerns over an increased risk of neutralising antibodies with short injection intervals which may largely be based on early studies with the original formulation of Botox to which he referred to as &lsquo;Old Botox&rsquo;.<wbr> He pushed for further investigation of this issue in order to challenge the 'myth'.<wbr> Upon speaking with him, he stated that he believed Xeomin was the only product on the market he could safely say will not cause antibody formation due to its lack of complexing proteins.<wbr> </div><div style="margin-bottom: 10px;">Merz also seems to be trying to clean up its image after the injunction scandal by conducting &lsquo;green&rsquo; trials in the form of greenhouse gas emissions due to secondary shipping packaging of temperature controlled and non-temperature controlled botulinum neurotoxin products.<wbr> </div><div style="margin-bottom: 10px;">Merz is clearly taking advantage of the fact that Xeomin does not require refrigeration - highlighting that the difference in GHG emissions between the shipping of 1000 packages of Xeomin vs Botox is equivalent to taking 0.<wbr>6 cars or light trucks off the road for one year or a reduction in the use of &gt;1500 litres of gasoline.<wbr> </div><div style="margin-bottom: 10px;">Merz sources on the booth stated that they are interested to move forward with pain and gynaecology indications in the future and hope to have a cell based assay by 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>POSTER REVIEW</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>CD FLEX (</STRONG>NCT01486264 - see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6155" class="defaultlink">Neurology6155: Merz to Start Comparison Study of Xeomin® in Cervical Dystonia Flex</a>)<STRONG>:</STRONG> An open label, non-inferiority study evaluation the efficacy and safety of 2 injection schedules of Xeomin (Short Flex vs Long Flex) in subjects with CD who receive treatment benefit of &lt;10 wks with Botox treatment.<wbr> Enrolment began in Jan 2012 and has not fully recruited to date.<wbr> Target is 424 pts with a study length of two years.<wbr> Results expected in 2016.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Following on from the flexible dosing theme, two posters highlighted the satisfaction with BoNT A treatment in post stroke spasticity &mdash; results from a patient survey (76 patients interviewed) and results from a physician survey (105 physicians interviewed) highlighted: </div><div style="margin-bottom: 10px;"><UL><LI>Most patients with post-stroke spasticity are basically satisfied with BoNT A toxin treatment
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Patient satisfaction typically declines over time and is lowest just prior to injection and highest at the time of peak effect
</LI>
<LI>When questioned about treatment intervals many patients prefer an injection interval of less than the standard 12 wks, although overall patients favoured a median interval of 12 wks
</LI>
<LI>Patients would prefer to be given the option of individualised BoNT-A treatment intervals
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Most physicians are basically satisfied with BoNT A toxin treatment
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Despite this, physicians believed that greater flexibility regarding the dose and duration of injection intervals for BoNT-A injections would benefit patients
</LI>
<LI>The majority of physicians felt that their patients would experience improved outcomes and greater satisfaction if dose and injection intervals were individualised
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">In addition, the two prior flexible interval studies in CD and blepharospasms was shown and have been previously reported in TRACTION (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6473" class="defaultlink">Neurology6473: Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</a>) and (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6410" class="defaultlink">Neurology6410: Intelligence From The AAN - Merz US Injunction Likely To Last Full 10 Months</a>).<wbr> </div><div style="margin-bottom: 10px;">The CD data was a part of Dr.<wbr> Steven Frucht&rsquo;s talk during the Merz Symposia whereby the Extended Period of this trial was presented.<wbr> The Main Period being presented at the previous Movement Disorders meeting as well as the blepharospasms data.<wbr> </div><div style="margin-bottom: 10px;">Study Design for Xeomin injected with flexible intervals in CD patients: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Main Period &mdash; Investigate the efficacy and safety of 2 different doses of Xeomin compared with placebo in subjects with CD
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>This part turned out to be safe and effective &mdash; no relevant safety findings
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Extended Period - Investigate the efficacy and safety of repeated injections of the two doses of Xeomin in subjects with CD over a year period
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Majority of patients received re-injections at intervals of 6 to 20 weeks
</LI>
<LI>Mean (SD) injection interval: 14:0 (7.<wbr>4) weeks (median: 13 weeks)
</LI>
<LI>Mean cumulative dose (SD) were 917.<wbr>8U (332.<wbr>0) in the 240U group and 423.<wbr>7U (166.<wbr>3) in the 120U group
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_6_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_7_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_8_ScreenCapture8.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Satisfaction with BoNT A treatment in CD &mdash; results from 2 cross sectional surveys (Patients and Physicians)</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Physicians survey indicated that there are still patients likely to be more effectively treated if shorter treatment intervals and higher doses are utilised
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Listed cost issues and reimbursement problems as biggest hurdles BoNT A treatment in CD with pain relief being the number one treatment goal
</LI>
<LI>Out of the 120 phyisicans surved, 66 said they would prefer shorter injection intervals
</LI>
<LI>Mainly due to efficacy not lasting long enough
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Structured patient interviews (n=136) were conducted in 4 countries (CAN,FR, DE, USA) by clinically experienced interviewers
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>All interviewed patients had received &ge;2 injection sessions with Botox or Xeomin
</LI>
<LI>Interviews were conducted wither at 7 to 8 weeks or 9 to 10 weeks after patients last injection sessions
</LI>
<LI>These time frames were considered to allow sufficient time for the BoNT A to confer peak clinical effects
</LI>
</UL> </div><div><BLOCKQUOTE dir="ltr" style="margin-right: 0px;">
<P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_14_ScreenCapture14.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_15_ScreenCapture15.jpg"></P>
<P><STRONG>TOWER (</STRONG>NCT01603459 - see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6414" class="defaultlink">Neurology6414: Dose-Titration Trial of Xeomin for Spasticity in the Leg and Arm</a><STRONG>)</STRONG>: Open label Xeomin dose titration study (&le; 800U) in LL/<wbr>UL spasticity.<wbr> Fifty patients have been recruited since end September 2012 and expect to complete enrolment by mid-2013.<wbr> Enrolment target is 150 patients.<wbr> Results expected in Q3/<wbr>4 2014.<wbr> Primary outcome of safety while also looking at antibody formation and pulmonary function.<wbr> Secondary objectives include usual clinical evaluations (Ashworth, REPAS, GAS etc).<wbr></P>
<P>Study Flow:</P>
<P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_17_ScreenCapture17.jpg"></P>
<P><STRONG>XCiDaBLE:</STRONG> <A href="http://clinicaltrials.gov/ct2/show/NCT01287247">NCT01287247</A> Phase IV, observational prospective trial evaluating Xeomin for CD or blepharospasm.<wbr> Data below outlines the preliminary baseline results for subjects with blepharospasm.<wbr> As of Feb 2012, 170 subjects (with blepharospasm) have participated in the study.<wbr> Final results are expected in Feb 2013.<wbr></P>
<P>Study design:</P>
<P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_18_ScreenCapture18.jpg"></P>
<P>Most subjects and their physicians described their baseline Global Impression of Severity as 'mild to marked'.<wbr> The mean SD baseline SF-12v2 scores were 49.<wbr>6 (10.<wbr>0) for the Mental score and 43.<wbr>8 (11.<wbr>7) for the Physical score.<wbr></P>
<P><STRONG>SPACE:</STRONG> An international, non-interventional study of BONT A in treatment-na&iuml;ve patients with spasticity.<wbr> Up to 100 study sites in 9 countries.<wbr> By end December 2011, 282 patients have been enrolled.<wbr> Target enrollment is 1000 patients.<wbr></P>
<P>The purpose of this study is to understand how spasticity is managed in the long term and gain insights into &lsquo;real life&rsquo; clinical practice.<wbr> Patients can receive any number of treatment sessions with any type of BONT A toxin available in their country.<wbr> The planned study duration is 2 yrs per patient.<wbr> Outcomes include daily practice information, HRQoL and efficacy assessments.<wbr></P>
<P>Interim analysis of 205 patients in 7 countries (UK, DE, CAN, MEX, RUS, FR, SE) is outlined below:</P>
<UL type="disc"><LI>Most patients had post-stroke spasticity
</LI>
<LI>At baseline, 26.<wbr>8% of patients reported no spasticity related pain, 25.<wbr>3% reported mild pain, and 11.<wbr>6% reported severe pain &mdash; no data were recorded for 15 patients
</LI>
<LI>48.<wbr>1% of participating physicians stated that would like to inject higher doses of than permitted by current product labeling
</LI>
<LI>Most important primary treatment goals for patient's improvement in dexterity and reaching (26.<wbr>8%), relief of pain (12.<wbr>7%) and improvement in mobility (11.<wbr>75)
</LI>
<LI>Improvement of self-care was the most common additional treatment goal
</LI>
</UL>
<P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_19_ScreenCapture19.jpg"></P>
<P><STRONG>Conversion from Dysport to Xeomin: Clinical experience in 257 pts: </STRONG>This study was initiated to assess the potential advantages of Xeomin including cost.<wbr></P>
<UL type="disc"><LI>Switching was generally initiated at a 4:1 ratio of botulinum toxin untils (Dysport: Xeomin)
</LI>
<LI>Switching to Xeomin was well tolerated without any significant problems suggestive of over-treatment such as ptosis, facial droop or swallowing difficulty
</LI>
<LI>Switching from Dysport to Xeomin reduced expenditure to 77.<wbr>2% of the pre-switch cost of botulinum toxin, saving &gt;22%
</LI>
<LI>Pre-switch, the expenditure for Dysport was &pound;329.<wbr>90 per patient, per year( $520, &euro;403)
</LI>
<LI>After switching, the expenditure for Xeomin was &pound;249.<wbr>60 per patient ($398, &euro;309)
</LI>
</UL>
<P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_20_ScreenCapture20.jpg"></P>
<P><STRONG>Observational Study With Xeomin In Post-Stroke ULS Patients In Nursing Homes</STRONG>.<wbr> This study took place in Austria at 18 nursing homes across the country.<wbr> It has been highlighted that nursing home residents suffering from ULS often lack treatment to BoNT- A treatment.<wbr></P>
<P>Outcome measures included changes in SAPS, pain intensity, changes in self- care activities, rating of response to treatment and safety.<wbr></P>
<P>Results</P>
<UL type="disc"><LI>Pain in the UL decreased dramatically
</LI>
<LI>A distinct improvement in UL self-care activities was noted
</LI>
<LI>Response to treatment was high
</LI>
</UL>
<P><STRONG>Xeomin demonstrated equivalent efficacy to Botox in the treatment of CD.<wbr> </STRONG>This was the results of the registration study from 2005 outlining that this H2H study demonstrated therapeutic equivalence of Xeomin to Botox at a 1:1 dosing conversation ration in the treatment of CD within the dose range of 70U and 300U.<wbr></P>
<P><STRONG>Xeomin demonstrated equivalent efficacy to Botox in the treatment of bleparhospasms</STRONG>This was the results of the registration study from 2006 outlining that this H2H study demonstrated therapeutic equivalence of Xeomin to Botox at a 1:1 dosing conversation ration in the treatment of blepharospasms with dose of up to 50U per eye.<wbr></P>
</BLOCKQUOTE> </div><!-- Comment details --><a name="neurology6682attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(107,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(105,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(48,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(151,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(74,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(70,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(71,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(70,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(88 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(88,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(89,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(803 B)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(55,1 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(31,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(108,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(98,8 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(45,7 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(106,9 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6682_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(122,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6682">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T11:44:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T11:44:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FirstWord Poll - Neurologists and Medical Meeting Attendance</title>
	<pubDate>2012-12-12T11:14:39+01:00</pubDate>
	<wp:post_id>3638</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  A poll of neurologists who are based in the US or five EU countries (Germany, France, Italy, Spain and the UK) shows that they attend approximately four medical conferences/<wbr>congresses each year, with most of these likely to be ones held in the country where they live.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Number of conferences</STRONG> </div><div style="margin-bottom: 10px;">On average, neurologists attend 3.<wbr>9 conferences per year.<wbr> Just 10 percent of respondents said that they had not attended a single medical conference over the past year, while around a third of neurologists indicated they had attended in excess of 5 conferences.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Location of conferences</STRONG> </div><div style="margin-bottom: 10px;">Of the physicians polled, 48 percent attended at least one medical conference which was held outside of their own country (51 percent only attended conferences in their own country).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The most useful conferences</STRONG> </div><div style="margin-bottom: 10px;">A number of conferences in the neurology calendar were more frequently cited by respondents as being the most informative over the past year - these included the American Academy of Neurology (AAN) meeting  &ndash; and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Proposed attendance for 2013</STRONG> </div><div style="margin-bottom: 10px;">Among neurologists it appears that attendance rates at medical conferences will increase over the next 12 months.<wbr> 58 percent of respondents indicated that they expect to attend a similar number of conferences over the forthcoming year (compared to the last 12 months).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Factors driving attendance</STRONG> </div><div style="margin-bottom: 10px;">Although expressed by respondents in a number of forms (content, subject, scientific interest, relevance, topic), assessment of the data indicates that content that is due to be presented at a particular medical conference acts as the a determiner on whether a physician will choose to attend or not.<wbr> Location (in particular) and cost appear to feature prominently among physician's thinking when attendance is considered.<wbr> </div><div>Source: FirstWord 12 December 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6681">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-12T11:14:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-12T11:14:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Another Round Of Seed Financing For A Peptide Therapeutics Company</title>
	<pubDate>2012-12-11T17:37:42+01:00</pubDate>
	<wp:post_id>3639</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: 
Cambridge based Bicycle Therapeutics Ltd, a developer of peptide libraries 
has raised a further tranch of equity financing of £3.<wbr>75m 
($6.<wbr>01m).<wbr> The financing was provided by the new investor Astellas Venture 
Management LLC along with the existing investors Atlas Venture, Novartis Venture 
Funds, SR One Ltd.<wbr> and SV Life Sciences Advisers LLP.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
company intends to use the proceeds to invest in selection of drug candidates 
using its bicyclic peptide technology platform.<wbr> Bicycle has developed a 
proprietary bicyclic peptide technology that enables the discovery of a new 
class of drug candidates with antibody-like selectivity and specificity that can 
be manufactured with economics similar to new chemical entities.<wbr> The company is 
applying the technology to drug discovery projects in oncology, metabolic and 
inflammatory diseases and will also make the platform accessible for 
collaborative discovery with pharma partners.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Rolf 
Gunther, CEO of Bicycle, said, “This financing marks our transition from 
technology development to drug discovery, using our bicyclic peptide libraries, 
high throughput screening and lead optimisation technology.<wbr> We are now expanding 
our discovery efforts to address multiple drug target classes.<wbr> We welcome 
Astellas Venture Management as a new strategic investor, further endorsing the 
potential of our platform.<wbr></SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: 
<A href="http://www.bicycletherapeutics.com">www.<wbr>bicycletherapeutics.<wbr>com</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10240">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-11T17:37:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-11T17:37:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AOTM Recommends Continued Reimbursement of Afinitor as Part of Non-standard Chemotherapy Programme in pNET</title>
	<pubDate>2012-12-11T16:03:14+01:00</pubDate>
	<wp:post_id>3640</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The president of the Agency for Health Technology Assessment in Poland has issued a recommendation for keeping Afinitor (everolimus) on the list of non-standard chemotherapy treatments reimbursed by the National Health Fund (NFZ) in the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin (pNET) in adults with progressive disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Therefore, the AOTM's president deferred to the recommendation of the agency's Transparency Board.<wbr> In the recommendation document, it is stated that Afinitor has proven clinical effectiveness and its safety profile was acceptable in the case of this group of medicines, emphasising that patients who do not tolerate Sutent (Pfizer) have potential clinical benefits from its use.<wbr> </div><div style="margin-bottom: 10px;">It is also stated that in comparison with Sutent, treatment with Afinitor is cost-effective, while if the proposed risk-sharing agreement is applied, it would also be cost-effective.<wbr> Meanwhile, the president of the AOTM deferred to the Transparency Board's suggestion that the cost of treatment with Afinitor be brought to around the same level as treatment with Sutent.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The decision to keep Afinitor on the list of non-standard chemotherapy treatments is not very positive for Novartis, since this list is associated with the most restrictive admission conditions for patients of all therapeutic (drug) programmes.<wbr> </div><div>Nevertheless, it is worthy of note that Afinitor is currently the medicine on the non-standard chemotherapy list on which the second-largest amount is spent – this amount went up from PLN20.<wbr>435 million (USD6.<wbr>41 million) in 2010 to PLN23.<wbr>680 million in 2011.<wbr> The implication is that if the producer is willing to follow the conditions as requested by the AOTM, regarding aligning the cost of treatment with Afinitor with that of Sutent, there would be a willingness to increase reimbursement.<wbr> <BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10238">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-11T16:03:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-11T16:03:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Growth Hormone Agents Set to Come Under Dutch's Hospital Budget</title>
	<pubDate>2012-12-11T11:32:22+01:00</pubDate>
	<wp:post_id>3641</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to the Dutch Foundation for Pharmaceutical Statistics, the provision of growth hormone (as well as oral antineoplastic agents) will be provided through hospitals' budgets from January 2013.<wbr> Interviewed on this news, S-K Chang (Pediatric Endocrinology) indicated that business model has turned from physician to account base, and that Ipsen has changed its approach to creating partnership with key centers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: large arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: large arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: large arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7192">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-11T11:32:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-11T11:32:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly and Boehringer Ingelheim Sign Chinese Diabetes Alliance</title>
	<pubDate>2012-12-11T11:23:21+01:00</pubDate>
	<wp:post_id>3642</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chen Xiaomei, BI executive, reported that cooperation will benefit both companies' product portfolios and enhance their local diabetes treatment capabilities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">At a joint press conference on December 10th, both companies also presented findings from a China Pharma Newspaper and Periodicals Association study that suggest that Chinese media reports regarding diabetes are increasingly accurate and scientifically-grounded.<wbr> </div><div style="margin-bottom: 10px;">Nevertheless, the companies conceded that considerable educational work remains to be done.<wbr> </div><div>Source: GBI </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7191">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-11T11:23:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-11T11:23:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: CHMP Recommends Approval of J&J's Zytiga</title>
	<pubDate>2012-12-11T09:57:11+01:00</pubDate>
	<wp:post_id>3643</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">CHMP Recommends Approval of J&J's Zytiga</span>&nbsp;<br><span style="font-size: 12px;">Comment: On Friday the CHMP recommended that J&amp;J's Zytiga (abiraterone) 
be approved for the treatment of chemotherapy naive patients with metastatic 
CRPC in combination with prednisone.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8611">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">FDA approved an sNDA to expand the label for </SPAN><A href="http://www.biocentury.com/products/zytiga" style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #1155cc; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank" title="Zytiga product news and analysis from BCIQ"><SPAN style="COLOR: #000000">Zytiga</SPAN></A><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> abiraterone from </SPAN><A href="http://www.biocentury.com/companies/johnson_and_johnson" style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #1155cc; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank" title="J&amp;J company profile and pipeline intelligence from BCIQ"><SPAN style="COLOR: #000000">Johnson &amp; Johnson</SPAN></A> <SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">to include use in combination with prednisone to treat chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC).<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">J&amp;J said the U.<wbr>S.<wbr> label for Zytiga does not include language restricting the use of Zytiga to patients who are asymptomatic or mildly asymptomatic.<wbr></SPAN></SPAN></SPAN><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><BR>In conjunction with the approval, The New England Journal of Medicine published additional data from the Phase III COU-AA-302 trial showing Zytiga plus prednisone improved median radiographic progression-free survival (PFS) vs.<wbr> prednisone alone in chemotherapy-naïve CRPC patients (16.<wbr>5 months vs.<wbr> 8.<wbr>3 months; p&lt;0.<wbr>001).<wbr> At a median follow-up of 22.<wbr>2 months, median overall survival (OS) has not been reached in the Zytiga plus prednisone arm.<wbr> Median OS is 27.<wbr>2 months for prednisone alone.<wbr> </SPAN></SPAN></SPAN></SPAN> </div><div><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Sources :</SPAN></SPAN></SPAN></SPAN><SPAN class="hP" id=":17t" style="OUTLINE-STYLE: none; OUTLINE-COLOR: invert; OUTLINE-WIDTH: medium; PADDING-RIGHT: 10px" tabindex="-1">BioCentury Extra for Monday, December 10, 2012<BR><A href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209096">http:/<wbr>/<wbr>www.<wbr>nejm.<wbr>org/<wbr>doi/<wbr>pdf/<wbr>10.<wbr>1056/<wbr>NEJMoa1209096</A></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8665">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8611">View thread  Oncology8611: CHMP Recommends Approval of J&J's Zytiga</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-11T09:57:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-11T09:57:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Biogen-Idec & Isis Form New Neuromuscular Disease Collaboration</title>
	<pubDate>2012-12-10T18:16:32+01:00</pubDate>
	<wp:post_id>3644</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Biogen-Idec & Isis Form New Neuromuscular Disease Collaboration</span>&nbsp;<br><span style="font-size: 12px;">Comment: Biogen-Idec and Isis have entered into an exclusive worldwide option 
and collaboration agreement to develop and commercialise an antisense 
programme targeting the neuromusucular disease mytonic dystrophy.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6490">...</a><br></div><div style="margin-bottom: 10px;">The companies have signed a third global collaboration agreement under which they will  discover and develop antisense drugs againt 3 undisclosed targets to treat neurological or neuromuscular disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Isis will receive an upfront payment of $30M and is responsible for the discovery of a lead antisense drug for each of the 3 undisclosed drugs.<wbr> </div><div style="margin-bottom: 10px;">Isis is eligible to receive substantial development milestone payments to support R&amp;D of each program prior to the exercise by Biogen Idec of its option to license each program.<wbr> </div><div>Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 trials.<wbr> Isis could receive up to another $200 million in a license fee and regulatory milestone payments per program.<wbr> In addition, Isis will receive double-digit royalties on sales of drugs.<wbr> Isis will be responsible for development of the drugs through the completion of the initial Phase 2 clinical trial, with Biogen Idec providing advice and assistance on research and the clinical trial design and conduct and regulatory strategy for each program.<wbr> If Biogen Idec exercises its option, it will assume global development, regulatory and commercialization responsibilities.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6679">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6490">View thread  Neurology6490: Biogen-Idec & Isis Form New Neuromuscular Disease Collaboration</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-10T18:16:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-10T18:16:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progress With Novel Peptide Development Programme</title>
	<pubDate>2012-12-10T15:23:48+01:00</pubDate>
	<wp:post_id>3645</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://www.ironwood.com/"></A> </SPAN><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10237">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-10T15:23:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-10T15:23:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chengdu Selected by Roche's 'West Plus' Initiative</title>
	<pubDate>2012-12-10T11:19:26+01:00</pubDate>
	<wp:post_id>3646</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lu Ke, Roche Asia-Pacific Region President, has specified that Chengdu, Sichuan Province, was selected to host the new facility due to its traditional role as a regional biopharmaceutical hub.<wbr> The West China Management Center is tasked with boosting sales in regions beyond coastal and eastern metropolises.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Roche, government collaboration efforts and R&amp;d activities will be expanded, particularly in <STRONG>oncology</STRONG> as well as in virology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company expects to double sales and headcount in this region by 2015, which currently accounts for 11% of its total China sales.<wbr> </div><div>Source: GBI </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10236">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-10T11:19:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-10T11:19:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Cost Issues with Signifor for Cushing in Germany</title>
	<pubDate>2012-12-10T11:15:42+01:00</pubDate>
	<wp:post_id>3647</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cost Issues with Signifor for Cushing in Germany</span>&nbsp;<br><span style="font-size: 12px;">Comment: </span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7086">...</a><br></div><div>Comment: Germany's Joint Federal Committee (GBA) issued a final assessment on Signifor (Novartis's  pasireotide) last week concluding that it provides only a "marginal degree of additional benefit" for patients with Cushing's disease for whom surgery has failed or is not an option.<wbr> Novartis will now negotiate a price with German's statuatory health insurance funds.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7190">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7086">View thread  Endocrinology7086: Cost Issues with Signifor for Cushing in Germany</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-10T11:15:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-10T11:15:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: NET-Nurses Europe Launches New Website E-Bulletin</title>
	<pubDate>2012-12-07T17:51:05+01:00</pubDate>
	<wp:post_id>3648</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NET-Nurses Europe Launches New Website E-Bulletin</span>&nbsp;<br><span style="font-size: 12px;">Comment: NET Nurses launched a new website and a new e-bulletin at the 
end of November, something we believe has the backing of Novartis.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7187">...</a><br></div><div style="margin-bottom: 10px;">This Net Nurses Europe website is an initiative from a British specialty nurse named Catherine Bouvier, specialized in NET management.<wbr> Catherine developed this website in the continuity of her initiative on raising neuro-endocrine tumors' awareness, and has been sponsored by <STRONG>Ipsen UK,</STRONG> Novartis, Pfizer, HRA Pharma, Delta.<wbr> ( <A href="http://www.netpatientfoundation.org/">http:/<wbr>/<wbr>www.<wbr>netpatientfoundation.<wbr>org/<wbr>)</A> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial, sans-serif; color: #222222; font-size: 13px;">At a corporate level, Ipsen has a dedicated action plan for Nurses in 2013, considering this specialty as a real stakeholder in the management of NET and pituitary disorders like Acromegaly.<wbr></SPAN> </div><div><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial, sans-serif; color: #222222; font-size: 13px;">Emilie Charlot on behalf of the Endocrinology Franchise</SPAN></DIV> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7189">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7187">View thread  Endocrinology7187: NET-Nurses Europe Launches New Website E-Bulletin</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-07T17:51:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-07T17:51:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novartis Has Started Ph1b of RAD001 in Chinese Patients with Advanced Pulmonary NET</title>
	<pubDate>2012-12-07T15:45:28+01:00</pubDate>
	<wp:post_id>3649</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis Has Started Ph1b of RAD001 in Chinese Patients with Advanced Pulmonary NET</span>&nbsp;<br><span style="font-size: 12px;">Comment: Clinicaltrials.<wbr>gov is listing a new open-label study, designed to collect safety/<wbr>tolerability data and explore the efficacy of RAD001 in advanced pulmonary neuroendocrine tumor in approx.<wbr> 20 patients.<wbr> Adverse events will be assessed as primary outcome measures.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=6244">...</a><br></div><div>Last month Novartis modified the completion dates to July 2015 from July 2013.<wbr> Also, three Novartis Investigator sites have been added : Changchun, Jilin; Shenyang, Liaoning; Beijing.<wbr> The number of patients is still expected to be nearly 20.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7188">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6244">View thread  Endocrinology6244: Novartis Has Started Ph1b of RAD001 in Chinese Patients with Advanced Pulmonary NET</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-07T15:45:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-07T15:45:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Comparison of Efficacy and Safety of Degarelix 1M Vs Goserelin in China</title>
	<pubDate>2012-12-07T15:06:20+01:00</pubDate>
	<wp:post_id>3650</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ferring-sponsored PhIII study which will evaluate degarelix 1M/<wbr>goserelin in nearly 280 Chinese patients with prostate cancer requiring androgen ablation therapy.<wbr> The PE will assess cumulative probability of testosterone at castrate level (≤0.<wbr>5 ng/<wbr>mL).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01744366?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=11%2F24%2F2012&amp;rank=72"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Dec 2012 - Completion: April 2014 (for PE) /<wbr> April 2015 </div><div style="margin-bottom: 10px;">Recruitment /<wbr> Inclusion Criteria : Patients should not have received previous hormonal treatment for prostate cancer.<wbr> </div><div><STRONG>Significance</STRONG>: Ferring expects to enter with degarelix1M in the hormone-naïve localized or locally advanced prostate cancer.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8897c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Feedback from Siew Kwan Chang has indicated that <SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Med.<wbr> Rep's in GuangZhou Hospital have reported that Ferring intend to have 15 cases from this hospital.<wbr></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8660">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-07T15:06:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-07T15:06:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Debiopharm Forms New Partnership With Dr Reddys</title>
	<pubDate>2012-12-07T14:58:21+01:00</pubDate>
	<wp:post_id>3651</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Debiopharm  has announced that Dr.<wbr> Reddy's 
Laboratories Ltd.<wbr> launched Pamorelin<B>®</B> LA in India for the treatment of locally advanced or 
metastatic, hormone-dependent prostate cancer on December 
3.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal With Debiopharm</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Dr.<wbr> Reddy's acquires 
exclusive marketing and sales rights for Pamorelin<B>®</B> LA Depot in India.<wbr> The product is exported in bulk 
from Debiopharm to Dr.<wbr> Reddy's.<wbr> Pamorelin<B>®</B> LA will be made 
available primarily to urologists and oncologists across India.<wbr> </div><div>Source: <a href="http://www.debiopharm.com" class="defaultlink" title="www.debiopharm.com">debiopharm.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8659">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-07T14:58:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-07T14:58:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PTC Therapeutics Seeks Conditional Approval For DMD Drug Based On PhII Data</title>
	<pubDate>2012-12-07T10:37:47+01:00</pubDate>
	<wp:post_id>3652</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left">Comment :The EMA has validated PTC Therapeutics MAA seeking 
conditional approval for ataluren, an investigational new drug for the treatment 
of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD).<wbr> We 
suspect this development will also pave the way for Sarepta Therapeutics to make 
a conditional filing as well.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Basis For The Validation By The EMA</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">A 48-week, 174-patient Phase 2b study showing that nmDMD 
patients treated with ataluren (10, 10, 20 mg/<wbr>kg given daily) walked on average 
31.<wbr>3 meters farther than patients on placebo, as measured by the change in 
six-minute walk distance (6MWD) from baseline to Week 48.<wbr> Patients receiving 
ataluren also demonstrated a slower rate of decline in ambulation, based on 
an analysis of time to 10percent worsening in 6MWD.<wbr> While 44 percent of patients 
receiving placebo declined 10 percent or more in walking as measured by the 
6-minute walk test (6MWT), only 26 percent of patients receiving ataluren 
declined 10 percent or more.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Safety results showed that ataluren was generally well tolerated 
and adverse events were similar to placebo.<wbr> Serious adverse events were 
infrequent and none were considered to be related to ataluren.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Commenting on this development, Dr.<wbr> Elizabeth Vroom, Chair, United 
Parent Project Muscular Dystrophy stated "We applaud PTC for its continued 
commitment to the DMD patient community and its comprehensive clinical 
development of ataluren.<wbr> There is an urgent need for new therapeutic options for 
the patients and families and the path to approval of a new therapy can be 
arduous.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Confirmatory PhIII To Support A Conditional 
Approval</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Alongside the statement about the EMA validatoin, PTC also 
announced the design of a confirmatory Phase 3 clinical trial of ataluren in 
patients with nmDMD that  is expected to be initiated in the first quarter 
of 2013.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">The primary objective of the multicenter,randomized, double-blind, 
placebo-controlled Phase 3 study is to confirm the ability of ataluren to slow 
disease progression as assessed by ambulatory ability based on the 6MWD in 
patients with nmDMD.<wbr> Secondary endpoints related to physical function and 
quality of life will also be assessed.<wbr> Approximately 220 patients are expected 
to be enrolled in this global study.<wbr> Further details concerning the study, 
including enrollment criteria, will be made available on <A href="http://www.clinicaltrials.gov">www.<wbr>clinicaltrials.<wbr>gov</A>.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Other Trials</STRONG></P> </div><div><P align="left">PTC also is currently conducting ongoing open-label safety and 
tolerability studies of ataluren for patients who were in previous ataluren 
clinical trials for nmDMD in both the United States and Europe.<wbr> The company has 
worldwide development and commercial rights for ataluren in all indications and 
territories.<wbr> Ataluren is also being developed for nonsense mutation cystic 
fibrosis and PTC is in discussions with regulators regarding next 
steps.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6677">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-07T10:37:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-07T10:37:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acino Name New Head Group Quality</title>
	<pubDate>2012-12-06T16:40:13+01:00</pubDate>
	<wp:post_id>3653</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Stefan Bier will be responsible for the Group-wide quality assurance and compliance in product development and at all manufacturing sites.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>PhD in Biochemistry, MSc in Chemistry, Saarland U.<wbr></LI>
<LI>German citizen, born 20.<wbr>7.<wbr>1968</LI>
<LI>&gt;20 years of experience in quality assurance and compliance with several pharma companies (Ferring and Sandoz).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Professional Background</U> </div><div><DIV class="csc-default" id="c3477">
<DIV class="csc-textpic-text">
<UL><LI><STRONG>2011 to 2012</STRONG> Senior Director Manufacturing Compliance with Ferring International Center S.<wbr>A.<wbr>, Saint-Prex, Switzerland 
</LI>
<LI><STRONG>2006 to 2011</STRONG> Region Head, Global Quality Assurance with Sandoz International, Holzkirchen, Germany 
</LI>
<LI>2005 to 2006 Quality Assurance Site Manager with Nextpharma, Waltrop, Germany 
</LI>
<LI>2002 to 2004 Process Development Specialist with Draxis Pharma Inc.<wbr>, Kirkland, Quebec, Canada 
</LI>
<LI>1999 to 2002 Technology Transfer Associate with Torcan Chemical Ltd.<wbr>, Aurora, Ontario, Canada</LI>
</UL></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=215">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T16:40:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T16:40:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Degarelix 80mg Vs Goserelin 3.6mg for the Treatment of Endometriosis Recurrence</title>
	<pubDate>2012-12-06T16:20:35+01:00</pubDate>
	<wp:post_id>3654</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01712763?term=Degarelix+Three-Month&amp;rank=7"><STRONG></STRONG></A></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">This PhIII is sponsored by the Center for Endocrinology and Reproductive Medicine in Italy, and is expected to recruit approx.<wbr> 100 women affected by the disease and showing recurrence of pain symptoms after surgery.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></P> </div><div style="margin-bottom: 10px;">Completion dates: Dec 2012 /<wbr> Oct 2013 </div><div><P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">PI: Marco Sbracia MD</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8653">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T16:20:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T16:20:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NET-Nurses Europe Launches New Website E-Bulletin</title>
	<pubDate>2012-12-06T15:56:24+01:00</pubDate>
	<wp:post_id>3655</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NET Nurses launched a new website and a new e-bulletin at the 
end of November, something we believe has the backing of Novartis.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7187_1_ScreenCapture1.jpg"> </div><div>The new nurse website can be accessed at <A href="http://www.netnurse.eu">www.<wbr>netnurse.<wbr>eu</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7189c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">This Net Nurses Europe website is an initiative from a British specialty nurse named Catherine Bouvier, specialized in NET management.<wbr> Catherine developed this website in the continuity of her initiative on raising neuro-endocrine tumors' awareness, and has been sponsored by <STRONG>Ipsen UK,</STRONG> Novartis, Pfizer, HRA Pharma, Delta.<wbr> ( <A href="http://www.netpatientfoundation.org/">http:/<wbr>/<wbr>www.<wbr>netpatientfoundation.<wbr>org/<wbr>)</A> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial, sans-serif; color: #222222; font-size: 13px;">At a corporate level, Ipsen has a dedicated action plan for Nurses in 2013, considering this specialty as a real stakeholder in the management of NET and pituitary disorders like Acromegaly.<wbr></SPAN> </div><div><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial, sans-serif; color: #222222; font-size: 13px;">Emilie Charlot on behalf of the Endocrinology Franchise</SPAN></DIV> </div></div><a name="endocrinology7187attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7187_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(164,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7187">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T15:56:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T15:56:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Q-Med Launches Legal Suit Claiming Medicis Deal Violates Licensing Agreement</title>
	<pubDate>2012-12-06T15:45:15+01:00</pubDate>
	<wp:post_id>3656</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Q-Med Launches Legal Suit Claiming Medicis Deal Violates Licensing Agreement</span>&nbsp;<br><span style="font-size: 12px;">Comment: Q-Med launched a suit in a New York federal court late last 
week to try and prevent Medicis from transfering marketing rights to its 
filler products Restylane, Perlane and Sub-Q to Valeant as part of the 
latters $2.<wbr>6bn purchase of Medicis.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6648">...</a><br></div><div>Just days before Valeant's acquisition of Medicis is due to complete, it is noted in Medicis 8k filing that the District Court for the Southern District of New York has dismissed Q-Med's case against Medicis.<wbr> The suit related to the transfer of rights of Restylane to Valeant.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6676">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6648">View thread  Neurology6648: Q-Med Launches Legal Suit Claiming Medicis Deal Violates Licensing Agreement</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T15:45:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T15:45:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Photocure Reports Positive PhIIb Results With Its PhotodynamicTherapy in HPV</title>
	<pubDate>2012-12-06T15:39:21+01:00</pubDate>
	<wp:post_id>3657</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Photcure reported yesterday the positive outcome of phIIb trial with 
its nenew drug delivery device and integrated light source as a treatment for 
HPV precancerous lesions of the cervix and is now looking to partner this 
product for future development.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8652_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8652_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8652_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8652attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8652_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(97,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8652_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(150,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8652_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(144,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8652">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T15:39:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T15:39:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Two Leading Drug Groups Aim To Halve The Cost Of Trials By 2017</title>
	<pubDate>2012-12-06T15:26:58+01:00</pubDate>
	<wp:post_id>3658</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : Both Roche and J&amp;J have stated their ambition to halve the 
costs of running clinical trials within 5 years.<wbr> </div><div style="margin-bottom: 10px;">Franz Humer (Chairman of Roche) is quoted in the FT as saying 
it should be possible to trim 30-50% off drug development costs through better 
co-ordination, design and implementation of clinical trials.<wbr> He argues in favour 
of a shift away from a "product to patient centred model" </div><div style="margin-bottom: 10px;">His views were also echoed by Joaquin Duato W/<wbr>W Chairman 
of Pharmaceuticals for J&amp;J who advocates "more intelligent clinical 
trial design" as having the potential to provide signficant 
efficiencies".<wbr> </div><div style="margin-bottom: 10px;">Both remarks were apparently made at the annual FT's Pharmaceutical 
Conference and came alongside the warning from Mr Humer that growth in 
emerging markets is unlikely to compensate for the slowdown in sales in 
industrialised countries and potential negative growth in Europe where he 
believes "there isn't one government or politician interested in the health of 
the industry".<wbr> </div><div>Source: FT December 5th </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10230">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T15:26:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T15:26:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Analysis of Clinical trial Activity Reveals Competitor Strategies</title>
	<pubDate>2012-12-06T13:28:37+01:00</pubDate>
	<wp:post_id>3659</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Citeline's analysis of industry-sponsored cancer trials started in the years 2004-2010 as captured in Trialtrove.<wbr> </div><div style="margin-bottom: 10px;">Overall, there was a slight increase (7%) in the number of industry-sponsored oncology trials started in 2010 versus 2004, with 1075 and 1007 trials, respectively.<wbr> This increase is driven solely by increased Phase I activity, as the number of Phase II and Phase III trials started actually diminished over that time period.<wbr> </div><div style="margin-bottom: 10px;">In most developed markets the overall change from 2004 to 2010 was unremarkable; the exception being Japan, with substantial increases in both the number of trials and percentage gain.<wbr> </div><div style="margin-bottom: 10px;">In low resources countries, a real gain in the number of trials started is seen in Poland, Ukraine, Romania, Russia, China, and India.<wbr> However, many countries experienced a decline over this time, with South Africa, Mexico, Argentina, and Brazil all host to fewer industry-sponsored oncology trials started in 2010 versus 2004.<wbr> </div><div style="margin-bottom: 10px;">In terms of analysis by company - for the five-year period, 2006-2010, AstraZeneca, Eli Lilly, Merck &amp; Co, and Sanofi have taken a fairly diversified approach with respect to low resource country selection; whereas Novartis, Pfizer, and Roche  have clear geographic areas of interest, namely China, Poland, and Russia.<wbr> </div><div style="margin-bottom: 10px;">Costs and ease of recruitment are the driving forces behind the movement of trials to low resource countries.<wbr> </div><div style="margin-bottom: 10px;">Citeline also hypothesize that one reason why the industry is trending toward trial activity in low resource countries is that, in oncology specifically, sponsors may be seeking treatment na&iuml;ve patients.<wbr> </div><div>Source: Scrip/<wbr>Citeline 4 December 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8651">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T13:28:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T13:28:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca to Cut Jobs in Germany</title>
	<pubDate>2012-12-06T11:25:10+01:00</pubDate>
	<wp:post_id>3660</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Citing the country's mandatory 16% drug rebates and pricing freeze, changes in the pharma's product portfolio and delays in R&amp;D, AstraZeneca has reported it plans to cut approx.<wbr> 400 (39%) to about 625 in Germany.<wbr> The company did not disclose how much it expects to save with the planned cuts.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The planned cuts would come from the pharma's sales force and internal support staff.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The country's increase in mandatory rebates to 16% from 6% and drug pricing freeze were enacted in 2010 to counteract financial difficulties of GKV, its public health insurance funds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>The company had reported a 19% year-on-year (y/<wbr>y) decline in its revenues in Q3 and a 21% y/<wbr>y fall in revenues in Q2.<wbr> The job cuts in Germany are, therefore not surprising and follows the announcement of planned 7,300 job cuts being implemented until 2014, as well as the 400 job cuts in Sweden in June.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10225">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-06T11:25:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-06T11:25:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Parabon NanoLabs Awarded NSF Grant for Prostate Cancer Drug Developed with Janssen R&D</title>
	<pubDate>2012-12-05T12:42:21+01:00</pubDate>
	<wp:post_id>3661</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Parabon NanoLabs, a nano-pharmaceutical company, has received a joint grant award from the National Science Foundation (NSF) for a project in collaboration with Janssen to support development of PJ-01, designed to deliver docetaxel specifically to prostate tumour cells.<wbr> The novel formulation, in PC development, aims to reduce side-effects as well as improve efficacy of docetaxel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Essemblix's "plug-and-play" molecular engineering makes it possible to create an enormous variety of multi-functional compounds.<wbr> </div><div style="margin-bottom: 10px;">Functional subcomponents of Essemblix compounds include: </div><div style="margin-bottom: 10px;"><UL><LI>cell-specific targeting agents </LI>
<LI>therapeutic payloads, such as small molecules or siRNA </LI>
<LI>imaging tracers; and, </LI>
<LI>precisely patterned antigens for eliciting strong immune response</LI>
</UL> </div><div>Detailed information @ <a href="http://www.parabon-nanolabs.com/nanolabs/therapeutics/" class="defaultlink" title="http://www.parabon-nanolabs.com/nanolabs/therapeutics/">parabon-nanolabs&hellip;.</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8640">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-05T12:42:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-05T12:42:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UniQure Licenses Benitec ddRNAI Gene-Silencing Technology for Huntington</title>
	<pubDate>2012-12-05T11:38:18+01:00</pubDate>
	<wp:post_id>3662</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: uniQure B.<wbr>V.<wbr>, a leader in the field of human gene therapy, has signed a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd.<wbr> giving uniQure access to Benitec's proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington's disease (HD).<wbr> Benitec’s licence covers the application of ddRNAi to target, and thereby silence, key genes identified as significant therapeutic targets in the treatment of the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In return, uniQure granted Benitec non-exclusive access to the Company's AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Profile</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Founded in 1997</LI>
<LI>Trading publicly since 2001 on the Australian Securities Exchange (ASX)</LI>
<LI>Deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Technology Platform</STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.benitec.com/rna-interference-rnai.php">http:/<wbr>/<wbr>www.<wbr>benitec.<wbr>com/<wbr>rna-interference-rnai.<wbr>php</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6674_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Partners</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6674_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology6674attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6674_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(65 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6674_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(56,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6674">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-05T11:38:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-05T11:38:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Increase Cost of Cancer Drug in Ireland</title>
	<pubDate>2012-12-05T11:03:17+01:00</pubDate>
	<wp:post_id>3663</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Director of Irelands' National Cancer Control Programme, Dr.<wbr> Susan O'Reilly has said that this year the cost of cancer drugs to hospitals in Ireland are expected to increase by almost 22%, reports <I>The Irish Times</I>.<wbr> Of note, the latest drug to be approved is Zytiga (which will be available from next week to a small group of men in late stages of prostate cancer that has spread to the bones).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According Dr.<wbr> O'Reilly, the cost of the top 10 oncology drugs in hospitals is expected to be EUR62.<wbr>5 million (USD 81.<wbr>7 million) in 2012, a 21.<wbr>6% year-on-year increase compared with the costs of EUR51.<wbr>4 million in 2011.<wbr> These additional costs include reserve of EUR3 million for Bristol-Myers Squibb's (US) Yervoy (ipilimumab) for malignant melanoma, the costs of which are expected to increase to EUR7 million in the coming year.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> O'Reilly noted that the high cost of oncology drugs was due to high failure rates.<wbr> Dr.<wbr> O'Reilly further added that the amount spent on oncology drugs by the country's healthcare system was moving towards EUR200 million per year from EUR150 million.<wbr> According to Dr.<wbr> O'Reilly, with a "properly funded cancer care programme", a 10% increase in the five-year survival rate for cancer patients could be achieved.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">While the above development by Dr.<wbr> O'Reilly shows that the value of more targeted cancer treatments with a smaller patient population are being recognised, however, given the current austerity programme, the costs of these drugs have to be considered.<wbr> </div><div style="margin-bottom: 10px;">However, given large-scale health reforms that are to be introduced in Ireland and since, according to the source, the number of people with cancer is expected to double to around 55,000 new cases annually, the government will potentially have to address the issue of the country's cancer care programme.<wbr> </div><div>Source: The Irish Times </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8639">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-05T11:03:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-05T11:03:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Study to Assess Acromegaly Treatment QoL</title>
	<pubDate>2012-12-04T19:13:26+01:00</pubDate>
	<wp:post_id>3664</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Study to Assess Acromegaly Treatment QoL</span>&nbsp;<br><span style="font-size: 12px;">Comment: Clinicaltrials.<wbr>gov is listing a new observational study sponsored by the Massachusetts General Hospital (MGH) in collaboration with Pfizer.<wbr> The objective of the trial is to investigate the effects of biochemical control of acromegaly by growth hormone (GH) receptor antagonism and somatostatin analogs in a large tertiary care pituitary referral center in the US.<wbr> Primary Endpoint will measure QoL.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7176">...</a><br></div><div><DIV class="im">
<P>Comment from the Endocrinology Franchise: This observational study conducted by Pfizer aims to demonstrate that the quality of life of the patients receiving pegvisomant (Somavert) is better than the one receiving somatostatin analogs or having active acromegaly.<wbr></P>
<P>Neggers and Van der Lely published already results of an interventional study showing that adding Somavert in SSA treated patients who are already controlled for IGF1 could further improve QOL.<wbr></P>
<P>Interesting also to note that Pfizer considers Pasireotide as a future direct competitor: this observational study by focusing on glycemic parameters (main secondary endpoints) will allow Pfizer to reinforce the well-known favorable effect of Somavert on glycemic parameters (Hyperglycemia is the main specific side effect from Pasireotide).<wbr></P>
<P>Interesting also to see that Pfizer invests in an observational study, as we do with SAGIT project.<wbr> </P>
<P>Harold Dumont on behalf of the Endocrinology Franchise.<wbr></P></DIV> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7184">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7176">View thread  Endocrinology7176: Study to Assess Acromegaly Treatment QoL</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-04T19:13:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-04T19:13:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Deloitte and Thomson Reuters Report on R&D</title>
	<pubDate>2012-12-04T18:19:12+01:00</pubDate>
	<wp:post_id>3665</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The report looks at the top 12 pharma companies globally, ranked by R&amp;D expenses.<wbr> </div><div style="margin-bottom: 10px;">The number of compound approvals has increased by approximately 30% in the last 12 months, the expected revenue has also declined by 30%.<wbr> This has resulted in the net value realized through product commercialization declining in over half of the 12 companies analyzed.<wbr> </div><div style="margin-bottom: 10px;">The analysts found some major pressure bearing down on drug prices, which has put a continuing squeeze on potential earnings.<wbr> </div><div style="margin-bottom: 10px;">The report  <STRONG><SPAN style="font-size: small;">Measuring the return from pharmaceutical innovation 2012 </SPAN></STRONG>can be downloaded from: </div><div><a href="http://www.deloitte.com/view/en_GB/uk/research-and-intelligence/deloitte-research-uk/deloitte-uk-centre-for-health-solutions/b47f30374ca4b310VgnVCM2000003356f70aRCRD.htm" class="defaultlink" title="http://www.deloitte.com/view/en_GB/uk/research-and-intelligence/deloitte-research-uk/deloitte-uk-centre-for-health-solutions/b47f30374ca4b310VgnVCM2000003356f70aRCRD.htm">deloitte.com/<wbr>view&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10224">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-04T18:19:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-04T18:19:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hexapeptide-8 is Safe for Extending Duration of BoNT for Blepharospasm (BSP)</title>
	<pubDate>2012-12-04T13:44:03+01:00</pubDate>
	<wp:post_id>3666</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The conclusion, from a pilot study in 24 patients, indicates that topical hexapeptide-8 is promising for extending the duration of action of BoNT therapy for BSP.<wbr> Additional results are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="cit" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 0.84em/1.45em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed/23146065?dopt=Abstract#" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px" title="European journal of neurology : the official journal of the European Federation of Neurological Societies.">Eur J Neurol.<wbr></A> 2012 Nov 12.<wbr> doi: 10.<wbr>1111/<wbr>ene.<wbr>12009.<wbr> [Epub ahead of print]</DIV> </div><div style="margin-bottom: 10px;"><H1 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0.37em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 1.23em/1.12em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy.<wbr></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: 0.92em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: normal; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 0.84em/1.09em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<H3 class="label" style="BORDER-BOTTOM: 0px; POSITION: absolute; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.2857; MARGIN: 1.28em 0px 0.64em; PADDING-LEFT: 0px; WIDTH: 1px; PADDING-RIGHT: 0px; HEIGHT: 1px; COLOR: rgb(114,65,40); FONT-SIZE: 1.07em; VERTICAL-ALIGN: baseline; OVERFLOW: hidden; BORDER-TOP: 0px; TOP: auto; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px; LEFT: -10000px">Source</H3>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Office of the Clinical Director, NINDS, NIH, Bethesda, MD, USA.<wbr></P></DIV> </div><div style="margin-bottom: 10px;"><DIV class="abstr" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 1.2em auto auto; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">BACKGROUND AND PURPOSE:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Injectable botulinum neurotoxin (BoNT) is the principal effective treatment for blepharospasm (BSP).<wbr> This trial explores the safety and efficacy of topical acetyl hexapeptide-8 (AH8), a competitive SNAP25 inhibitor, as a potential new therapy in BSP.<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">METHODS:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP.<wbr> The primary outcome was time to return to baseline Jankovic Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8.<wbr> Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included.<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">RESULTS:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">There were no significant adverse events.<wbr> There was a trend for longer time until return to baseline JBRS after injection in the active group compared to placebo (3.<wbr>7 months vs.<wbr> 3.<wbr>0 months), and for better scores in the active group.<wbr> One-third (4/<wbr>12) of the patients in the active group had a considerable extension of symptom control after BoNT (range: 3.<wbr>3-7.<wbr>1 months).<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">CONCLUSIONS:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Topical AH8 is safe and promising for extending the duration of action of BoNT therapy for BSP.<wbr></P></DIV> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=4468" class="defaultlink">Neurology4468: AH8 As A Potentiator of BoNT</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6672">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-04T13:44:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-04T13:44:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NDA Filing For Tivozanib Accepted By FDA</title>
	<pubDate>2012-12-03T16:57:03+01:00</pubDate>
	<wp:post_id>3667</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8634">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-03T16:57:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-03T16:57:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Report Highlights Problems of High German Drug Prices</title>
	<pubDate>2012-12-03T16:28:30+01:00</pubDate>
	<wp:post_id>3668</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The latest Drug Prescription Report (AVR), which is published every year and contains data from the prescriptions issued to the account of the Association of Statutory Health Insurance Funds (GKV), shows that the prices of medicines in Germany are, on average, 30% higher than in the Netherlands, reports private-krankenversicherung.<wbr>de.<wbr> </div><div style="margin-bottom: 10px;">The source added that in some cases, the differences are as high as 71%, pointing out that the pharmaceutical industry prefers to contend that it is not possible to compare prices of medicines in different countries, since it is necessary to take a number of considerations which vary from country to country, including pharmacists' fees, mandatory discounts and the average size of packages sold.<wbr> </div><div style="margin-bottom: 10px;">In particular, the prices of generics are reported to be much higher in Germany than in the Netherlands – on average by as much as 42%.<wbr> The main reason for the disparity is said by the authors of the report to be the fact that Germany was very late in starting to control the prices of new medicines coming to the market – this only began in 2011, under the Pharmaceutical Market Restructuring Act (AMNOG).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">While there are indeed a number of mandatory discounts in place in Germany, which do not affect a drug's list price, but mean that it is cheaper for the GKV and the patient, the fact remains that prices in Germany are still considerably higher than in many other European countries.<wbr> </div><div style="margin-bottom: 10px;">Indeed, since it has only been a fairly short time since price regulation was brought in for new medicines – and even now, in the first year of marketing, their prices remain unregulated – it can be expected that it will take a fairly long time until the legislation introduced in the AMNOG will have the effect of bringing prices in Germany more into line with neighbouring countries.<wbr> It would appear likely, too, that additional legislation will be proposed to speed up this process.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10221">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-03T16:28:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-03T16:28:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Everolimus Plus Octreotide LAR in Patients With Advanced Lung NETs</title>
	<pubDate>2012-12-03T14:49:40+01:00</pubDate>
	<wp:post_id>3669</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Conclusion of the subgroup analysis of the Ph3, randomized, placebo-controlled RADIANT-2 study indicates that in patients with advanced lung NET, the addition of everolimus to octrotide LAR improves median PFS by 2.<wbr>4 fold compared with placebo plus octreotide LAR.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><H1 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0.37em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 1.23em/1.12em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></H1> </div><div style="margin-bottom: 10px;">Fazio N<SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">, </SPAN>Granberg D<SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">, </SPAN>Grossman A<SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">, </SPAN>Saletan S<SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">, </SPAN>Klimovsky J<SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">, </SPAN>Panneerselvam A<SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">, </SPAN>Wolin EM<SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px/16px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"> </div><div><STRONG></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8633">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-03T14:49:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-03T14:49:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Top 10 Takeaways from the 5th Annual World Generic Medicines Conference</title>
	<pubDate>2012-12-03T12:14:16+01:00</pubDate>
	<wp:post_id>3670</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analysts at Canaccord have detailed their top 10 takeaways from presentations, discussions and meetings.<wbr> The "industry" was well represented with leadng manufacturers such as Watson, Momenta, Hikma, Sandoz, Hopira among a host of others.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">1.<wbr> Biosimilars and what type of penetration opportunities to expect – the biggest source of debate between payers, manufacturers and drug store executives in attendance.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>There was clear debate on what type of penetration rates we’ll see from generic biologics (interchangeability a big unknown) and what generic manufacturers are going to have to do to drive that penetration.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
2.<wbr> Growing concern we’ll see “authorized biologics” to impede generics – most are pointing to TEVA’s Tbo-filgrastim launch in Sept.<wbr> 2013 (under BLA) as key to watch.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Concern that the biotech industry will launch lower priced versions of its own brands early intending to create a road block for biosimilars by way of adoption and profit opportunity.<wbr> </LI>
<LI>There are several strategies expected from the brand side but this one got a lot of discussion.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
3.<wbr> Industry consensus that more M&amp;A is coming – no slowdown in pace expected.<wbr> Several companies proactively brought up the need for more deals, citing: </div><div style="margin-bottom: 10px;"><UL><LI>an interest in expanding geographies (South America, Eastern Europe and Asia consistent); </LI>
<LI>a focus on technology and a sense that we may see more “mid-size” deals going forward; and </LI>
<LI>no change in the “partnering” strategy around biosimilars, as most are still uncomfortable making a big bet on an undefined opportunity.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
4.<wbr> Injectables seem to be the “hot” space right now for potential M&amp;A.<wbr> </div><div style="margin-bottom: 10px;">5.<wbr> Industry concerns on perceptions of quality and interchangeability – this will come into play in getting physicians and patients comfortable with biosimilars.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The discussion really focused on consumer perception of generic products ahead of a broader biosimilar market opportunity.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
6.<wbr> Foreign site inspections likely to pick up – widely discussed on the heels of Ranbaxy’s generic Lipitor recall.<wbr> Supplier relationships are key as ~80% of API comes from abroad.<wbr> </div><div style="margin-bottom: 10px;">7.<wbr> Congressman Waxman laid out his priorities – biologics still at the top.<wbr> </div><div style="margin-bottom: 10px;">8.<wbr> FDA backlog already shrinking and this will continue under GDUFA – secondary market for old ANDA files formed.<wbr> </div><div style="margin-bottom: 10px;">9.<wbr> FTC is still focused on pay-for-delay deals but REMS, citizen petitions and product hopping are also high on the priority list.<wbr> </div><div style="margin-bottom: 10px;">10.<wbr> Is Sub-Saharan Africa the “next” India or China? Unclear but market is potentially big.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Mylan has a growing business in South Africa (driven by its antiretroviral products).<wbr> </LI>
<LI>Africa is a big market with ~ 1.<wbr>1 billion people (50% under 30 years of age), estimated pharma market of $23 billion in 2020 and improving business environment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
Source: Canaccord - 12022012 - <EM>Our Top 10 Takeaways from the World Generic Medicines Conference.<wbr></EM> </div><div><STRONG></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10218">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-03T12:14:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-03T12:14:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Survey Supports High Pancreatic Expectations for Celgene's Abraxane</title>
	<pubDate>2012-12-03T11:43:10+01:00</pubDate>
	<wp:post_id>3671</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The ICI Survey includes feedback fom 98 medical oncologists, who in average have reported treating 15 pts with pancreatic cancer in the past 90 days.<wbr> Bottom line highlight big potential for the drug given limited current treatment options.<wbr> Key figures are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current status</STRONG> </div><div style="margin-bottom: 10px;">Top-line Ph3 results in November 2012 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8592" class="defaultlink">Oncology8592: A Breakthrough Development In Pancreatic Cancer</a>).<wbr> </div><div style="margin-bottom: 10px;">Full Ph3 data at ASCO in January 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">As of July, 18% of surveyed medical oncologists identified Abraxane as a new treatment strategy for pancreatic cancer that would be likely to lead to improved patient outcomes.<wbr> </div><div style="margin-bottom: 10px;">More than 70% of front-line pancreatic patients receive chemotherapy and approx.<wbr> 30% of 2nde-line patients receive chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8630_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">- Gemzar single agent is the dominant front-line therapy wth 39% share.<wbr> </div><div style="margin-bottom: 10px;">- Gemzar + Tarceva is the second most preferred regimen with 22% share.<wbr> </div><div style="margin-bottom: 10px;">- Assuming a meaningful Abraxane OS benefit is validated with full data publication at ASCO in January, analysts assume 70%+ peak penetration.<wbr> </div><div style="margin-bottom: 10px;">Source: Baird 12032012 - <EM>Survey Supports High Abraxane Pancreatic Expectations</EM> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="oncology8630attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8630_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8630">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-03T11:43:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-03T11:43:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Report On Drug Development Costs & Timelines</title>
	<pubDate>2012-12-03T10:16:31+01:00</pubDate>
	<wp:post_id>3672</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A new AstraZeneca sponsored report compiled by the Office of Health Economics, estimates that the cost of developing a new drug has risen to &pound;1.<wbr>25bn.<wbr> </div><div style="margin-bottom: 10px;">The new estimate calculated using a different methodology to previous reports cites a figure that lies between two sided-quoted previous US academic studies that placed the cost in 2011 at $1bn and $1.<wbr>9bn respectively.<wbr> </div><div style="margin-bottom: 10px;">The study suggests that longer development times and lower success rates have pushed costs high particularly in terms of the development of  neurology, respiratory and oncology therapies.<wbr> </div><div style="margin-bottom: 10px;">It also suggests cost of capital is around 11%, out-of pocket costs for companies has risen to  $220m, the average duration of clinical trials in humans before regulatory approval is 6.<wbr>5 years and success rates in late-stage trials around 50-71%.<wbr> </div><div style="margin-bottom: 10px;">Access to the 100 page report can be found through the following link:- </div><div>Source: <a href="http://ohematerials.org/NMECost/RD_READ/index.html#/0" class="defaultlink" title="http://ohematerials.org/NMECost/RD_READ/index.html#/0">ohematerials.org/<wbr>&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10217">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-12-03T10:16:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-12-03T10:16:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Reports 2011/12 Financial Results</title>
	<pubDate>2012-11-30T17:01:29+01:00</pubDate>
	<wp:post_id>3673</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company reported an increase of 17% in Group revenue to €913.<wbr>1M (vs €780.<wbr>4M).<wbr> The international business as well as the aesthetics business (with revenue growing by 35.<wbr>8%) 'become important drivers for growth'.<wbr> Key figures are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Memantine was the main source of revenue with a gorwth of 22% (to almost €1.<wbr>7billion in the year).<wbr> </div><div style="margin-bottom: 10px;">No precise information was reported on Xeomin except that "Merz was able to expand its position with Xeomin®, a drug for treating neurologically induced movement disorders".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This business unit generted revenue of €154.<wbr>6M (prior year: €113.<wbr>8M).<wbr> </div><div style="margin-bottom: 10px;">Revenues of Radiesse increased by 25% vs previous year.<wbr> </div><div style="margin-bottom: 10px;">Revenues generated by Bocouture "almost doubled vs previous year".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">42.<wbr>6 % of Merz` business was generated in North America (USA, Canada).<wbr> </div><div style="margin-bottom: 10px;">Asia (up 49 %) and Russia (up 29 %) are the fastest growing country businesses.<wbr> </div><div style="margin-bottom: 10px;">The European subsidiaries in Italy, Spain and Switzerland also recorded significant improvements in sales revenue.<wbr> </div><div style="margin-bottom: 10px;">In Germany, sales revenue dropped by 4.<wbr>8 %, sliding from EUR 163.<wbr>0 million to EUR 155.<wbr>1 million.<wbr> </div><div style="margin-bottom: 10px;">Less than one fifth of Group revenues was generated in the German market in the reporting period.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">€125.<wbr>3M vs €133.<wbr>4M (prior year).<wbr> </div><div>Source: Merz </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6667">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-30T17:01:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-30T17:01:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Euroscreen Raises €10M in Equity to Advance its Endometriosis Programme</title>
	<pubDate>2012-11-30T10:49:08+01:00</pubDate>
	<wp:post_id>3674</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The proceeds will be primarily used to fund the pre-IND, Ph1 and initial Ph2 clinical development of ESN364, a NK3 antagonist.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Preclinical data had demonstrated that ESN-364 offered a superior potency and preliminary safety profile when compared to competing agents.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Mid 2013 - Filing of IND with US FDA</LI>
<LI>
End 2013 - Start of Ph1 clinical trial</LI>
<LI>
2014 - POC studies</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Private Belgian, preclinical-stage, Drug Discovery and Development Company targeting G-Protein-Coupled-Receptors (GPCRs) </div><div style="margin-bottom: 10px;">- Pipeline </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8627_3_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8627_2_ScreenCapture2.jpg"> </div><div>Source: Euroscreen; TPP; </div><!-- Comment details --><a name="oncology8627attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8627_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8627_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(651 B)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8627_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(88,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8627">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-30T10:49:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-30T10:49:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves Cabozantinib For Medullary Thyroid Cancer</title>
	<pubDate>2012-11-30T10:42:52+01:00</pubDate>
	<wp:post_id>3675</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Comment: Yesterday the FDA approved Exelixis's NDA </SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">for Cometriq cabozantinib to treat progressive, metastatic medullary thyroid cancer (MTC).<wbr> Exelixis plans to launch this VEGFR2/<wbr>c-Met tyrosine kinase</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> in early January.<wbr> It represents an important milestone for the group as it will be its first commercialised product.<wbr> Its revenue potential in this indication, however is small relative to what it might generate in other indications such as CRPC.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>Pricing</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The wholesale acquisition cost will be $9,900 for a 28-day supply.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>European Situation</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Separately, EMA accepted for review an MAA for Cometriq to treat progressive, unresectable, locally advanced or metastatic MTC.<wbr> Cometriq has Orphan Drug status for MTC.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>Key Competitors</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The only other FDA-approved drug for MTC is </SPAN>Caprelsa<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> vandetanib from AZ</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> which has the same WAC.<wbr> FDA approved Caprelsa with a REMS something that Cometriq does not have.<wbr> AstraZeneca reported revenues of $19 million for Caprelsa for the first nine months of 2012.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font-style: normal; font-variant: normal; font-size: 13px; line-height: normal; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; display: inline !important;">Market Size &amp; Commercialisation Plans</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font-style: normal; font-variant: normal; font-size: 13px; line-height: normal; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; display: inline !important;">Exelixis estimates that  there are between 500 and 700 drug eligible first and second line metastatic MTC patients in the US and a similar number in Europe.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font-style: normal; font-variant: normal; font-size: 13px; line-height: normal; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; display: inline !important;">It will use an outsourced sales team of five individuals to market the product in the US, but there are plans to create an internal team.<wbr> No further information was provided about European commercialisation plans.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font-style: normal; font-variant: normal; font-size: 13px; line-height: normal; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; display: inline !important;">Other Indications</SPAN></STRONG> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">FDA clearance for cabozantinib also has implications for other disease areas as the drug is also in phIII developedment for prostate cancer (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8580" class="defaultlink">Oncology8580: Exelixis - Expands Development Plans For Cabozantinib in CRPC</a>) and shown promising efficacy in HCC (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8459" class="defaultlink">Oncology8459: Exelixis- Update On Pipeline Progress</a>).<wbr> </SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7180">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-30T10:42:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-30T10:42:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck Withdraws Oral mTOR Inhibitor Drug in EU</title>
	<pubDate>2012-11-30T10:31:02+01:00</pubDate>
	<wp:post_id>3676</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has pulled its application seeking EU approval of ridaforolimus as a maintenance treatment for patients with soft tissue sarcoma or primary bone tumour as the EMA' CMPHU determined that the available data were not sufficient for approval.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Last year, at its R&amp;D Day, Merck reported its mTOR inhibitor has a tolerability profile similar to other mTOR inhibitors, with the most common AEs being stomatis and mouth ulcers (which can be easily treated with palliative medicines).<wbr> </div><div>The company will continue to study ridaforolimus in combination with other treatments for additional tumour types.<wbr> Of note, ridaforolimus + AKT inhibitor (MK-2206) for HRPC.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8626">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-30T10:31:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-30T10:31:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer and Leiden U. to Explore Novel Concept in Modern Drug Discovery (DD)</title>
	<pubDate>2012-11-29T17:27:34+01:00</pubDate>
	<wp:post_id>3677</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new 5-year project of the newly founded international consortium (K4DD: Kinetics dor Drug Discovery) will focus on 'optimizing binding kinetics' for drug candidates with the goal to improve drug design.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Kinetic aspects of drug-target interactions can routinely be studied in robust and accessible assays for all main drug target classes within and outside the consortium.<wbr> </div><div style="margin-bottom: 10px;">‘Kinotypic’ knowledge should guide the identification and optimization process of drug candidates in the early phases of drug discovery in the future.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The consortium is financially supported with €20M by Europe's Innovative Medicines Initiative (IMI).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>IMI is the world’s largest public-private partnership in health.<wbr> </LI>
<LI>IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Coordinator: Dr Anke Müller-Fahrnow, VP and Head of Lead Discovery Berlin at Bayer Healthcare Drug Discovery.<wbr> </div><div>Academic Lead: Prof.<wbr> Ad P.<wbr> IJerman, professor of medicinal chemistry at the Leiden/<wbr>Amsterdam Center for Drug Research of Leiden University.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10213">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-29T17:27:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-29T17:27:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Management Appointments in Dermatology/Aesthetics at Valeant</title>
	<pubDate>2012-11-29T14:10:01+01:00</pubDate>
	<wp:post_id>3678</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Changes will be effective on December 11th, upon the close of Valeant's acquisition of Medicis.<wbr> Below is the detail of the four people concerned by the reorganization.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG><U>R.<wbr> Weldon</U></STRONG> will assume the role of Ex VP/<wbr>Company Group Chairman where he will lead the US Dermatology Operations (including prescription dermatology, aesthetics and podiatry).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>Joined Valeant in 2008.<wbr> </P>
<P>Has served as VP &amp; GM, Aesthetics since Dec 2011</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG><U>J.<wbr> Hanson</U></STRONG> will relocate to N-Jersey where he will assume the role of Ex VP/<wbr>Company Group Chairman and lead certain US and international Businesses and functions (to be named later).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>Joined Medicis in 2006.<wbr> </P>
<P>Has served as Ex VP, COO of Medicis since July 2010</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG><U>Vince Ippolito</U></STRONG> will be appointed Sr VP, GM, Aesthetics.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>Has been with Medicis for 10 years.<wbr> Prior to joining Medicis, he was employed by Novartis.<wbr> </P>
<P>Has served as Ex VP, S&amp;M</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG><U>Justin Smith</U></STRONG> will be appointed Sr VP, GM US Rx Dermatology.<wbr></LI>
</UL> </div><div><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>Has been with Medicis for 15 years.<wbr> </P>
<P>Has served as Sr VP Marketing for both dermatology and aesthetic products.<wbr></P></BLOCKQUOTE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10210">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-29T14:10:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-29T14:10:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Observational Study of Ferring's Degarelix to Describe Distribution of CaP Stages in France</title>
	<pubDate>2012-11-29T11:13:41+01:00</pubDate>
	<wp:post_id>3679</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The main objective of the FACT STUDY is to describe the distribution of prostate cancer stages when 1st-line hormonal therapy is introduced.<wbr> PE will evaluate the estimated percentage of different prostate cancer stages (overall and by region).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Heterogeneous distribution of the risk of mortality from prostate cancer according to region.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01729676?term=fact+study&amp;rank=2"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Secondary Endpoints: </div><div style="margin-bottom: 10px;"><UL><LI>the characteristics of the patients with prostate cancer by region</LI>
<LI>the influence of regional factors on staging of prostate cancer</LI>
</UL> </div><div style="margin-bottom: 10px;">Recruitment: apprrox.<wbr> 300 men (&gt;18 years) never previously treated with hormononal therapy for prostate cancer </div><div>Start date: Dec 2012 - Completion date: Oct 2013 /<wbr> Dec 2013 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8624">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-29T11:13:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-29T11:13:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: COMP at the EMA Recommended Somatoprim for Designation as Orphan Medical Product for Acromegaly</title>
	<pubDate>2012-11-29T10:04:14+01:00</pubDate>
	<wp:post_id>3680</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">COMP at the EMA Recommended Somatoprim for Designation as Orphan Medical Product for Acromegaly</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Committee for Orphan Medicinal Products at the European Medicines Agency has issued a positive opinion on an application for orphan medicinal product status for Aspireo’s Somatoprim (DG3173) for the treatment of acromegaly.<wbr> The positive opinion and recommendation has been forwarded to the European Commission for approval.<wbr> The designation would grant Aspireo 10 years of marketing exclusivity in the EU upon obtaining market authorization as an orphan medicinal product.<wbr> In addition, Aspireo would benefit from reduced regulatory fees.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7177">...</a><br></div><div>This article triggers one question outside of this consideration but link with patent extension concept : could we have a specific protection extension by generating some data in the paediatric field for Somatuline ? </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7179">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7177">View thread  Endocrinology7177: COMP at the EMA Recommended Somatoprim for Designation as Orphan Medical Product for Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-29T10:04:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-29T10:04:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: COMP at the EMA Recommended Somatoprim for Designation as Orphan Medical Product for Acromegaly</title>
	<pubDate>2012-11-28T19:13:41+01:00</pubDate>
	<wp:post_id>3681</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">COMP at the EMA Recommended Somatoprim for Designation as Orphan Medical Product for Acromegaly</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Committee for Orphan Medicinal Products at the European Medicines Agency has issued a positive opinion on an application for orphan medicinal product status for Aspireo’s Somatoprim (DG3173) for the treatment of acromegaly.<wbr> The positive opinion and recommendation has been forwarded to the European Commission for approval.<wbr> The designation would grant Aspireo 10 years of marketing exclusivity in the EU upon obtaining market authorization as an orphan medicinal product.<wbr> In addition, Aspireo would benefit from reduced regulatory fees.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7177">...</a><br></div><div>From the Endocrinology Franchise: This product is part of our radar screen and assumptions are that it could not be on the market before 2017.<wbr> The Proof of concept study described in the Aspireo press release ( CI 6 Nov 2012) is very unclear in terms of study design and no further information can be found in the public domain except that it is performed in Ukraine.<wbr> The status of orphan drug announced above has probably been granted on the fact that this SSA targets the receptors SSTR4.<wbr> For information, all recent drugs developed  in acromegaly have this status ( such as somavert, pasireotide.<wbr>.<wbr>)   However this status does not accelerate the time to come to the market and then does not challenge our first assumptions.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7178">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7177">View thread  Endocrinology7177: COMP at the EMA Recommended Somatoprim for Designation as Orphan Medical Product for Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-28T19:13:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-28T19:13:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>US Specialty Pharmaceutical Spending Increased by 22.6% Y/Y Mainly Driven By Cost Increases</title>
	<pubDate>2012-11-28T15:34:07+01:00</pubDate>
	<wp:post_id>3682</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Express Scripts <I>2012 Q3 Drug Trend Quarterly </I>reviews year-to-date and quarter-over-quarter changes in national drug spending for all major therapy classes.<wbr> Its latest publication is the first to reflect the combined data of both Express Scripts and Medco.<wbr> According to its Prescription Price Index, prices on a market basket of the most highly utilized brand-name medications increased 13.<wbr>3 percent from September 2011 to September 2012, far outpacing the overall economic inflation level of 2.<wbr>0 percent.<wbr> During the same timeframe, prices of generic medications declined 21.<wbr>9 percent.<wbr> </div><div style="margin-bottom: 10px;">This 35.<wbr>2 percentage point net inflationary effect is the largest widening of brand and generic prices since Express Scripts began calculating its Prescription Price Index in 2008.<wbr> </div><div style="margin-bottom: 10px;"><B>Drivers of Traditional Drug Trend </B> </div><div style="margin-bottom: 10px;">During the first three quarters of 2012, spending on traditional medications decreased 0.<wbr>6 percent over the same period in 2011, primarily driven by lower prices brought on by increased use of generic medications.<wbr> </div><div style="margin-bottom: 10px;">The top traditional therapy class is mental and neurological disorders (including antidepressants), which now consumes 24.<wbr>7 percent of all traditional drug spend.<wbr> Although use of these medications has increased 3.<wbr>1 percent compared to the first three quarters of 2011, total spending in this class is down 1.<wbr>9 percent due to newly available generic antidepressants and antipsychotics.<wbr><BR> </div><div style="margin-bottom: 10px;">Total spending on medications to treat high blood pressure and high cholesterol decreased 7.<wbr>7 percent, primarily driven by the continued impact of patent expirations for blockbuster drugs.<wbr><BR> </div><div style="margin-bottom: 10px;"><B>Drivers of Specialty Drug Trend </B> </div><div style="margin-bottom: 10px;">Specialty drug trend continues its year-over-year double-digit growth.<wbr> During the first three quarters of 2012, spending on specialty medications increased 22.<wbr>6 percent over the same period in 2011, primarily driven by unit cost increases.<wbr> In the first nine months of 2012, specialty drug costs consumed 20.<wbr>8 percent of total pharmacy spend.<wbr> </div><div style="margin-bottom: 10px;">"The continued rise in spend on specialty medications underscores the nation's need to accelerate the pathway for biosimilars," Dr.<wbr> Miller said.<wbr> "Additional competition within these therapy classes would provide a necessary market control against price inflation.<wbr>" </div><div style="margin-bottom: 10px;">The three therapy classes representing the largest amount of specialty drug spend continue to be rheumatoid arthritis/<wbr>autoimmune conditions, multiple sclerosis and cancer.<wbr> </div><div style="margin-bottom: 10px;">Medications commonly used to treat hepatitis C continue to have the largest specialty spend increase, 117.<wbr>3 percent over the same period in 2011.<wbr> Increased utilization is driving this trend, as new patients begin and continue treatment with one of two new medications.<wbr> </div><div style="margin-bottom: 10px;">Eight of the nine notable new medications approved in the third quarter are specialty medications.<wbr> Many of these medications are second-line and third-line drugs indicated to treat advanced cancers.<wbr> </div><div>The complete <A href="http://digital.turn-page.com/i/95262" target="_blank"><I>Drug Trend Quarterly</I></A> is available at DrugTrendReport.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10207">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-28T15:34:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-28T15:34:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Breakthrough Results In Pivotal Trial For PD Psychosis</title>
	<pubDate>2012-11-27T18:49:16+01:00</pubDate>
	<wp:post_id>3683</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acadia has today announced that its pivotal phIII study with 
pimvanserin has met key primary and secondary endpoints in its Parkinson's 
disease psychosis trial.<wbr> Based on this data and a confirmatory trial pimvanserin 
has the potential to be the first drug approved to treat PD Psychosis.<wbr> Acadia 
currently retains full commercialisation rights for pimvanserin.<wbr> </div><div style="margin-bottom: 10px;">Pimavanserin is ACADIA’s proprietary, non-dopaminergic product candidate that 
selectively blocks serotonin 5-HT<SUB>2A</SUB> receptors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key PhIII Data</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Pimavanserin met the primary endpoint in the Phase III trial by demonstrating 
highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD 
scale (p=0.<wbr>001).<wbr> Pimavanserin also met the key secondary endpoint for motoric 
tolerability as measured using Parts II and III of the Unified Parkinson’s 
Disease Rating Scale, or UPDRS.<wbr> These results were further supported by a highly 
significant improvement in the secondary efficacy measure, the Clinical Global 
Impression Improvement, or CGI-I, scale (p=0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">In addition, clinical benefits were observed in all exploratory efficacy 
measures with significant improvements in nighttime sleep, daytime wakefulness 
and caregiver burden.<wbr> Consistent with previous studies, pimavanserin was safe 
and well tolerated in this Phase III trial.<wbr> </div><div style="margin-bottom: 10px;">Consistent with previous studies, pimavanserin was safe and well tolerated in 
this trial.<wbr> Based on a preliminary analysis of safety data, the most common 
adverse events were urinary tract infection (11.<wbr>7% PBO vs.<wbr> 13.<wbr>5% PIM) and falls 
(8.<wbr>5% PBO vs.<wbr> 10.<wbr>6% PIM).<wbr> Adverse events were generally characterized as mild to 
moderate in nature.<wbr> The only serious adverse events that occurred in more than 
one patient were urinary tract infection (1-PBO vs.<wbr> 3-PIM) and psychotic 
disorder (0-PBO vs.<wbr> 2-PIM).<wbr> Ninety percent of the patients who completed the 
clinical phase of this trial elected to roll over into the ongoing open-label 
safety extension study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How Important Is This Data?</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the data Jeffrey Cummings, M.<wbr>D.<wbr>, Sc.<wbr>D.<wbr>, Director of 
the <ORG>Cleveland Clinic Lou Ruvo Center for Brain Health 
</ORG>stated “These data represent an unprecedented advance for Parkinson’s 
patients who suffer from the psychosis frequently associated with this disease.<wbr> 
The results of this study suggest that a selective, non-dopaminergic-based 
therapy has the potential to transform the treatment landscape for patients with 
this debilitating disorder.<wbr>” </div><div style="margin-bottom: 10px;">He noted that among Parkinson’s patients, psychosis is the leading cause of 
institutionalization and dramatically increases the risk of mortality.<wbr> 
Neurologists have limited options to treat this serious disorder, and off-label 
use of current antipsychotics is linked to increased risk of death and serious 
adverse events, as well as loss of motor control.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_5_ScreenCapture5.jpg"></STRONG> </div><div>Source: <A href="http://www.acadia.com">www.<wbr>acadia.<wbr>com</A> </div><!-- Comment details --><a name="neurology6666attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(202,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(138,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(163,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(108,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6666_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(98,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6666">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-27T18:49:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-27T18:49:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Allergan Publication: Cell-based Assay to Replace the Mouse Bioassay</title>
	<pubDate>2012-11-27T14:41:01+01:00</pubDate>
	<wp:post_id>3684</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Publication of the alternate assay used by Allergan.<wbr> </div><div style="margin-bottom: 10px;">Thanks to Michel Auguet  for his comments   'First publication (to my knowledge) on the alternate method used by Allergan.<wbr> Note the use of antibody against cleaved SNAP25 in this paper' </div><div style="margin-bottom: 10px;">This is an open access article published on 21 November 2012 </div><div><a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0049516" class="defaultlink" title="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0049516">plosone.org/<wbr>artic&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6663">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-27T14:41:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-27T14:41:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Effectiveness and Safety of BOTOX in SCI Patients with UI Due to NDO</title>
	<pubDate>2012-11-27T13:09:45+01:00</pubDate>
	<wp:post_id>3685</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In this Ph2 EDR trial of spinal cord injury (SCI) patients with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO), conclusion shows that the 200U was the most effective dose.<wbr> The AE profile was comparable across all groups.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="cit" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 0.84em/1.45em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed/23160758?dopt=Abstract#" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px" title="World journal of urology.">World J Urol.<wbr></A> 2012 Nov 18.<wbr> [Epub ahead of print]</DIV> </div><div style="margin-bottom: 10px;"><H1 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0.37em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 1.23em/1.12em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.<wbr></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: 0.92em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: normal; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Apostolidis%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23160758" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Apostolidis A</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Thompson%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23160758" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Thompson C</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Yan%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23160758" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Yan X</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Mourad%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23160758" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Mourad S</A>.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 0.84em/1.09em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<H3 class="label" style="BORDER-BOTTOM: 0px; POSITION: absolute; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.2857; MARGIN: 1.28em 0px 0.64em; PADDING-LEFT: 0px; WIDTH: 1px; PADDING-RIGHT: 0px; HEIGHT: 1px; COLOR: rgb(114,65,40); FONT-SIZE: 1.07em; VERTICAL-ALIGN: baseline; OVERFLOW: hidden; BORDER-TOP: 0px; TOP: auto; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px; LEFT: -10000px">Source</H3>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">2nd Department of Urology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, 56403, Thessaloníki, Greece, zefxis@yahoo.<wbr>co.<wbr>uk.<wbr></P></DIV> </div><div style="margin-bottom: 10px;"><DIV class="abstr" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 1.2em auto auto; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">PURPOSE:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">To explore the dose response to onabotulinumtoxinA 50, 100, and 200 U in patients with spinal cord injury (SCI) with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO).<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">METHODS:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Patients (N = 73) with SCI (level T1 or lower) with NDO and UI (≥14 UI episodes/<wbr>week) received 30 intradetrusor injections of onabotulinumtoxinA (50 U [n = 19], 100 U [n = 21], or 200 U [n = 17]) or placebo (n = 16) via cystoscopy, avoiding the trigone.<wbr> Changes from baseline in UI episodes/<wbr>week, volume voided/<wbr>micturition, maximum cystometric capacity, and maximum detrusor pressure (MDP) during first involuntary detrusor contraction (IDC) were evaluated.<wbr> Adverse events (AEs) were assessed.<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">RESULTS:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">A significant linear dose response for UI episodes/<wbr>week was identified at weeks 18, 30, 36, 42, and 54 (P &lt; 0.<wbr>05) with a similar trend (P = 0.<wbr>092) at week 6 (primary time point).<wbr> A significant linear dose response was observed in volume/<wbr>void at all post-treatment time points up to week 54 (P &lt; 0.<wbr>05) and in MDP during first IDC at week 6 (P = 0.<wbr>034).<wbr> The proportion of patients who achieved continence at week 6 was highest in the 200 U group.<wbr> Duration of effect was longest with the 200 U dose, compared with other treatment groups.<wbr> The AEs were comparable across groups; urinary tract infection was the most common AE across all treatment groups.<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; COLOR: rgb(0,0,0); FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px">CONCLUSIONS:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">In this exploratory dose-response study of SCI patients with UI due to NDO, onabotulinumtoxinA 200 U was the most effective dose.<wbr> The AE profile was comparable across all groups</P></DIV> </div><div><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT00575016?term=spinal+AND+cord+AND+INJURY&amp;intr=BOTULINUM&amp;rank=15"><STRONG></STRONG></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6662">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-27T13:09:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-27T13:09:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novel MOA Potentially Addresses Muscle Fatigue In Myasthenia Gravis & ALS</title>
	<pubDate>2012-11-27T10:39:33+01:00</pubDate>
	<wp:post_id>3686</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cytokinetic has announced positive POC data from a recently completed phII study of tirasemtiv in patients with generalised myasthenia gravis.<wbr> The drug is also being evaluated as a potential treatment for ALS in the BENEFFIT-ALS trial, an international phIIb study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Tirasemtiv's Profile of Action</STRONG> </div><div style="margin-bottom: 10px;">tirasemtiv selectively activated the fast skeletal muscle troponin complex by increasing its sensitivity to calcium thereby increasing skeletal muscle force in response to neuronal input and delaying the onset and reducing the degree of muscle fatigue.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhII POC Data From The CY 4023 Trial</STRONG> </div><div style="margin-bottom: 10px;">In this double-blind randomised 3-period crossover, placebo controlled PK &amp; PD study, evaluating two dosage strengths 250 and 500mg in 32 patients, the main objective of the trial was also to assess the effects of tirasemtiv on muscle strength, muscle fatigue and pulmonary function.<wbr> </div><div style="margin-bottom: 10px;">After six hours of dosing, statistically significant dose dependent improvements i.<wbr>e.<wbr> decreases in the Quantitative MG score QMG were noted.<wbr> The QMG is a validated endpoint in myasthenia gravis trials.<wbr> </div><div style="margin-bottom: 10px;">Also after six hours of dosiong a statistically signficant dose dependent increase in pulmonary forced vital capacity was seen.<wbr> </div><div style="margin-bottom: 10px;">Both doses of tirasemtiv were well tolerated in this study.<wbr> The most commonly reported adverse event was dizziness which increased in frequency with dose and was reported as mild in all but one case that was classified as moderate.<wbr> </div><div style="margin-bottom: 10px;">"This study provides clear evidence of a pharmacodynamic effect of tirasemtiv to increase skeletal muscle performance and reduce fatigue in patients with generalized myasthenia gravis," stated Donald B.<wbr> Sanders, MD, Professor, Division of Neurology and Founder of the Duke Myasthenia Gravis Clinic and Chair, Tirasemtiv in Myasthenia Gravis Study Group.<wbr> </div><div style="margin-bottom: 10px;">He went on to comment "This Phase IIa clinical trial represents a rigorous evaluation of the novel mechanism of action of tirasemtiv in this disease population; these data suggest that tirasemtiv may have the potential to meaningfully improve the lives of patients with myasthenia gravis and other neuromuscular diseases.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Cytokinetics has now completed POC stuidies with tirasemtiv in three different disease all of which involve impaired muscle function, each of which has demonstrated a clinically meaningful pharmacodynamic effect.<wbr> The companies priority focus is on completing the BENEFIT-ALS but it is suggesting that these new results provide further validation of the potential therapeutic utility of fast skeletal troponin activators across a broad spectrum of diseases characterised by muscle weakness and fatigue.<wbr> </div><div style="margin-bottom: 10px;">Cytokinetics has been awared a $3.<wbr>5m grant from the NINDS to fund research and development of tirasemtiv in myasthenia gravis.<wbr> </div><div>Source: <A href="http://www.cytokinetic.com/">www.<wbr>cytokinetic.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6661">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-27T10:39:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-27T10:39:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Belgian MoH old to Cut €370M from Healthcare Budget in 2013</title>
	<pubDate>2012-11-27T09:49:35+01:00</pubDate>
	<wp:post_id>3687</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Belgian Ministry of Health (MoH) has been instructed to cut the healthcare budget by EUR370 million (USD476.<wbr>5 million), under new austerity measures put forward by the coalition government for the 2013 national budget, as reported by <I>La Libre</I> newspaper.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Among the provisions foreseen by the Belgian government to meet the required savings, the MoH will focus on pricing and reimbursement.<wbr> The government has announced a reduction of 1.<wbr>95% on the prices of reimbursed drugs.<wbr> Furthermore, tighter controls will be applied on prescriptions and a fee will be levied on the marketing of pharmaceutical companies.<wbr> </div><div style="margin-bottom: 10px;">These decisions will impact on the pharmaceutical companies operating in the Belgian market.<wbr> The consequence of a reduction of prices and policies aimed at reducing the level of prescriptions of reimbursed medicines will have an impact on the level of sales and revenues in this market.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10205">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-27T09:49:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-27T09:49:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Next Launch of GP Pharm's Leuprorelin 1M in Spain</title>
	<pubDate>2012-11-27T09:20:41+01:00</pubDate>
	<wp:post_id>3688</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Next Launch of GP Pharm's Leuprorelin 1M in Spain</span>&nbsp;<br><span style="font-size: 12px;">Attached some images of the product brochure that is being given by GP Pharma reps to the physicians in Spain.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=210">...</a><br></div><div style="margin-bottom: 10px;">The device is the same like the mixject device which is used from Watson in US for Trelstar.<wbr> </div><div>Claudia </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=214">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171">View thread  DKPHybrids171: Next Launch of GP Pharm's Leuprorelin 1M in Spain</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-27T09:20:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-27T09:20:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' FGFR inhibitor Dovitinib to Enter Ph2 for Bladder Cancer</title>
	<pubDate>2012-11-26T17:14:03+01:00</pubDate>
	<wp:post_id>3689</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The POC trial, spondored by the Hoosier Oncology Group, will assess the 6-month complete response rate (primary outcome measures), and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01732107?no_unk=Y&amp;fund=2&amp;rcv_s=11%2F11%2F2012&amp;rank=83"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 50 </div><div style="margin-bottom: 10px;">Start date: Jan.<wbr> 2013 </div><div style="margin-bottom: 10px;">Completion dates: Jan.<wbr> 2014 /<wbr> Jan.<wbr> 2015 </div><div style="margin-bottom: 10px;"><U>Protocol</U> </div><div style="margin-bottom: 10px;"><DIV align="center">
<TABLE border="1" cellpadding="5" cellspacing="0" class="data_table" width="100%"><TBODY><TR align="left" valign="top"><TD class="body3">
<DIV class="indent2" style="MARGIN-TOP: 0.5ex">Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.<wbr> </DIV>
<DIV class="indent2" style="MARGIN-TOP: 0.5ex">Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.<wbr></DIV></TD>
</TR>
</TBODY>
</TABLE></DIV> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death.<wbr> In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis.<wbr> The activation of FGFR3 is associated with cell proliferation and survival in certain cancer cell types.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8623">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-26T17:14:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-26T17:14:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New OECD/EC Report On Health Care Spending In The European Union</title>
	<pubDate>2012-11-26T12:57:54+01:00</pubDate>
	<wp:post_id>3690</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The report documents the first fall in health care spending per 
capita across the EU since 1975.<wbr> Data for 2010 demonstrated a 0.<wbr>6% fall in the 
annual average growth rate which was 4.<wbr>6% between 2000 and 2009.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Individual country declines in some cases were far 
greater:</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Ireland average growth of 6.<wbr>5% pap between 2000 and 2009 fell 7.<wbr>9% in 
  2010</LI>
<LI>Estonia where annual growth was 7% in the previous 10 years fell by 
  7.<wbr>3%</LI>
<LI>Greece where annual growth was 5.<wbr>7% fell by 6.<wbr>7%</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>The countries with the highest spend as % of GDP in 
2010 included:-</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Netherlands 12% </LI>
<LI>France &amp; Germany 11.<wbr>6% </LI>
<LI>Across all countries the average was 9.<wbr>0% down from 9.<wbr>2% in 2009</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Pharmaceutical spend per capita continues to show signficant 
variation</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Ireland 528 euros per capita (50% above the EU average of 349 euros</LI>
<LI>Germany 349 euros per capita</LI>
<LI>Belgium 479 euros per capita</LI>
<LI>France 468 euros per capita</LI>
<LI>Romania 164 euros per capita</LI>
<LI>Denmark, Estonia, Latvia and Poland all spend 70% less than the EU 
  average</LI>
</UL> </div><div style="margin-bottom: 10px;">
Pharmaceutical spending accounted for 1.<wbr>6% of GDP on average across EU member 
states, ranging from below 1% in nations such as Denmark, Luxembourg and Norway 
to more than 2% in Bulgaria, Hungary, the Slovak Republic and 
Serbia.<wbr> </div><div style="margin-bottom: 10px;">The report warns that the reduction or slowdown in health spending in nearly 
all EU countries may have a long-term impact on health care outcomes.<wbr> </div><div>Source: <A href="http://www.oecd.org">www.<wbr>oecd.<wbr>org</A> &amp; <A href="http://www.ec-europa.eu">www.<wbr>ec-europa.<wbr>eu</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10201">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-26T12:57:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-26T12:57:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>COMP at the EMA Recommended Somatoprim for Designation as Orphan Medical Product for Acromegaly</title>
	<pubDate>2012-11-26T11:04:18+01:00</pubDate>
	<wp:post_id>3691</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Committee for Orphan Medicinal Products at the European Medicines Agency has issued a positive opinion on an application for orphan medicinal product status for Aspireo’s Somatoprim (DG3173) for the treatment of acromegaly.<wbr> The positive opinion and recommendation has been forwarded to the European Commission for approval.<wbr> The designation would grant Aspireo 10 years of marketing exclusivity in the EU upon obtaining market authorization as an orphan medicinal product.<wbr> In addition, Aspireo would benefit from reduced regulatory fees.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Aspireo's Somatoprim is in Ph1b/<wbr>Ph2a ongoing studies in Switzerland and Ukraine.<wbr> Initial data from this study is expected to be available in the first quarter of 2013.<wbr> Please also see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7158" class="defaultlink">Endocrinology7158: Aspireo Starts Ph2a Study with Somatoprim for Acromegaly</a>.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7177_1_ScreenCapture1.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7178c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>From the Endocrinology Franchise: This product is part of our radar screen and assumptions are that it could not be on the market before 2017.<wbr> The Proof of concept study described in the Aspireo press release ( CI 6 Nov 2012) is very unclear in terms of study design and no further information can be found in the public domain except that it is performed in Ukraine.<wbr> The status of orphan drug announced above has probably been granted on the fact that this SSA targets the receptors SSTR4.<wbr> For information, all recent drugs developed  in acromegaly have this status ( such as somavert, pasireotide.<wbr>.<wbr>)   However this status does not accelerate the time to come to the market and then does not challenge our first assumptions.<wbr> </div></div><a name="Endocrinology7179c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>This article triggers one question outside of this consideration but link with patent extension concept : could we have a specific protection extension by generating some data in the paediatric field for Somatuline ? </div></div><a name="endocrinology7177attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7177_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7177">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-26T11:04:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-26T11:04:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: MHRA Says that 'EU Equivalence' Could Cause Drug Shortages</title>
	<pubDate>2012-11-26T10:14:39+01:00</pubDate>
	<wp:post_id>3692</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></SPAN></SPAN></SPAN></span>&nbsp;<br></div><div style="margin-bottom: 10px;">Switzerland has become  the first country to receive an "equivalence" rating from the European Commission for its regulations on APIs,  however many of the biggest API manufacturing countries including India and China have still not even applied for an equivalence assessment.<wbr> </div><div style="margin-bottom: 10px;">Under the EU's falsified medicines Directive, whose provisions come into force on 2 January 2013, all APIs imported into the EU as of that date must have been manufactured to GMP standards that are at least equivalent to those of the EU.<wbr> Only four other countries have so far applied for an equivalence assessment: Israel, Australia, Singapore and Brazil.<wbr> </div><div style="margin-bottom: 10px;">The large API producers such as India, China, South Korea, Japan, Taiwan and Mexico have not yet applied.<wbr> </div><div>Source: Scrip 26 November 2012 </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10199">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9896">View thread  PharmaWorld9896: MHRA Says that 'EU Equivalence' Could Cause Drug Shortages</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-26T10:14:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-26T10:14:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study to Assess Acromegaly Treatment QoL</title>
	<pubDate>2012-11-23T17:15:00+01:00</pubDate>
	<wp:post_id>3693</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new observational study sponsored by the Massachusetts General Hospital (MGH) in collaboration with Pfizer.<wbr> The objective of the trial is to investigate the effects of biochemical control of acromegaly by growth hormone (GH) receptor antagonism and somatostatin analogs in a large tertiary care pituitary referral center in the US.<wbr> Primary Endpoint will measure QoL.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01732406?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=11%2F08%2F2012&amp;rank=103"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 120 </div><div style="margin-bottom: 10px;"><DIV class="indent2">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">There will be 3 groups/<wbr>cohorts: 1) Patients with active acromegaly (n=30), 2) patients receiving pegvisomant monotherapy resulting in biochemical control of acromegaly (n=30), and 3) patients receiving somatostatin analog monotherapy resulting in biochemical control of acromegaly (n=60).<wbr></P></DIV> </div><div style="margin-bottom: 10px;">Start date: Dec.<wbr> 2012 /<wbr> Completion date: Dec.<wbr> 2014 </div><div>Principal Investigator: Karen Miller, MD (MGH).<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7184c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><DIV class="im">
<P>Comment from the Endocrinology Franchise: This observational study conducted by Pfizer aims to demonstrate that the quality of life of the patients receiving pegvisomant (Somavert) is better than the one receiving somatostatin analogs or having active acromegaly.<wbr></P>
<P>Neggers and Van der Lely published already results of an interventional study showing that adding Somavert in SSA treated patients who are already controlled for IGF1 could further improve QOL.<wbr></P>
<P>Interesting also to note that Pfizer considers Pasireotide as a future direct competitor: this observational study by focusing on glycemic parameters (main secondary endpoints) will allow Pfizer to reinforce the well-known favorable effect of Somavert on glycemic parameters (Hyperglycemia is the main specific side effect from Pasireotide).<wbr></P>
<P>Interesting also to see that Pfizer invests in an observational study, as we do with SAGIT project.<wbr> </P>
<P>Harold Dumont on behalf of the Endocrinology Franchise.<wbr></P></DIV> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7176">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-23T17:15:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-23T17:15:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>European Commission to Phase-In "Black Symbol" Requirement?</title>
	<pubDate>2012-11-23T16:19:26+01:00</pubDate>
	<wp:post_id>3694</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The EC is looking at whether  a phasing-in arrangement will be needed for the black symbol to be included on all medicines subject to additional monitoring, so that companies have enough time to make the necessary changes to their product labelling.<wbr> </div><div style="margin-bottom: 10px;">Under the EU pharmacovigilance legislation, a list of all products that are subject to additional monitoring &ndash; and will have to carry the symbol &ndash; is to be drawn up by the European Medicines Agency.<wbr> The list will include all medicinal products containing a new active substance, and all new biological medicines, as well as specific product subject to post-authorisation safety commitments or restrictions.<wbr> </div><div style="margin-bottom: 10px;">The symbol will have to be printed in the summary of product characteristics (SmPC) and on the pack leaflet.<wbr> </div><div style="margin-bottom: 10px;">The EC has launched a public consultation to gauge the views of stakeholders - comments are invited by 10 January 2013 at the latest.<wbr> </div><div>Source: Scrip 22 November 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10197">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-23T16:19:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-23T16:19:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MAP Resubmission Accepted By The FDA</title>
	<pubDate>2012-11-23T15:16:58+01:00</pubDate>
	<wp:post_id>3695</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: MAP Pharmaceuticals announced yesterday that its resubmission for 
LEVADEX its orally inhaled migraine drug, partnered with Allergan for the US, 
has been accepted by the FDA as complete.<wbr> Ex-US MAP is still looking for a 
partner.<wbr> </div><div style="margin-bottom: 10px;">The resubmission was in response to FDA's March 26 2012 action letter and has 
a new PDUFA data of April 15 2013.<wbr> </div><div style="margin-bottom: 10px;">Should it be approved Allergan will complement MAP's commercialisation effort 
by helping to promoted the drug to the neurology community, expanding MAP's 
reach and assisting with access and reimbursement in the managed care setting.<wbr> 
Allergan will clearly benefit having another drug it can promote to neurologists 
alongside Botox for chronic headache.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Levadex's Profile</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Commercial Opportunity</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_12_ScreenCapture12.jpg"> </div><div>source: <A href="http://www.mappharma.com">www.<wbr>mappharma.<wbr>com</A> </div><!-- Comment details --><a name="neurology6660attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(115,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(91,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(111,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(94,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(75,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(142,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(107,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(124,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(101,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(125,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6660_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(105,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6660">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-23T15:16:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-23T15:16:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence on DongKooK's Triptorelin Depot 3,75 mg</title>
	<pubDate>2012-11-23T15:04:21+01:00</pubDate>
	<wp:post_id>3696</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Clemence Leprince (Uro-Onco Franchise) and Ipsen Korea we have learnt that the triptorelin Depot Injection is GMP certified, meaning that the drug could be registered in Europe.<wbr> </div><div style="margin-bottom: 10px;">At the CPhI congress in Madrid (Oct.<wbr>9 2012), a representative of DongKook told us that the company was still seeking a partner for EU who would have to conduct a clinical development programme.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_211_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="dkphybrids211attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_211_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=211">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-23T15:04:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-23T15:04:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hospitalization Trends After Prostate and Bladder Surgery: Implications of Potential Payment Reforms</title>
	<pubDate>2012-11-23T13:31:42+01:00</pubDate>
	<wp:post_id>3697</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In this recent paper, the conclusion indicates that reductions in hospital stays were more dramatic for patients who underwent prostatectomy and were associated with stable short-term outcomes.<wbr> Conversely, smaller reductions in hospitalization for patients undergoing cystectomy were met with substantial increases in the use of post-acute care.<wbr> Close surveillance of how imminent policy reforms affect patterns and quality of care will be necessary.<wbr> Rationale for publishing this paper in Traction CI is provided below by Audrey Schweitzer (Uro-Onco Franchise).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">.<wbr> </DIV> </div><div style="margin-bottom: 10px;"><STRONG>Hospitalization Trends After Prostate and Bladder Surgery: Implications of Potential Payment Reforms</STRONG> </div><div><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<DIV style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; FONT-SIZE: 0.92em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Jacobs BL, Zhang Y, Tan HJ, Ye Z, Skolarus TA, Hollenbeck BK.<wbr> </DIV>
<DIV style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.09em; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; FONT-SIZE: 0.84em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Department of Urology, Divisions of Oncology, VA Ann Arbor Healthcare System, Ann Arbor, Michigan; Health Services Research, University of Michigan, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.<wbr> Electronic address: <A href="mailto:brucejac@med.umich.edu" style="COLOR: rgb(17,85,204)" target="_blank">brucejac@med.<wbr>umich.<wbr>edu</A>.<wbr></P></DIV>
<DIV style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 17px; MARGIN: 1.2em auto auto; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">
<H3 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.2857; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(152,87,53); FONT-SIZE: 1.07em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"><SPAN style="LINE-HEIGHT: 17px; TEXT-TRANSFORM: uppercase; FONT-SIZE: 1em"><B>PURPOSE:</B></SPAN></H3>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Hospital stays have decreased for patients undergoing surgery for urological cancer.<wbr> However, there are concerns that patients are being discharged from the hospital prematurely.<wbr> We examined associations between hospital stay and short-term outcomes for a low risk procedure (prostatectomy) and high risk procedure (cystectomy).<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"><B>MATERIALS AND METHODS</B></H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">We used SEER (Surveillance, Epidemiology and End Results)-Medicare data from 1992 through 2005 to identify 46,781 prostatectomy and 9,035 cystectomy cases.<wbr> We assessed our main outcome (adjusted likelihood of hospital readmission within 30 days) using a logistic regression model.<wbr> Secondary outcomes included mortality rates and discharge disposition.<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"><B>RESULTS</B>:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">In comparing patients from 1992 to 1993, to 2004 to 2005, hospital stay decreased approximately 3 days for both surgeries (relative decrease of more than 50% for prostatectomy and 21% for cystectomy).<wbr> Hospital readmission rates were 4.<wbr>5% and 25.<wbr>2% for prostatectomy and cystectomy, respectively, and remained stable with time.<wbr> Skilled nursing/<wbr>intermediate care use was stable for patients who underwent prostatectomy (approximately 1%), but increased from 8.<wbr>2% (95% CI 5.<wbr>4-11.<wbr>4) to 18.<wbr>9% (95% CI 16.<wbr>8-21.<wbr>3) for those treated with cystectomy.<wbr> Use of home care increased from 8.<wbr>1% (95% CI 7.<wbr>3-9.<wbr>0) to 11.<wbr>1% (95% CI 10.<wbr>1-12.<wbr>1) and from 34.<wbr>2% (95% CI 29.<wbr>7-38.<wbr>7) to 47.<wbr>5% (95% CI 44.<wbr>5-50.<wbr>1) for prostatectomy and cystectomy cases, respectively.<wbr></P>
<H4 style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FLOAT: left; FONT-SIZE: 1em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"><B>CONCLUSIONS</B>:</H4>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Reductions in hospital stay were more dramatic for patients who underwent prostatectomy and were associated with stable short-term outcomes.<wbr> Conversely, smaller reductions in hospitalization for patients undergoing cystectomy were met with substantial increases in the use of post-acute care.<wbr> Going forward, close surveillance of how imminent policy reforms affect patterns and quality of care will be necessary.<wbr></P>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Copyright © 2013 American Urological Association Education and Research, Inc.<wbr> Published by Elsevier Inc.<wbr> All rights reserved.<wbr> </P>
<DT style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.4em; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; DISPLAY: inline; WHITE-SPACE: nowrap; COLOR: rgb(87,87,87); FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">PMID:</DT>


<DD style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.4em; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; DISPLAY: inline; WHITE-SPACE: nowrap; COLOR: rgb(87,87,87); FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">23164391</DD>


<DD style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.4em; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; DISPLAY: inline; WHITE-SPACE: nowrap; COLOR: rgb(87,87,87); FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">[PubMed - as supplied by publisher]</DD>

</DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8617">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-23T13:31:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-23T13:31:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Next Launch of GP Pharm's Leuprorelin 1M in Spain</title>
	<pubDate>2012-11-23T09:25:58+01:00</pubDate>
	<wp:post_id>3698</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Next Launch of GP Pharm's Leuprorelin 1M in Spain</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to Esther Minguell we have learnt that GP Pharm intends to launch its monthly leuprorelin, Lutrate&reg; Depot 3.<wbr>75mg, in September 2012 for the prostate cancer indication.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=171">...</a><br></div><div style="margin-bottom: 10px;">Attached some images of the product brochure that is being given by GP Pharma reps to the physicians in Spain.<wbr> </div><div style="margin-bottom: 10px;">You will find some information about the device.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_210_1_image.jpeg%20%2d%20Windows%20Photo%20Viewer.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_210_2_image%20(1).jpeg%20%2d%20Windows%20Photo%20Viewer.jpg"> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="DKPHybrids214c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The device is the same like the mixject device which is used from Watson in US for Trelstar.<wbr> </div><div>Claudia </div></div><a name="dkphybrids210attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_210_1_image.jpeg%20%2d%20Windows%20Photo%20Viewer.jpg">image.jpeg - Windows Photo Viewer.jpg</a>&nbsp;&nbsp;(101,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_210_2_image%20(1).jpeg%20%2d%20Windows%20Photo%20Viewer.jpg">image (1).jpeg - Windows Photo Viewer.jpg</a>&nbsp;&nbsp;(106,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=210">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171">View thread  DKPHybrids171: Next Launch of GP Pharm's Leuprorelin 1M in Spain</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-23T09:25:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-23T09:25:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Toxin Aesthetic Landscape</title>
	<pubDate>2012-11-22T13:25:44+01:00</pubDate>
	<wp:post_id>3699</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached an overview of the competitive landscape compiled by the CI department in close collaboration with the Neurology Aesthetic Franchise.<wbr> We hope you will find this a useful tool and feel more inclined to contribute to our internal knowledge of the toxin aesthetic area.<wbr> By keeping us informed of developments in your countries, we can build our internal knowledge base, and together leverage the utility of the tool for everybody's benefit.<wbr> Highlighted below is a small selection of some of the slides from the attached presentation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6658_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6658_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6658_3_ScreenCapture3.jpg"> </div><div>Compiled by the CI Department and the Neurology Aesthetic Franchise </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6749c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>To respond one of the KIQs, PhII study demonstrated that Purtox has &gt; 30-60 days longer duration than Botox with the optimal dose of Purtox 30U vs.<wbr> Botox 20U (source Dr MAAS lecture at Toxins 2012).<wbr> </div></div><a name="neurology6658attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6658_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(142 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6658_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(85,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6658_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(140,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6658_4_AESTHETIC%20%e2%80%93%20Final%20Competitive%20Landscape%255ffor%20Traction%255fNov2012%20(1).pptx">AESTHETIC – Final Competitive Landscape_for Traction_Nov2012 (1).pptx</a>&nbsp;&nbsp;(343,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6658">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-22T13:25:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-22T13:25:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Next Launch of GP Pharm's Leuprorelin 1M in Spain</title>
	<pubDate>2012-11-22T09:33:32+01:00</pubDate>
	<wp:post_id>3700</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Next Launch of GP Pharm's Leuprorelin 1M in Spain</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to Esther Minguell we have learnt that GP Pharm intends to launch its monthly leuprorelin, Lutrate&reg; Depot 3.<wbr>75mg, in September 2012 for the prostate cancer indication.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=171">...</a><br></div><div style="margin-bottom: 10px;">On the web, GP Pharm drug product presentation is made of a small device (mix ject from Medimop/<wbr>West pharmaceuticals) to facilitate solvent transfer and reconstitution .<wbr> This device is not mentionned in the above information .<wbr> Is the final presentation changed ? </div><div style="margin-bottom: 10px;">This device is also used in the Watson /<wbr>US presentation of Pamorelin (from Debio) named TRELSTAR .<wbr> </div><div>More info on the GP-Pharm presentation @ <A href="http://www.packagingdigest.com/article/447084-Drug_delivery_with_ease_and_comfort.php">http:/<wbr>/<wbr>www.<wbr>packagingdigest.<wbr>com/<wbr>article/<wbr>447084-Drug_delivery_with_ease_and_comfort.<wbr>php</A> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=208">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171">View thread  DKPHybrids171: Next Launch of GP Pharm's Leuprorelin 1M in Spain</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-22T09:33:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-22T09:33:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sarepta Seeks Ex-US Partner For Its Duchenne Drug</title>
	<pubDate>2012-11-21T17:51:49+01:00</pubDate>
	<wp:post_id>3701</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment With phIIb data on its exon-skipping drug Eteplirsen demonstrating 
that the drug addresses the underlying cause of Duchenne Muscular Dystrophy, 
Sarepta Therapeutics is potentially at an inflexion point in the group's 
history.<wbr> Discussions with the FDA in Q113 will reveal whether it can file for 
accelerated approval based on its phIIb data or whether a pivotal trial is 
required for approval.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Partnership Requirements</STRONG> </div><div style="margin-bottom: 10px;">Based on the success of its phIIb trial, Christopher Garabedian President 
&amp; CEO during its Q3 webcast this week made the following comments 
regarding partnership.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Related to our additional exon skipping DMD drug candidates 
and the broader DMD pipeline and global opportunity, I'd like to speak about our 
current plans for a potential partnership.<wbr> First, we are committed to 
determining what will be required to get eteplirsen through FDA approval, and 
are confident in our ability to execute on this development program and the 
potential commercial activities associated with the product approval.<wbr> Therefore, 
we are not seeking a partner to help us with eteplirsen in the U.<wbr>S.<wbr> We have 
stated our willingness to consider a partner for ex-U.<wbr>S.<wbr> or ex-North American 
rights across our current and future DMD drug candidates.<wbr> To be clear, we are 
not holding up our development in pursuit of additional DMD drug candidates and 
have utilized mostly non-dilutive funding to advance these candidates through 
the IND-enabling work through collaborative government and academic grants.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"However, we believe that with the right partner, we might 
benefit from having additional resources to expand drug supply production and 
accelerate clinical development of additional exon skipping targets.<wbr> We have 
received a tremendous amount of interest from potential partners, including 
large pharma, large biotech, and mid-sized biotech companies that are interested 
in the rare disease and/<wbr>or neuromuscular disease areas.<wbr> We have been contacted 
by about a dozen companies and are at various stages of discussions with each of 
them.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG><U>Eteplirsen PhIIb Trial Data</U></STRONG></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_10_ScreenCapture10.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_11_ScreenCapture11.jpg"> </div><!-- Comment details --><a name="neurology6656attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(83,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(120,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(116,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(104,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(113,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(90 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(92,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(142,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(142,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6656_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(95,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6656">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-21T17:51:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-21T17:51:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda's Adcetris Launched in UK</title>
	<pubDate>2012-11-21T14:09:27+01:00</pubDate>
	<wp:post_id>3702</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="document">Comment: Takeda last week launched Hodgkin lymphoma treatment Adcetris (brentuximab vedotin) in the United Kingdom.<wbr> The drug recently gained approval in Europe for: 1/<wbr>in patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and 2/<wbr>for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma.<wbr> </DIV> </div><div style="margin-bottom: 10px;"><DIV class="document"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="document">As reported on the National Health Service (NHS) website National electronic Library of Medicines on 14 November, the recommended dose is 1.<wbr>8 mg/<wbr>kg administered as intravenous infusion over 30 minutes every three weeks, with an NHS list price of GBP2,500 (USD3,978) per 50 mg single-use vial.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="document"><BR><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="document">Adcetris was first developed by Seattle Genetics, and that firm is continuing development of the drug together with Takeda's US subsidiary Millennium: the Takeda Oncology Company.<wbr> </DIV> </div><div><DIV class="document">Further applications for different indications can be expected in future, with a Phase III trial of Adcetris in previously untreated advanced Hodgkin lymphoma started earlier this month, and the results of recent trials of the drug as a frontline treatment for ALCL and other CD30-positive mature T-cell and NK-cell lymphomas to be reported at the American Society of Hematology annual meeting next month.<wbr> Given the conditions attached to European approval, the drug is currently available to only a small patient pool in the UK.<wbr></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8615">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-21T14:09:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-21T14:09:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norgine Extends Partnership with PharmaSwiss in Central and Eastern EU</title>
	<pubDate>2012-11-21T13:18:00+01:00</pubDate>
	<wp:post_id>3703</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PharmaSwiss, a division of Valeant, will bring MOVICOL (for constipation) to the Central and Eastern EU market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=7614" class="defaultlink">PharmaWorld7614: Norgine Announces 2008 Results and a Moviprep's Partner in Eastern Europe</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>In 2011 Valeant acquired PharmaSwiss (<A href="http://www.pharmaswiss.com/pages/PRDetail.aspx?FilterField1=ID&amp;FilterValue1=16">http:/<wbr>/<wbr>www.<wbr>pharmaswiss.<wbr>com/<wbr>pages/<wbr>PRDetail.<wbr>aspx?FilterField1=ID&amp;FilterValue1=16</A>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1867">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-21T13:18:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-21T13:18:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Next Launch of GP Pharm's Leuprorelin 1M in Spain</title>
	<pubDate>2012-11-21T10:56:00+01:00</pubDate>
	<wp:post_id>3704</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Next Launch of GP Pharm's Leuprorelin 1M in Spain</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to Esther Minguell we have learnt that GP Pharm intends to launch its monthly leuprorelin, Lutrate&reg; Depot 3.<wbr>75mg, in September 2012 for the prostate cancer indication.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=171">...</a><br></div><div style="margin-bottom: 10px;">On November 20th, GP Pharma started the promotion of Lutrate Depot 3.<wbr>75mg in Spain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>GP Pharm keeps the price of €159.<wbr>12 PVPIVA (same as Procrin 1M) but the funding maximum price is € 133.<wbr>71.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=206">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171">View thread  DKPHybrids171: Next Launch of GP Pharm's Leuprorelin 1M in Spain</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-21T10:56:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-21T10:56:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Generic Defense Strategies</title>
	<pubDate>2012-11-20T17:27:50+01:00</pubDate>
	<wp:post_id>3705</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In this recent <EM>Business Insights</EM> issue, several critical topics are reported such as current challenges facing pharma, as well as developmental, commercial  and legal lifecycle management strategies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">.<wbr>.<wbr>.<wbr> the most effective generic defense strategies tend to marry multiple strands together, highlighting the desirability of developing an integrated approach to LCM.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL class="iReport_bullets"><LI>are implemented typically in the early or mid stages of the drug’s lifecycle</LI>
<LI>demand high upfront investment, both in terms of cash and time</LI>
<LI>have potential for protection through patents or regulatory exclusivity</LI>
<LI>enable product differentiation on clinical advantages</LI>
<LI>require focus on meeting unmet need.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10192_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>employed typically later in the product lifecycle</LI>
<LI>require lower upfront investment, are quicker to implement and are faster to respond to market changes</LI>
<LI>unlikely to be protected by patents or regulatory exclusivity</LI>
<LI>differentiate products mainly on access and price;</LI>
<LI>require focus on maximizing overall profitability</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL class="iReport_bullets"><LI>typically a core-area of focus at extreme ends of the lifecycle – early protection and late defense</LI>
<LI>require investment, but this is less of an issue than feasibility</LI>
<LI>focus on maximizing the protection available from all brand efforts and as such work together with other lifecycle management tactics.<wbr></LI>
</UL> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="pharmaworld10192attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10192_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(126,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10192_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(197,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10192">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-20T17:27:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-20T17:27:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Final Ph3 Results of Maintenance BCG in NMIBC</title>
	<pubDate>2012-11-20T13:43:04+01:00</pubDate>
	<wp:post_id>3706</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT00002990?term=NCT00002990&amp;rank=1"><STRONG></STRONG></A></SPAN> </div><div style="margin-bottom: 10px;"><DIV class="cit" style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; font: 0.84em/1.45em arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; vertical-align: baseline; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;"></DIV> </div><div style="margin-bottom: 10px;"><DIV class="cit" style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; font: 0.84em/1.45em arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; vertical-align: baseline; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;"><A href="http://www.ncbi.nlm.nih.gov/pubmed/23141049?dopt=Abstract" style="margin: 0px; color: #660066; font-size: 11px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;" title="European urology."></A></DIV> </div><div style="margin-bottom: 10px;"><H1 style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0.37em 0px; font: bold 1.23em/1.12em arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; vertical-align: baseline; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;"></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths" style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; margin: 0px; font-family: arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 0.92em; vertical-align: baseline; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Oddens%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Brausi%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Sylvester%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bono%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=van%20de%20Beek%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=van%20Andel%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Gontero%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Hoeltl%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Turkeri%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Marreaud%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Collette%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Oosterlinck%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23141049" style="margin: 0px; color: #660066; font-size: 12px; vertical-align: baseline; text-decoration: underline; border: 0px; padding: 0px;"></A></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff" style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; font: 0.84em/1.09em arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; vertical-align: baseline; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;">
<H3 class="label" style="position: absolute; line-height: 1.2857; margin: 1.28em 0px 0.64em; width: 1px; height: 1px; color: #724128; font-size: 1.07em; vertical-align: baseline; overflow: hidden; top: auto; font-weight: bold; left: -10000px; border: 0px; padding: 0px;"></H3>
<P style="margin: 0.5em 0px; font-size: 11px; vertical-align: baseline; border: 0px; padding: 0px;"></P>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="abstr" style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 1.2em auto auto; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; vertical-align: baseline; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;">
<H4 style="text-transform: uppercase; margin: 0px 0.25em 0px 0px; float: left; color: #000000; font-size: 1em; vertical-align: baseline; font-weight: bold; border: 0px; padding: 0px;"></H4>
<P style="margin: 0px 0px 0.5em; font-size: 13px; vertical-align: baseline; border: 0px; padding: 0px;"></P>
<H4 style="text-transform: uppercase; margin: 0px 0.25em 0px 0px; float: left; color: #000000; font-size: 1em; vertical-align: baseline; font-weight: bold; border: 0px; padding: 0px;"></H4>
<P style="margin: 0px 0px 0.5em; font-size: 13px; vertical-align: baseline; border: 0px; padding: 0px;"></P>
<H4 style="text-transform: uppercase; margin: 0px 0.25em 0px 0px; float: left; color: #000000; font-size: 1em; vertical-align: baseline; font-weight: bold; border: 0px; padding: 0px;"></H4>
<P style="margin: 0px 0px 0.5em; font-size: 13px; vertical-align: baseline; border: 0px; padding: 0px;"></P>
<H4 style="text-transform: uppercase; margin: 0px 0.25em 0px 0px; float: left; color: #000000; font-size: 1em; vertical-align: baseline; font-weight: bold; border: 0px; padding: 0px;"></H4>
<P style="margin: 0px 0px 0.5em; font-size: 13px; vertical-align: baseline; border: 0px; padding: 0px;"></P>
<H4 style="text-transform: uppercase; margin: 0px 0.25em 0px 0px; float: left; color: #000000; font-size: 1em; vertical-align: baseline; font-weight: bold; border: 0px; padding: 0px;"></H4>
<P style="margin: 0px 0px 0.5em; font-size: 13px; vertical-align: baseline; border: 0px; padding: 0px;"></P>
<H4 style="text-transform: uppercase; margin: 0px 0.25em 0px 0px; float: left; color: #000000; font-size: 1em; vertical-align: baseline; font-weight: bold; border: 0px; padding: 0px;"></H4>
<P style="margin: 0px 0px 0.5em; font-size: 13px; vertical-align: baseline; border: 0px; padding: 0px;"></P>
</DIV> </div><div><DIV class="aux" style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 1.2em auto auto; font: 13px/1.4em arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; vertical-align: baseline; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;">
<DIV class="resc" style="margin: 0px; color: #575757; font-size: 13px; vertical-align: baseline; border: 0px; padding: 0px;"><DL class="rprtid" style="line-height: 1.4em; margin: 0px 15px 0px 0px; display: inline; color: #575757; font-size: 0.84em; vertical-align: baseline; border: 0px; padding: 0px;"><DT style="margin: 0px; display: inline; white-space: nowrap; font-size: 11px; vertical-align: baseline; border: 0px; padding: 0px;">PMID:</DT>
</DL>23141049[PubMed - as supplied by publisher]</DIV>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8612">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-20T13:43:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-20T13:43:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study to Assess Primary Hemifacial Spasm in Chinese Patients Has Been Completed</title>
	<pubDate>2012-11-19T17:16:54+01:00</pubDate>
	<wp:post_id>3707</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by Peking Union Medical College Hospital and in collaboration with GSK, the observational study started in Q1:12, and enrolled approx.<wbr> 1003 patients in 15 centers across China.<wbr> The outcome measures include the percentage of the treatment methods of primary hemifacial spasm (HFS) in outpatients subjects, aggravated and relieved factors of HFS symptoms, concomitant symptoms of HFS, and AEs of botulinum toxin treatment in HFS patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details</STRONG> - <A href="http://clinicaltrials.gov/ct2/show/NCT01728428?no_unk=Y&amp;fund=2&amp;rcv_s=11%2F05%2F2012&amp;rank=96">NCT01728428</A> </div><div style="margin-bottom: 10px;"><STRONG>Business Development</STRONG> </div><div>2005 GSK in-licensed all developmental and commercial rights for Allergan's Botox (botulinum toxin type A) treatment in Japan and China.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6654">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-19T17:16:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-19T17:16:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan to Take a Leadership Position in Topical Aesthetics Skin Care</title>
	<pubDate>2012-11-19T11:02:53+01:00</pubDate>
	<wp:post_id>3708</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has entered into an agreement to buy SkinLedica's topical aesthetic skin care business for $350M, including an additional $25M in payments dependent on SkinMedica's products reaching certain sales milestones.<wbr> Following the acquisition, Allergan plans to operate SkinMedica as a separate global business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Quoting David Pyott: ".<wbr>.<wbr>.<wbr> The acquisition of SkinMedica will nicely complement our existing facial aesthetics business, which includes products such as Botox Cosmetic, Juvderm and Latisse, and will enable us to take a leadership position in the growing “physician dispensed” topical aesthetics skin care category.<wbr> Most importantly, the acquisition will allow us to expand our product portfolio to better meet the needs of our existing base of physician customers and their patients.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Management</U> </div><div style="margin-bottom: 10px;">Bob Rhatigan, who currently serves as senior VP, facial aesthetics, Allergan, will assume the role of senior VP, general manager and chief executive of SkinMedica.<wbr> </div><div style="margin-bottom: 10px;">Mary Fisher, CEO of SkinMedica, will join Allergan and assist Mr Rhatigan in the acquisition integration to ensure the maximization of revenue building opportunities.<wbr> </div><div style="margin-bottom: 10px;"><U>Sales Force</U> </div><div style="margin-bottom: 10px;">The Allergan topical aesthetics sales force and the SkinMedica sales force will continue to represent their respective product lines over the near term.<wbr> Following the completion of the acquisition, a larger and combined SkinMedica sales force will assume responsibility for the line of products including the revolutionary SkinMedica TNS product line, Allergan’s Vivite product line and Latisse, the one and only FDA-approved product to treat inadequate or not enough eye lashes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- TNS Essential Serum and Hallmark TNS recovery Complex </div><div style="margin-bottom: 10px;">- Prescription product VANIQA Cream 13.<wbr>9%*, which is physician dispensed and fits nicely into Allergan's existing business that includes Botox Cosmetic, Juvederm, and Latisse.<wbr> </div><div style="margin-bottom: 10px;">*(IMS LTM sales of ~$15M), the only FDA approved Rx treatment for the reduction of unwanted facial hair in women.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6651_1_ScreenCapture1.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6651">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-19T11:02:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-19T11:02:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CHMP Recommends Approval of Sanofi's GLP-1 analogue</title>
	<pubDate>2012-11-19T08:43:20+01:00</pubDate>
	<wp:post_id>3709</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On Friday the CHMP recommended the approval of Lyxumia (lixisnenatide) for the treatment of type II diabetes, a drug it inlicensed from Zealand Pharam.<wbr> </div><div style="margin-bottom: 10px;">This will be the first W/<wbr>W approval for Lyxumia, with an application to the US authorities planned for next month.<wbr> The approved indication is for the treatment of type II diabetic to achieve control of blood glucose in combination with oral-glucose lowering agents or basal insulin when these together with diet and exercise do not provide adequate glycaemic control.<wbr> </div><div style="margin-bottom: 10px;">The most common side-effects noted are nausea, vomiting and diarrhoea.<wbr> In addition hypoglycaemia when used in combination with sulphonylurea and or basal insulin and headache occurr commonly.<wbr> Allergic reactions have been reported in 0.<wbr>4% of patients.<wbr> </div><div style="margin-bottom: 10px;">Specific safety issues regarding the risk of medullary thyroid cancer, pancreatitis, malignant neoplasa, a propensity to induce a transient increased heart rate, and malformations observed in animal development studies have been evaluated and will be addressed in the SmPC and/<wbr>or in the risk management plan.<wbr> </div><div>Source:www.<wbr>ema.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7174">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-19T08:43:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-19T08:43:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CHMP Recommends Approval of J&J's Zytiga</title>
	<pubDate>2012-11-19T08:39:35+01:00</pubDate>
	<wp:post_id>3710</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On Friday the CHMP recommended that J&amp;J's Zytiga (abiraterone) 
be approved for the treatment of chemotherapy naive patients with metastatic 
CRPC in combination with prednisone.<wbr> </div><div style="margin-bottom: 10px;">The recommendation included a new contraindicaiton of severe hepatic 
impairment.<wbr> </div><div style="margin-bottom: 10px;">Zytiga is under priority reveiw in the UF for the same indication with an 
undisclosed PDUFA data in mid-December.<wbr> </div><div style="margin-bottom: 10px;">The drug is currently approved in both the US and EU in combination with 
prednisone to treat metastatic CRPC patients who have received prior 
chemotherapy containing docetaxel.<wbr> </div><div>Scource.<wbr><a href="http://www.ema.com" class="defaultlink" title="www.ema.com">ema.com</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8665c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">FDA approved an sNDA to expand the label for </SPAN><A href="http://www.biocentury.com/products/zytiga" style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #1155cc; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank" title="Zytiga product news and analysis from BCIQ"><SPAN style="COLOR: #000000">Zytiga</SPAN></A><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> abiraterone from </SPAN><A href="http://www.biocentury.com/companies/johnson_and_johnson" style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #1155cc; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank" title="J&amp;J company profile and pipeline intelligence from BCIQ"><SPAN style="COLOR: #000000">Johnson &amp; Johnson</SPAN></A> <SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">to include use in combination with prednisone to treat chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC).<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">J&amp;J said the U.<wbr>S.<wbr> label for Zytiga does not include language restricting the use of Zytiga to patients who are asymptomatic or mildly asymptomatic.<wbr></SPAN></SPAN></SPAN><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><BR>In conjunction with the approval, The New England Journal of Medicine published additional data from the Phase III COU-AA-302 trial showing Zytiga plus prednisone improved median radiographic progression-free survival (PFS) vs.<wbr> prednisone alone in chemotherapy-naïve CRPC patients (16.<wbr>5 months vs.<wbr> 8.<wbr>3 months; p&lt;0.<wbr>001).<wbr> At a median follow-up of 22.<wbr>2 months, median overall survival (OS) has not been reached in the Zytiga plus prednisone arm.<wbr> Median OS is 27.<wbr>2 months for prednisone alone.<wbr> </SPAN></SPAN></SPAN></SPAN> </div><div><SPAN style="COLOR: #000000"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Sources :</SPAN></SPAN></SPAN></SPAN><SPAN class="hP" id=":17t" style="OUTLINE-STYLE: none; OUTLINE-COLOR: invert; OUTLINE-WIDTH: medium; PADDING-RIGHT: 10px" tabindex="-1">BioCentury Extra for Monday, December 10, 2012<BR><A href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209096">http:/<wbr>/<wbr>www.<wbr>nejm.<wbr>org/<wbr>doi/<wbr>pdf/<wbr>10.<wbr>1056/<wbr>NEJMoa1209096</A></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8611">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-19T08:39:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-19T08:39:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Antares - A Company At The Forefront Of Injection Devices For Drug Delivery</title>
	<pubDate>2012-11-16T14:39:30+01:00</pubDate>
	<wp:post_id>3711</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Antares Pharma's latest (November) presentation highlights its continuing progress with its advanced injectable product portfolio, including its own internal programmes and those being undertaken in partnership with Teva (5 products in total, TevTropin (hGH), Epinephrine and 3 undisclosed products).<wbr> Analysts believe Teva's 2nd autoinjector product will be a new formulation of its MS drug copaxone.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="pharmaworld10186attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(152,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(137,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10186_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(139,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10186">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-16T14:39:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-16T14:39:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intarcia and Quintiles Plan to Start Ph3 of Implantable GLP-1</title>
	<pubDate>2012-11-16T10:04:25+01:00</pubDate>
	<wp:post_id>3712</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Intarcia recently raised $210M in a venture round ($160M in equity + $50M in debt).<wbr> Both companies plan Ph3 testing of ITCA650 in Q1:13.<wbr> The DUROS® device was first used as a drug delivery technology for the delivery of leuprolide acetate, under the brand name Viadur®.<wbr><WBR></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The diabetes drug is a continuous subcutaneous delivery of exenatide, from an implantable Duros osmotic mini-pump.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7172_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The delivery system is a matchstick-sized device consisting of a cylindrical titanium alloy reservoir.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7172_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Business Development</STRONG> </div><div style="margin-bottom: 10px;">Under a 2006 deal, Quintiles has an undisclosed equity stake in Intarcia and is a financial and development partner.<wbr> (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=6802" class="defaultlink">Endocrinology6802: Intarcia Finalizes Innovative Two-Step Alliance for its Once-Yearly GLP-1</a>).<wbr> </div><div>Source: BioCentury </div><!-- Comment details --><a name="endocrinology7172attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7172_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7172_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7172">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-16T10:04:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-16T10:04:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>KARL STORZ Revolutionizes the Management of the Operating Room (OR)</title>
	<pubDate>2012-11-15T17:00:55+01:00</pubDate>
	<wp:post_id>3713</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"><SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #fbfbfb; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
</UL> </div><div><SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #fbfbfb; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><A href="http://www.karlstorz.de/cps/rde/xchg/SID-53663E8B-02A7A306/karlstorz-en/hs.xsl/17127.htm"></A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8606">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-15T17:00:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-15T17:00:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Approves 1st In A New Class Of Diabetes Drugs - An SGLT-2 Inhibitor</title>
	<pubDate>2012-11-15T16:42:33+01:00</pubDate>
	<wp:post_id>3714</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Good news for the BMS/<wbr>AstraZenca Diabetes alliance as the EU 
authorities have approved Forxiga, this is in spite of the drug having 
been rejected by US regulators in January.<wbr> The news has positive implications 
for companies such as Lexicon and J&amp;J.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Safety Concerns</STRONG> </div><div style="margin-bottom: 10px;">The US regulators concerns centred around cancer and liver injury but the 
European authorities appear to be satisfied that those issues have been 
addressed in the drug's product label and via a risk management plan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Forxiga's Profile</STRONG> </div><div style="margin-bottom: 10px;">Forxiga is an oral drug that in addition to controlling blood glucose levels 
cuts weight and reduces blood pressure.<wbr> It works by blocking a protein called 
SGLT2 or sodium-glucose cotransporte 2.<wbr> It is intended to be used in combination 
with other treatments for type 2 diabetes, including insulin or as a standalone 
treatment for patients who cannot tolerate oral metformin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">In terms of the US BMS has stated that it aims to resubmit its US marketing 
application by mid 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Implications For Other Companies</STRONG> </div><div style="margin-bottom: 10px;">This development is good news for other companies with this class of drug 
(e.<wbr>g.<wbr> J&amp;J, GSK, Lexicon etc), as at one point there was growing uncertainty 
about whether any product in this class would be approved.<wbr> </div><div>Source: <A href="http://www.bms.com">www.<wbr>bms.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7171">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-15T16:42:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-15T16:42:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PWC's Latest Industry Report - From Vision To Decision 2020</title>
	<pubDate>2012-11-15T14:47:12+01:00</pubDate>
	<wp:post_id>3715</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PWC's latest Pharmaceutical industry reports suggests the industry 
may be facing numerous challenges but in the long-term it is on the cusp of a 
golden era of renewed productivity and prosperity.<wbr> It advocates that much will 
have to change during the difficult transitional period ahead but for those that 
do survive they need to be willing to prune pipelines and make tough 
decisions to address rising customer expectations, poor scientific productivity 
and cultural barriers.<wbr> </div><div style="margin-bottom: 10px;">In its report it recommends what companies can do to both increase their 
chances of reaching 2020, maximise the value of new and existing medicines, 
develop business models for growth markets, improve scientific productivity and 
reinvigorate the corporate culture.<wbr> </div><div style="margin-bottom: 10px;">Some of the themes that the report covers are highlighted by some pertinent 
examples below.<wbr> However, the full report is attached for you all to read.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_7_ScreenCapture7.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="pharmaworld10175attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(69,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(45 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(49 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(72,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(69,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(36,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(106,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10175_9_pwc%2dpharma%2dsuccess%2dstrategies%5b1%5d.pdf">pwc-pharma-success-strategies[1].pdf</a>&nbsp;&nbsp;(1,7 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10175">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-15T14:47:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-15T14:47:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Reference Pricing Proposal In Sweden</title>
	<pubDate>2012-11-15T12:15:04+01:00</pubDate>
	<wp:post_id>3716</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Reference Pricing Proposal In Sweden</span>&nbsp;<br><span style="font-size: 12px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment 
Sweden may implement international reference pricing (IRP) after a branded drug 
has been on the market for five years, according to Swedish pharmaceutical trade 
association LIF.<wbr> </SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10155">...</a><br></div><div>There have been communications from TLV (the Swedish health Authorities) on their willingess to implement reference pricing.<wbr> The targeted basket countries mentionned to be interesting for reference pricing are: Belgium, Denmark, Finland, The Netherlands, Norway and Austria.<wbr> However, some indicated that this reference pricing will not be implemented before another 3-5 years.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10174">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10155">View thread  PharmaWorld10155: Reference Pricing Proposal In Sweden</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-15T12:15:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-15T12:15:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis's Biosimilar Presentation - Key Takeaways</title>
	<pubDate>2012-11-15T11:56:39+01:00</pubDate>
	<wp:post_id>3717</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday at the Credit Suisse H/<wbr>C conference , Ameet Mallik, Global 
Head of Sandoz's Biopharmaceuticals &amp; Oncology Injectable 
business gave a very interesting account of the current regulatory 
climate surrounding biosimilar approvals, something that may have parallels with 
current thinking on hybrids.<wbr> He also highlighted the commercial success of some 
of the new biosimilar molecules.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>With regard to the regulatory climate Mallik's slides and comments 
were as follows:-</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">"If you look at the way the FDA is moving right now this slide from the 
FDA indicates its stance.<wbr> The more analaytical characterization and the more 
highly similar your molecule is, the lower the clinical burden is.<wbr> They want a 
very high bar for showing that your molecule's the same and if you can do that 
then the clinical burden is much lower.<wbr> </div><div style="margin-bottom: 10px;">Now for companies who can't do that and have more analytical differences in 
the molecule, the development is going to move and look more like a novel drug 
development where the clinical trial hurdle is going to be more significant 
and this is wherer the FDA is moving.<wbr>" </div><div style="margin-bottom: 10px;">We think the FDA concept is moving overall in the right direction.<wbr> They 
really see analytical characterization as the foundation, they see clinical 
trial design as being a confirmation and they are even willing to look at 
non-approved indicationas, and more sensitive indications, novel biomarkers, 
novel endpoints just to confirm  that the molecule biologically works the 
same.<wbr> But without proving again and reproducing the same phIII clinical program 
that was done by the orginator.<wbr>" </div><div style="margin-bottom: 10px;">Also we think a big with the FDA is that it is now allowing phIII studies 
with EU comparator molecules, the EU is allowing the same.<wbr> This allows a lot 
more flexibility for a company to do clinical trials and helps avoid what we 
feared originally was the need to do redundant phIII trials in the US &amp; 
Europe, so this is again we think good progress by the FDA in allowing this.<wbr> The 
FDA also allows for extrapolation across indications.<wbr> So we think all of these 
are very positive.<wbr> </div><div style="margin-bottom: 10px;">Now with the FDA there is still some uncertainty and there is still some risk 
and so I want to highlight that as well.<wbr> There is still no guidance on 
interchangeability and on naming.<wbr>, so these are tow unknowns right now.<wbr> We still 
find clinical reveiwers at the FDA to be conservative and although they're 
moving in the right direction, the experience level at the FDA isn't as high and 
as robutst as what we see at the EMA, so there is still a progress and still I'd 
say back and forth to really get to the clinical trial designs that are 
reasonable and smaller.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commercial Success</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_9_ScreenCapture9.jpg"> </div><div>A copy of the full presentation is attached which also highlights in more 
detail the broad range of capabilities required by a biosimilar 
manufacturer.<wbr> </div><!-- Comment details --><a name="pharmaworld10171attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(115,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(147,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(127,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(107,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(116 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(99 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(131,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10171_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(88,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10171">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-15T11:56:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-15T11:56:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Algeta Provides Additional Highlights on Alpharadin</title>
	<pubDate>2012-11-15T11:05:17+01:00</pubDate>
	<wp:post_id>3718</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside its Q3:12 financial results, the company provided new highlights regarding the commercial production facility, the distribution network as well as the reimbursement process.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In September, the Algeta Group celebrated the official opening of the offices and facilities of Algeta US in Cambridge, MA.<wbr> </div><div style="margin-bottom: 10px;">Algeta US currently employs 17 people, and plans to deliver a phased build-up of resources in anticipation of a US commercial launch.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8603_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Algeta’s new commercial production facility for Alpharadin was completed during the quarter and the three documentation batches required for the CMC1 sections of the submissions to regulatory authorities have been successfully produced.<wbr> Stability testing of these batches is now underway.<wbr> These data analyses are being shared with Bayer for the completion of the regulatory dossiers </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8603_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8603_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8603_4_ScreenCapture4.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8603">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-15T11:05:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-15T11:05:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PhIII PROSPECT Trial In CRPC Aims To Complete Enrollment in 2013</title>
	<pubDate>2012-11-14T16:50:27+01:00</pubDate>
	<wp:post_id>3719</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: 
During its Q3 earnings webcase, Bavarian Nordic provided a progress update 
on developments with its phIII cancer vaccine PROSTVAC under development 
for the treatment of CRPC.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The vaccine 
is being investigated in a number of NCI-sponsored clinical trials in different 
settings.<wbr> In total, there are 19 ongoing and completed clinical trials involving 
more than 1,900 patients.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">A 
large randomized, placebo-controlled Phase 2 trial demonstrated the vaccine’s 
ability to extend the median overall survival by 8.<wbr>5 months in patients with 
advanced prostate cancer, leading to the initiation of a Phase 3 trial 
(“PROSPECT”).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Other 
clinical trials of PROSTVAC in combination with radiation, hormonal therapy or 
chemotherapy, either concomitantly or sequentially, have indicated potential 
synergies for these treatment combinations.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>The 
PROSPECT trial</STRONG> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
PROSPECT Phase 3 trial was initiated in the USA in November 2011 as planned.<wbr> 
This global randomized, double-blind, placebo-controlled study being conducted 
under an SPA with the FDA is expected to enroll about 1,200 patients with 
asymptomatic or minimally symptomatic mCRPC.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Since 
July, the study has also been actively enrolling patients outside the USA.<wbr> 
Collectively, more than 60 study sites are now active across five countries.<wbr> A 
somewhat lengthier and more arduous regulatory process than anticipated in 
certain European countries has apparently delayed the study initiation into 2013 
in these countries.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Bavarian 
Nordic has responded to this delay by implementing a number of measures, aimed 
at maintaining the overall planned schedule for completing enrollment in 
2013.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Other 
ongoing PROSTVAC clinical trials </SPAN><BR></STRONG><BR><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">PROSTVAC 
is currently the subject of three NCI-sponsored clinical studies, evaluating the 
vaccine in combination with other therapies.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">1) 
A Phase 2 study comparing the samarium-153 (radioactive drug) with or without 
PROSTVAC therapy in 68 mCRPC patients.<wbr> An interim analysis, presented at the 
2012 ASCO Annual Meeting, suggests that the combination of PROSTVAC and 
samarium-153 is well tolerated with similar toxicity profile to samarium-153 
alone.<wbr> The early indication of improved time to progression (TTP) warrants 
continued study accrual.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">2) 
A Phase 2 study comparing flutamide (antihormone therapy) with or without 
PROSTVAC in patients with non-metastatic prostate cancer.<wbr> In the study, planned 
to enrol a total of 65 patients, results from 41 patients indicate an 
improvement in TTP for those patients receiving PROSTVAC in combination with 
flutamide (median TTP = 192 days) compared to flutamide alone (median TTP = 108 
days).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">3) 
A Phase 2 study in 50 patients with PSA progression after local therapy (surgery 
and/<wbr>or radiation).<wbr> 19 patients continued to the second stage of the trial that 
combines PROSTVAC with androgen ablation therapy.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">A 
Phase 2 study conducted by Eastern Cooperative Oncology Group (ECOG) and NCI was 
recently terminated due to enrollment challenges.<wbr> The study was designed to 
compare the use of PROSTVAC followed by docetaxel (chemotherapy) versus 
docetaxel alone.<wbr> </SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: <a href="http://www.bavarin-nordic.com" class="defaultlink" title="www.bavarin-nordic.com">bavarin-nordic.co&hellip;</a></SPAN><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8602">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-14T16:50:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-14T16:50:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progress Update For New Huntington's Disease Drug</title>
	<pubDate>2012-11-14T16:37:53+01:00</pubDate>
	<wp:post_id>3720</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Comment: Prana Biotechnology has reported on its progress in the Reach2HD trial, following a presentation by Dianne Angus, COO of Prana, at the Huntington Study Group Annual Conference held in Seattle, US.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; font-size: 11px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Trial Design &amp; Status</SPAN></STRONG><BR><BR><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The Reach2HD trial is a Phase IIa, six month trial in 100 patients with early to mid-stage Huntington disease that are treated with one of two doses of PBT2 or placebo.<wbr> Enrollment commenced in April 2012 following approval from the FDA to conduct the trial across sites in the USA and Australia.<wbr> All 20 Reach2HD sites are open and recruiting.<wbr> Based on current recruitment activity, the company said that it expects that over 80% of patients will be in dosing by the end of November 2012 in line with Prana&rsquo;s recruitment completion target at the end of the year 2012 and reporting of results in second half of 2013.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Kempler, Prana&rsquo;s chairman and CEO, said, &ldquo;The first patient has already completed the 6 month treatment period and no patients have withdrawn from the trial for any safety or other reasons, so we are very pleased with our progress to date.<wbr> The Data Safety Monitoring Board will report again next February.<wbr>"</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>PBT2</STRONG> <STRONG>Therapeutic Actions In HD</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">During the presentation, Angus noted that PBT2 has a unique therapeutic action because of its specialized ability to prevent the toxic relationship between disease proteins and biological metals in the brain.<wbr> Of special relevance to Huntington disease, PBT2 has been shown in animal modeling that it can reduce the aggregation of a mutant form of the Huntingtin protein that is associated with the disease, improve motor function, preserve neuronal tissue and significantly improve life expectancy.<wbr> Moreover PBT2 has demonstrated a significant ability to improve cognitive Executive Function (thinking ability) in a Phase IIa study in Alzheimer&rsquo;s disease, Angus reported.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Based on the breadth of pre-clinical and clinical data to date, Prana&rsquo;s Reach2HD trial has been designed to investigate safety and tolerability of PBT2 in Huntington disease patients and to measure potential cognitive, functional and motor benefits in patients and also explore mechanistic biomarker readouts.<wbr> </SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px Verdana, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">source: <A href="http://www.pranabiotech.com">www.<wbr>pranabiotech.<wbr>com</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6649">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-14T16:37:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-14T16:37:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's R&D Day - Key Takeaways</title>
	<pubDate>2012-11-14T14:53:36+01:00</pubDate>
	<wp:post_id>3721</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer highlighted the strong progress being made with its 
development pipeline, with five new drugs expected to generate peak sales of 
&gt;$5.<wbr>5bn, amongst them the new prostate cancer drug Alpharadin.<wbr> Also emphaised 
was the manner in which Bayer utilises different types of partnerships to fuel 
its development pipeline.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_1_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">The group has currently 35 products in clinical development with the key 
projects as shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_2_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Following the introductory remarks by.<wbr>.<wbr>.<wbr>.<wbr>.<wbr> Professor Plischke took a closer 
look at the manner in which Bayer undertakes some of its collaborative research 
in healthcare </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_3_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">He noted some of the successes Bayer has had with partnershiips covering 
Xarelto, Nexavar, Stivargo and Eylea and then proceeded to explain more about 
some of Bayer's partnership models.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_5_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_6_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_7_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_9_ScreenCapture10.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_10_ScreenCapture11.jpg"> </div><!-- Comment details --><a name="oncology8599attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_1_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(102,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_2_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(98,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(88 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(109,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(100,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(103,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(81,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8599_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(83,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8599">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-14T14:53:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-14T14:53:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Repros Presents Proellex Clinical Updates @ the Lazard Capital Market H/C Conference</title>
	<pubDate>2012-11-14T14:24:01+01:00</pubDate>
	<wp:post_id>3722</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management presented encouraging progress on Proellex development.<wbr> The company has initiated the 1st clinical site for the Ph2 low dose oral study of Proellex in the treatment of severe endometriosis and expects to commence enrollment shortly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Repros expects to complete enrollment of the 90 subject, 4 month active dosing trial in Q2:2013 and release results during Q4:2012.<wbr> </div><div style="margin-bottom: 10px;">The Company plans to conduct the study at 10 U.<wbr>S.<wbr> sites.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reopros has reviewed the preliminary results from the women that have completed dosing with Proellex-V at 3, 6 and 12 mg.<wbr> The 12 mg dose achieved statistically significant improvement in menstrual bleeding, uterine fibroid symptoms and reduction in fibroid volume even with the low number of subjects enrolled into the study (n=12 @ 12 mg).<wbr> </div><div style="margin-bottom: 10px;">Based on these findings the Company believes the 12 mg dose is appropriate for further development.<wbr> Exposure levels of the drug after vaginal administration of the 12 mg dose were extremely low, yet these low levels were able to produce significant clinical benefit.<wbr> </div><div style="margin-bottom: 10px;">The two lower doses did not achieve the same level of improvement and the 12 mg dose was able to achieve separation from the two lower doses that approached or were statistically significant.<wbr> The 12 mg dose was well tolerated.<wbr> The majority of the women in the 12 mg group have elected to roll into a one year extension study.<wbr> </div><div style="margin-bottom: 10px;">To eliminate the need for hysterectomy </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Early efficacy signal detected for Proellex-V </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Repros expects vaginal delivery to exceed shrinkage efeccts of highest oral dose tested </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="oncology8597attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(59,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(85,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(57 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8597_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(32,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8597">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-14T14:24:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-14T14:24:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Findings From a Ph2 Trial of Allergan's Botox in Treating LUTS Due to BPH</title>
	<pubDate>2012-11-14T13:46:20+01:00</pubDate>
	<wp:post_id>3723</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Conclusions of the trial show reductions in LUTS/<wbr>BPH symptoms were seen in all groups, including placebo, with no significant between-group differences owing to a large placebo effect from the injectable therapy.<wbr> The findings from the post hoc analysis in men previously treated with α-blockers will be further explored in an appropriately designed study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG> </STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT00284518?term=NCT00284518&amp;rank=1">NCT00284518</A></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">BACKGROUND:</H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Botulinum toxin treatment has been investigated as a minimally invasive alternative to oral medications in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (LUTS/<wbr>BPH).<wbr></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">OBJECTIVE:</H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">To explore the efficacy of onabotulinumtoxinA 100 U, 200 U, and 300 U versus placebo in men with LUTS/<wbr>BPH in a phase 2 dose-ranging study.<wbr></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">DESIGN, SETTING, AND PARTICIPANTS:</H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">A multicenter double-blind randomized, placebo-controlled 72-wk study enrolled men ≥50 yr of age with LUTS/<wbr>BPH, International Prostate Symptom Score (IPSS) ≥12, total prostate volume (TPV) 30-100ml, and maximum flow rate (Q(max)) 5-15ml/<wbr>s.<wbr></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">INTERVENTION:</H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Single transperineal (n=63) or transrectal (n=311) administration of placebo (n=94) or onabotulinumtoxinA 100 U (n=95), 200 U (n=94), or 300 U (n=97) into the prostate transition zone.<wbr></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:</H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The primary efficacy end point was a change from baseline in IPSS at week 12.<wbr> Secondary end points were Q(max), TPV, and transition zone volume (TZV).<wbr> Analysis of covariance and the Cochran-Mantel-Haenszel method assessed the efficacy and proportion of IPSS responders.<wbr> Adverse events (AEs) were assessed.<wbr></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">RESULTS AND LIMITATIONS:</H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Significant improvements from baseline in IPSS, Q(max), TPV, and TZV were observed for all groups, including placebo, at week 12 (p&lt;0.<wbr>001), with no significant differences between onabotulinumtoxinA and placebo.<wbr> However, in an exploratory post hoc analysis, a significant reduction in IPSS versus placebo was observed with onabotulinumtoxinA 200 U in prior α-blocker users (n=180) at week 12.<wbr> AEs were comparable across all groups.<wbr></P> </div><div style="margin-bottom: 10px;"><H4 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: uppercase; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0.25em 0px 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: left; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">CONCLUSIONS:</H4> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Reductions in LUTS/<wbr>BPH symptoms were seen in all groups, including placebo, with no significant between-group differences owing to a large placebo effect from the injectable therapy.<wbr> The findings from the post hoc analysis in men previously treated with α-blockers will be further explored in an appropriately designed study.<wbr></P> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Authors : </SPAN><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, Zhou J, Patel A, Haag-Molkenteller C - Medical U.<wbr> of Vienna, Vienna, Austria</SPAN> </div><div><DIV class="aff" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 0.84em/1.09em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<H3 class="label" style="BORDER-BOTTOM: 0px; POSITION: absolute; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.2857; MARGIN: 1.28em 0px 0.64em; PADDING-LEFT: 0px; WIDTH: 1px; PADDING-RIGHT: 0px; HEIGHT: 1px; COLOR: rgb(114,65,40); FONT-SIZE: 1.07em; VERTICAL-ALIGN: baseline; OVERFLOW: hidden; BORDER-TOP: 0px; TOP: auto; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px; LEFT: -10000px">Source</H3>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Publication : Eur Urol.<wbr><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px/15px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> 2012 Oct 12.<wbr> pii: S0302-2838(12)01224-9.<wbr> doi: 10.<wbr>1016/<wbr>j.<wbr>eururo.<wbr>2012.<wbr>10.<wbr>005.<wbr> [Epub ahead of print]</SPAN>.<wbr></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8595">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-14T13:46:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-14T13:46:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche's Market-Access Strategy for Cancer Drugs in China</title>
	<pubDate>2012-11-14T11:16:07+01:00</pubDate>
	<wp:post_id>3724</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche is getting together with Swiss Re, the world's second-biggest reinsurer, to sell a Swiss-engineered private insurance that is on track to garner 10 million clients in 2012.<wbr> The two companies may introduce the concept in Thailand and Indonesia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Roche provides health data needed to set up the policies.<wbr> Swiss Re, based in Zurich, does the statistical heavy lifting and then re-insures local insurers who sell the policies.<wbr> </div><div style="margin-bottom: 10px;">According to <A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2960278-5/abstract">'Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study' </A>published in the Lancet in March 2012, state funding for China’s health insurance programs has sextupled to 240 yuan per person in the past five years.<wbr> While that’s enough to cover basic treatment, about 13% of Chinese households last year had to "foot so-called catastrophic health expenses accounting for more than 40% of their income".<wbr> </div><div>Source: <A href="http://www.bloomberg.com/news/2012-11-13/roche-propels-cancer-drug-sales-in-china-with-insurance.html">Bloomberg</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10161">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-14T11:16:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-14T11:16:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Beijing Hanmi Continues to Grow in China Thanks to Pediatric's Diarrhea Drug</title>
	<pubDate>2012-11-14T11:09:40+01:00</pubDate>
	<wp:post_id>3725</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sales of Hanmi's flagship probiotic drug (Mami-Ai) for the treatment of diarrhea are expected to expand 31% YoY in 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Beijing Hanmi Pharmaceutical, Hanmi Pharm's affiliate in China, is drawing the attention with its achievement of the largest sales in the third quarter, 207 million RMB.<wbr> </div><div style="margin-bottom: 10px;">This is due to marketing reinforcement of Beijing Hanmi's main product '<A href="http://www.bjmamiai.com/">Mami-Ai</A>' as an OTC product with 35% of growth.<wbr> </div><div style="margin-bottom: 10px;">OTC drugs accounted for approx.<wbr> 24% of the China's drug market in 2011.<wbr> </div><div style="margin-bottom: 10px;">Since its opening in 1996, Beijing Hanmi has shown substantial growth each year with focused efforts on pediatric market, represented by `Mami-Ai` which is the top brand pediatric digestive supplement.<wbr> </div><div>Sources: Hanmi; Hyundai Research </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1865">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-14T11:09:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-14T11:09:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Antibody Targeted Drug Demonstrates Benefit In CRPC</title>
	<pubDate>2012-11-13T18:34:33+01:00</pubDate>
	<wp:post_id>3726</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Data presented last week at the Symposium on Molecular Targets 
and Cancer Therapeutics in Dublin, highlighted a new type of targeted drug 
therapy which has shown early positive results in men with metastatic, 
castration-resistant porstate cancer (mCRPC), patients who had failed at 
least two forms of chemotherapy </div><div style="margin-bottom: 10px;">A press release issued by the organisers ECCO states that, the new form of 
therapy directly targets prostate cancer cells via a molecule 
known as prostate-specific membrane antigen or PSMA.<wbr> The drug does this by 
combining a targeting agent (a PSMA monoclonal antiobody) and a cancer 
cell-killing agent called monomethyl auristatin E (MMAE).<wbr> </div><div style="margin-bottom: 10px;">Reportedly, a phI trial has been completed in 50 men at doses of PSMA-ADC 
between 0.<wbr>4 and 2.<wbr>8 mg/<wbr>kg for four cylces of therapy with each cycle 
lasting 3 weeks.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Anti-tumor activity was observed in patients who were treated at the 
higher doses.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>About 50 percent of patients treated with doses of ≥ 1.<wbr>8 
mg/<wbr>kg showed  
<UL><LI>A ≥ 50 percent reduction in PSA levels, or</LI>
<LI>A reduction in serum levels of circulating tumor cells (CTCs)  
  to less than five cells per 7.<wbr>5 ml of blood, or</LI>
<LI>Both of the above</LI>
</UL></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The drug was “generally well tolerated”, but </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Neutropenia (low levels of white blood cells) was 
  significant at the highest dose of the drug (2.<wbr>8 mg/<wbr>kg).<wbr></LI>
<LI>One patient died on the highest dose of the drug but “the cause of the 
  death is unclear.<wbr>”</LI>
<LI>A Phase II trial of PSMA-ADC in up to 75 patients has been initiated 
  with a dose of PSMA-ADC of 2.<wbr>5 mg/<wbr>kg</LI>
</UL> </div><div style="margin-bottom: 10px;">Whilst there is no reference to the drug’s developer in the media release, we 
believe the drug is an asset of Progenics Pharmaceuticals.<wbr> <A href="http://www.progenics.com/antibody.cfm">http:/<wbr>/<wbr>www.<wbr>progenics.<wbr>com/<wbr>antibody.<wbr>cfm</A> </div><div>Source: <A href="http://prostatecancerinfolink.net">http:/<wbr>/<wbr>prostatecancerinfolink.<wbr>net</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8594">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-13T18:34:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-13T18:34:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Breakthrough Development In Pancreatic Cancer</title>
	<pubDate>2012-11-13T17:33:00+01:00</pubDate>
	<wp:post_id>3727</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Comment: Yesterday Celgene reported positive phIII results with ABRAXANE in pancreatic cancer a development that potentially raises the bar for other late-stage competitors.<wbr> </SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></SPAN> </div><div style="margin-bottom: 10px;">In the MPACT(Metastatic Pancreatic Adenocarcinoma Clinical Trial) study, a Celgene-sponsored, open-label, randomized, international study 861 metastatic pancreatic cancer patients were randomized to receive either ABRAXANE plus gemcitabine (125 mg/<wbr>m<SUP>2</SUP> followed by 1000 mg/<wbr>m<SUP>2</SUP> gemcitabine for 3 weeks followed by a week of rest) or gemcitabine alone (1000 mg/<wbr>m<SUP>2</SUP> administered weekly for 7 weeks followed by a week of rest followed by cycles of weekly administration for 3 weeks followed by one week of rest).<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint for the study was improvement in overall survival.<wbr> Secondary endpoints include evaluation of progression-free survival, objective tumor response and the safety and tolerability of this combination in this patient population.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">A late-breaker placeholder abstract for this study has been submitted to the American Society of Clinical Oncology&rsquo;s (ASCO) 2013 Gastrointestinal Cancers Symposium being held inSan FranciscoonJanuary 24-26, 2013.<wbr> </div><div style="margin-bottom: 10px;">Based on the results of theMPACTstudy, the company plans to submit dossiers for registration in the US,Europeand other markets.<wbr> </div><div style="margin-bottom: 10px;"><BR><STRONG>Competitive Context</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Celgene's phase III success with Abraxane could change the pancreatic cancer treatment landscape, and &ndash; depending on the magnitude of the survival benefit and the safety profile demonstrated &ndash; raise the bar for late-stage competitors.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The Abraxane result stands as a rare positive in a field much more used to failure &ndash; as demonstrated recently by Clavis Pharma and Amgen </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">However, despite many setbacks pancreatic cancer remains a hot area for late-stage research, probably because of the paucity of current treatment options, and there are no fewer than five projects with phase III readouts over the next 12 months.<wbr></SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Source: <A href="http://www.celgene.com">www.<wbr>celgene.<wbr>com</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8592">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-13T17:33:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-13T17:33:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Patent Covering PROLOR's Reversible-Pegylation Platform</title>
	<pubDate>2012-11-13T16:52:03+01:00</pubDate>
	<wp:post_id>3728</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The U.<wbr>S.<wbr> Patent and Trademark Office issued a notice of allowance for a patent application covering the company's long-acting reversible-pegylation technology (RPeg).<wbr> Upon issuance, the new patent will provide added intellectual property protection, including additional compositions and configurations of long-acting drug product, in addition to the already-issued U.<wbr>S.<wbr> patent covering the RPeg platform.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The RPeg technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a variety of peptides and small molecules, including compounds that need to cross the blood-brain barrier, such as the appetite suppressant peptide PYY, PROLOR's GLP-1/<wbr>Glucagon dual receptor agonist MOD-6030 in development for obesity and type 2 diabetes, and the diabetes-related compound exendin-4, the blood pressure controlling hormone ANP and the intravenous antibiotic drug gentamicin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">PROLOR licensed the RPEG technology platform from Yeda R&amp;D Ltd.<wbr>, the commercial arm of the Weizmann Institute of Science in Israel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company expects this new U.<wbr>S.<wbr> patent will be issued in the next few months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7119" class="defaultlink">Endocrinology7119: PROLOR Progress with its Reversible-Pegylation Technology Platform</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7169">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-13T16:52:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-13T16:52:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Japanese Government Policies to Encourage Use of Generics</title>
	<pubDate>2012-11-13T16:41:35+01:00</pubDate>
	<wp:post_id>3729</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The latest round of semi-annual financial releases in Japan have revealed that a number of pharma firms have underestimated the effects of generic competition against former blockbuster drugs, exacerbated by National Health Insurance (NHI) price cuts, and been forced to issue reduced sales forecasts.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Astellas Pharma's hyperlipidemia treatments Lipitor (atrovastatin) and Caduet (atorvastatin + amlodipine) saw generic competition from November 2011, with sales falling 22.<wbr>8% year-on-year (y/<wbr>y) to JPY36.<wbr>6 billion (USD460 million), while sales of Lipitor alone fell by 32.<wbr>4%.<wbr> In its results release, Astellas states that generics took up a 20% share of the Lipitor market, and lowered its full-year sales forecast for the drug by JPY18 billion to JPY71.<wbr>8 billion.<wbr> The firm was also surprised by falling sales of Harnal (tamsulosin) and Gaster (famotidine) among others, and reduced the forecast for overall ethical drugs sales by JPY14.<wbr>3 billion to JPY541.<wbr>8 billion.<wbr> </div><div style="margin-bottom: 10px;">Eisai's Alzheimer's drug Aricept (donepezil) – which faced generic competition from November 2011 – and proton pump inhibitor Pariet (rabeprazole) were also badly affected, down 34.<wbr>3% and 15.<wbr>8% y/<wbr>y to JPY53.<wbr>426 billion and JPY53.<wbr>278 billion respectively.<wbr> Eisai estimates the share of generics against Aricept has increased to 25% in terms of sales volume, up from 16% in March this year.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, generic competition against neuroprotective drug Radicut (edaravone) took Mitsubishi Tanabe Pharma by surprise: sales fell by 45.<wbr>4% to JPY6.<wbr>9 billion, and the firm slashed its full-year forecast for the drug by JPY500 million.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The combination of the April 2012 NHI price reductions combined with loss of patent protection, and apparently greater generic uptake in Japan has surprised a number of Japanese firms.<wbr> This may reflect the increasing effectiveness of Japanese government policies to encourage use of generics, such as use of prescribing by generic name </div><div style="margin-bottom: 10px;">Eisai is taking positive steps to counter the news, and hopes to meet a JPY90-billion full-year sales target for Aricept by finding 160,000 new Alzheimer's patients during the remainder of the year, and increasing the usage of the drug among existing patients by extending the drug administration period by 15% and setting up a telephone reminder service to improve adherence.<wbr> The results may be indicative of a sea change in the Japanese domestic market, however, with off-patent "long-listed" drugs seemingly no longer enjoying longevity of brand loyalty, with resistance from patients and doctors to generics use on the wane.<wbr> This may encourage firms to continue to look abroad and to emerging markets to stimulate sales.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10159">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-13T16:41:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-13T16:41:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Launch of Bayer's Visanne Delayed in Italy</title>
	<pubDate>2012-11-13T11:23:52+01:00</pubDate>
	<wp:post_id>3730</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8590">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-13T11:23:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-13T11:23:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aeterna Zentaris Moves Forward With the Development of AEZS-108 in CRPC</title>
	<pubDate>2012-11-13T10:31:31+01:00</pubDate>
	<wp:post_id>3731</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The trial is being supported by a three-year $1.<wbr>6m grant from the National Institutes of Health to Jacek Pinski, associate professor of medicine at the Norris Comprehensive Cancer Center of the University of Southern California.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Preliminary data for the Phase I portion of this trial, presented in February 2012 at ASCO GU Symposium, demonstrated that AEZS 108 was well tolerated and demonstrated early evidence of antitumor activity in men with CRPC.<wbr> Final Phase I data are expected to be presented at an upcoming conference in 2013.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Dr Pinski said, "AEZS-108 has been very well tolerated in this heavily pre-treated population, and its efficacy, so far, is impressive.<wbr> We are fully committed to the Phase 2 portion of the study as shown with the opening of additional sites at the Los Angeles County Hospital, West Los Angeles and Pasadena clinics.<wbr>" </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>PhII Study Design</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">A single-arm Simon Optimum design Phase II study involving up to 37 patients with pre treated CRPC, using the dose selected (210mg/<wbr>m2) in the Phase I portion.<wbr> Six patients that were administered the 210mg/<wbr>m2 dose in the Phase I portion of the trial, have already been included in the Phase II portion.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">For the Phase II portion, patients receive AEZS 108 intravenously over two hours in repeating 21 day cycles, until progression of the disease, unacceptable toxicity or patient withdrawal.<wbr> If clinical benefit is observed, up to six cycles will be administered.<wbr> Patient's continuation beyond six cycles is left at the discretion of the principal investigator.<wbr> </SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Premedication includes dexamethasone 8mg.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Maximal Prostate Specific Antigen (PSA) response is calculated using PSA Working Group 2 guidelines.<wbr> Response Evaluation Criteria in Solid Tumors (RECIST, v.<wbr> 1.<wbr>1) is used to assess response for patients with measurable disease.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Key Endpoints</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The primary endpoint of the Phase II portion is to evaluate the clinical benefit of AEZS 108 for these patients.<wbr> Clinical benefit will be defined as non-progression at 12 weeks with no dose limiting toxicity or other toxicity requiring termination of treatment.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Secondary endpoints include toxicity, time to RECIST and PSA progression, RECIST response rate for patients with measurable disease, PSA response rate, pain palliation, and overall survival.<wbr> In addition, there will be correlative studies to investigate potential predictors of response and outcomes.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Development Status</SPAN><BR><BR></STRONG><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">AEZS-108 has successfully completed Phase II studies for the treatment of endometrial and ovarian cancer, and is also in Phase II trials in prostate and bladder cancer.<wbr> </SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px Verdana, Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(51,51,51); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The company is currently planning a Phase III trial in endometrial cancer.<wbr> AEZS 108 has been granted orphan-drug designation by the FDA and orphan medicinal product designation from the European Medicines Agency for the treatment of ovarian cancer.<wbr> An investigational new drug in the US is in place for the treatment of prostate, bladder and triple-negative breast cancer.<wbr> Aeterna Zentaris owns the worldwide rights to AEZS 108.<wbr></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8589">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-13T10:31:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-13T10:31:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Medivation's Q3:12 Financial Results</title>
	<pubDate>2012-11-12T10:34:31+01:00</pubDate>
	<wp:post_id>3732</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management highlighted that for the first 12 business days that XTANDI was on the market, the drug generated $14.<wbr>1M in net product sales in the U.<wbr>S, as reported by Astellas.<wbr> D.<wbr> Hung, President &amp; CEO believes that the most substantial commercial opportunity for the drug lies in pre-chemo patients as well as breast cancer (Ph1 enrolling).<wbr> Given the "phenomenal" patent life of the drug, Medivation is looking to run additional registration trials as well as combination studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Commenting on Astellas' guidance ($86M), management indicated that " .<wbr>.<wbr>.<wbr> With respect to the Astellas guidance, this is something that they were required to do by Tokyo Stock Exchange rules.<wbr> This was a number that we had no involvement in determining, and it's frankly a number that we're just not going to comment on because to us, we don't yet feel that we have sufficient data to reliably start predicting the future at this point".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">2- Milestone-related payments to UCLA </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> So you'll remember, we owe them 10% of any development milestone payments that we get from Astellas.<wbr> So we received $45M from Astellas in Q3.<wbr> So $4.<wbr>5 million of that went through to UCLA.<wbr> That's running through the R&amp;D line.<wbr> We also had a $2 million milestone payment to UCLA due to them under our license agreement for receipt of the NDA approval in the US".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Patrick Machado outlined that "the company market research indicates that approx.<wbr> 88% of surveyed oncologists were aware of XTANDI 4 wees after launch, and that more that half of physician-reported details for post-chemo mCRPC products in the month of September were for XTANDI".<wbr> </div><div style="margin-bottom: 10px;">Lynn Seely, Chief Medical Officer, added that " .<wbr>.<wbr>.<wbr> Each specialty is different.<wbr> The oncologists care more about the science and the urologists care more about, give me the short synopsis about the efficacy and safety of your profile.<wbr> So that's the only major differences, but it's gone very well since launch with our messaging, and it's been very receptive .<wbr>.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Lynn Seely indicated that "the company is covering a majority of the oncologists, the large urology, physicians that see a lot of metastatic castration-resistant prostate cancer patients as well".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Background </U> </div><div style="margin-bottom: 10px;">- Both TERRAIN and STRIVE are randomized, double-blind trials of enzalutamide head-to-head against bicalutamide, with a primary endpoint of progression-free survival.<wbr> The trials differ in that TERRAIN is enrolling only metastatic patients and is being conducted primarily in EU, while STRIVE will enroll both metastatic and non-metastatic patients and be conducted primarily in the US.<wbr> </div><div style="margin-bottom: 10px;">Management reported that STRIVE is "enrolling both metastatic and non-metastatic patients, and we're pleased with the progress to date in that trial.<wbr> TERRAIN is "a trial that's being operationalized by our colleagues at Astellas, and that trial is enrolling metastatic only patients, and so the guidance from that will come from them".<wbr> </div><div>Full document is attached.<wbr> </div><!-- Comment details --><a name="oncology8586attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8586_1_Medivation%255f10Q%255fNov92012.pdf">Medivation_10Q_Nov92012.pdf</a>&nbsp;&nbsp;(883,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8586">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-12T10:34:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-12T10:34:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Q-Med Launches Legal Suit Claiming Medicis Deal Violates Licensing Agreement</title>
	<pubDate>2012-11-12T10:18:45+01:00</pubDate>
	<wp:post_id>3733</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Q-Med launched a suit in a New York federal court late last 
week to try and prevent Medicis from transfering marketing rights to its 
filler products Restylane, Perlane and Sub-Q to Valeant as part of the 
latters $2.<wbr>6bn purchase of Medicis.<wbr> </div><div style="margin-bottom: 10px;">Q-Med is describing the legal action as "an action in aid of arbritration".<wbr> 
It asserts that it will sustain “irreparable harm” if those rights are 
transferred while arbitration is pending.<wbr> Q-Med has asked the court for an 
order temporarily blocking the transaction.<wbr> </div><div style="margin-bottom: 10px;">U.<wbr>S.<wbr> District Judge Richard J.<wbr> Sullivan ordered Medicis to respond to the 
injunction request by Nov.<wbr> 14 and scheduled oral argument for Dec.<wbr> 3.<wbr> </div><div style="margin-bottom: 10px;">Medicis shares fell by 7% after the disclosure on Friday.<wbr> </div><div>Source: Bloomberg </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6676c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Just days before Valeant's acquisition of Medicis is due to complete, it is noted in Medicis 8k filing that the District Court for the Southern District of New York has dismissed Q-Med's case against Medicis.<wbr> The suit related to the transfer of rights of Restylane to Valeant.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6648">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-12T10:18:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-12T10:18:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda's New Strategy Targets the Vaccine Market</title>
	<pubDate>2012-11-12T10:12:06+01:00</pubDate>
	<wp:post_id>3734</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Through a recently created unit, Takeda is targeting growth in the vaccines market.<wbr> The company will initally focus on infectious diseases, such as gastroenteritis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Takeda recently bought LigoCyte Pharm for $60M, gaining access to the latter's experimental vaccine to prevent norovirus gastroenterisits (Ph1/<wbr>Ph2).<wbr> </div><div style="margin-bottom: 10px;">In addition to the norovirus vaccine candidate, LigoCyte has also initiated preclinical development of vaccines against respiratory syncytial virus, influenza and rotavirus.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>Location of executive offices: Bozeman, Montana</LI>
<LI>Representative: Donald P.<wbr> Beeman, CEO and Member of the Board of Directors</LI>
<LI>Year of establishment: 1998</LI>
<LI>Common Stock Equity: $10,000</LI>
<LI>Number of employees: Approximately 40 employees.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1864">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-12T10:12:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-12T10:12:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novartis R&D Day Features A Strong Pipeline Of Oncology Products</title>
	<pubDate>2012-11-09T19:14:15+01:00</pubDate>
	<wp:post_id>3735</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis R&D Day Features A Strong Pipeline Of Oncology Products</span>&nbsp;<br><span style="font-size: 12px;">Comment: Today Novartis profiled what it terms its "industry-leading pipeline" highlighting its development acitivity with 73 new compounds across 139 development projects,emphasising in particular the potential for its oncology pipeline.<wbr> Late-stage oncology projects are expected to generate $1bn in sales by 2017 and Afinitor around $2bn in sales just from breast cancer alone.<wbr> Reference to Signifor was made in the context of it being " a strategic brand" following on from a statement about Sandostatin LAR being one of the base products expected to generate continued growth over the next 4 years.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8582">...</a><br></div><div style="margin-bottom: 10px;">As mentioned in Jacquelyne Cantle's summary : "There was no reference in the presentation to Camurus or its fluid crystal injection technology".<wbr>  This remark applies for Signifor future registration in Acromegaly.<wbr> It applies as well for Sandostatin for which no life-cycle innovation is reported.<wbr> </div><div style="margin-bottom: 10px;">As it has been previously discussed ( ie yesterday  by the Somatuline Taskforce for Hybrids and off patent drugs) we must understand with the support of RA team if  the change of injection technology is considered by Novartis as a "minor modification" or if there is another reason behind  this lack of reporting.<wbr> </div><div>Emilie and Philippe for Endo Franchise </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7168">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8582">View thread  Oncology8582: Novartis R&D Day Features A Strong Pipeline Of Oncology Products</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-09T19:14:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-09T19:14:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FIM Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer</title>
	<pubDate>2012-11-09T17:42:14+01:00</pubDate>
	<wp:post_id>3736</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph1, which PE will determine the safety, tolerability and MTD of Bayer's PSMA/<wbr>CD3-bispecific BiTE antibody in patients with CRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01723475?recr=Open&amp;no_unk=Y&amp;cond=prostate+OR+botulinum+OR+neuroendocrine+OR+or+spasticity&amp;fund=2&amp;rcv_s=11%2F01%2F2012&amp;rank=1"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 80 </div><div style="margin-bottom: 10px;">Start date: Nov.<wbr> 2012 - Completion date: August 2014 </div><div style="margin-bottom: 10px;">MOA: sc administration one daily </div><div style="margin-bottom: 10px;">Locations: Austria; Germany </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">@ AACR (Chicago - March 31 - April 4, 2012) </div><div><EM>Subcutaneous administration of PSMA/<wbr><WBR>CD3-bispecific BiTE antibody MT112/<wbr></WBR><WBR>BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice.<wbr></WBR></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8585">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-09T17:42:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-09T17:42:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz' BELOTERO BALANCE® Dermal Filler Available in the U.S</title>
	<pubDate>2012-11-09T10:34:08+01:00</pubDate>
	<wp:post_id>3737</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Approved by the US FDA in November 2011, the hyaluronic acid-based filler joins the Merz Aesthetics portfolio of injectable products, including RADIESSE® Volumizing Filler and Asclera® (polidocanol) Injection.<wbr> Of note, the re-entry of Xeomin is expected on January 9, 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Description: sterile, bioresorbable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel device.<wbr> </div><div style="margin-bottom: 10px;">- Indication: for injection into the mid-to-deep dermis for correction of moderate-to-severe facial wrinkles and folds, such as nasolabial folds.<wbr> </div><div style="margin-bottom: 10px;">- Volume per injection: 1.<wbr>5ml per nasolabial fold to achieve optimal correction.<wbr> </div><div>Source: Merz Aesthetics </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6644">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-09T10:34:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-09T10:34:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Nordisk Establishes a Wider Presence in Vietnam</title>
	<pubDate>2012-11-09T09:27:55+01:00</pubDate>
	<wp:post_id>3738</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <STRONG>.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- new office in Ho Chi Minh </div><div style="margin-bottom: 10px;">- 52 employees </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">- to increase its diabetes-related activities </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Vietnam is experiencing a rapid rise in the incidence of non-communicable diseases such as diabetes and hypertension.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U><STRONG>Prevalence</STRONG></U> </div><div style="margin-bottom: 10px;"><UL><LI>1.<wbr>2% in 1994 and 3.<wbr>8% in 2001</LI>
<LI>The most recent data from Ho Chi Minh City published in 2009 show a prevalence close to 11%.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U><STRONG>National Actions</STRONG></U> </div><div style="margin-bottom: 10px;">The Vietnam Diabetes Care Programme (VDCP) was launched in Hanoi on Nov.<wbr> 7th.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 14px/22px Helvetica, Arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(26,26,26); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(49,102,50); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 14px/22px Helvetica, Arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(26,26,26); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(49,102,50); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7167">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-09T09:27:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-09T09:27:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Reference Pricing Proposal In Sweden</title>
	<pubDate>2012-11-09T08:39:10+01:00</pubDate>
	<wp:post_id>3739</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment 
Sweden may implement international reference pricing (IRP) after a branded drug 
has been on the market for five years, according to Swedish pharmaceutical trade 
association LIF.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">A 
special investigator appointed by the Swedish government to evaluate pricing and 
market conditions for drugs in Sweden proposed introducing a ceiling price for 
drugs after five years that is updated annually based on IRP, along with other 
proposed changes.<wbr> According to a summary obtained by BioCentury, the proposals 
could save about SEK2.<wbr>4 billion ($357.<wbr>6 million) annually.<wbr> </SPAN><BR> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Since 
2002, Sweden has had a value-based pricing (VBP) system, under which a drug 
manufacturer requests reimbursement from the Swedish pricing and reimbursement 
authority, the Dental and Pharmaceutical Benefits Agency (TLV).<wbr> The price of the 
branded drug is based on cost effectiveness and a number of other factors, 
including patients' maximum willingness to pay for a quality-adjusted life year 
(QALY).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">If 
TLV agrees with the company's proposed price, the price is set and is unchanged 
while the drug is under patent protection unless TLV decides to review its 
decision.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">According 
to the summary, Swedish prices for new drugs are comparable to other European 
countries but prices for older drugs are "higher in Sweden than in comparable 
countries.<wbr>" Under the proposals, Sweden would continue to use a VBP system for 
the first five years a drug is on the market.<wbr> </SPAN><BR> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">According 
to a LIF spokesperson, the Swedish government "will now decide on a formal 
referral or consultation process on the proposals, which will likely run for at 
least three months.<wbr>" The proposals are slated to take effect by July 1, 
2014</SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: 
Biocentury</SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10174c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>There have been communications from TLV (the Swedish health Authorities) on their willingess to implement reference pricing.<wbr> The targeted basket countries mentionned to be interesting for reference pricing are: Belgium, Denmark, Finland, The Netherlands, Norway and Austria.<wbr> However, some indicated that this reference pricing will not be implemented before another 3-5 years.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10155">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-09T08:39:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-09T08:39:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis R&D Day Features A Strong Pipeline Of Oncology Products</title>
	<pubDate>2012-11-08T14:31:18+01:00</pubDate>
	<wp:post_id>3740</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Today Novartis profiled what it terms its "industry-leading pipeline" highlighting its development acitivity with 73 new compounds across 139 development projects,emphasising in particular the potential for its oncology pipeline.<wbr> Late-stage oncology projects are expected to generate $1bn in sales by 2017 and Afinitor around $2bn in sales just from breast cancer alone.<wbr> Reference to Signifor was made in the context of it being " a strategic brand" following on from a statement about Sandostatin LAR being one of the base products expected to generate continued growth over the next 4 years.<wbr> </div><div style="margin-bottom: 10px;">The most notable points to emerge from the presentations regarding developments with Signifor (pasireotide) are that:- </div><div style="margin-bottom: 10px;">i) The filing for Signifor in acromegaly has now moved from 2012 to 2013 </div><div style="margin-bottom: 10px;">II) The filing of the Signifor LAR formulation for Cushing's disease is planned for 2015 as is the filing for Afinitor for non-functioning carcinoid syndrome.<wbr> With regard to the latter some soft intelligence gathered from Novartis at ESMO did suggest that there is a pre-planned interim analysis included in the non-functioning carcinoid trial, which if positive in terms of data generation could lead to an earlier than expected filing in this indication.<wbr> </div><div style="margin-bottom: 10px;">There was no reference in the presentation to Camurus or its fluid crystal injection technology.<wbr> </div><div style="margin-bottom: 10px;">We may learn more once the presentation transcript is available.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Success To Date</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Upcoming Oncology Pipeline </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_10_ScreenCapture10.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_11_ScreenCapture11.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7168c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">As mentioned in Jacquelyne Cantle's summary : "There was no reference in the presentation to Camurus or its fluid crystal injection technology".<wbr>  This remark applies for Signifor future registration in Acromegaly.<wbr> It applies as well for Sandostatin for which no life-cycle innovation is reported.<wbr> </div><div style="margin-bottom: 10px;">As it has been previously discussed ( ie yesterday  by the Somatuline Taskforce for Hybrids and off patent drugs) we must understand with the support of RA team if  the change of injection technology is considered by Novartis as a "minor modification" or if there is another reason behind  this lack of reporting.<wbr> </div><div>Emilie and Philippe for Endo Franchise </div></div><a name="oncology8582attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(157,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(208,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(154,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(130,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(126,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(136,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(126,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(136,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(92,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(87,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8582_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(156,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8582">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-08T14:31:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-08T14:31:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA EMDAC Unanimously Voted in Support for the Use of Pasireotide for Cushing's Disease</title>
	<pubDate>2012-11-08T08:55:55+01:00</pubDate>
	<wp:post_id>3741</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The panel vote was based on data from clinical trials including the late-stage PASPORT-CUSHING study, which showed that mean urinary-free cortisol (UFC) was rapidly decreased and sustained in a majority of patients, with a sunbset of patients achieving normalised levels.<wbr> According to Head of Clinical Development for Novartis Oncology, the company is planning an intervention study for proactive hyperglycemia management.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The study also showed that, on average, as UFC levels were reduced, clinical manifestations of Cushing's disease improved.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The US FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 10-0 that Novartis' efficacy and safety data were sufficient to support the marketing of Signifor in Cushing's disease.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
liver issues: The committee urged that all patients have baseline liver function test, without monitoring continued for 6 months.<wbr></LI>
<LI>
hyperglycemia issues: The company is planning a multi-center, open-label hypergycemia management study in approx.<wbr> 25 patients with the disease receiving Signifor &gt;52 weeks.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Last February, the FDA approved Corcept Therapeutics' Korlym (mifepristone), a cortisol blocker, to "control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have Type II diabetes or glucose intolerance and have failed surgery or are not candidate for surgery".<wbr> see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=6871" class="defaultlink">Endocrinology6871: Corcept's Korlym™ Gains FDA Approval For Cushing's</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7165">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-08T08:55:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-08T08:55:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis - Expands Development Plans For Cabozantinib in CRPC</title>
	<pubDate>2012-11-08T08:17:38+01:00</pubDate>
	<wp:post_id>3742</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Exelixis is currently very focused on the upcoming regulatory review of cabazantanib for medullary thyroid disease (PDUFA November 27th) and its commercial build-out ahead of potential launch.<wbr> Meanwhile, the development of the prostate indications continues to advance with the group now also actively evaluating the use of the drug in combination in earlier stages of the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines For The Pivotal COMET Studies</STRONG> </div><div style="margin-bottom: 10px;">Exelixis noted that the timeline for top-line results for both COMET studies is 1H 2014, </div><div style="margin-bottom: 10px;"><STRONG>Combination studies</STRONG> </div><div style="margin-bottom: 10px;">The group has two separate ongoing combination trials with abiraterone and docetaxel as well as a trial to investigate the combination of cabo with enzalutamide which is currently in planning.<wbr> </div><div style="margin-bottom: 10px;">Additionally, Exelixis is also exploring options for pivotal trials in additional indications, including an in-depth analysis of RCC and HCC pivotal trials </div><div style="margin-bottom: 10px;"><STRONG>Potential From Partnered Programms</STRONG> </div><div style="margin-bottom: 10px;">In addition to cabozantanib, Exelixis has an economic interest in </div><div style="margin-bottom: 10px;">GDC-0973.<wbr> Under the terms of our agreement with Genentech, we are entitled to an initial equal share of U.<wbr>S.<wbr> profits and losses, which will decrease as sales increase, and will share equally in the U.<wbr>S.<wbr> marketing and commercialization costs.<wbr> As disclosed in ClinicalTrials.<wbr>gov, GDC-0973 is moving forward into a phase 3 pivotal trial in combination with vemurafenib in treatment na&iuml;ve melanoma patients carrying a BRAFV600 mutation.<wbr> </div><div style="margin-bottom: 10px;">Additional partnered compounds also continue to advance in phase 2, including two PI3K inhibitors with Sanofi; foretinib with GSK; the Hedgehog antagonist, XL139, or BMS-833923 with Bristol-Myers; the MR antagonist, XL550, or CS-3150 with Daiichi-Sankyo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Latest CRPC Data</STRONG> </div><div style="margin-bottom: 10px;">This was data from the non-randomized expansion cohort of the randomized discontinuation trials that was presented at ESMO by Dr Johann De Bono.<wbr> All of these CRPC patients had been previously treated failed prior docetaxel.<wbr>, 67% had received prior abiraterone or enzalutamide and 25% had received prior cabazitaxel.<wbr> 71% of patients had received at least two prior lines of therapy for CRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">Clinically significant pain, that&rsquo;s defined as a baseline pain score by Brief Pain Inventory or BPI of greater than or equal to 4, was present in 53% of patients, and 45% of patients received chronic narcotic administration.<wbr> Interim data from this study with 40-milligram cabozantinib was consistent with respect to anti-tumor activity compared with the 100-milligram data published earlier this year at ASCO by Dr.<wbr> Matthew Smith.<wbr> However, tolerability was improved compared to the 100-milligram cohort.<wbr> </div><div style="margin-bottom: 10px;">Specifically, a bone scan response evaluated by an Independent Radiology Committee was seen in 49% of patients, with another 29% of patients achieving stable disease and 14% of patients having a best response of progressive disease.<wbr> Importantly, </div><div style="margin-bottom: 10px;">The initial data suggests that cabozantinib&rsquo;s effect on bone scan are linked to induction of tumor necrosis in bone metastases.<wbr> Progression-free survival was 4.<wbr>2 months in this cohort and that was regardless of prior therapy status.<wbr>79% of evaluable patients had tumor regression and measurable lesions and pain response was seen in 69% of evaluable patients with reduction in narcotic medication seen in 54%.<wbr> </div><div style="margin-bottom: 10px;">Adverse events were generally less frequent than with the 100-milligram dose cohort and no grade 5 adverse events were reported.<wbr> Only 25% of patients experienced a dose reduction due to an adverse event.<wbr> These data show that a lower and better tolerated dose of cabozantinib is active in previously treated patients with CRPC.<wbr> It is important to notew that the ongoing COMET-1 and 2 phase 3 studies are both using a 60-milligram QD dose of cabozantinib.<wbr> </div><div>Source: <A href="http://www.exelixis.com">www.<wbr>exelixis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8580">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-08T08:17:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-08T08:17:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon Is Hoping To Partner Diabetes Drug LX4211 In 1H2013</title>
	<pubDate>2012-11-07T14:50:53+01:00</pubDate>
	<wp:post_id>3743</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During yesterday's earnings call, Lexicon focused most of its 
discussion on its diabetes drug LX4211 and its new European carcinoid 
drug data.<wbr> It also emphaised the potential for partnership of its 
diabetes drug LX4211 and noted that it remains committed to conducting 
the phIII trial itself for carcinoid disease.<wbr> However, subject to positive phII 
ulcerative colitis data it does plan to partner this programe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regarding The Status of LX4211 Partnering Jeff Wade made the 
following comment:-</STRONG> </div><div style="margin-bottom: 10px;">"We've been very pleased with the process, overall and with its prgression.<wbr> 
It continues to be ou objective and expectation to complete a partnership before 
phIII launch and we're continuing to work towards the phIII launch in the first 
half of 2013.<wbr>.<wbr>.<wbr>.<wbr> We're still talking to companies about different types of 
structures at this point.<wbr> So our key is to progress the programm forward.<wbr> We're 
obviously expecting a partnership to be a big, big driver in terms of funding 
that development program going forward.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Reinforcing this point Arthur Sands stated:-</STRONG> </div><div style="margin-bottom: 10px;">"I think our expectation and our 
plan is to have a partner in place before we launch phIII.<wbr> Its and expensive 
development programme.<wbr> And that's our plan and that's our expectation.<wbr> and we'll 
expect to have that in place before we actually launch the studies".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regarding Timelines For 
The PhIII Carcinoid Study Arthur Sands noted</STRONG> </div><div style="margin-bottom: 10px;">"We continue to forecast and 
18=month enrollment period from initiation (the trial has now started screening 
patients), which would make the total study time to completion (with 12 weeks 
follow-up approximately two years from now".<wbr> </div><div style="margin-bottom: 10px;">When questioned about durability 
of response beyond 12 weeks Pablo Lapuerta noted that the company does have some 
experience from long-term extensions and from what has been observed it is 
comfortable that benefits are maintained.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Below are the slides, 
Lexicon presented on its phII European data.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Financial Picture</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_14_ScreenCapture14.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_15_ScreenCapture15.jpg"> </div><!-- Comment details --><a name="endocrinology7164attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(51,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(37,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(32 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(37,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(40,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(58,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(47,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(82 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(41,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(57,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(43,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(54,6 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7164_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(29,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7164">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-07T14:50:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-07T14:50:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aspireo Starts Ph2a Study with Somatoprim for Acromegaly</title>
	<pubDate>2012-11-07T09:20:43+01:00</pubDate>
	<wp:post_id>3744</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Israeli biopharm company has enrolled its first patient in a Ph2a study designed to assess the safety, tolerability and efficacy of its drug in untreated acromegaly patients.<wbr> Initial data from this study is expected to be available in the first quarter of 2013.<wbr> Aspireo has been looking to partner this product for some while but has so far been unsuccessful, most probably because of the short patent life that remains.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: &gt;20 participants </div><div style="margin-bottom: 10px;">Protocol: ascending single doses of Somatoprim and one dose of octreotide.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Under the terms of  its prior agreement with Evotec, it will provide Aspireo with strategic and operational advice on the partnering of Somatoprim.<wbr> In addition, Evotec will consult Aspireo on matters of clinical and pre-clinical development.<wbr> In return for such services, Evotec will retain advisory fees as well as participate in the commercial success of Somatoprim.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Novel and proprietary somatostatin analog (SSA) that is based on a novel amino acid composition.<wbr> Somatoprim has demonstrated a unique receptor binding and pharmacological profile which is significantly differentiated from SSAs that are currently marketed or in clinical development.<wbr> </div><div style="margin-bottom: 10px;">In particular, Somatoprim has shown an improved side effect profile with reduced adverse effects on the gastrointestinal tract and metabolic control.<wbr> Aspireo is suggesting that based on assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with Somatoprim , the drug may have the potential  to significantly increase the response rate of acromegalic patients to SSA therapy (currently unproven).<wbr> </div><div>Somatoprim is in phase I/<wbr>II of clinical development with a phase Ib study in Switzerland and a Phase IIa study in the Ukraine, both currently underway.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7235c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><STRONG>Besides Novartis SSAs ( Octreotide and Pasireotide) do we have a new competitor to Somatuline to consider ?</STRONG> </div><div style="margin-bottom: 10px;">Somatoprim (DG3173) is a SSA developed by the Israeli biopharm company Aspireo (Project Focused Company ; <A href="http://www.aspireopharma.com/">www.<wbr>aspireopharma.<wbr>com</A>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG> </STRONG>As mentioned by Brigitte, Aspireo is looking for partnership, their only one current investor is TVM Capital.<wbr> </div><div style="margin-bottom: 10px;">Looking at Pubmed, there are currently only 3 referenced publications with a main one reporting a recent German in vitro study.<wbr> ( Pl&ouml;ckinger et al, 2012 Charit&eacute; Hosp, Berlin).<wbr> </div><div style="margin-bottom: 10px;">Regarding the results of this preclinical study and also a clinical Phase I single ascending dose study in HV, Somatoprim is described as follows </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"> From International Journal of Endocrinology, 2012</SPAN> : A recently developed somatostatin multireceptor ligand, Somatoprim, may be at least as potent, as Octreotide, but without a negative effect on glucose metabolism.<wbr> This molecule has a GH suppressing effect but a very low insulin-suppressing action in vitro.<wbr> If these in vitro data are confirmed in vivo in acromegalic patients, Somatoprim will be a valuable alternative to other SRL.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">From Nature Review Endocrinology</SPAN> : Somatoprim causes greater GH suppression than octreotide when applied to primary cell cultures of somatotroph adenomas according to a German Study.<wbr> In contrast to octreotide, somatoprim has a high affinity for SSTR3, in addition to SSTR2 and SSTR5.<wbr> All analyzed adenomas highly exptessed SSTR3, the activation of which might have been responsible for the higher number of tumors responsive to somatoprim compared to octreotide.<wbr> Previous studies have shown a very low insulin-suppressing effect of somatoprim (NB: leading to less risk of hyperglycemia), which is an advantage vs Pasireotide and Octrotide.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"> Prof Ursula Pl&ouml;ckinger</SPAN> : &ldquo;If clinical trials confirm the in vitro data, we feel that the drug may well become the treatment of choice for medical therapy in acromegaly owing its high efficacy, potential for tumor shrinkage and its negligible effect on insulin secretion&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Concerning the results of the clinical Phase I study</SPAN>: it is indicated that Somatoprim had an excellent tolerability profile at all doses administered.<wbr> An exploratory analysis of plasma growth hormone levels was consistent with a suppression of growth hormone release thus indicating that Somatoprim is able to suppress growth hormone release in humans.<wbr> </div><div style="margin-bottom: 10px;">Finally, Somatoprim is also expected to enter in phase II for its development in GEP-NET.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Main Bibliographic References</STRONG> </div><div style="margin-bottom: 10px;">U.<wbr> Ploeckinger, U.<wbr> Hoffmann, M.<wbr> Geese et al.<wbr>, &ldquo;DG3173 (Somatoprim), a unique Somatostatin receptor subtype 2-, 4- and 5-selective analogue, effectively reduces GH-secretion in human growth hormone secreting pituitary adenomas even in Octreotide non-responsive tumours,&rdquo; <EM>European Journal of Endocrinology</EM>, vol.<wbr> 166, no.<wbr> 2, pp.<wbr> 223&ndash;234, 2012.<wbr> </div><div>Shimon I,  Rubinek T,  Hadani M, and Alhadef N, &ldquo;PTR- 3173 (Somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion,&rdquo; <EM>Journal of Endocrinological Investigation</EM>, vol.<wbr> 27, no.<wbr> 8, pp.<wbr> 721&ndash;727, 2004.<wbr> </div></div><a name="endocrinology7158attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7158_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7158_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(21,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7158">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-07T09:20:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-07T09:20:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Enrollment of the SYNERGY Trial Completed</title>
	<pubDate>2012-11-06T16:57:29+01:00</pubDate>
	<wp:post_id>3745</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The SYNERGY study is designed to evaluate a survival benefit for Oncogenex' custirsen, when added to 1st-line chemotherapy, in men with mCRPC.<wbr> The SYNERGY study is the first of two, ongoing, pivotal Ph3 studies evaluating a potential survival benefit for custirsen treatment in prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: &gt;1000 men </div><div style="margin-bottom: 10px;">Location: 142 sites (primarily in North America and Europe).<wbr> </div><div style="margin-bottom: 10px;">Timelines: Results are expected by the end of 2013.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8575_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8575_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8575attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8575_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(39,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8575_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(35,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8575_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(129 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8575">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-06T16:57:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-06T16:57:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Madrid's Healthcare System to be Partially Privatised as Part of Spanish Austerity Measures</title>
	<pubDate>2012-11-06T14:38:07+01:00</pubDate>
	<wp:post_id>3746</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Madrid's mayor Ignacio Gonzales announced on 1 November his intention to privatise a substantial part of Madrid's regional healthcare system as part of 2013 austerity measures.<wbr> According to <I>El Pais</I>, under Gonzales' proposal, the administration of 6 recently built hospitals will be tendered out to the private sector in an attempt to cut public healthcare spending.<wbr> </div><div style="margin-bottom: 10px;">According to the source, the planned healthcare spending in the region for next year will see a cut of 7% to EUR7.<wbr>108 billion (USD9.<wbr>09 billion).<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">Gonzales' plan to privatise six hospitals in the Madrid region comes as part of a wider budget saving plan for 2013, in which the Spanish government is looking at overall savings of EUR2.<wbr>7 billion.<wbr> </div><div style="margin-bottom: 10px;">The privatisation of some public healthcare structures will start in Madrid as a pilot project and will then, if successful, be exported as a healthcare model to other regions in the country.<wbr> Privatisation is envisaged by the government as part of the new austerity measures plan for 2013.<wbr> Madrid is a good reference region as it accounts for 19.<wbr>4% of Spain's GDP (source: <I>El Pais</I>).<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10153">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-06T14:38:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-06T14:38:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Endo Discontinues Second Ph3 Trial with Urocidin for Non-muscle Invasive Bladder Cancer</title>
	<pubDate>2012-11-06T13:51:41+01:00</pubDate>
	<wp:post_id>3747</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The trial, being run by Endo Pharm.<wbr>, has not been recruiting at the expected rate.<wbr> Endo and Bioniche are jointly considering potential next steps for the program in order to build on the outome of the first Ph3 and to continue to work toward regulatory approval.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The second Ph3 trial for Urocidin has been running for &gt;2 years (the clinical trials database notes Sept 12, 2010, as the trial start date).<wbr> </div><div style="margin-bottom: 10px;">Recall that before starting the trial Endo revised the clinical trial protocol from the protocol for which Bioniche was granted a SPA (Special Protocol Assessment) by the FDA.<wbr> Endo’s revised trial included a comparator arm to randomize patients to receive treatment with Urocidin or Mitomycin C (chemotherapy typically administered intravenously).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In July 2009, Endo licensed from Bioniche the exclusive rights to dev.<wbr> and market the drug in the U.<wbr>S (with an option for global rights) Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=5452" class="defaultlink">Oncology5452: Endo Expands Bladder Cancer Franchise By Acquiring US Rights To Urocidin</a>.<wbr> </div><div>Source: Bioniche; Endo Pharm.<wbr>;ThomsonOne </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8699c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Last week, Bioniche and Endo </SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">came to an agreement that a mutually favourable path forward for the product is to return global rights to Bioniche.<wbr> In exchange for this agreement, Endo will receive a royalty on future revenue.<wbr></SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; background-color: #316632; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="background-color: #ffffff;">Bioniche now has the opportunity to seek alternate partnership arrangements, which would be expected to generate income to offset the costs of any additional clinical trial work required.<wbr></SPAN></SPAN></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8572">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-06T13:51:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-06T13:51:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acino Expands its Business in the CIS Region</title>
	<pubDate>2012-11-06T11:09:29+01:00</pubDate>
	<wp:post_id>3748</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agreement signed between Acino and Medial D&amp;P, a Swiss company based in Basel, will cover Kazakhstan, Turkmenistan, Mongolia, Georgia, Azerbaijan, Armenia, and Uzbekistan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial: not disclosed </div><div style="margin-bottom: 10px;">Terms: Medial will provide registration, logistics as well as marketing and promotion services.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Acino's Chief Commercial Officer, " .<wbr>.<wbr>.<wbr> Medial's local teams of professional staff will not only promote our product range, but will also provide registration and logistic services in the region.<wbr>" </div><div style="margin-bottom: 10px;"><UL><LI>- to expand the geographic reach of its direct marketing business.<wbr></LI>
<LI>- to take advantage of the strong local expertise of Medial in this emerging region, and its local network with KOLs and authorities.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Business: provides all services related to registration, marketing and promotion, distribution and licensing of pharmaceutical products with a strong focus on countries in the CIS region.<wbr> </div><div>The company has over 40 years of experience and a well-established organization with local teams of professional staff.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=203">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-06T11:09:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-06T11:09:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pasireotide Briefing Documents Posted Ahead of FDA Meeting</title>
	<pubDate>2012-11-06T10:51:06+01:00</pubDate>
	<wp:post_id>3749</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA reviewers reported that pasireotide is effective for Cushing's disease, but cautionned that the "efficacy results need to be considered in the context of the overall safety profile" of the somatostatin analog (in particular the development/<wbr>worsening of hyperglycemia/<wbr>diabetes, and elevations in liver enzymes).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The reviewers' comments came in briefing documents (please see attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20121231&edate=20120901&rs=/link%20Endocrinology7157%401" class="defaultlink">@1</a> and <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20121231&edate=20120901&rs=/link%20Endocrinology7157%402" class="defaultlink">@2</a>) released ahead of Wednesday's Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the pasireotide submission.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>On Feb 17, Novartis submitted an NDA application.<wbr> PDUFA date is not disclosed.<wbr> </div><!-- Comment details --><a name="endocrinology7156attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7156_1_Novartis%255fBriefing%20Doc%255fPasireotide.pdf">Novartis_Briefing Doc_Pasireotide.pdf</a>&nbsp;&nbsp;(2 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7156_2_FDA%20Briefing%20Doc%255fPasireotide.pdf">FDA Briefing Doc_Pasireotide.pdf</a>&nbsp;&nbsp;(1,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7156">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-06T10:51:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-06T10:51:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Progresses with Bimatoprost for Increasing Eyelash Growth</title>
	<pubDate>2012-11-05T17:22:51+01:00</pubDate>
	<wp:post_id>3750</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3 study, which primary endpoint will assess Investigator's Assessment of Overall Eyelash Prominence as Measured by the 4-point Global Eyelash Assessment (GEA) Scale.<wbr> Bimatoprost is a key driver for Allergan.<wbr> The drug also is in development for scalp hair growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01698554?recr=Open&amp;no_unk=Y&amp;spons=allergan+OR+merz&amp;fund=2&amp;rank=26"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Nov 2012 - Completion: June 2014 /<wbr> July 2014 </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 454 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6641">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-05T17:22:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-05T17:22:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Q3 Earning Webcast Suggests a Busy 2013 for Neurocrine Biosciences</title>
	<pubDate>2012-11-05T11:29:53+01:00</pubDate>
	<wp:post_id>3751</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company and its partner Abbott are making progress with Elagolix.<wbr> In H1:13, the drug Ph2 uterine fibroid data should be announced.<wbr> Around mid-2013, 2 NBI-98854 (for moderate or severe tardive dyskinesia) Ph2b data should also read out.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>KINECT II -  Ph2b trial</U> </div><div style="margin-bottom: 10px;">Mangement reported that ".<wbr>.<wbr>.<wbr> screening subjects began at the latter half of September .<wbr>.<wbr>.<wbr> 34 sites out of the 40 planned are up and running".<wbr> The Ph2 study is designed to "enroll 90 subjects", and " .<wbr>.<wbr>.<wbr> will be exploring doses between 25 and 75 milligrams".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Uterine Fibroids Trial</U> </div><div style="margin-bottom: 10px;">When questionned about timelines, management reported " .<wbr>.<wbr>.<wbr> Abbott 'll have the current ongoing trial, the Phase IIa in the first half it'll be complete.<wbr> And then we have to see what and we don't know this yet, what is their timing if they seek proof of concept, which we anticipate they would, what would be their timing to start the Phase IIb study.<wbr> And we don't have clarity on that at this point in time.<wbr> We have, I'd say, it's not clarity, we don't have any visibility on what that is at this point in time".<wbr> </div><div style="margin-bottom: 10px;"><U>Endometriosis Trial</U> </div><div style="margin-bottom: 10px;">The 1st Ph3 Endometriosis trial (is enrolling patients as planned, and should yield topline data in early 2014 (NDA filing expected in 2016).<wbr> A 2nd Ph3 trial should also be starting in 2013.<wbr> </div><div style="margin-bottom: 10px;"><U>Leerink Swann Estimates</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8564_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Morgan Stanley Projection</U> </div><div style="margin-bottom: 10px;">While a majority (~60-70%) of treated patients with endometriosis pain are well served with oral contraceptives (OCP) and NSAIDs (non-steroidal anti inflammatory drug – e.<wbr>g.<wbr> ibuprofen), there is a large population of patients (~700K in the US) that require more intensive treatment.<wbr> </div><div>Elagolix’ profile compares favorably to currently used 2nd/<wbr>3rd line therapies such as Lupron (Abbott) and Depo-provera (Pfizer).<wbr> </div><!-- Comment details --><a name="oncology8564attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8564_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8564">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-05T11:29:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-05T11:29:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UK Government to Fund New Approach for Ovarian Cancer Treatment</title>
	<pubDate>2012-11-05T10:40:04+01:00</pubDate>
	<wp:post_id>3752</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The UK Government awarded £1.<wbr>7M grant to PsiOxus Therapeutics.<wbr> The approach, developed by the development satge biotechnology company, represents a new generation of so-called "self-amplifying" cancer therapy that has the effect of killing tumors and acting as a cancer vaccine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Design: the OCTAVE (Ovarian Cancer Treatment with AdenoVirus) will assess the safety and efficacy of PsiOxus' ColoAd1 when given by intra-peritoneal perfusion at multiple UK cancer centers.<wbr> </div><div style="margin-bottom: 10px;">Start date: 2013 </div><div style="margin-bottom: 10px;">PI: Professor Iain McNeish from the Institute of Cancer Sciences at the U.<wbr> of Glasgow.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: &gt; 50 ovarian cancer patients </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ColoAd1 was developed using the evolutionary principle of natural selection to generate an oncolytic vaccine with optimal anti-cancer properties.<wbr> The vaccine is injected into the bloodstream, and is then delivered to the cancer sites, where it replicates inside of cancer cells and kills them.<wbr> Each infected cell produces thousands of new copies of ColoAd1, which spread to nearby cancer cells and kills them, as well, while ignoring normal cells.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Founded: 2010 </div><div style="margin-bottom: 10px;">- Focus: non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases </div><div style="margin-bottom: 10px;">- PsiOxus is advised by : Prof Len Seymour (Chair of Gene Medicine at Oxford University and Secretary General of the European Society for Gene and Stem Cell Therapy), Dr Kerry Fisher (an internationally-recognized specialist in molecular medicine, also of Oxford University), Prof Andrew Coats (Norwich Research Park Professor-at-Large, University of East Anglia), and Prof Stefan Anker (Professor of Cardiology and Cachexia Research at Charité Medical School, Berlin and President of the Society on Sarcopenia, Cachexia and Wasting Diseases).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reference in Traction: See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=9713" class="defaultlink">PharmaWorld9713: UK Life Science Research To Be Given Financial Impetus</a>.<wbr> </div><div>The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a programme of public funding designed to deliver growth to the UK life sciences sector.<wbr> Delivered jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst provides responsive and effective support for the best life science opportunities arising in the UK.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8562">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-05T10:40:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-05T10:40:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>US Commercialisation of Korlym For Cushing's Disease Gaining Momentum</title>
	<pubDate>2012-11-05T10:16:13+01:00</pubDate>
	<wp:post_id>3753</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Corcept reported a third quarter loss last week of $8.<wbr>3m.<wbr> This 
quarter was the first full quarter in which Corcept's Cushing's disease therapy 
was available in the US and sales were $1.<wbr>1m.<wbr> </div><div style="margin-bottom: 10px;">For the second quarter, Korlym registered sales of $875,000 </div><div style="margin-bottom: 10px;">R&amp;D costs were $3.<wbr>0m compared to $3.<wbr>2m in 2011 due to decreased clinical 
trial costs following completion of the phIII study for Korlym.<wbr> However, these 
decreases were partially ofsett by costs of the group's phIII trial of 
mifepristone in the treatment of psychotic depression and the discovery and 
development costs associated with next generation selective GR-II 
antagonists.<wbr> </div><div style="margin-bottom: 10px;">Following its fund raising in July, the group's cash balances stand at 
$101.<wbr>6m, more than sufficient to support the group's ongoing efforts to 
establish its commercial infrastructure and further development projects.<wbr> </div><div>Source: <A href="http://www.corcept.com">www.<wbr>corcept.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7155">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-05T10:16:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-05T10:16:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Algeria's Drug Imports Rocket</title>
	<pubDate>2012-11-05T10:15:47+01:00</pubDate>
	<wp:post_id>3754</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Algeria has increased its imports of drugs with total pharmaceutical imports in the first 9 months of 2012 totalling USD1.<wbr>6 billion, according to reports from the <EM>Algerian Press Service</EM>.<wbr> This figure represents a 26.<wbr>8% increase from the same period in 2011 when imports amounted to USD1.<wbr>32 billion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The volume of drug imports increased significantly with imports growing from 16,730 tons in Q1–3 2011 to 25,884 tons in the same period of 2012.<wbr> Of these imports, human medicines accounted for approximately 95% of import value.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Increasing levels of imports cement Algeria's position as the largest pharmaceutical market in the North Africa region.<wbr> Increasing efforts to improve standards and coverage of healthcare provision within the country have driven these high importation levels.<wbr> </div><div style="margin-bottom: 10px;">Conversely, the latest drug importation figures continue to demonstrate that domestic producers still lack the resources to extend capabilities beyond the manufacturing of basic generics, despite some recent efforts to change this.<wbr> </div><div style="margin-bottom: 10px;">The latest figures therefore suggest that Algeria has a long way to go to meet its 2014 target of 70% of medicine needs being manufactured locally.<wbr> Curbing the high costs associated with drug importation while boosting domestic manufacturing will be vital to increasing Algeria's funding for improvements in healthcare provision.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10152">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-05T10:15:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-05T10:15:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon's Revenues Slip A Little Compared To Q2</title>
	<pubDate>2012-11-02T18:18:33+01:00</pubDate>
	<wp:post_id>3755</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PROVENGE  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">The positive 
performance are the community accounts was offset by a 25% decline in academic 
accounts, which it is suggested is largely being driven by an increase 
in clinical trial activity and side activations by other companies in these 
accounts.<wbr> There are six Phase 3 or large Phase 2 clinical trials ongoing in the 
pre-chemo advanced prostate cancer space which is in addition to the number of 
the investigator led trials also in this area.<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Given this clinical trial activity, Dendreon continues to expect 
to see headwinds in this segment in the quarters ahead.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><STRONG>Payer Perspective</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt">With regard to 
payers, Dendreon had an important policy milestone earlier this 
month, when it announced that it expanded its coverage policy for 
PROVENGE.<wbr> It believe this decision is testament to its commercial 
progress and the value of benefits of PROVENGE therapy.<wbr> Moreover, in 
September it received the contract award from the Department of Veteran 
Affairs.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>Manufacturing Footprint</STRONG> </div><div style="margin-bottom: 10px;">Dendreon is 
continuing to make progress on restructuring its manufacturing footprint.<wbr> 
It is on track to close its Morris Plains New Jersey facility by the end of 
2012 and has started to ramp up production at our Union City Georgia plant.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>European Developments </STRONG> </div><div style="margin-bottom: 10px;">Dendreon claims 
to have been working on its expansion plans for Europe where it 
sees a large addressable market with similar characteristics to the U.<wbr>S.<wbr> Just 
last week, it completed its first patient treatment in 
its European Union open-label study, a study that is crucial to EU 
expansion.<wbr> It claims to be on track for mid to late 2013 regulatory 
decision.<wbr> </div><div>Source: <A href="http://www.dendreon.com">www.<wbr>dendreon.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8561">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-02T18:18:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-02T18:18:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Top Ten Neurology Projects To Watch For 2012</title>
	<pubDate>2012-11-02T18:00:00+01:00</pubDate>
	<wp:post_id>3756</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cynapsus Therapeutics APL130277, a sublingual formulation of 
apomorphine has been recognized as one of the Top Ten Neurology 
Projects to Watch in 2012 by a joint selection committee including Dr.<wbr> Harry 
Tracy, a noted authority on pharmacological interventions for diseases of the 
brain and editor of the highly respected biotechnology publication 
NeuroPerspective, as well as with Elsevier Business Intelligence, the publishers 
of In Vivo, Startup and The Pink Sheet </div><div style="margin-bottom: 10px;">Cynapsus has been invited to present the APL-130277 Project at Elsevier’s 
Therapeutic Area Partnerships Meeting taking place on November 28-30, 2012 at 
the Westin Copley in Boston.<wbr> </div><div style="margin-bottom: 10px;">Criteria for selection of the Top 10 Neurology Projects to Watch in 2012 
were: </div><div style="margin-bottom: 10px;">• Large market, large unmet need, with increasing opportunity <BR>• History 
of the molecule and drug<BR>• Strong science <BR>• Strong company <BR>• 
Diversity of indications <BR>• Potential for new opportunities beyond the 
initial indications <BR>• Multi-level partnering opportunities, i.<wbr>e.<wbr>, biotech to 
biotech as well as pharma to biotech </div><div style="margin-bottom: 10px;">Apomorphine is administered as a subcutaneous injection or infusion to 
Parkinson’s patients experiencing daily “OFF” or motor fluctuation episodes.<wbr> </div><div style="margin-bottom: 10px;">APL‐130277 would provide patients with a convenient and more tolerable 
alternative to multiple daily injections.<wbr> </div><div style="margin-bottom: 10px;">Cynapsus suggests that its development plan will follow a bioequivalence 
regulatory and clinical path which should culminate in a New Drug Approval 
application in 2015.<wbr> </div><div style="margin-bottom: 10px;">Commenting on this aclaim, Mr.<wbr> Anthony Giovinazzo, 
President and Chief Executive Officer of Cynapsus stated “We are humbled to be 
recognized from among several hundred worthy neuroscience projects, worldwide.<wbr> 
This is a significant honor and further independent validation of the potential 
of APL-130277.<wbr> This comes only a few months after receiving a significant grant 
from The Michael J.<wbr> Fox Foundation for Parkinson’s Research (MJFF) to help 
support our next clinical study (CTH103).<wbr> The MJFF Clinical Intervention Award 
was provided through the Edmond J.<wbr> Safra Core Programs for Parkinson’s 
Research,” </div><div style="margin-bottom: 10px;">He went onto comment “Since we started this project, we determined that there 
are a large number of Parkinson’s patients who would benefit from needle-free 
delivery of the drug.<wbr> This includes patients who want a convenient alternative 
to a very painful injection regimen, patients who have resisted initiating 
therapy because of the needle issues, and the increase in PD population as a 
result of the growing aging baby boomer generation.<wbr> These factors combined 
indicate that the number of Parkinson’s patients worldwide could potentially 
increase 2-to-3 fold over the next 8 to 10 years.<wbr> This significant potential 
unmet medical need coupled with a short and lower risk clinical pathway would be 
of interest to many in global and specialty pharma, especially given that our 
pending patent estate, when approved and granted, would provide protection to 
2031 at a minimum.<wbr>” </div><div>Source: <A href="http://www.cynapsus.com">www.<wbr>cynapsus.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6640">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-02T18:00:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-02T18:00:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncology Highlights from Astellas Q2 Results</title>
	<pubDate>2012-11-02T16:16:23+01:00</pubDate>
	<wp:post_id>3757</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Xtandi sales in the US have reached $14M in 1.<wbr>5 months and Astellas is gearing up for the EU launch.<wbr> </div><div style="margin-bottom: 10px;">Astellas announced their Q2 2012 results with steady growth seen across its Oncology franchise.<wbr>  Combined Tarceva, Eligard and Xtandi sales grew to 2.<wbr>5B Yen - with the much awaited launch of Xtandi in the US this September garnering $14M in sales.<wbr>  
The following slide outlines the Oncology Pipeline 
<img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8560_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Enzalutamide (post-chemo setting) was granted US approval on August 31<SUP>st</SUP>  2012 and launched 13 days later with the EU submission taking place in June 2012.<wbr> It has also been filed in Canada as of October 2012 and a priority review is taking place.<wbr> </div><div style="margin-bottom: 10px;">A number of studies are on-going with enzalutimide: </div><div style="margin-bottom: 10px;"><UL type="square"><LI>PREVAIL study (pre-chemo setting) — enrolment completed in May 2012</LI>
<LI>Phase II studies for LHRH analogue failure cases and hormone-naïve patients - data are being analysed now</LI>
<LI>Phase I study for breast cancer patients</LI>
</UL> </div><div style="margin-bottom: 10px;">
During the Q&amp;A, one analyst asked if Astellas had the EU infrastructure  in place in order to sell enzalutimide.<wbr> The response focused around the potential to utlise Eligard infrastructure which is currently undergoing internal discussion but Astellas realises that they will need to on-board specific Oncology specialists in the post-chemo setting.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8560_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Tivozanib submission for renal cell carcinoma was filed in US on the 28<SUP>th</SUP> September 2012 with the EU package being finalised this year so that it can be submitted in 2013.<wbr> </div><div style="margin-bottom: 10px;">In addition, studies are going on for other indications such as the colorectal cancer and breast cancer.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8560_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Other movement in the Oncology pipeline includes: </div><div><UL type="square"><LI>Launch of Gonax (sub-Q GnRH antagonist for prostate cancer) in Japan this October</LI>
<LI>Discontinuation of ASP9521 for prostate cancer.<wbr>  This was due to poor results in the phase 1 study and ‘other strategic reasons’</LI>
<LI>Phase II trial of Degarelix is ongoing in Japan</LI>
</UL> </div><!-- Comment details --><a name="oncology8560attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8560_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(135,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8560_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(93,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8560_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(102,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8560">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-02T16:16:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-02T16:16:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Successfully Completes PhI Development Of Oral GLP-1</title>
	<pubDate>2012-11-01T18:54:10+01:00</pubDate>
	<wp:post_id>3758</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merrion announced today the successful completion of this trial by 
its partner Novo Nordisk.<wbr> The oral formulation utilises Merrion's proprietary 
GIPET technology to enhance the oral biovailability of the drug.<wbr> </div><div style="margin-bottom: 10px;">The aim of the trial was to investigate the safety, tolerance and 
pharmacokinetics, of the GLP-1 analogue NN9926.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the license agreement signed in January 2009, Merrion will 
receive payments based on achievement of certain development, regulatory and 
sales milestones as well as royalties.<wbr> Certain milestone payments have been 
received by Merrion as a result of this successful Phase 1 trial.<wbr> </div><div>Source: <A href="http://www.merrion.com">www.<wbr>merrion.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7154">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-01T18:54:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-01T18:54:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Russian Prostate Cancer Market Will See Steady Growth</title>
	<pubDate>2012-11-01T18:51:53+01:00</pubDate>
	<wp:post_id>3759</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Russian prostate cancer market is set for 6% annual growth over the next 4 years.<wbr> </div><div style="margin-bottom: 10px;">A report from Decision Resources has highlighted that an expanding patient population and a raft of novel product launches will result in steady growth for the Russian market over the coming four years.<wbr>   The report also estimated that the number of diagnosed incident cases of prostate cancer in Russia will increase by 5% each year over this time period.<wbr> </div><div style="margin-bottom: 10px;">Russia will also realise the launch of three novel branded agents: Orteronel (TAK 700), Alpharadin (radium-223 chloride) and Xtandi (enzalutamide)over the course of the next five years which will support this growth.<wbr> </div><div style="margin-bottom: 10px;">Together with the recent approvals of Sanofi's Jevtana (cabazitaxel) and Johnson &amp; Johnson's Zytiga, these therapies are expected to contribute 19% of the total market sales in 2016.<wbr> </div><div>Currently, a locally manufactured Buserelin (Pharma-Sintez), is the most popular  LHRH agonist prescribed in Russia today.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8559">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-01T18:51:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-01T18:51:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Active Biotech Sees Success With its Phase IIa Study in Crohn’s Disease</title>
	<pubDate>2012-11-01T16:25:19+01:00</pubDate>
	<wp:post_id>3760</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Teva and Active Biotech announce positive findings for laquinimod in Crohn’s Disease (CD) at the United European Gastroenterology (UEG) congress.<wbr> </div><div style="margin-bottom: 10px;">The phase IIa dose ranging study demonstrated that treatment with 0.<wbr>5 mg/<wbr>day oral laquinimod resulted in a robust, early and consistent effect on remission and response rates in patients with moderate-to-severe CD versus placebo.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Michael Hayden, President of Global R&amp;D and CSO for Teva stated “Our developmental program for laquinimod has demonstrated that the immunomodulatory effects of this oral compound stand to apply to multiple autoimmune diseases, and data presented at UEG showed an impressive impact on clinical remission in Crohn’s disease as early as one week of treatment,” </div><div>The data are currently undergoing further analysis and evaluation to finalize next steps in the CD clinical development plan.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1862">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-01T16:25:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-01T16:25:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda's Key Priority Is To Improve Profitability</title>
	<pubDate>2012-11-01T15:49:56+01:00</pubDate>
	<wp:post_id>3761</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda has reported a 12% increase in revenues but a 49% drop in 
operating income, the latter due to acquisition related costs and increased 
R&amp;D spending on late-stage development assets such as TAK-700.<wbr> Development 
of this product for CRPC is progressing well, however, timelines 
for approval in Europe and Japan appear to have slipped a little compared 
to those presented at the R&amp;D Day in May 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Income Statement Developments</STRONG> </div><div style="margin-bottom: 10px;">The group's sales performance is shown below.<wbr> Sales of new products and those 
associated with the acquisition of Nycomed appear to be absorbing sales declines 
amongst the group's older products including that of Takeda's GnRH-agonist 
Leuprorelin.<wbr> </div><div style="margin-bottom: 10px;">During the group's webcast, company President Hasegawa made several 
referecences to his pre-occupation with profitability and noted that a project 
would be implemented with the aim of achieveing an operating margin of 20% 
post-transition to IFRS.<wbr> The company plans to reduce costs by Y60bn on top of 
the Y200bn cost reductions coming from the acquisition of Nycomed.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key R&amp;D Developments</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_3_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_5_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_6_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Noticeably, in terms of pipeline approvals by region the approval of TAK-700 
has slipped from FY14 to FY15-FY16 for Japan and from FY14 to FY15-FY16 for 
Europe.<wbr> The US approval time at FY2014 remains the same.<wbr> Takeda'a year-end is 
March.<wbr> </div><div> </div><!-- Comment details --><a name="oncology8558attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(102,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(153,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(136,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(165,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(132,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8558_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(178 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8558">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-01T15:49:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-01T15:49:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Another Feather In Avastin’s Cap</title>
	<pubDate>2012-11-01T15:33:48+01:00</pubDate>
	<wp:post_id>3762</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Avastin is now the first biological therapy approved for newly diagnosed and recurrent ovarian cancer.<wbr> </div><div style="margin-bottom: 10px;">Roche has received an EC approval for Avastin in combination with standard chemotherapy as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.<wbr> </div><div style="margin-bottom: 10px;">The approval is based off the back of the Phase III OCEANS study which showed a statistically significant improvement in PFS for patients being treated with Avastin plus gemcitabine and carboplatin versus those receiving gemcitabine, carboplatin and placebo.<wbr> </div><div>Avastin is already approved as a front-line treatment for women with advanced ovarian cancer.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8557">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-11-01T15:33:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-11-01T15:33:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trial Will Assess Benefit of Early Switch from 1st-line Docetaxel to Cabazitaxel</title>
	<pubDate>2012-10-31T17:32:13+01:00</pubDate>
	<wp:post_id>3763</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The primary objectives of the TAXYNERGY Ph2 trial will explore the benefit of an early switch from docetaxel/<wbr>prednisone to cabazitaxel/<wbr>prednisone in men with mCRPC who do not achieve &gt;30% PSA decline from baseline by cycle 4 with the initial docetaxel treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01718353?no_unk=Y&amp;fund=2&amp;rcv_s=10%2F25%2F2012&amp;rank=23"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures: </DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Progression-free survival [ Time Frame: up to max 5 years ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">PSA progression-free survival rate [ Time Frame: up to max 5 years ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Objective response rate [ Time Frame: up to max 5 years ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Radiographic progression-free survival (rPFS) rate [ Time Frame: up to max 5 years ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Clinical progression-free survival (cPFS) [ Time Frame: up to max 5 years ] [ Designated as safety issue: No ]<BR>
</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Overall survival [ Time Frame: up to max 5 years ] [ Designated as safety issue: No ]<BR></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Recruitment: approx.<wbr> 100</P> </div><div style="margin-bottom: 10px;">Start date: Nov 2012 - Completion date: July 2015 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8556">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-31T17:32:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-31T17:32:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' New Facility in Singapore Will Support Biologics Porfolio</title>
	<pubDate>2012-10-31T13:08:17+01:00</pubDate>
	<wp:post_id>3764</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The construction is to start in early 2013, and will represent an investment of &gt;$500M.<wbr> It will focus on drug substance manufacturing based on cell culture technology, and pharmaceutical production.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The site will be designed to operate in a flexible manner to handle small and large scale volumes.<wbr> It is planned to support both clinical and commercial production of potential new products that include monoclonal antibodies for use in helping patients with diseases in autoimmune, respiratory and oncology indications.<wbr> </div><div style="margin-bottom: 10px;">The biologics pipeline currently accounts for 25% of the clinical pharmaceutical research pipeline with a trend for future growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>Lucentis<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP> (ranibizumab)</LI>
<LI>Xolair<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP> (omalizumab)</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10149">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-31T13:08:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-31T13:08:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Comer in the Iranian Aesthetic Market</title>
	<pubDate>2012-10-31T12:11:02+01:00</pubDate>
	<wp:post_id>3765</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thank to the recent feedback from M.<wbr> Raimbault and our partner, we have learnt that the safety of MasoonDarou Pharm's Botulinum Toxin A for moderate-to-severe glabellar lines (GL) is being evaluated vs Neuronox (Medy-Tox) at the Razi Hospital in approx.<wbr> 12 participants.<wbr> According to the source, the efficacy phase in unlikely to be assessed.<wbr> The objective of the company is to register as soon as possible.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Tahoma; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,206,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;">Name of the drug: <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Tahoma; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,206,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> 500 IU ( </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Tahoma; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,206,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Tahoma; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,206,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;">Protocol: <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Tahoma; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,206,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;">Results: "effective, without side effect".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to the source: </div><div><UL><LI>Clinical: tests on animals were not performed</LI>
<LI>MSO: the company have produced around 5,000 vials in their first batch</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6630">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-31T12:11:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-31T12:11:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norditropin® Sales Increase in the First Nine Months of 2012</title>
	<pubDate>2012-10-31T11:46:29+01:00</pubDate>
	<wp:post_id>3766</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Q3 results were driven by a 62% jump in sales of diabetes drug Victoza, and a 23% rise in modern insulin sales.<wbr> Novo Nordisk reported that 9Mo-sales of Norditropin® increased by 14% measured in Danish kroner to DKK 4,237 million and by 8% measured in local currencies.<wbr> The sales growth is primarily driven by North America and International Operations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Novo Nordisk is the second-largest company in the global growth hormone market with a 24% market share measured by volume.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7151_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7151_2_ScreenCapture2.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7151">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-31T11:46:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-31T11:46:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's Q3 Financial Results</title>
	<pubDate>2012-10-31T11:33:31+01:00</pubDate>
	<wp:post_id>3767</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"> </SPAN><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;">
The top ten markets for neuro-modulators are roughly $1.<wbr>8 billion, growing at a rate of roughly 13%.<wbr> BOTOX has approximately an 84% market share.<wbr> Year-to-date that market is growing 11% and year-to-date BOTOX market share is 84%.<wbr> The worldwide market for neuro-modulators is roughly $2.<wbr>3 billion, growing at a rate of roughly 13%.<wbr> BOTOX has approximately a 76% market share.<wbr> Year-to-date that market is growing 12% and year-to-date BOTOX market share was 76%.<wbr> </div><div style="margin-bottom: 10px;">The worldwide market for dermal facial fillers is roughly $1 billion, growing at around a rate of 11%.<wbr> Allergan has approximately a 37% market share.<wbr> Year-to-date that market is growing 6% and year-to-date Allergan’s share is about 40%.<wbr> </div><div style="margin-bottom: 10px;">The worldwide breast aesthetics market for aesthetic and reconstructive is roughly $880 million, growing at a rate of around 7%.<wbr> Allergan has approximately a 42% market share.<wbr> Year-to-date that market is growing 10% and year-to-date Allergan’s share is around 41%.<wbr> </div><div>Source: Allergan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6629">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-31T11:33:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-31T11:33:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FIM of Merz' Drug for Glaucoma</title>
	<pubDate>2012-10-30T18:01:50+01:00</pubDate>
	<wp:post_id>3768</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph1 study aimed at assessing the safety and tolerability of repeat doses of MRZ-99030 ophtalmic solution in approx.<wbr> 70 participants.<wbr> This investigational drug represents the one and only compound in development for this indication in the company's pipeline.<wbr> </div><div>Study Details <A href="http://clinicaltrials.gov/ct2/show/NCT01714960?term=merz&amp;rank=14&amp;submit_fld_opt=">NCT01714960</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6628">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-30T18:01:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-30T18:01:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>US Healthcare Reform Success Hinges on Election Results</title>
	<pubDate>2012-10-30T13:17:16+01:00</pubDate>
	<wp:post_id>3769</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This report examines the presidential candidates' diverging views on healthcare and the impact on the Affordable Care Act (ACA) of the possible election outcomes.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B></B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>The presidential election on 6 November will decide not only who the country's next leader is, but also whether the United States moves closer to the implementation of a nearly universal healthcare system.<wbr> 
</LI>
<LI>Healthcare is the second most significant issue for voters in the run up to the election, after the "economy".<wbr> 
</LI>
<LI>More than two years after its passing, the ACA remains highly controversial, especially as a recent Supreme Court decision has chipped away at some of its original provisions.<wbr> 
</LI>
<LI>The individual mandate to purchase health insurance has remained in effect following the Supreme Court's ruling but the states will not be required to expand Medicaid, as originally intended under the ACA – with the result that more people than originally expected will have to purchase health insurance in the insurance exchanges or face financial penalties.<wbr> 
</LI>
<LI>The rivals for the presidential post – incumbent Barrack Obama (Democrat) and former Massachusetts governor Mitt Romney (Republican) – have vastly diverging views on the future of healthcare reform and the role the federal government should play in healthcare provision.<wbr> 
</LI>
<LI>If re-elected, Obama intends to press on with reform implementation.<wbr> His ability to do so would be facilitated if Republicans fail to win a 60-seat Senate representation.<wbr> 
</LI>
<LI>If Republican candidate Romney is elected, he plans to "act to repeal" the ACA in its entirety – and introduce in its place a system where the market and states play a greater role in healthcare provision.<wbr> 
</LI>
<LI>Whatever the election outcome, it is clear that the momentum for change of the healthcare system is undeniably there: some of the elements of that change are already under way and are unlikely to be reversed completely, and a future Republican president may not be a in a position to undertake a complete repeal of the healthcare reform.<wbr></LI>
</UL></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">The next US presidential election, due to be held on 6 November, will see Republican candidate Mitt Romney challenge the incumbent Democrat president Barrack Obama.<wbr> In choosing between the two candidates voters are also asked to make a decision on the future healthcare system of the United States.<wbr> The Patient Protection and Affordable Care Act, known simply as the Affordable Care Act (ACA), is at the centre of increasingly heated pre-election debates.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B></B></P></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>2010</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>Ban insurance companies' policy of dropping people from coverage and of imposing lifetime coverage limits; health insurer annual cover limits to be restricted for new plans.<wbr> 
</LI>
<LI>Bar insurers from denying coverage to children (under 19) due to pre-existing conditions.<wbr> 
</LI>
<LI>Establishing consumer assistance programmes in states and an appeals process for insurance company decisions; providing new resources to help combat healthcare fraud.<wbr> 
</LI>
<LI>Require insurers to keep young adults on their parents' health plans until the age of 26.<wbr> 
</LI>
<LI>Set up a temporary programme allowing uninsured adults with pre-existing conditions to obtain health coverage (this will expire once new insurance exchanges begin operating in 2014).<wbr> 
</LI>
<LI>Create a temporary (until 2014) reinsurance programme to help companies maintain health coverage for early retirees between the ages of 55 and 65 and their spouses and dependents.<wbr> 
</LI>
<LI>Provide a USD250 rebate to Medicare drug beneficiaries who reach the "doughnut hole" coverage gap.<wbr> 
</LI>
<LI>Provide a tax credit to some small businesses to help provide coverage for workers.<wbr> 
</LI>
<LI>Require new insurance plans to provide free preventive care, such as mammograms and colonoscopies.<wbr> 
</LI>
<LI>Allow states to cover more people under Medicaid – with federal matching funds available.<wbr></LI>
</UL></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>2011</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>Require insurance companies to spend at least 85% of all premium dollars for larger employers and at least 80% for smaller employers and individuals on healthcare services and quality improvement.<wbr> 
</LI>
<LI>Require insurers to provide preventative care services to Medicare beneficiaries at little or no cost to patients.<wbr> 
</LI>
<LI>States to offer home and community-based care for Medicaid beneficiaries under a new programme coming into effect in October.<wbr> 
</LI>
<LI>Payments to insurers offering Medicare Advantage services to be gradually reduced to bring them more in line with basic Medicare.<wbr> 
</LI>
<LI>Offer 50% discount to seniors who reach the doughnut hole coverage gap on Medicare Part D covered brand-name prescription drugs.<wbr></LI>
</UL></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>2012</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>Provide incentives for physicians to join together to form Accountable Care Organisations; implement physician payment reforms.<wbr> 
</LI>
<LI>Incentivise hospitals to improve the quality of care under the Value-Based Purchasing programme in Traditional Medicare.<wbr> 
</LI>
<LI>Create a voluntary long-term care insurance programme (CLASS) to provide cash benefits for adults who become disabled.<wbr></LI>
</UL></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>2013</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>Expand number of Americans with access to preventive care by granting new funding to state Medicaid programmes which offer preventive care at little or no cost to patients.<wbr> 
</LI>
<LI>Establish a national pilot programme on payment bundling under Medicare aiming to improve patient care-co-ordination.<wbr> Savings to be shared between providers and Medicare.<wbr> 
</LI>
<LI>Require states to increase Medicaid payments to primary care physicians, paying them no less than 100% of Medicare payment rates in 2013 and 2014.<wbr> 
</LI>
<LI>Provide additional funding to states for two more years to continue coverage of children not eligible for Medicaid under the Children's Health Insurance Program (CHIP).<wbr> 
</LI>
<LI>Raise the threshold for claiming medical expenses on tax returns to 10%, from 7.<wbr>5% of income (excluding the elderly, for whom the threshold remains at 7.<wbr>5% through 2016).<wbr> 
</LI>
<LI>Raise the Medicare payroll tax to 2.<wbr>35% from 1.<wbr>45% for individuals with income of more than USD200,000 and for married couples with incomes of more than USD250,000.<wbr> </LI>
</UL></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>2014</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>State health insurance exchanges to be opened for small businesses and individuals.<wbr> 
</LI>
<LI>The majority of Americans to be required to obtain health insurance coverage or face penalties.<wbr> Healthcare tax credits for purchasing health coverage on the insurance exchange to be made available to people with a family income of up to four times the federal poverty limit (equivalent to USD88,000 in 2010).<wbr> 
</LI>
<LI>Fines to be imposed on employers with 50 or more workers who do not offer coverage (USD2,000 for each employee).<wbr> Tax credits available to small businesses to help with health insurance costs.<wbr> 
</LI>
<LI>Health plans to be banned from excluding people from coverage due to pre-existing conditions or gender.<wbr> 
</LI>
<LI>Annual limits on insurance coverage to be eliminated.<wbr> 
</LI>
<LI>Prohibit insurers from dropping coverage for individuals participating in clinical trials.<wbr> 
</LI>
<LI>Allow Americans with income of less than 133% of the poverty level (USD14,000 for an individual or USD29,000 for a family of four in 2010) to enrol on Medicaid.<wbr> States to receive 100% of federal funding for the first three years of expanded Medicaid coverage, phasing to 90% federal funding after that.<wbr></LI>
</UL></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>2015</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>Improve cost-efficiency in medical treatment by rewarding Medicare physicians for providing quality of treatment rather than by volume of services provided.<wbr></LI>
</UL></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>2018</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Encourage a gradual switch to lower-cost plans by introducing additional tax on high-cost employer-provided plans from 2018.<wbr></P></TD>
</TR>
<TR><TD class="tableNotes" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Sources: Key Features of the Affordable Care Act, by Year; Patient Protection and Affordable Care Act of 2010 (available <A href="http://housedocs.house.gov/energycommerce/ppacacon.pdf" target="_blank">here</A>)</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Obama ran his last election campaign on the promise of passing a wide-reaching healthcare reform providing access to healthcare to millions of currently uninsured or underinsured Americans.<wbr> He won the election, but passing the reform was no easy task as the president's initiatives were kept in check by Republicans in the House of Representatives.<wbr> Even after the ACA passed Congressional review in 2010, House Republicans have made attempts to repeal it as a whole or dismantle certain aspects of it.<wbr> Although such attempts secured enough support in the House, similar endeavours have failed to gain majority support in the Senate where Republicans have only 47 seats at present.<wbr> </div><div style="margin-bottom: 10px;">Crucially, the ACA also survived a review by the US Supreme Court, which ruled in July 2012 that the reform was not anti-constitutional.<wbr> Although weakening some federal demands on the states (in particular the requirement for states to expand their Medicaid programme), the Supreme Court confirmed that it was within the power of Congress to impose an individual mandate on Americans to purchase health insurance.<wbr> The latter had been challenged by Republicans as evidence of Big Government infringing on individual freedoms.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Although the ACA has been approved by Congress and now has successfully passed the scrutiny of the US Supreme Court, it clearly remains at the heart of party differences.<wbr> Healthcare is one of the distinguishing issues in the election as far as voters are concerned.<wbr> In a recent national survey of a representative sample of likely voters by polling company Rasmussen Reports, healthcare was ranked second (with 66% of votes) as an issue affecting how respondents would vote – after the economy with 80% of votes.<wbr> Considering that the economy as an issue is also closely related to whether the ACA is fully implemented – given the latter's impact on government spending – it can be argued that even those voters that are primarily focused on economic policy as a deciding factor in the voting decision cannot avoid considering healthcare policy as an issue.<wbr> </div><div style="margin-bottom: 10px;">The electoral debate this year is also made more interesting by the fact that voters are not only electing a new president.<wbr> All the seats in the House of Representatives and a third of the Senate seats are also up for grabs.<wbr> The outcome of these Congressional elections has the potential to impact how much power the new president-elect has to press ahead with healthcare reform or alternatively move to repeal it.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">As the pre-election debates heated up, both candidates have moved to disclose their healthcare reform plans.<wbr> They recently articulated these views in statements ran side by side in the <I>New England Journal of Medicine</I>.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B></B></P></TD>
<TD align="middle" class="tableTitleBold" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B></B></P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent"><B>Follow through with implementation of the ACA by requiring individuals to purchase heath insurance while denying health insurers the ability to deny coverage based on pre-existing conditions.<wbr></B></P>
<UL type="disc"><LI><B>The law "roots out waste and fraud in Medicare and Medicaid, gets rid of insurance overpayments, reinvests those savings back into the system, and adds eight years to the solvency of Medicare".<wbr></B> 
</LI>
<LI><B>By closing the doughnut hole, the ACA provisions are "saving people an average of USD600 last year".<wbr></B> 
</LI>
<LI><B>"Provider groups are working with us to form accountable care organisations and more and more hospitals are moving toward bundled payments.<wbr>"</B> 
</LI>
<LI><B>Looking ahead, additional steps are needed, including: a "permanent fix to Medicare's flawed payment formula" that threatens physicians' reimbursement; medical malpractice reform to prevent needless lawsuits; continued support for life-sciences research; and building the healthcare workforce to meet the demands of an aging population.<wbr></B> 
</LI>
<LI><B>The aim is to "keep Medicare and Medicaid strong, working to make the programmes more efficient without undermining the fundamental guarantees".<wbr></B></LI>
</UL></TD>
<TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent"><B>Act to repeal the ACA on day one of presidency; replace it with a healthcare law that gives more power to the states and encourages people without health insurance to purchase it in the private market – including in other states which offer lower-cost insurance plans.<wbr></B></P>
<UL type="disc"><LI><B>Pass regulations preventing insurers from discriminating against people with pre-existing conditions who maintain continuous coverage.<wbr></B> 
</LI>
<LI><B>End tax discrimination against people purchasing insurance, strengthen and expand health savings accounts, establish strong consumer protection.<wbr></B> 
</LI>
<LI><B>Limit malpractice lawsuits targeting physicians.<wbr></B> 
</LI>
<LI><B>Insurance market reforms must "promote competition by eliminating onerous mandates, facilitating purchasing pools, and opening up the interstate market".<wbr></B> 
</LI>
<LI><B>Convert Medicaid into a block grant that properly aligns each state's incentives around using resources efficiently.<wbr></B> 
</LI>
<LI><B>Reform Medicare: without making changes for people enrolling today or during the next 10 years, but providing future beneficiaries "a set of Medicare-approved, guaranteed-coverage plans to choose from, including today's traditional fee-for-service option".<wbr></B></LI>
</UL></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Unsurprisingly, Obama's plans are clearer given that the recently approved – if still controversial – reform is his signature bill.<wbr> The president has even moved to embrace the term "Obamacare" that the bill's critics have used to refer to the healthcare reform.<wbr> In recent weeks, he's stated: "Supporters and detractors alike refer to the law as Obamacare.<wbr> I don't mind, because I do care.<wbr>" </div><div style="margin-bottom: 10px;">His opponent, on the other hand, remains somewhat vague on the details of his plans.<wbr> It is one thing to state one would repeal Obamacare, but another altogether to come up with a detailed plan on what Obamacare is to be replaced with.<wbr> Given the pre-election pressures, Romney also needs to be careful not to alienate potential voters who like some aspects of the ACA legislation.<wbr> </div><div style="margin-bottom: 10px;">Gaining access to health insurance for those with pre-existing conditions is one of the few things that Romney is clearly keen to assure voters about.<wbr> So under his plans for healthcare reform, people with a pre-existing condition who have been "continuously insured" would be guaranteed to have access to health cover if they lose their job or change jobs.<wbr> But this policy has been questioned on grounds that it is already incorporated in the provisions of former president Bill Clinton's Health Insurance Portability and Accountability Act, which was enacted in 1996.<wbr> Enforcing the act, however, is the stumbling block and Romney has been vague on what enforcement action would be taken if the ACA – which also incorporates a similar provision – were to be repealed in its entirety.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Another aspect of Romney's healthcare reform vision is that more power should be given to the states.<wbr> Shifting the focus from the federal to the state level is also a strategy to help Romney distance himself from the ACA.<wbr> After all, the ACA is closely modelled on the healthcare reform the state of Massachusetts adopted while Romney was state governor.<wbr> Massachusetts now has nearly universal health cover as a result of that reform – and that is all good and well from Romney's perspective, it seems, as long as such policy is undertaken at the state level rather than being enforced at the federal level.<wbr> </div><div style="margin-bottom: 10px;">Romney recognises in his NEJM statement one of the ACA provisions which is proving popular with voters – allowing children to stay on their parents' health insurance until the age of 26.<wbr> However, he states that this is an initiative that health insurers are already implementing, suggesting that under his health reform plans this would not be a mandatory requirement for insurers, but something insurers would do nonetheless because "they are responding to consumer demands".<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Given the two candidates' diverging visions of healthcare provision, IHS Global Insight expects one of two possible scenarios to unfold in the US following the election: with different possible permutations under each.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">If Obama wins the presidential election, he is expected to push ahead with the implementation of the ACA.<wbr> The main provisions of the bill are due to come into effect at the start of 2014.<wbr> With Obama as president – and assuming that Republicans do not win a filibuster-proof majority of 60 seats in the Senate – implementation of the ACA is expected to proceed without delay.<wbr> </div><div style="margin-bottom: 10px;">The main mandatory element of the healthcare bill – with immediate implications for individuals – is the enrolment on healthcare plans.<wbr> The vast majority of US residents without health insurance and who are not otherwise exempt through Medicaid or Medicare eligibility would be required to purchase health insurance in 2014.<wbr> Enrolment in health insurance plans offered by states through the so-called insurance exchanges is due to commence from October 2013.<wbr> Should some states fail to set up insurance exchanges, Obama is expected to direct the Department of Health and Human Services (DHHS) to step in and create the exchanges on behalf of non-compliant states without any delay.<wbr> </div><div style="margin-bottom: 10px;">Obama would also be expected to use his presidential authority to encourage the states to implement some expansion of their Medicaid programme as envisaged under the ACA provisions.<wbr> However, achieving this may prove difficult – especially in Republican-run states – following the July 2012 Supreme Court ruling.<wbr> Based on the ruling, it is not mandatory for states to expand their Medicaid programme.<wbr> As a result, some states will choose not to expand Medicaid, leaving a higher number of individuals with no health insurance who would then face penalties if they do not purchase health cover.<wbr> A recent CBO analysis indicates that as fewer individuals choose to purchase health insurance or can afford to purchase it, the overall spending impact will be a net reduction in federal healthcare spending as "the projected decrease in total federal spending on Medicaid is larger than the anticipated increase in total exchange subsidies".<wbr> Hence, for Obama, the removal of the state mandate to expand Medicaid should not at least cause problems by pushing federal spending up.<wbr> Blaming Republican-run states which fail to expand Medicaid – thus forcing more individuals to buy health insurance or pay the financial penalties – could earn the Democrats some political credit.<wbr> As such the Supreme Court ruling has not necessarily made implementation of the ACA that much more difficult for Obama during a second term in the Oval Office.<wbr> </div><div style="margin-bottom: 10px;">On another note, health insurance premiums – particularly for younger people – will probably increase if the ACA implementation proceeds promptly.<wbr> This trend will be partly driven by the ACA provisions preventing health insurers from discriminating against people based on pre-existing conditions or age.<wbr> The real challenge for Obama, if re-elected, will be to ensure insurance premiums do not rise substantially, while also allowing free market forces to guide the health insurance market dynamics.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Scenario 2: Romney wins</B></P> </div><div style="margin-bottom: 10px;">If Mitt Romney were to win the presidential election, he would have no choice but to attempt a repeal of the ACA.<wbr> Romney has stated repeatedly throughout the campaign that he would seek to repeal the ACA.<wbr> Following the Supreme Court ruling in support of the ACA, Romney said: "What the court did not do in its last day in session, I will do on my first if elected president of the United States.<wbr> I will act to repeal Obamacare.<wbr>" </div><div style="margin-bottom: 10px;">It is clear that repealing the bill and acting to repeal it are two different things.<wbr> Realistically, Romney's only chance of repealing the ACA would be if somehow Conservatives secured a majority in the House Representatives and at least 60 seats in the Senate.<wbr> They currently have 47 seats in the Senate – which is the reason why they have so far failed to secure a repeal of the ACA.<wbr> Although securing 60 seats in the Senate seems to be a long shot at present, if Conservatives were to win a simple majority of 51 seats they could potentially attempt to disable the ACA by diverting federal funding needed for its implementation.<wbr> Through the so-called budget reconciliation process, Senate Republicans could vote against the financial provisions of the ACA as they are due to take effect.<wbr> Provisions of the bill such as individual tax breaks for people purchasing health insurance and additional funding for the states agreeing to expand their Medicaid programme could be rendered powerless if their funding is removed through the Senate budget reconciliation process.<wbr> </div><div style="margin-bottom: 10px;">Another potential route that Romney could take would be to order the secretary of the DHHS not to implement the law.<wbr> This could be done via granting waivers to states allowing them to not implement certain the ACA provisions or failing to act if some states choose not to set up the health insurance exchanges (under the ACA provisions the DHHS can step in and set up insurance exchanges for states which fail to create them by 2014).<wbr> </div><div style="margin-bottom: 10px;">One other option open to Romney – albeit a rather extreme one – would be to unilaterally repeal the ACA, using his interpretation of the Constitution to reject the Supreme Court's ruling.<wbr> This outcome is possible, but, in our view, highly unlikely considering that a) it would trigger a Constitutional crisis and b) it may incentivise the other pillars of power – the Senate and the House of Representatives, the Supreme Court, and the media (often considered the Fourth Pillar in US politics) to attempt to curb a presidential "power grab".<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">The options for Obama and Romney would be somewhat limited following the elections.<wbr> Obama, if he were re-elected, would have fewer constraints it seems.<wbr> The main challenge for him would be to rein in health insurance premium rises without giving Republicans cause to complain that the president is interfering in the free market.<wbr> Even without a mandatory requirement for states to expand their Medicaid programme, the ACA provisions would come into effect one by one, under an Obama second term, and even states unwilling to support the reform may be persuaded into setting up insurance exchanges and allowing Medicaid expansion.<wbr> </div><div style="margin-bottom: 10px;">The future of healthcare reform is somewhat more unpredictable under a Romney presidency.<wbr> It is fairly certain that a full repeal of the ACA is unlikely – despite Romney's promises that he would attempt it.<wbr> Only a filibuster-proof Republican majority in the Senate could lead to complete repeal of the ACA, unless, of course, Romney were to unilaterally declare the bill unconstitutional – in breach of the recent Supreme Court ruling.<wbr> Both of these options are highly unlikely, leading us to conclude that a full the ACA repeal is not to be expected.<wbr> A simple Republican majority in the Senate could, however, lead to removal of funding for some the ACA provisions.<wbr> Accompanied by a presidential campaign to discourage implementation of the ACA by the various levels of the executive, such de-funding could seriously destabilise the ACA implementation.<wbr> </div><div style="margin-bottom: 10px;">Even if the ACA implementation were to stop on day one of a Romney presidency, the few provisions of the bill that have already come into effect have changed the US healthcare landscape so much that going back to the pre-2010 situation is impossible.<wbr> Americans – regardless of their political orientation – have begun to see the attractiveness of certain measures to curb health insurance excesses.<wbr> Allowing children up to the age of 26 to remain on parents' health insurance and barring health insurers from denying coverage to people with pre-existing conditions are just two examples of those.<wbr> More importantly, it appears that the American public has warmed up to the need for healthcare reform.<wbr> Even if the unlikely scenario of a complete the ACA repeal were to materialise, the removal of the ACA would leave a vacuum that needs to be filled by healthcare reform of some kind.<wbr> Such is the momentum for change that the future occupant of the Oval Office after the 6 November election would have a clear healthcare reform mandate – although interpreting and implementing that mandate in unlikely to be easy.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10148">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-30T13:17:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-30T13:17:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's Q3 Financial Results Driven by HealthCare</title>
	<pubDate>2012-10-30T12:42:33+01:00</pubDate>
	<wp:post_id>3770</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pharma sales grew 13% to €2,734M, mainly driven by sales of Kogenate.<wbr> The growth in North Amrica and China helped offset a declining Europe.<wbr> Additionally, Bayer announced the €1.<wbr>2bn acquisition of Schiff Nutrition, which underlines Bayer's strategy to focus more on Healthcare.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10145_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The strongest growth was recorded in China.<wbr> The company raised sales there by 27.<wbr>5% (Fx adj.<wbr>) in Q3 through increased marketing activities, especially the expansion of its distribution network.<wbr> </div><div style="margin-bottom: 10px;">Business developed well in Latin America and in Eastern Europe, particularly Russia.<wbr> </div><div style="margin-bottom: 10px;">The emerging markets accounted for 32.<wbr>9% of total HealthCare sales in the first nine months of 2012 and 33.<wbr>4% in the third quarter.<wbr> </div><div>Source: Bayer </div><!-- Comment details --><a name="pharmaworld10145attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10145_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10145">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-30T12:42:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-30T12:42:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Former Amgen Executive to Head Spectrum Sales & Commercial Operations</title>
	<pubDate>2012-10-29T14:35:51+01:00</pubDate>
	<wp:post_id>3771</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Spectrum Pharm has appoined Joseph Turgeon, who will be responsible for the commercialization and sales of 3 anticancer drugs on the market (bringing approx.<wbr> $300M in pro forma revenue).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10143_1_ScreenCapture1.jpg"> </div><div><A href="http://www.sppirx.com/310-spectrum-products-commercial.html">http:/<wbr>/<wbr>www.<wbr>sppirx.<wbr>com/<wbr>310-spectrum-products-commercial.<wbr>html</A> </div><!-- Comment details --><a name="pharmaworld10143attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10143_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(22,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10143">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-29T14:35:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-29T14:35:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence - Status of Acino's Goserelin in Belgium</title>
	<pubDate>2012-10-29T12:23:53+01:00</pubDate>
	<wp:post_id>3772</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to S.<wbr> Massart (Brand Manager Uro-Onco franchise in Belgium) we have learnt that Acino's Goserelin is unlikely to reach the Belgium market before 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to an undisclosed source, the drug may be facing regulatory issues in Belgium, and in 'many other countries' as well.<wbr> </div><div style="margin-bottom: 10px;">Of note, AstraZeneca has not planned the arrival of Goserelin in its strategic plan before 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">If you hear of notice a similar situation in your country, please contact the CI department.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=162" class="defaultlink">DKPHybrids162: Acino Is Confident to Have the First "Generic" Goserelin Coming to the Market</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=196">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-29T12:23:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-29T12:23:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Ph3 Trial of Zytiga in Newly Diagnosed Patients with High-Risk mHNPC</title>
	<pubDate>2012-10-26T16:36:41+02:00</pubDate>
	<wp:post_id>3773</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Recently listed in clinicaltrials.<wbr>gov the goal of this Ph3 trial is to determine if newly diagnosed (within previous 3 months) patients with metastatic prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate and low-dose prednisone to androgen deprivation therapy (ADT; LHRH agonists or surgical castration).<wbr> PE will assess OS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01715285?no_unk=Y&amp;fund=2&amp;rcv_s=10%2F19%2F2012&amp;rank=59"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Sponsor: Janssen Research &amp; Development LLC </div><div style="margin-bottom: 10px;">Recruitment: approx 1270 </div><div style="margin-bottom: 10px;">Start date: Dec 2012 /<wbr> Completion date: July 2018 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8555">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-26T16:36:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-26T16:36:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spanish Pharma Industry Set to Shrink 5% Annually As a Result of Citizens' Co-payment Measure</title>
	<pubDate>2012-10-26T13:33:20+02:00</pubDate>
	<wp:post_id>3774</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to <EM>El Economista</EM>, the citizen co-payment austerity measure is also affecting the volume of drugs that are being purchased through the public healthcare system, and prescriptions have also been greatly affected throughout the months of September and October.<wbr> </div><div style="margin-bottom: 10px;">The drop in sales and expenditure did not come as surprise as citizens were preparing for weeks before the new rule came into effect, by purchasing additional drugs.<wbr> Two weeks after the mandatory co-payments came into place on 1 July, pharmacies experienced a 23% drop in drug sales in comparison to two weeks before the co-payments come into force, equating to an 11% year-on-year drop in drug sales in July.<wbr> </div><div style="margin-bottom: 10px;">According to the source, 14 weeks into the co-payment enforcement, the volume of drugs sold in pharmacies across the country has decreased in all segments, including generics.<wbr> The sector is not forecast to achieve any further growth until at least 2015/<wbr>16.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Although there is uncertainly on whether the citizens' co-payment will be staying in place as an effective cost-cutting measure in the short-to-medium term, the effects of the austerity measure have already started to be felt, not only by the citizens and pharmacies, but also by the domestic and multinational pharmaceutical sector operating in the country, aggravating their already delicate position in the country as their volume of drugs sold will decrease with a consequent direct effect on revenues.<wbr> </div><div style="margin-bottom: 10px;">The Spanish pharmaceutical sector will experience a decrease in sales, revenues, and volume of drugs purchased through the public healthcare sector, which is realistically not forecast to increase for at least three years.<wbr> In terms of foreign multinational companies operating in the country, there is a risk that some may think to relocate their production to other Southern European countries, such as Portugal, in an attempt to escape the unwelcoming business climate in Spain as a consequence of the co-payment and other recent tough cost-cutting austerity measures.<wbr> </div><div style="margin-bottom: 10px;">Domestic firms, will also experience a decrease in sales and volume.<wbr> For the generics industry, the recent measures will also have a negative impact, despite governmental efforts to boost the sector as much as possible through its pro-generic stance with the enforcement of Royal Decree 9/<wbr>11 on mandatory prescriptions by active pharmaceutical ingredients.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10142">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-26T13:33:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-26T13:33:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence - Teva Possible Interest in Leuprorelin and Goserelin</title>
	<pubDate>2012-10-26T11:07:24+02:00</pubDate>
	<wp:post_id>3775</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to a recent feedback from D.<wbr> Pugliese (PM in Italy), we have learnt that strong rumours are currently conveying the involvement of Teva Pharm in the marketing of GP Pharm's Lutrate in Italy.<wbr> On the other hand, intelligence gathered at last year CPhI, indicated that "several discussions" between Teva and Acino were ongoing re Goserelin and Leuprorelin.<wbr> In order to validate and double-checked the relevancy of the information, if you hear or notice any similar situation in your country, please contact the CI department.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="ii"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8549_1_ScreenCapture1.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV class="ii"><STRONG></STRONG></DIV> </div><div><DIV class="ii"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8549_2_ScreenCapture2.jpg"></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8549">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-26T11:07:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-26T11:07:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence - Marketing of Firmagon in France</title>
	<pubDate>2012-10-26T10:32:11+02:00</pubDate>
	<wp:post_id>3776</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to the Oncology Team, we have learnt that Sanofi and Ferring may have signed an agreement to promote Firmagon in France.<wbr> </div><div>This information coming from the field should be validated.<wbr> If you hear or notice any similar situation in your country, please contact the CI department.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8548">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-26T10:32:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-26T10:32:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' Q3 Results Supported by Recently Launched Products</title>
	<pubDate>2012-10-25T15:50:03+02:00</pubDate>
	<wp:post_id>3777</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management reported flat pharma sales in Q3:12 (0% growth in cc), and a notable performance on the Chinese market with 22% (cc) growth.<wbr> Outlook for 2012 remains unchanged.<wbr> The agenda of the company's R&amp;D Day (Nov.<wbr> 8th), highlighted at the end of the presentation, indicates a strong focus in Oncology (translational medicine, portfolio update, strategy for growth).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7144_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7144_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 8.5pt; BACKGROUND: white; COLOR: black; FONT-FAMILY: 'Tahoma','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 8.5pt; BACKGROUND: white; COLOR: black; FONT-FAMILY: 'Tahoma','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7144_4_ScreenCapture4.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7144_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="endocrinology7144attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7144_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7144_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(36,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7144_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(33,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7144">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-25T15:50:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-25T15:50:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>An Orally Active Ghrelin Mimetic Macimorelin (AEZS-130) as New Available Test for Diagnosis of Adults GH Deficiency</title>
	<pubDate>2012-10-25T15:36:53+02:00</pubDate>
	<wp:post_id>3778</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the 6th International Congress of the Growth Hormone Research Society and the IGF Society, Aeterna Zentaris (AEZS) announced a Phase 3 results for its ghrelin agonist AEZS-130 (please see below).<wbr> </div><div style="margin-bottom: 10px;">The objective of the study was to evaluate the safety and efficacy of AEZS-130 in the diagnostic accuracy of Adults GH Deficency.<wbr> <BR>Previous comparison of this test with GHRH+L-Arginine test showed a better response of AEZS-130 as rapidity and as ROC (receiver operating characteristic) area under the curve (Slide 27 and 46 of the Investor Presentation of Aeterna Zentaris (October 2012)).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7143_2_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7143_3_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Adverse Effects were mild and 70% of patients undergoing both tests expressed a favorable preference for AEZS 130.<wbr> </div><div style="margin-bottom: 10px;">As first oral diagnostic tool AEZS-130 has a market oppurtunity of about 160.<wbr>000 Diagnostic Tests (Slide 12 of the Investor Presentation of Aeterna Zentaris (October 2012)).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7143_4_ScreenCapture3.jpg"> </div><div>Conclusion: AEZS-130 would be a promising short, rapid, safe and well-tolerated diagnostic test for adult patients with GH Deficiency </div><!-- Comment details --><a name="endocrinology7143attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7143_1_aezs130%20tables.doc">aezs130 tables.doc</a>&nbsp;&nbsp;(314 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7143_2_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(34,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7143_3_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(57,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7143_4_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(82 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7143">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-25T15:36:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-25T15:36:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Predicts Price Cuts Will Lead to Drop in French Sales</title>
	<pubDate>2012-10-25T12:56:47+02:00</pubDate>
	<wp:post_id>3779</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Corinne Le Goff, the president of Roche (Switzerland)'s French pharma division, has predicted that price cuts will cause the company's drug sales in France to decline in 2012.<wbr> According to <EM>AWP Swiss News</EM>, Le Goff singled out a 15% reduction in the price of the oncology drug Avastin (bevacizumab) as being particularly significant.<wbr> </div><div style="margin-bottom: 10px;">On a broader level, Le Goff bemoaned the fact that medicines are being made to play a "disproportionate" part in the government's budget cuts.<wbr> Nevertheless, she predicted that the company's overall drug sales in France would pick up again in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Despite Roche's concerns over the difficult operating environment in France, the country's size and level of development mean that it remains a key market for the Swiss company.<wbr> </div><div style="margin-bottom: 10px;">Notably, Roche currently has more than 35,000 patients participating in clinical trials in France, out of its global total of 300,000 clinical trial patients.<wbr> The company is planning to launch 16 products in France over the next six years, mainly in the areas of oncology and nervous system diseases.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10141">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-25T12:56:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-25T12:56:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Pediatric Trial with Versartis' Once-Monthly rhGH</title>
	<pubDate>2012-10-24T15:00:00+02:00</pubDate>
	<wp:post_id>3780</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The <SPAN style="TEXT-DECORATION: underline">Ver</SPAN>sartis <SPAN style="TEXT-DECORATION: underline">T</SPAN>rial <SPAN style="TEXT-DECORATION: underline">I</SPAN>n <SPAN style="TEXT-DECORATION: underline">C</SPAN>hildren to <SPAN style="TEXT-DECORATION: underline">A</SPAN>ssess <SPAN style="TEXT-DECORATION: underline">L</SPAN>ong-Acting Growth Hormone (VERTICAL) Ph1b/<wbr>2a study is being conducted in &gt; to 26 sites in the US, and was initiated following the successful completion of a Ph1 trial in AGHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> </div><div style="margin-bottom: 10px;">The VERTICAL study is a randomized, open-label, multi-center Phase 1b/<wbr>2a study being conducted in pre-pubertal GHD children that have not been previously treated with rhGH.<wbr> </div><div style="margin-bottom: 10px;">The study is designed in two stages: </div><div style="margin-bottom: 10px;"><U>the first stage</U> (Phase Ib) utilizes an ascending dose design to evaluate the safety and tolerability of up to four dosing levels of a single subcutaneous (SC) dose of VRS-317 in approximately 48 pre-pubertal GHD children.<wbr> </div><div style="margin-bottom: 10px;"><U>the second stage</U> (Phase 2a) will further study these patients to determine the efficacy of VRS-317 as defined by an increase in height velocity over six months of treatment.<wbr> </div><div style="margin-bottom: 10px;">Secondary objectives of the six-month Phase 2a study include evaluating the safety and tolerability of repeat dosing as well as change in bone age, body weight and other measures of growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Presented at ESPE2012 by George M.<wbr> Bright, MD, Vice President of Medical Affairs at Versartis - (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7094" class="defaultlink">Endocrinology7094: Intelligence from ESPE 2012 (Part1) - Developments and New Results of rhGH Drugs</a>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7142">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-24T15:00:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-24T15:00:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Octreotide Fails To Benefit MBO Patients In PhIII Trial</title>
	<pubDate>2012-10-24T14:04:37+02:00</pubDate>
	<wp:post_id>3781</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Octreotide Fails To Benefit MBO Patients In PhIII Trial</span>&nbsp;<br><span style="font-size: 12px;">Comment: Disappointing results from a phIII trial with octreotide in 
malignant bowel obstruction has prompted Dr Currow, the study PI, to suggest 
that ranitidine plus dexamethosone may be a more cost-effective alternative.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7135">...</a><br></div><div style="margin-bottom: 10px;">As mentioned by Raphael this poster has been presented at ASCO 2012 and the Medical Franchise liaised after ASCO with Dr Currow the PI of the study to get more data on it.<wbr> The same data were presented again at the 19th International Congress on Palliative Care 2 weeks ago and made more noise than at ASCO with a Medscape article.<wbr> The main point is that this Australian octreotide study, a double blind, placebo controlled, well designed study is negative (same effect for octreotide and placebo on the vomiting endpoint) challenging then the place of octreotide for this indication in some EU SMPC (Italy for example) and in many guidelines (US, Fr, Be, NL, UK.<wbr>.<wbr>.<wbr>), the cost of the treatment being put upfront.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">Within the context of our on going MBO dossier preparation with Somatuline 30mg, the Endo Medical Franchise and Clin Devpt are currently revisiting all the different studies performed with octreotide and lanreotide in MBO to illustrate similarities and differences of these studies (in terms of study population, drug formulation, endpoint, treatment duration, stage of the disease.<wbr>.<wbr>.<wbr>).<wbr> </div><div>This information will be shared.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7139">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7135">View thread  Endocrinology7135: Octreotide Fails To Benefit MBO Patients In PhIII Trial</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-24T14:04:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-24T14:04:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Polish Healthcare Reform Plans Move Forward</title>
	<pubDate>2012-10-24T13:57:37+02:00</pubDate>
	<wp:post_id>3782</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Poland's health minister Bartosz Arłukowicz has presented a five-point schedule for the next stage of the reform of the Polish public healthcare system that includes the abolition of the central office of the National Health Fund and for the first time the proposal for the abolition of the Agency for Health Technology Assessment in Poland (AOTM) and the assumption of its responsibilities by a new pricing and evaluation agency, which will also take over the responsibilities of the NFZ in this area.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Source: Polish newspaper <I>Gazeta Wyborcza</I> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The abolition of the central office of the NFZ.<wbr> For this to happen, there will need to be a change in the law on healthcare, and the proposals for this legal change are due to be presented around the end of 2012 and the beginning of 2013.<wbr> The date for the abolition of the NFZ's central office has not yet been finally established.<wbr> 
</LI>
<LI>Increased responsibility being given to individual NFZ branches, which will be able to decide what they spend their budget on.<wbr> It has not yet been decided whether the current regional branch structure of the NFZ, with a branch in every voivodship, will be maintained, or if a set of wider regional divisions will be created.<wbr> 
</LI>
<LI>All activities involving the assessing and pricing of treatment by the NFZ will stop, and a new agency will be set up that will have responsibility for the pricing of medical treatment and the assessment of its quality and cost-effectiveness.<wbr> Additionally, the AOTM is to be abolished and its responsibilities will also be taken over by this new agency, together with those of the Centre for the Monitoring of Quality in Health Care.<wbr> 
</LI>
<LI>Patients are due to register at general practitioners' surgeries and hospitals from January 2012 using only their electronic registration number, found on their identity cards.<wbr> This will enable those treating them to verify that they are eligible for treatment.<wbr> From 2014, an electronic card system is to be introduced that will include all information about a patients' treatment, including prescribed medicines, and medical history.<wbr> 
</LI>
<LI>Once the new card system is in place, the Ministry of Health (MoH) will turn its attention to the introduction of additional, voluntary health insurance.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The pace of the reforms is certainly being influenced by the pressure from the main opposition party, Law and Justice, which has recently presented its vision for public healthcare at a time when the government is susceptible to attacks on the healthcare front, following the sometimes ineptly managed introduction of reforms in the past year – particularly reforms included in the Reimbursement Act, relating principally to regulations on reimbursed medicines.<wbr> The government has until the latter half of 2015 before it must call an election – barring any catastrophic loss of popularity.<wbr> Therefore it is possible that it could implement many of these reforms in the time it has remaining.<wbr> </div><div style="margin-bottom: 10px;">With regional NFZ branches being able to decide what they spend money on, there will be a more heterogeneous system in Poland, with regional variations, and the possibility of certain NFZ branches being more generous than others with their reimbursement budgets.<wbr> This could present both opportunities and challenges to pharmaceutical companies.<wbr> Another point worth bearing in mind is that the NFZ was created and came into operation in 2004 in response to the financial chaos of the regional sickness funds.<wbr> It is yet to be demonstrated how such chaos is to be avoided this time around.<wbr> </div><div style="margin-bottom: 10px;">In earlier statements on the reforms, there is no specific mention of the AOTM's liquidation, and indeed it was seen as a possibility that the new pricing agency would be established around the AOTM.<wbr> For efficiency reasons, putting all these related competencies together makes sense, but there will be questions regarding exactly how independent this new agency will be.<wbr> The AOTM is still a dependent agency of the MoH, and for all their squabbles and disputes, the NFZ and the MoH are equally a part of the state apparatus.<wbr> The AOTM has a Transparency Board, which includes independent and non-partisan members who assess treatments – usually medicines – and this new board, along with the Economic Commission, which is responsible for negotiating prices with applicants and making cost-effectiveness decisions, represents a structure that only came into place at the beginning of 2012.<wbr> How this model for pricing and reimbursement in Poland is changed by these reforms – if it is at all – will be monitored very closely.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10139">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-24T13:57:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-24T13:57:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights of Leerink Swann's 3Q Cosmetic Survey Results</title>
	<pubDate>2012-10-24T11:21:09+02:00</pubDate>
	<wp:post_id>3783</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey polled 32 U.<wbr>S based dermatologists and 30 plastic surgeons.<wbr> Bottom lines suggest that despite interest in Merz's Xeomin &amp; Belotero, physicians only forecast ~6% share for either product through 2014.<wbr> Interestingly, many respondents responded that they are particularly excited about bringing Merz’s Xeomin and Belotero into their practices in the next 6-12 months citing cost savings with this new market entrant.<wbr> Over 75% of respondents were aware of Valeant's acquisition of Medicis but a minority expect it to impact their practice.<wbr> Key results are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6626_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6626_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6626_3_ScreenCapture3.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="neurology6626attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6626_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(51,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6626_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6626_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(23,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6626">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-24T11:21:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-24T11:21:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca to Co-Develop/Commercialize IBS-C Drug for the Chinese Market</title>
	<pubDate>2012-10-23T17:47:48+02:00</pubDate>
	<wp:post_id>3784</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca and Ironwood will co-develop and co-commercialize Ironwood’s linaclotide in China for adult patients suffering from irritable bowel syndrome with constipation (IBS-C).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Development and Marketing</U> </div><div style="margin-bottom: 10px;">AstraZeneca and Ironwood are jointly responsible for strategic oversight of the development and commercialization of linaclotide in China.<wbr> </div><div style="margin-bottom: 10px;">AstraZeneca will have primary responsibility for the local operational execution.<wbr> </div><div style="margin-bottom: 10px;"><U>Financial</U> </div><div style="margin-bottom: 10px;">AstraZeneca will make an upfront payment of $25M to Ironwood and will share the net profits and losses associated with linaclotide in China, with AstraZeneca carrying 55% of each until a certain specified milestone is achieved, moving to a 50/<wbr>50 split thereafter.<wbr> </div><div style="margin-bottom: 10px;">Ironwood will also be eligible for $125M in additional commercial milestone payments contingent on the achievement of certain sales targets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- IBS-C is a chronic and prevalent functional gastrointestinal disorder in China and there are currently few treatment options for this condition.<wbr> </div><div>- To capitalize on its leadership in the gastrointestinal sector in the emerging markets.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1861">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-23T17:47:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-23T17:47:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First Ph3 Results of Botox Vs Placebo for Crow's Feet Lines (CFL)</title>
	<pubDate>2012-10-23T15:13:16+02:00</pubDate>
	<wp:post_id>3785</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First Ph3 Results of Botox Vs Placebo for Crow's Feet Lines (CFL)</span>&nbsp;<br><span style="font-size: 12px;">Comment: According to study results presented at the American Society for Dermatologic Surgery's Annual Meeting (Atlanta, USA), all primary and secondary endpoints were achieved.<wbr> On the competitive front, Revance is to start a Ph3 with its topical toxin by the end of 2012 /<wbr> early 2013.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6623">...</a><br></div><div>Please be informed that Dr Carruthers has been the "Botox"s pioneering in aesthetic.<wbr> He and his wife are very popular worldwide.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6625">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6623">View thread  Neurology6623: First Ph3 Results of Botox Vs Placebo for Crow's Feet Lines (CFL)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-23T15:13:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-23T15:13:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Firmagon Added to Poland's Reimbursement List in Draft November Update</title>
	<pubDate>2012-10-23T14:05:49+02:00</pubDate>
	<wp:post_id>3786</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Polish Ministry of Health (MoH) has published the draft of the update to the country's reimbursement list, which is set to come into force at the beginning of November.<wbr> </div><div style="margin-bottom: 10px;">Another important change introduced in the reimbursement list update involves the availability of a number of oncology drugs which were previously only available in hospitals via the outpatient system – these are busulfan, chlorambucil, melphalan and thioguanine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Firmagon was recommended by then Consultative Council of the AOTM in January 2012 – also with some price-related conditions, indicating that some concession has also been made here.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8547">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-23T14:05:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-23T14:05:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SPA for Tivantinib in 2nde-Line Ph3 Trial in MET-High HCC Patients</title>
	<pubDate>2012-10-23T13:47:23+02:00</pubDate>
	<wp:post_id>3787</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Daiichi and ArQule have announced a SPA agreement with the FDA for the design of the Ph3.<wbr> Details of the trial as well as ongoing development program with the drug are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: randomized, double-blinded trial of tivantinib as single agent therapy in previously treated patients with MET diagnostic-high inoperable HCC.<wbr></LI>
<LI>PE: OS</LI>
<LI>SE: PFS</LI>
<LI>Recruitment: approx.<wbr> 300 patients are planned</LI>
<LI>Location: approx.<wbr> 120 centers WW</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8545_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8545_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8537" class="defaultlink">Oncology8537: ESMO Intelligence Part 3 - Key Developments In Hepatocellular Cancer</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8763c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The first patient has been enrolled in the pivotal Phase 3 METIV-HCC (<STRONG>MET</STRONG>-high patients with <STRONG>tiv</STRONG>antinib in HCC) trial of tivantinib (ARQ 197).<wbr> PE will assess Overall survival (OS) in Intent to Treat (ITT) population.<wbr> </div><div style="margin-bottom: 10px;">The <a href="http://www.clinicaltrials.gov/ct2/show/NCT01755767?term=metiv&rank=1" class="defaultlink">METIV-HCC</a> trial is a randomized, double-blinded, controlled study of previously treated patients with MET-high inoperable HCC who will receive tivantinib or placebo.<wbr> The primary endpoint is overall survival (OS), and the secondary endpoint is progression-free survival (PFS).<wbr> Approximately 300 patients are planned to be enrolled at approximately 120 clinical centers worldwide.<wbr> </div><div>Tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kinase, is being evaluated for the treatment of patients diagnosed with hepatocellular carcinoma (HCC) who have received one or two prior systemic anti-cancer therapies.<wbr> </div></div><a name="oncology8545attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8545_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(59,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8545_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(94 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8545">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-23T13:47:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-23T13:47:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dr Reddy's Intended Acquisition of OctoPlus to Bring Complementary Skill Set</title>
	<pubDate>2012-10-23T10:52:54+02:00</pubDate>
	<wp:post_id>3788</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The strategy to build capabilities rather than acquire products is seen as very positive by analysts at Kotak and Morgn Stanley.<wbr> OctoPlus, a small specialty company, will provide the required formulation skills for complex injectables (the US market size of long-acting injectable drugs is close to $2bn).<wbr> Though OctoPlus appears to have built expertise in difficult technologies, its product visibility is limited (i.<wbr>e.<wbr>, only Locteron in Ph2b).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>to enhance Dr Reddy's formulation capabilities for complex injectables.<wbr></LI>
<LI>to complement its existing API strength.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Financial</STRONG> </div><div style="margin-bottom: 10px;">- Acquisition of all outstanding shares of OctoPlus at EUR0.<wbr>52/<wbr>share is valuing the entity at €27.<wbr>4 mn.<wbr> The offer price is at 30% premium to the last closing price of OctoPlus and has been supported by the OctoPlus board.<wbr> </div><div style="margin-bottom: 10px;">- The transaction is expected to be closed by end of FY2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Business Model: 3 segments </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10136_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">- Founded in 1995 </div><div style="margin-bottom: 10px;">- Staff: 111 (in 2011) </div><div style="margin-bottom: 10px;">- Business: formulation development and manufacturing of complex injectables.<wbr> </div><div style="margin-bottom: 10px;">- Location: Leiden, Netherlands where it operates an injectable formulation facility and research centre.<wbr> </div><div style="margin-bottom: 10px;">- Business model : development services to global pharma and biotech companies and also license/<wbr>partner to monetize the proprietary technologies.<wbr> </div><div style="margin-bottom: 10px;">- Revenues: EUR4.<wbr>8 mn in 1HCY2012; (fee for services contributed 73% of sales).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10136_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">- Key Projects </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10136_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="pharmaworld10136attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10136_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10136_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10136_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(72,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10136">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-23T10:52:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-23T10:52:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly's Once-Weekly GLP-1 Analog Tops Byetta Metformin and Januvia in Trials</title>
	<pubDate>2012-10-23T09:53:41+02:00</pubDate>
	<wp:post_id>3789</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lilly reported it aims to seek marketing approval for dulaglutide in 2013, based on data from the trio of 'favorable Ph3 studies'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- dulaglutide lowered hemoglobin A1c levels more than twice-daily injections of BMS' Byetta given for 6 months, oral metformin taken for 26 weeks and Merck &amp; Co's once-daily oral Januvia taken for 1 year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7138_1_ScreenCapture1.jpg"> </div><div>Lilly is also conducting a trial that compares dulaglutide with Victoza.<wbr> The study is expected to be wrapped up by late 2013 or early 2014.<wbr> </div><!-- Comment details --><a name="endocrinology7138attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7138_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7138">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-23T09:53:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-23T09:53:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Octreotide Fails To Benefit MBO Patients In PhIII Trial</title>
	<pubDate>2012-10-23T07:39:12+02:00</pubDate>
	<wp:post_id>3790</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Octreotide Fails To Benefit MBO Patients In PhIII Trial</span>&nbsp;<br><span style="font-size: 12px;">Comment: Disappointing results from a phIII trial with octreotide in 
malignant bowel obstruction has prompted Dr Currow, the study PI, to suggest 
that ranitidine plus dexamethosone may be a more cost-effective alternative.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7135">...</a><br></div><div>The poster (attached) had been presented at ASCO 2012.<wbr> </div><!-- Comment details --><br><a name="endocrinology7136attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7136_1_Poster%20Flinders.pptx">Poster Flinders.pptx</a>&nbsp;&nbsp;(2,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7136">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7135">View thread  Endocrinology7135: Octreotide Fails To Benefit MBO Patients In PhIII Trial</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-23T07:39:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-23T07:39:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>VTX-2337 + Doxil in Ph2 for Ovarian Cancer</title>
	<pubDate>2012-10-22T18:05:42+02:00</pubDate>
	<wp:post_id>3791</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The randomized, double-blind, placebo-controlled Ph2 trial is being conducted in collaboration with the Gynecologic Oncology Group (GOG) Partners Program.<wbr> The trial will enroll approx.<wbr> 210 patients with recurrent/<wbr>persistent epithelial ovarian cancer who ave faled prior platinum-based chemotherapy.<wbr> The primary endpoint of the trial is OS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01666444?term=VTX-2337&amp;rank=2"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Oct.<wbr> 3 2012 - exclusive, WW collaboration with Celgene Corporation for the development of VTX-2337 for the treatment of cancer.<wbr> </div><div style="margin-bottom: 10px;">As part of the strategic agreement, Celgene will retain the exclusive option to acquire VentiRx.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">VTX-2337 is a small molecule Toll-like receptor 8 (TLR8) agonist that stimulates myeloid dendritic cells (mDc), monocytes, and enhances natural killer (NK) cell responses.<wbr> It is administered subcutaneously (SC) on a weekly basis.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8544_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases.<wbr> </div><div>Privately held organization with operations in Seattle, Washington </div><!-- Comment details --><a name="oncology8544attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8544_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8544">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-22T18:05:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-22T18:05:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hikma Signs License and Supply Agreement with GP Pharm for Lutrate 1M</title>
	<pubDate>2012-10-22T16:22:11+02:00</pubDate>
	<wp:post_id>3792</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agreement covers the MENA Zone (Middle East and North Africa), and the prostate cancer indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Hikma will have the licensing rights to register, market and distribute Lutrate 1M in 23 countries across MENA.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8542">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-22T16:22:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-22T16:22:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Ph3 Results of Botox Vs Placebo for Crow's Feet Lines (CFL)</title>
	<pubDate>2012-10-22T10:40:57+02:00</pubDate>
	<wp:post_id>3793</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to study results presented at the American Society for Dermatologic Surgery's Annual Meeting (Atlanta, USA), all primary and secondary endpoints were achieved.<wbr> On the competitive front, Revance is to start a Ph3 with its topical toxin by the end of 2012 /<wbr> early 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 14px/17px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(68,68,68); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Carruthers A.<wbr> “Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Crow’s Feet Lines.<wbr>” Presented at: American Society for Dermatologic Surgery 2012 Annual Meeting; Oct.<wbr>11-15, Atlanta.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Primary outcome measures</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Severity of Crow's Feet Lines at maximum smile using the Facial Wrinkle Scale.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Secondary outcome measures</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Investigator's assessment of the severity of Crow's Feet Lines at rest using the Facial Wrinkle Scale [ Time Frame: Day 30 ] [ Designated as safety issue: No ]<BR></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject's Global Assessment of change in appearance of Crow's Feet Lines [ Time Frame: Day 30 ] [ Designated as safety issue: No ]<BR></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject's assessment of facial appearance [ Time Frame: Day 30 ] [ Designated as safety issue: No ].<wbr></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;">- Recruitment: 445 patients (mean age 46.<wbr>4 years) with moderate-to-severe crow's feet lines at maximum smile.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>222 patients received Botox (24U; 3 inj/<wbr>side; 4U/<wbr>inj site)</LI>
<LI>223 patients received placebo</LI>
</UL> </div><div>Visits: 1 and 2 weeks and 30,60,90,120 and 150 days </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6625c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Please be informed that Dr Carruthers has been the "Botox"s pioneering in aesthetic.<wbr> He and his wife are very popular worldwide.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6623">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-22T10:40:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-22T10:40:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</title>
	<pubDate>2012-10-22T10:14:09+02:00</pubDate>
	<wp:post_id>3794</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</span>&nbsp;<br><span style="font-size: 12px;">Comment: Methylene Blue MMX<SUP>®</SUP> (for the diagnosis of lesions, polyps and adenomas in the colon) will be presented to approx.<wbr> 500 specialists from around the world during the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano/<wbr>Italy.<wbr> The Methylene blue-MMX<SUP>®</SUP> tablet, currently assessed in Ph2, is an oral colon-release formulation in form of coated tablets, containing methylene blue.<wbr> The company expects market entry end 2013.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1800">...</a><br></div><div style="margin-bottom: 10px;">According to the company, the Ph3 trials should end no later than H2 2013.<wbr> Approx.<wbr> 1500 patients will be screened, the majority of these are classical colon cancer screening patients but the clinical trials program will also include patients diagnosed with active ulcerative colitis for more than 8 years.<wbr> </div><div style="margin-bottom: 10px;">Locations: Major North American and European hospitals </div><div style="margin-bottom: 10px;">Alessandro Repici, the Head of Endoscopy Dept.<wbr> at Istituto Clinico Humanitas said: &ldquo;If the excellent results we saw in this clinical trial are confirmed in the phase III trials then I am convinced that besides me, most of my colleagues on a worldwide basis will be prescribing Methylene Blue MMX&reg; tablets to all their patients.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>Phase2 Results</STRONG> </div><div style="margin-bottom: 10px;">Ph2 II clinical trials program for the evaluation of the polyp and adenoma detection rate in patients undergoing full colonoscopy after colonic staining with Methylene Blue MMX&reg; tablets attained all the objectives and has generated the information required to complete the design of the phase III clinical trials.<wbr> </div><div>In the tested patient population (n=96) the polyp detection rate in the whole colon was on average 1.<wbr>8 polyps per patient and the adenoma detection rate was 0.<wbr>9 detected adenomas per patient.<wbr> Polyps were detected in 63.<wbr>5% of patients, adenomas in 46.<wbr>9% and serrated lesions in 27.<wbr>1% of patients.<wbr> According to literature, polyps are normally detected in 35% or less of patients, and according to an abstract published in 2012 by the Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic in Ohio USA, based on 18&rsquo;003 colonoscopies, the adenoma detection was 31.<wbr>5% and the serrated lesions detection rate was 20.<wbr>6%.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1860">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1800">View thread  GastroEnterology1800: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-22T10:14:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-22T10:14:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Launch of Astellas' Gonax (degarelix) in Japan for Prostate Cancer</title>
	<pubDate>2012-10-22T09:57:05+02:00</pubDate>
	<wp:post_id>3795</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As part of Astellas' near term plan announced last month, the company today reported it will be launching Gonax on Oct.<wbr> 23rd, 2012.<wbr> The drug was granted Japanese marketing approval in June.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8539_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8539_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology8539attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8539_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8539_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(28,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8539_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(32,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8539">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-22T09:57:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-22T09:57:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Octreotide Fails To Benefit MBO Patients In PhIII Trial</title>
	<pubDate>2012-10-22T09:12:15+02:00</pubDate>
	<wp:post_id>3796</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Disappointing results from a phIII trial with octreotide in 
malignant bowel obstruction has prompted Dr Currow, the study PI, to suggest 
that ranitidine plus dexamethosone may be a more cost-effective alternative.<wbr> </div><div style="margin-bottom: 10px;">Dr David Currow, Professor of Palliative &amp; Supportive Care at Flinder 
University Hopsital Adelaide Australia presented the results of the study at the 
19th Interanational Congress on Palliative Care </div><div style="margin-bottom: 10px;">Octreotide has been used in the treatment of MBO for more than 20 years and 
has even been described in recent literature (Clin Rev Oncol Hematol 
2012:82:388) as the the antisecretory agent of choice for MBO.<wbr> It is approved 
for this indication in  some markets and in other such as the US is used 
off-label.<wbr> </div><div style="margin-bottom: 10px;"><B><SPAN style="FONT-FAMILY: Arial, sans-serif; COLOR: windowtext; FONT-SIZE: 9.5pt">Negative 
Trial</SPAN></B> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: Arial, sans-serif; COLOR: windowtext; FONT-SIZE: 9.5pt">The 
phIII study just reported was well powered and involved 86 patients with MBO 
from 12 sites.<wbr> Patients were randomised to receive a continuous 24-hour 
subcutaneous infrusion of octreotide 600 ug or placebo.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: Arial, sans-serif; COLOR: windowtext; FONT-SIZE: 9.5pt">In 
addition, all patients received ranitidine (200mg over 24 hours), dexamethasone 
(8mg over 24 hours), and hydration.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: Arial, sans-serif; COLOR: windowtext; FONT-SIZE: 9.5pt">The 
primary outcome was the number of days free of comiting in the initial 72-hour 
period.<wbr> Secondary outcomes were Global Impression of Change Score, number of 
vomiting episodes, symptom control,  additional medication use, nasogastric 
tube placement and surgery during the study period.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: Arial, sans-serif; COLOR: windowtext; FONT-SIZE: 9.5pt">When 
the octreotide and placebo groups were compared, the number of days free of 
vomiting (p-0.<wbr>724) was non-significant, as were all but one of the secondary 
outcomes.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Dr Currow is reported as saying that the new findings "put under 
a cloud a very expensive therapy and suggest that far less expensive therapies 
are as efficacious, well tolerated and importantly have a place in our clinical 
practice".<wbr> He also noted that although there have been 3 other randomised 
positive trials with octreotide those have included smaller numbers of 
patients.<wbr> </div><div>Source: 19th Interantional congress on Palliative Care Abstract 
D08-B<SPAN style="TEXT-ALIGN: center; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px 'Times New Roman', serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">.<wbr></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7136c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The poster (attached) had been presented at ASCO 2012.<wbr> </div></div><a name="Endocrinology7139c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">As mentioned by Raphael this poster has been presented at ASCO 2012 and the Medical Franchise liaised after ASCO with Dr Currow the PI of the study to get more data on it.<wbr> The same data were presented again at the 19th International Congress on Palliative Care 2 weeks ago and made more noise than at ASCO with a Medscape article.<wbr> The main point is that this Australian octreotide study, a double blind, placebo controlled, well designed study is negative (same effect for octreotide and placebo on the vomiting endpoint) challenging then the place of octreotide for this indication in some EU SMPC (Italy for example) and in many guidelines (US, Fr, Be, NL, UK.<wbr>.<wbr>.<wbr>), the cost of the treatment being put upfront.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">Within the context of our on going MBO dossier preparation with Somatuline 30mg, the Endo Medical Franchise and Clin Devpt are currently revisiting all the different studies performed with octreotide and lanreotide in MBO to illustrate similarities and differences of these studies (in terms of study population, drug formulation, endpoint, treatment duration, stage of the disease.<wbr>.<wbr>.<wbr>).<wbr> </div><div>This information will be shared.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7135">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-22T09:12:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-22T09:12:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: GP Pharm's Lutrate 1M Launched in Spain</title>
	<pubDate>2012-10-22T08:58:57+02:00</pubDate>
	<wp:post_id>3797</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">GP Pharm's Lutrate 1M Launched in Spain</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to E.<wbr> Minguell we have learnt that <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=177">...</a><br></div><div style="margin-bottom: 10px;">Esther Minguell recently reported that the effective launching of the Spanish Lutrate 1M has been delayed due to a double price confusion that is to be clarified by the MoH in the coming days.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In July, Lutrate 1M was given the same price than Procrin Depot 3,75mg in Spain (EFP 107,09€, published in July 2012).<wbr> </div><div style="margin-bottom: 10px;">However, in September the EFP was modified to 85,50€ (a discount of 20%), and published in the September nomenclator.<wbr> </div><div style="margin-bottom: 10px;">Back in October, the price has returned to the initial approved price as of July.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Now the drug is still retained until clarification of an 'official price'.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=193">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids177">View thread  DKPHybrids177: GP Pharm's Lutrate 1M Launched in Spain</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-22T08:58:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-22T08:58:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 3 - Key Developments In Hepatocellular Cancer</title>
	<pubDate>2012-10-19T18:23:02+02:00</pubDate>
	<wp:post_id>3798</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Interesting data on the HCC therapeutic landscape was presented at both the Novartis symposium and during a special HCC symposium featuring the GIDEON data and Daiichi Sankyo's MET inhibitor tivantinib.<wbr> </div><div style="margin-bottom: 10px;">After many late-stage setbacks in the field, Novartis appeared to be positioning itself for perhaps more promising data from its mTOR inhibitor everolimus with which one phIII trial in the 2nd line advanced setting is currently underway (due to complete March 2013).<wbr> </div><div style="margin-bottom: 10px;">A selection of the key slides presented is shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_24_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_25_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_26_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_27_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_28_ScreenCapture28.jpg"> </div><div style="margin-bottom: 10px;">Of equal intererst was the data presented from the GIDEON trial showing the aetiological diversity in response to Sorafenib and the aetiological variability in the disease according to geographic region.<wbr> </div><div style="margin-bottom: 10px;">Whilst promising phII data has not always translated into good phIII efficacy in this field, at this juncture the phase II data on tivantanib does appear to suggest a promising way forward for patients in MET overexpressing tumours.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_14_ScreenCapture14.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_15_ScreenCapture15.jpg"> </div><!-- Comment details --><a name="oncology8537attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(84,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(80,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(89,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(73,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(89,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(90,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(83,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(89,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(85,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(106 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(97,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(82,9 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(79,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(78,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(94,9 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(57 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(72,5 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(56,6 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(57,9 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(85 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(76,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(95,2 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(82,4 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(95 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(73,8 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(94,3 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8537_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(81 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8537">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-19T18:23:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-19T18:23:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Potential Disease Modifying Therapy For Parkinson's Disease</title>
	<pubDate>2012-10-19T16:22:01+02:00</pubDate>
	<wp:post_id>3799</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Proteostatis Therapeutics reportedly presented some interesting 
data at the recent Society for Neuroscience meeting demonstrating how small 
molecule inhibition of USP14 can stimulate the degredation of alpha synuclein a 
protein linked to progression of PD.<wbr> </div><div style="margin-bottom: 10px;">Proteostatis Presentation was entitled "Proteolytic degradation and 
clearnance of misfoled proteisn associated with neurodegenerative diseases by 
small molecule inhibition of Usp14 </div><div style="margin-bottom: 10px;">The company is advancing compounds toward lead nomination.<wbr> In addition to 
alpha-synuclein, Usp 14 inhibition was whon to influence the degradation of 
other aggregation prone proteins suggesting that such agents may also have 
therapeutic application in Alzheimer's disease, ALS, SCA and frontotemporal 
dementia.<wbr> </div><div style="margin-bottom: 10px;">Based on its findings so far, Proteostatis intends to begin clinical 
development in Parkinson's disease in 2014.<wbr> </div><div>Source: Pharma-E-Track </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6620">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-19T16:22:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-19T16:22:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New CRPC Study With Tokai's galeterone</title>
	<pubDate>2012-10-18T17:49:07+02:00</pubDate>
	<wp:post_id>3800</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing a new Ph2 study with Tokai's androgen modulator galeterone.<wbr> The randomised 2 part trial will evaluate safety and efficacy in CRPC patients who have yet to receive TAK-700, ARN-509 , ketoconazole or enzalutamide as well as CRPC patients who have demonstrated progression on Zytiga.<wbr> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Part 1 will confirm dose to be used in Part B of the study by assessing safety and efficacy by means PSA response.<wbr> [ Time Frame: 3 months ] </P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Part 2 of this study will further assess efficacy of the dose of galeterone chosen in Part 1 of the study in terms of changes from baseline in PSA concentration and tumor response rate by RECIST criteria [ Time Frame: 3 months ] RECIST will be evaluated by tumor changes measurements as seen on CT/<wbr>MRI.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">The study will enroll 172 patients and is scheduled to start in December.<wbr> Its primary completion date is June 2014.<wbr> The location of the trial has yet to be specified.<wbr></P> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">ClinicalTrial Identifier: <A href="http://clinicaltrials.gov/ct2/show/NCT01709734?term=NCT01709734&amp;rank=1">NCT01709734</A></P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8674c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Tokai has announced the treatment of the first patient in the ARMOR2 trial.<wbr> With its improved new tablet formulation, ARMOR2 will provide the company with additional important insights on the clinical utility of galeterone in several distinct CRPC patient populations.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Investigators</SPAN> </div><div>The study is being led by co-principal investigators Bruce Montgomery, M.<wbr>D.<wbr>, associate professor of medical oncology at the University of Washington School of Medicine and Mary-Ellen Taplin, M.<wbr>D.<wbr>, associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8535">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-18T17:49:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-18T17:49:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon's Fund Raising</title>
	<pubDate>2012-10-18T17:29:58+02:00</pubDate>
	<wp:post_id>3801</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lexicon Pharmaceutical has today announced the pricing of a public 
offering of its common stock which is likely to raise in aggregate net proceeds 
of approximately $37.<wbr>2m.<wbr> The public offering consists of 17,500,000 shares of 
its common stock at a price of $2.<wbr>25 per share.<wbr> </div><div style="margin-bottom: 10px;">J.<wbr>P.<wbr> Morgan Securities and Jefferies &amp; Company are acting as joint 
book-runners for the offering, with Needham &amp; company, Stifel Nicolaus 
Weisel and Wedbush PacGrow Life Sciences acting as co-managers.<wbr> </div><div>source; <a href="http://www.lexicon.com" class="defaultlink" title="www.lexicon.com">lexicon.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7131">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-18T17:29:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-18T17:29:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence Insights from the World Stroke Congress - Allergan</title>
	<pubDate>2012-10-18T14:02:33+02:00</pubDate>
	<wp:post_id>3802</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan’s Post Stroke Checklist will roll out in the EU in 2013.<wbr> Additional tools are being developed including a HRQoL measure and a screening tool.<wbr> </div><div style="margin-bottom: 10px;">Allergan’s WSC activities included a symposia entitled <I>Improving Life After Stroke — A New Approach</I> and three posters.<wbr> No clinical data were presented.<wbr> Neither Merz nor Medytox were present.<wbr> </div><div style="margin-bottom: 10px;">Hand-outs at the Allergan stand were in the local language (Portuguese) with only two staff which spoke English.<wbr> Materials consisted of a spasticity post stroke booklet and a leaflet on 10 questions frequently asked after stroke.<wbr> </div><div style="margin-bottom: 10px;">It is clear that Allergan is focusing heavily on stroke support initiatives and is positioning itself as a company who is present through-out the continuum of care for a stroke survivor.<wbr> Allergan is developing an arsenal of tools for patients and physicians alike which promote involvement with and action for the patient and/<wbr>or the physicians.<wbr> In addition to the Post Stroke Checklist (PSC), Allergan is developing a HRQoL measure for stroke survivors with spasticity and a screening tool to detect disabling spasticity in stroke survivors.<wbr> Please open attachment 22 and 29 for a copy of the PSC.<wbr> </div><div style="margin-bottom: 10px;">Their moto is ACTS — Advancing Care for Treatment of Stroke with the strap line Advocacy, Education, Evidence.<wbr> </div><div style="margin-bottom: 10px;">Allergan’s approach and presentation of these initiatives have been similar to that of announcing results (of a clinical trial) so as to ‘speak’ to the audience in a clinical way even though the content is tool-based.<wbr> The symposia was very professional and communicated the story of the PSC very well.<wbr> </div><div style="margin-bottom: 10px;">Furthermore, the imagery chosen for the handouts/<wbr>background to the symposia had a local flavour (picture was taken from a sculpture of hands at the Rio De Janerio Carnival) and depicts an air of ‘togetherness’ and a wish to ‘help’ (Allergan + patients).<wbr> </div><div style="margin-bottom: 10px;"><B>Symposia Summary:</B> </div><div style="margin-bottom: 10px;">Following on from the theme at WCNR 2012, Allergan’s symposia provided an update on the progress, methodology and validation of the PSC (Post-Stroke Checklist).<wbr> Anthony Ward stated that the UK roll-out of the PSC should take place in January 2013 and translations for other EU countries are being finalised.<wbr> Within the UK, the PSC will be distributed via Healthcare Providers and Stroke Networks.<wbr> This distribution channel is expected to be utlised in the rest of the EU also.<wbr> </div><div style="margin-bottom: 10px;">Mobility will feature in the future in that the PSC will be delivered via an App or a web-based tool which will remind the patient of their check-up.<wbr> The patient will be enticed (although not mandatory) to complete the PSC prior to an appointment so that time spent at the clinic is focused on actions and follow up.<wbr> </div><div style="margin-bottom: 10px;">The following slides outline the PSC rational and guiding principles along with a brief summary.<wbr> A key aspect of the PSC is that is it so simple, it does not require training or additional resource from Allergan but is very helpful for the patients and the physicians </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The PSC should be administered 6, 12 months post stroke and then annually thereafter although the speaker stated this can vary depending on the patient — (more frequent admission) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Methodology as to how the PSC came to fruition </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Members of the Global Delphi Panel are below: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">The panel of experts first defined the areas which were relevant to post stroke, these where then weighted according to importance — paying close attention that the PSC will focus on areas where there are evidence-based interventions that have the largest impact on a patients QOL but not is intended to cover every possible area.<wbr> The theme of evidence based intervention was repeated through out the discussion.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">This slide shows the results after the review and a second reweighing of domains </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">From the 40+ domains initially identified, the PSC was whittled down to 11 domains of importance and impact </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">The talk then moved to a review of the UK and Singapore pilot studies with the key findings from both geographies.<wbr> The questions to answer included: </div><div style="margin-bottom: 10px;"><UL><LI>User-friendliness</LI>
<LI>Clinical value</LI>
<LI>Impact of the PSC on the patient visit</LI>
<LI>Patient satisfaction</LI>
</UL> </div><div style="margin-bottom: 10px;">Firstly, the Singapore pilot was set in the context of the Cognitive Outcomes After Stoke (COAST) study, an ongoing investigation of 400 stroke patients recruited from the acute stroke service </div><div style="margin-bottom: 10px;">Methods and key outcomes of the study below: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">Clinicans view of the PSC were very high as were the patients, with an  added  9.<wbr>2 minutes after the consultation to implement the PSC (10 mintues consulation increased to 20 min) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_30_ScreenCapture28.jpg"> </div><div style="margin-bottom: 10px;">Unmet needs identified with the PSC with cognition ranking the highest.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">Moving onto the UK pilot study, the methods and outcomes are similar to the Singapore studies (with less patients) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">Like the Singapore pilot, the patient and physician satisfaction was high although it took almost double the amount of time to administerthe checklist than it did in Singapore.<wbr> Consultation’s were 22.<wbr>8 minutes with the PSC taking 16.<wbr>5 minutes to administer.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;">Unmet needs in the UK also highlighted cognition as the main need to be addressed </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;">Other observations included that the PSC items were understood by most patients at the first attempt of reading them and was relevant to the stroke patient </div><div style="margin-bottom: 10px;">Anthony Ward then continued with a case study — a female stroke survivor (63yrs) whose mobility had further deteriorated and reverted back to walking with a quadripod but had not reported these issues to anyone as she thought it was a natural outcome of stroke </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;">The patient underwent the PSC and her unmet needs were identified and she was then referred to the North Staff’s Spasticity Service for assessment.<wbr> Anthony Ward highlighted that the PSC helps patients who might ‘fall through the net’ and enables them to maintain, in this patients case, her QOL.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;">Anthony closed his session with a reminder of UP/<wbr>LL spasticity but did not mention BOTOX as a treatment </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;">The session was then wrapped up by Stephen Davis who concluded that the </div><div style="margin-bottom: 10px;"><UL><LI>PSC is a simple and east to use tool with a strong content validity</LI>
<LI>PSC is able to identify a wide range of unmet needs for stroke survivors</LI>
<LI>Clinicians and patients expresses a high overall satisfaction with the PSC</LI>
<LI>PSC was generally well understood</LI>
</UL> </div><div style="margin-bottom: 10px;">The PSC global implementation plan is outlined below </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><B>Poster Review</B>: Continuing with the support initiatives, two additional tools are being designed and validated, both are in the first rounds of formalization and will continue to evolve over the coming months </div><div style="margin-bottom: 10px;"><U>Poster: Conceptual design and content validation of a HR-QOL Measure for Stroke Survivors With Spasticity</U> </div><div style="margin-bottom: 10px;"><UL><LI>Objective is to develop a multidimensional HRQoL that 1) assess the impact of PSS on the lives of stroke survivors 2)measures changes in the HRQoL as a result of the clinicians intervention</LI>
<LI>Conclusions: The HRQoL domains and concepts identified provide for an in-depth and multidimensional description of the impact of spasticity on the lives of a stroke survivors</LI>
<LI>Although all impact concepts relevant to a general population of stroke survivors with spasticity were observed, additional qualitative work may be required to clearly distinguish the subsets of concepts relevant to patients with UL/<wbr>LL involvement</LI>
<LI>Next steps will be to assess the draft item pool for readability and comprehension through patient cognitive interviews and examine the resulting scale in assessing the impact of spasticity on the HRQoL of stroke survivors</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_23_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_24_ScreenCapture23.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_25_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><U>Poster: Conceptual design and content validation of a Screening Tool to Detect Disabling Spasticity in Stroke Survivors</U> </div><div style="margin-bottom: 10px;"><UL><LI>Objective: to identify the conceptual dimensons and content for a screening tool able to discriminate between disabling and non-disabling spasticity in stroke survivors</LI>
<LI>Conclusions: Stroke survivors with spasticity provided a robust matrix of PSS symptoms that will be used to design a screening tool to detect disabling spasticity</LI>
<LI>Additional qualitative work may be required to capture all symptoms concepts relevant to patients with PSS</LI>
<LI>Further measurement design activites will select those items for the final measure that best discriminates between strok survivors with disabling spasticity and those with non disabling spasticity</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_26_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_27_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_28_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;">· <U>Poster: The PSC, a tool for standardizing long term patient follow-up</U> </div><div style="margin-bottom: 10px;"><UL><LI>Poster highlights are captured in the Symposia detailed above</LI>
</UL> </div><div style="margin-bottom: 10px;">Other intelligence collected at the congress: </div><div style="margin-bottom: 10px;">· <B>Allergan: </B>Further confirmation that the CP trials were underway but no additional intell was forthcoming </div><div style="margin-bottom: 10px;">· <B>Merz:</B> LL studies are now recruiting children in Eastern Europe.<wbr> Thank you to Jovita Balcaitiene for this insight.<wbr> </div><div>· <B>International Guidelines: </B>have stalled due to the participants wanting additional companies/<wbr>organisations involved (not only Allergan).<wbr> The hope is to have guidelines formalized by the next two years.<wbr> </div><!-- Comment details --><a name="neurology6616attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(52,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(65,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(65,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(72 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(27,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(51,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(36,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(57,9 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(60,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(55,6 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(62,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(71,2 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(64,2 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(63 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(74,9 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(75,8 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_22_PSC%20Copy%201.pdf">PSC Copy 1.pdf</a>&nbsp;&nbsp;(34,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_23_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(179,4 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_24_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(238,8 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_25_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(126,4 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_26_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(182,8 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_27_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(138,6 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_28_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(111 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_29_PSC%202.pdf">PSC 2.pdf</a>&nbsp;&nbsp;(35,3 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6616_30_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(36,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6616">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-18T14:02:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-18T14:02:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>More Details on Medy-Tox' New Factory</title>
	<pubDate>2012-10-17T17:09:44+02:00</pubDate>
	<wp:post_id>3803</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The aims of the brand new factory in Osong is to meet EU and US production standards.<wbr> The construction started last June, and is expected to complete by mid-2013.<wbr> </div><div style="margin-bottom: 10px;">After construction is complete, the new plant is expected to commercialize new formulation of Meditoxin and be inspected by EU and US regulators before 2015.<wbr> </div><div style="margin-bottom: 10px;">The company expects a 10x rise in capacity by end of 2013.<wbr> </div><div style="margin-bottom: 10px;">Licensing-out with EU &amp; US companies is now scheduled to begin in 2013 (previously slated for 2012).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6613_1_ScreenCapture1.jpg"> </div><div>Source: Nomura (Oct.<wbr> 16, 2012) <EM>Wrinkle-free growth ahead</EM> </div><!-- Comment details --><a name="neurology6613attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6613_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6613">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-17T17:09:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-17T17:09:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Usage Of Higher Dose Octreotide LAR In Mid-Gut Carcinoids</title>
	<pubDate>2012-10-17T15:23:30+02:00</pubDate>
	<wp:post_id>3804</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Usage Of Higher Dose Octreotide LAR In Mid-Gut Carcinoids</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to Jean-Francois Mocho (Endocrinology Franchise), who was in attendance at the NANETs, you will find attached a slide presentation detailing the intelligence from this meeting.<wbr> One of the key points highlighted by Novartis's the degree to which there is utilisation of higher doses octreotide LAR in clinical practice.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7123">...</a><br></div><div>Comment: According to Nigel Homer (UK Endocrinology Business Unit) and intelligence from the field, Novartis is hosting an NET meeting for clinicians in Athens on the 26th October.<wbr> Interestingly, one of the key topics on the agenda is the dosing of octreotide in NET.<wbr> The meeting will apparently be chaired by Martin Caplin.<wbr> If anyone, gather any more information on the content of this meeting, please forward it to the Franchise or the CI Dept.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7127">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7123">View thread  Endocrinology7123: Usage Of Higher Dose Octreotide LAR In Mid-Gut Carcinoids</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-17T15:23:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-17T15:23:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Advisory Committee Recommends Approval of Gattex For Short Bowel Syndrome</title>
	<pubDate>2012-10-17T13:58:15+02:00</pubDate>
	<wp:post_id>3805</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NPS Pharmaceuticals received good news yesterday when the Gastrointestinal advisory committee of the FDA unanimously recommended that Gattex should be approved for the treatment of short bowel syndrome The PDUFA date for completion of the review is December 30, 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is Gattex</STRONG> </div><div style="margin-bottom: 10px;">Gattex is a novel, recombinant analog of human glucagon-like peptide 2 (GLP-2), a peptide involved in normal intestinal function and fluid and nutrient absorption.<wbr> If approved, Gattex would be the first FDA-approved therapy indicated for the long-term treatment of adults with SBS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Is Short-Bowel Syndrome</STRONG> </div><div style="margin-bottom: 10px;">SBS is a serious, complex disorder in which the body is unable to absorb enough nutrients and fluids through the gastrointestinal track to sustain life.<wbr> SBS is typically treated with PN/<wbr>IV fluids that do not treat the underlying disorder, which is the body's inability to absorb nutrients and fluids.<wbr> In addition, long-term use of PN/<wbr> IV fluids can be associated with life-threatening complications such as liver damage, serious bloodstream infections, and blood clots.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Approval</STRONG> </div><div style="margin-bottom: 10px;">The advisory committee reviewed data from the Gattex program, which is derived from 14 completed and one ongoing clinical study.<wbr> A total of 566 subjects have been treated with teduglutide.<wbr> Of the 566 subjects treated with Gattex, 299 subjects were treated in the clinical pharmacology studies, 94 subjects in Crohn&rsquo;s disease studies, and 173 subjects in the SBS efficacy and safety studies.<wbr> Of the 566 Gattex-treated subjects, 97 SBS subjects had at least 12 months of exposure to Gattex.<wbr> Across the company&rsquo;s Phase 3 studies, a total of 15 patients were able to achieve independence from PN/<wbr>IV while on 0.<wbr>05 mg/<wbr>kg/<wbr>day Gattex.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the results of the advisory committee Francoi Nader MD stated &ldquo;<STRONG>The unique mechanism of Gattex could make it the first and only long-term therapy that treats the underlying cause of this rare disorder by helping patients increase their ability to absorb nutrients and fluids to reduce or even eliminate their dependence on parenteral support.<wbr></STRONG> With 14 percent of patients completely eliminating the need for parenteral support in STEPS 2, we believe Gattex could be a life-changing therapy for patients with short bowel syndrome.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>Further Positive Results From The STEP-2 Trial</STRONG> </div><div style="margin-bottom: 10px;">NPS also today reported that five additional patients have successfully achieved independence from parenteral nutrition (PN) and intravenous (IV) fluids while on long-term Gattex&reg; (teduglutide) therapy in STEPS 2, a 24-month open-label study in adult SBS.<wbr> To date, 12 patients or 14 percent have achieved independence from PN/<wbr>IV fluids while on Gattex therapy in the ongoing STEPS 2 study.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Gattex, gained the European green light two months ago, but US approval  is expected to be far more significant for NPS since the New Jersey company has retained the rights to market the drug in the US.<wbr>  Commercialisation rights to tedglutide outside North America and Israel are ceded to Takeda, which now markets the drug as Revestive.<wbr> Importantly, US sales are set to dwarf those in the rest of the world, at an estimated $238m in 2018 compared with $9m in Europe, according to EvaluatePharma.<wbr></SPAN> </div><div>Source: <a href="http://www.npsp.com" class="defaultlink" title="http://www.npsp.com">npsp.com</a> <a name="Endocrinology7205c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The FDA approved Gattex on 21 December 2012.<wbr> NPS said it plans to launch it in the U.<wbr>S.<wbr> in 1Q13 and will disclose details on the drug's pricing during a 2 January early evening conference call with investors and analysts.<wbr> </div><div style="margin-bottom: 10px;">The approval comes with a REMS that includes a communication plan and training for prescribers.<wbr> NPS is also required to conduct a postmarketing study in SBS patients to evaluate the drug's potential increased risk of causing colorectal cancer and other conditions.<wbr> </div><div><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333171.htm" class="defaultlink" title="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333171.htm">fda.gov/<wbr>NewsEvent&hellip;</a> </div></div></div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7126">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-17T13:58:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-17T13:58:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Out-of-pocket Healthcare Expenditure Hit by Inflation in Iran</title>
	<pubDate>2012-10-17T12:14:43+02:00</pubDate>
	<wp:post_id>3806</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Out-of-pocket Healthcare Expenditure Hit by Inflation in Iran</span>&nbsp;<br><span style="font-size: 12px;">Comment: Sanctions imposed on Iran as part of a programme of international pressure against its increasingly hostile relationship with regional neighbours and its own population has resulted in the decline of the Iranian rial, which in turn is expected to have an impact on access to healthcare, according to <I>The Economist</I>.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10119">...</a><br></div><div style="margin-bottom: 10px;">Two comments on this article.<wbr> The first one on :  : The access to hard currencies at 'preferential rates' for pharma companies is theoretical.<wbr> In practice, the Central Bank of Iran has very little amount of hard currencies and it is extremely difficult to get access to them (competition between local importers is high).<wbr> </div><div><DIV>
<DIV> The Iranian pharma manufacturing capabilities are limited.<wbr> </DIV>
<DIV>In addition, like every industrial activity, it is suffering a lot from the embargo which makes very difficult the access to raw materials.<wbr></DIV>
<DIV>However, it is true that Iranian government has enforced laws to encourage the local manufacturing of pharmaceuticals.<wbr> But it will take time (especially if the embargo lasts) to have the majority of pharmaceutical products manufactured locally.<wbr></DIV></DIV> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10124">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10119">View thread  PharmaWorld10119: Out-of-pocket Healthcare Expenditure Hit by Inflation in Iran</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-17T12:14:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-17T12:14:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Therapy Area Landscapes - A New Traction Service</title>
	<pubDate>2012-10-17T10:57:15+02:00</pubDate>
	<wp:post_id>3807</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Therapy Area Landscapes (TALs)</span>&nbsp;<br><span style="font-size: 12px;"><DIV class="i" id="pharmaworld7400.04i">
<DIV class="ii" id="pharmaworld7400.04ii">Comment: We would like to introduce you to a new concept within Traction, the so called "Therapy Area Landscapes" (TAL) This area has been designed to provide you with a distilled overview of the competitive landscape in each of our specialised therapy areas.<wbr> The links, which can be accessed through one of the "Traction Short-Cuts" on the right hand side of the Traction screen, will in time provide access to a presentation on each topic area; a presentation that will be regularly updated with new intelligence as and when it is received.<wbr> The first slide presentation will be on the acromegaly therapy area, however.<wbr> we hope to be in a position to provide a number of other TALs within a matter of weeks.<wbr></DIV>
</DIV></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10099">...</a><br></div><div>Excellent - thank you, should be really helpful </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10123">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10099">View thread  PharmaWorld10099: Therapy Area Landscapes (TALs)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-17T10:57:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-17T10:57:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Usage Of Higher Dose Octreotide LAR In Mid-Gut Carcinoids</title>
	<pubDate>2012-10-16T18:50:23+02:00</pubDate>
	<wp:post_id>3808</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Jean-Francois Mocho (Endocrinology Franchise), who was in attendance at the NANETs, you will find attached a slide presentation detailing the intelligence from this meeting.<wbr> One of the key points highlighted by Novartis's the degree to which there is utilisation of higher doses octreotide LAR in clinical practice.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Poster C46</STRONG>, in particular, addressed the usage of above-label doses of octreotide LAR in patients with metatatic small intestinal carcinoid tumours.<wbr> </div><div style="margin-bottom: 10px;">Its main message was that in clinical practice, octreotide LAR is commonly prescrived in doses or schedules aboed the labelled dose frequency </div><div style="margin-bottom: 10px;"><UL><LI>27% of patients underwent at least one increase in dose or frequency of octreotide above the standard labeled dose.<wbr>
</LI>
<LI>37% used 40mg every 4 weeks, 34% used 60mg every 4 weeks and 17% used 30mg every 3 weeks.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="text-align: left; margin-top: 0pt; unicode-bidi: embed; direction: ltr; margin-bottom: 0pt; vertical-align: baseline; language: en-GB;">Of additional interest, was the range and nature of the clinical trials the audience was asked to vote on in terms of the next NANETS sponsored clinical trial and several posters focused on the RADIANT data with Afinitor.<wbr> One highlighted the ongoing RADIANT 4 study in functioning and non-functioning gastro and pulmonary NETS.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: left; margin-top: 0pt; unicode-bidi: embed; direction: ltr; margin-bottom: 0pt; vertical-align: baseline; language: en-GB;">Due to technical difficulties the attachment will be attached tomorrow.<wbr></P> </div><div><P style="text-align: left; margin-top: 0pt; unicode-bidi: embed; direction: ltr; margin-bottom: 0pt; vertical-align: baseline; language: en-GB;">Source: NANETS</P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7127c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: According to Nigel Homer (UK Endocrinology Business Unit) and intelligence from the field, Novartis is hosting an NET meeting for clinicians in Athens on the 26th October.<wbr> Interestingly, one of the key topics on the agenda is the dosing of octreotide in NET.<wbr> The meeting will apparently be chaired by Martin Caplin.<wbr> If anyone, gather any more information on the content of this meeting, please forward it to the Franchise or the CI Dept.<wbr> </div></div><a name="endocrinology7123attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7123_1_NANETS%20Meeting%20Overview%20Oct%202012.pptx">NANETS Meeting Overview Oct 2012.pptx</a>&nbsp;&nbsp;(17,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7123">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T18:50:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T18:50:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Octreotide LAR Assessed to Prevent GI Bleeding in Patients With LVAD</title>
	<pubDate>2012-10-16T17:24:21+02:00</pubDate>
	<wp:post_id>3809</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of this small interventional Ph1 trial is to study whether the regular administration of monthly octreotide LAR is safe, and if it will decrease the incidence of gastrointestinal bleeding (GI) in patients undergoing implantation of non-pulsatile, continuous flow left ventricular assist devices (LVAD).<wbr> Primary outcome measures will assess the safety of the drug in those patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Patients undergoing implantation of non-pulsatile, continuous-flow LVAD have a higher incidence of GI.<wbr> </div><div style="margin-bottom: 10px;">This is a significantly associated morbidity and can threaten a patient's life as well as their ability to undergo eventual heart transplantation secondary to both general health/<wbr>strength and the potential development of antibodies to blood products that would make future transfusions and transplantations more difficult.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01707225?no_unk=Y&amp;fund=2&amp;rcv_s=10%2F08%2F2012&amp;rank=69"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Investigator: Virginia Commonwealth U.<wbr> </div><div style="margin-bottom: 10px;">Sponsors: Novartis; Thoratec Corp.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 10 </div><div style="margin-bottom: 10px;">Start date: Oct.<wbr> 2012 - Completion date: June 2013 </div><div style="margin-bottom: 10px;"><U>Protocol</U> </div><div style="margin-bottom: 10px;"><STRONG>During weeks 0-24</STRONG> the subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>During weeks 25-36</STRONG> the subject will receive a telephone call every 4 weeks +/<wbr>- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped.<wbr> Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects.<wbr> </div><div style="margin-bottom: 10px;">Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen.<wbr> </div><div>Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment.<wbr> The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7121">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T17:24:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T17:24:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>News from ABRAXANE for Pancreatic Cancer Expected This Quarter</title>
	<pubDate>2012-10-16T16:59:01+02:00</pubDate>
	<wp:post_id>3810</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The results of a Ph3 trial in patients with metastatic disease are likely by the end of this quarter.<wbr> In pancreatic cancer, many tumours and stroma overexpress SPARC, and ABRAXANE, a formulation of paclitaxel incorporated with albumin, is thought to impact pancreatic cancer through albumin-SPARC binding.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01461915?intr=abraxane&amp;rank=2"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">PE: Progression-Free Survival (PFS) according to RECIST Guidelines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8534_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8534_2_ScreenCapture2.jpg"> </div><div>Sources: Celgene; Cantor </div><!-- Comment details --><a name="oncology8534attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8534_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(8,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8534_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(22,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8534">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T16:59:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T16:59:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Reports Strong Q3 Zytiga Sales</title>
	<pubDate>2012-10-16T16:19:59+02:00</pubDate>
	<wp:post_id>3811</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Third quarter global sales of Rx drugs jumped 7% to $6.<wbr>4bn, helped by leaping sales of J&amp;J's new prostate cancer drug Zytiga.<wbr> Its sales grew to $260m in the quarter up 15% on the previous quarter and this is still prior to approval for the pre-chemotherapy indication, approval for which was sought at the end of June.<wbr> </div><div style="margin-bottom: 10px;">Management is very pleased with the performance of Zytiga, with sales amounting to $697 million year to date, It claims that Zytiga is the most successful global oral oncology launch ever and that the drug is now approved in more than 50 countries around the world.<wbr> Physician uptake is quoted as " remarkable" with the number of post chemo patients treated growing to 75% from 40% at the time of launch.<wbr> More than 30,000 patients have received treatments since 2011.<wbr> </div><div style="margin-bottom: 10px;">J&amp;J estimates that its patient share in the U.<wbr>S.<wbr> chemo refactory market is approximately 67 percent, and in the G 5, it's approximately 81%.<wbr> </div><div style="margin-bottom: 10px;">It is now waiting to see the response of the FDA in December to the pre-chemo indication, approval for which it suggests could triple the patient population.<wbr><BR>When questioned more about the number of chemo naive patients already receiving Zytiga off-label.<wbr> J&amp;J estimates that usage is currently low and running around 30% in the US and "very low" in Europe.<wbr>.<wbr> </div><div>Source: <A href="http://www.jnj.com">www.<wbr>jnj.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8531">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T16:19:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T16:19:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Out-of-pocket Healthcare Expenditure Hit by Inflation in Iran</title>
	<pubDate>2012-10-16T15:55:37+02:00</pubDate>
	<wp:post_id>3812</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sanctions imposed on Iran as part of a programme of international pressure against its increasingly hostile relationship with regional neighbours and its own population has resulted in the decline of the Iranian rial, which in turn is expected to have an impact on access to healthcare, according to <I>The Economist</I>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The rial fell from a high of IRR12,150 against the dollar in early September to a low of IRR11,894 in early October.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>- for the Population</STRONG> </div><div style="margin-bottom: 10px;">Inflation has become a severe problem with reports in Bloomberg that even basic foodstuffs such as meat have become a luxury for large sections of the population.<wbr> </div><div style="margin-bottom: 10px;">In order to decrease the threat from currency speculation, the Iranian government has introduced an artificially created exchange rate, thus discouraging currency traders from exchanging dollars.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>- for the Pharma Companies</STRONG> </div><div style="margin-bottom: 10px;">International pharmaceutical companies, unlike other industries, have been allowed access to preferential rates of exchange outside those imposed by the government domestically.<wbr> Yet, the Iranian market has typically been a largely closed one for international pharmaceutical companies with government protectionist policies resulting in 95% of the pharmaceutical market by volume being manufactured locally.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Although international pharmaceutical companies have been largely unaffected by the decline of the rial, for local patients the situation is somewhat bleaker.<wbr> </div><div>Despite insurance covering 95% of the population, out-of-pocket expenditure on medicines still remains high.<wbr> Therefore, despite the provision of medicines, inflation is likely to be harming patient access.<wbr> In addition, difficulties in access to food and other necessities are likely to result in rising rates of malnutrition, adding an additional burden on healthcare providers.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10124c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Two comments on this article.<wbr> The first one on :  : The access to hard currencies at 'preferential rates' for pharma companies is theoretical.<wbr> In practice, the Central Bank of Iran has very little amount of hard currencies and it is extremely difficult to get access to them (competition between local importers is high).<wbr> </div><div><DIV>
<DIV> The Iranian pharma manufacturing capabilities are limited.<wbr> </DIV>
<DIV>In addition, like every industrial activity, it is suffering a lot from the embargo which makes very difficult the access to raw materials.<wbr></DIV>
<DIV>However, it is true that Iranian government has enforced laws to encourage the local manufacturing of pharmaceuticals.<wbr> But it will take time (especially if the embargo lasts) to have the majority of pharmaceutical products manufactured locally.<wbr></DIV></DIV> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10119">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T15:55:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T15:55:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Australian Federal Minister of Health Launches Clinical Trials Website</title>
	<pubDate>2012-10-16T15:50:04+02:00</pubDate>
	<wp:post_id>3813</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new website aims at encouraging and facilitating patient recruitment.<wbr> It was developed in response to the needs of consumer groups, the pharma industry and research institutions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The National Health and Medical Research Council built the Australian Clinical Trials website, while the Department of Industry, Innovation, Science, Research and Tertiary Education provided funding of A$40,000 to support the website’s development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Adress: <A href="http://www.australianclinicaltrials.gov.au/">http:/<wbr>/<wbr>www.<wbr>australianclinicaltrials.<wbr>gov.<wbr>au/<wbr></A> </div><div style="margin-bottom: 10px;">There are tailored sections for consumers, healthcare providers, researchers and industry/<wbr>sponsors, as well as testimonies from these four constituencies.<wbr> </div><div>There is also a link to a “Find a clinical trial” website, with details of trial registries (e.<wbr>g.<wbr>, <A href="http://www.anzctr.org.au/">the Australian New Zealand Clinical Trials Registry</A>, ClinicalTrials.<wbr>gov), clinical trial organisations, research networks, co-ordinating hubs and support groups.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10118">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T15:50:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T15:50:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PROLOR Progress with its Reversible-Pegylation Technology Platform</title>
	<pubDate>2012-10-16T15:17:40+02:00</pubDate>
	<wp:post_id>3814</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PROLOR is using its RevPeg technology to develop long-acting therapeutic peptides, such as MOD-6030, a GLP-1/<wbr>Glucagon dual receptor agonist peptide, in preclinical development for the dual indications of obesity and type 2 diabetes.<wbr> Preclinical results demonstrate that RevPeg was safe and well-tolerated at high doses following repeated administration in rats.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">PROLOR's RevPEG technology is complimentary to the CTP technology and allows the development of long-acting small peptides and small chemical molecules for which CTP is not suitable.<wbr> The company intendS to apply RPeg to internal projects, and also to share these data with potential partners whose drug candidates may benefit from the technology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Description</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">- Used to develop long-acting therapeutic peptides and small molecules.<wbr> </div><div style="margin-bottom: 10px;">- Ability to enable development of long-acting drugs that target the brain and that therefore must penetrate the blood-brain barrier, such as </div><div style="margin-bottom: 10px;"><UL><LI>the appetite suppressant peptide PYY</LI>
<LI>MOD-6030</LI>
<LI>the diabetes-related compound exendin-4, </LI>
<LI>the blood pressure controlling hormone ANP</LI>
<LI>and the intravenous antibiotic drug gentamicin</LI>
</UL> </div><div style="margin-bottom: 10px;">- Enhance the half-life and improve the biological activity of a variety of peptides and small molecules.<wbr> </div><div>Source: PROLOR </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7119">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T15:17:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T15:17:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from Roche's YTD Sept 2012 Pharma Sales</title>
	<pubDate>2012-10-16T12:48:04+02:00</pubDate>
	<wp:post_id>3815</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On October 16th, the company reported sales in the Pharma Division rose by 4% to CHF26.<wbr>2 billion, mainly due to the oncology portfolio, which grew 9%.<wbr> The division benefited from strong growth in the US (+6%), China (+26%) and Brazil (+13%).<wbr> Of note on the R&amp;D front, RG7450 (Anti-Steap1 ADC), RG7422 (PI3 kinase/<wbr>mTOR dual inhibitor), RG7440 (AKT inhibitor) in development for prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">US and Emerging Markets contribute to sales growth </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Projects in Prostate Cancer</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_8_ScreenCapture7.jpg"> </div><div>Full Presentation attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20121231&edate=20120901&rs=/link%20Oncology8530%407" class="defaultlink">@7</a> </div><!-- Comment details --><a name="oncology8529attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(25,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(39,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(36,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(41,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(90,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_7_Roche%255firp3q12e%5b1%5d.pdf">Roche_irp3q12e[1].pdf</a>&nbsp;&nbsp;(1,7 MB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8529_8_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(48,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8529">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-16T12:48:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-16T12:48:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Baxter Venture Fund Invests In Novel Peptide</title>
	<pubDate>2012-10-15T19:50:50+02:00</pubDate>
	<wp:post_id>3816</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Baxter Venture Fund Invests In Novel Peptide</span>&nbsp;<br><span style="font-size: 12px;"></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10112">...</a><br></div><div style="margin-bottom: 10px;">A) Time has changed! Baxter's oncology core business was ASTA MEDICA (GE) portfolio made of originators or generics of cytostatic chemotherapy drugs such as cyclophosphamide, ifosphamide and mesna.<wbr> They were even looking (4 years ago)  for buyers.<wbr> </div><div style="margin-bottom: 10px;">B) As mentioned: licensed peptide in development (phase II) is a "cytoprotective peptide to improve peritoneal immune competence and protect peritoneal membrane integrity".<wbr> This peptide might play a role in the therapeutic management of peritoneal carcinomatosis.<wbr> It is remarkable to see that the topic is of interest: As you know it has been decided to submit early next year a new variation for Somatuline PR 30 mg in palliative treatment of clinical symptoms associated with upper intestinal obstruction due to peritoneal carcinomatosis in inoperable patients on top of other symptomatic medication.<wbr>(based on study 156 results) </div><div>Endocrinology Franchise </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10117">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10112">View thread  PharmaWorld10112: Baxter Venture Fund Invests In Novel Peptide</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T19:50:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T19:50:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: GP Pharm Starts To Commercialise Immediate Release Octreotide Through European Partners</title>
	<pubDate>2012-10-15T19:28:29+02:00</pubDate>
	<wp:post_id>3817</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">GP Pharm Starts To Commercialise Immediate Release Octreotide Through European Partners</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to Barbara Krzystofowicz in Poland, we have learnt that the Polish Authorities have granted a marketing authorisation to CSC Pharmaceuticals Handels GmbH, for three immediate release formulations of octreotide manufactured by Spanish company GP Pharm.<wbr> Intelligence gathering at CPhI, suggests that the company is continuing to progress with the development of a long-acting formulation and that it should be in a position to file in the EU later than first proposed in Q414.<wbr> Development timelines will be evaluated further to help validate this timeliine.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7110">...</a><br></div><div style="margin-bottom: 10px;">Generics of the Immediate Release (IRF) Octreotide are already available in most European countries and the US.<wbr> The launch of Generics of IRF Octreotide may lead to a price cut of the existing Octreotide Sandostatin LAR in the country.<wbr> </div><div style="margin-bottom: 10px;">GP Pharm is also developing hybrid of Octreotide LAR and is looking for European partner(s) for this future commercialization: filling in Q4 2014 in EU countries may be an optimistic assumption from GP Pharm (launch timelines to be validated by the Hybrids Task Force) and the global current assumption is that hybrids of Octreotide LAR are not expected before 2016-2017 in the USA and most EU countries (to be validated by the Hybrids Task Force).<wbr> </div><div>Endocrinology Franchise </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7117">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7110">View thread  Endocrinology7110: GP Pharm Starts To Commercialise Immediate Release Octreotide Through European Partners</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T19:28:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T19:28:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo's Once-Weekly GH to Enter Clinical Trial in AGHD</title>
	<pubDate>2012-10-15T17:25:31+02:00</pubDate>
	<wp:post_id>3818</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The newly listed Ph1 trial in clinicaltrials.<wbr>gov will assess safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (NNC0195-0092) compared to once daily Norditropin NordiFlex®.<wbr> Primary endpoint will measure incidence of AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01706783?no_unk=Y&amp;fund=2&amp;rcv_s=10%2F01%2F2012&amp;rank=126"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Timelines </div><div style="margin-bottom: 10px;"><UL><LI>Start date: October 2012</LI>
<LI>Completion date: July 2013</LI>
</UL> </div><div style="margin-bottom: 10px;">Recruitment </div><div style="margin-bottom: 10px;"><UL><LI>approx.<wbr> 32 patients</LI>
<LI>Stable human growth hormone (hGH) replacement therapy for at least 3 months</LI>
<LI>Insulin-like growth factor I (IGF-I) level within -2.<wbr>0 to +2.<wbr>0 standard deviation score (SDS) of the age and sex normal range </LI>
</UL> </div><div style="margin-bottom: 10px;">Location </div><div style="margin-bottom: 10px;"><UL><LI>Sweden; Denmark</LI>
</UL> </div><div>
Other source: <A href="http://www.novonordisk-trials.com/website/search/trial-registry-details.aspx?id=40030">http:/<wbr>/<wbr>www.<wbr>novonordisk-trials.<wbr>com/<wbr>website/<wbr>search/<wbr>trial-registry-details.<wbr>aspx?id=40030</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7503c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">A second Ph1 is planned to start in Dec 2013 in EU and Asia in PGHD.<wbr> PE will assess incidence of AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Completion dates: Nov 2014 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=32 </div><div style="margin-bottom: 10px;"><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Confirmed diagnosis of GHD (growth hormone deficiency) as defined by two different GH (growth hormone) stimulation tests, peak GH level below or equal to 7.<wbr>0 ng/<wbr>ml.<wbr> For children with three or more pituitary hormone deficiencies only one GH stimulation test will be needed.<wbr> If in accordance with country specific practice, growth hormone deficiency can be defined by only one GH stimulation test, peak GH level below or equal to 7.<wbr>0 ng/<wbr>ml.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Pre-pubertal children at screening.<wbr> Boys: Tanner stage 1 and age above or equal to 6 years and below 13 years.<wbr> Girls: Tanner stage 1 and age above or equal to 6 years and below 12 years
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Body weight above or equal to 16.<wbr>0 kg and below or equal to 50.<wbr>0 kg
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Stable GH replacement treatment for at least 3 months
</LI>
</UL> </div><div><P class="color-bullet" style="margin-top: 0.7ex;">Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01973244?recr=Open&no_unk=Y&fund=2&rcv_s=09%2F30%2F2013&rank=142" class="defaultlink">NCT01973244</a></P> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7115">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T17:25:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T17:25:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly Announces Positive Results For Ramucirumab in Phase III Gastric Cancer Trial</title>
	<pubDate>2012-10-15T15:12:18+02:00</pubDate>
	<wp:post_id>3819</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Eli Lilly has announced today positive top-line results from 
the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with 
metastatic gastric cancer.<wbr> The study met its primary endpoint of 
improved overall survival and also showed prolonged progression-free survival.<wbr> </div><div style="margin-bottom: 10px;"><B>About Ramucirumab</B> </div><div style="margin-bottom: 10px;">Ramucirumab is a fully human IgG1 monoclonal antibody receptor antagonist 
designed to bind  the extracellular domain of vascular endothelial growth 
factor (VEGF) receptor-2, thereby blocking the interaction of VEGF ligands 
(VEGF-A, VEGF-C, and VEGF-D) and inhibiting receptor activation.<wbr> VEGF receptor-2 
is considered a primary mediator of angiogenesis.<wbr> When activated by VEGF 
ligands, VEGF receptor-2 promotes endothelial cell proliferation and survival, 
migration, and vascular permeability.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About The REGARD Trial</STRONG> </div><div style="margin-bottom: 10px;">The REGARD trial compared ramucirumab and best supportive care to placebo and 
best supportive care <STRONG>as a second-line treatment in patients with 
metastatic</STRONG> gastric and gastroesophageal junction cancers.<wbr> The most 
frequent adverse reaction (any grade) occurring at a higher rate on the 
ramucirumab arm was hypertension (12%).<wbr> Other adverse reactions ( &gt; 5%) 
occurring at a higher rate on the ramucirumab arm compared to the placebo arm 
were diarrhea and headache.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>REGARD </STRONG>is one of two ramucirumab Phase III studies in 
gastric cancer.<wbr> <STRONG>RAINBOW</STRONG>, a Phase III trial of ramucirumab in 
combination with paclitaxel in the 2nd line treatment setting, completed patient 
enrollment last month.<wbr> </div><div style="margin-bottom: 10px;">Lilly plans to review the resuls from the REGARD trial at an upcoming 
scientific meeting and will discuss submission plans with regulatory 
authorities.<wbr> </div><div style="margin-bottom: 10px;">Commenting on these results Richard Gaynor, M.<wbr>D.<wbr>, vice president, 
product development and medical affairs for Lilly Oncology.<wbr> stated "We are 
pleased with this data of ramucirumab used as monotherapy in a second-line 
setting in this difficult-to-treat disease.<wbr> It reinforces our confidence in the 
ramucirumab development program, in which we currently have six Phase III 
studies ongoing in five tumor types — breast, colorectal, gastric, 
hepatocellular and lung cancer.<wbr>" </div><div>Source: <A href="http://www.lilly.com">www.<wbr>lilly.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8748c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><P align="left">Ramucirumab a drug according to Goldman Sachs analysts with "game changing commercial potential not widely recognised in brokers forecasts " and highlighted as one of 10 in a recent report in Scrip, has reported additional data from the phIII REGARD study in gastric cancer at the recent ASCO Gastrointestinal Cancer Symposium in San Franscisco.<wbr></P> </div><div><P align="left">The double-blind, international Phase III REGARD trial in 355 patients with metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum or fluoropyrimidine-containing combination therapy showed that 8 mg/<wbr>kg IV ramucirumab every 2 weeks plus best supportive care (BSC) led to a median OS, the primary endpoint, of 5.<wbr>2 months vs.<wbr> 3.<wbr>8 months for placebo plus BSC (p=0.<wbr>0473).<wbr> On secondary endpoints, ramucirumab plus BSC led to a median PFS of 2.<wbr>1 months vs.<wbr> 1.<wbr>3 months for placebo plus BSC (p&lt;0.<wbr>0001).<wbr> Additionally, ramucirumab led to a 12-week PFS rate of 40% vs.<wbr> 16% for placebo and an ORR of 3.<wbr>4% vs.<wbr> 2.<wbr>6% for placebo.<wbr> Furthermore, ramucirumab led to a disease control rate (DCR) of 49% vs.<wbr> 23% for placebo (p&lt;0.<wbr>0001).<wbr> BSC included anti-emetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.<wbr> Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.<wbr></P> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8528">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T15:12:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T15:12:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date</title>
	<pubDate>2012-10-15T13:54:53+02:00</pubDate>
	<wp:post_id>3820</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Impax Pharmaceuticals has announced that the <ORG>U.<wbr>S </ORG><ORG>FDA 
has extended the PDUFA date for its review of the Rytary<SUP>TM</SUP> 
(IPX066) NDA from <CHRON>October 21, 2012</CHRON>, to <CHRON>January 21, 
2013 due to the submission by Impax of information on an excipient in the 
Rytary<SUP>TM</SUP> formulation.<wbr></CHRON></ORG> </div><div style="margin-bottom: 10px;"><ORG></ORG>Since the receipt of the date was within three months of 
the PDUFA date, the <ORG>FDA</ORG> has exercised its option to extend the PDUFA 
date to review the information.<wbr> </div><div style="margin-bottom: 10px;"><B>About Rytary</B><SUP>TM</SUP><B> (IPX066)</B> </div><div style="margin-bottom: 10px;">Rytary<SUP>TM </SUP>is an investigational extended release capsule 
formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson’s 
disease.<wbr> It is not approved or licensed anywhere in the world but phIII results 
from several pivotal phase III studies of IPX066, APEX-PD (early PD), 
ADVANCE-PD (advanced PD) and ASCEND-PD (advanced PD) have previously been 
announced.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6611_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Rytary<SUP>TM </SUP>has been licensed to GlaxoSmithKline (GSK) for countries 
outside the U.<wbr>S.<wbr> and <LOCATION value="LC/tw;LB/eas">Taiwan</LOCATION> for development and marketing.<wbr> </div><div style="margin-bottom: 10px;">Results of A Survey Conducted By Leerink &amp; Swann Analysts </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6611_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6611_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">For those interested in the full report including the analysts sales 
forecast, please contact the CI Dept.<wbr> </div><div>Source: <A href="http://www.impax.com">www.<wbr>impax.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6759c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Impax failed to win U.<wbr>S.<wbr> approval for a new version of an extended-release drug used to relieve spasms in patients with Parkinson&rsquo;s disease.<wbr> The US Agency requires a re-inspection of a plant involved in the development of Rytary, which combines standard Parkinson&rsquo;s medications in a new sustained release formulation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Piper Jaffray Forecasts</STRONG> </div><div style="margin-bottom: 10px;">The medication would likely be used most among patients for whom the standard medicines, levodopa and carbidopa, have stopped working as reliably </div><div>Analyst with Piper Jaffray &amp; Co.<wbr> predicts Rytary could generate peak sales of $200 million to $300 million.<wbr> </div></div><a name="neurology6611attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6611_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(101,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6611_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(80,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6611_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(115,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6611">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T13:54:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T13:54:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NHS Reports that the Use of PDD for NMIBC Could Lead to Potential Benefits</title>
	<pubDate>2012-10-15T13:14:10+02:00</pubDate>
	<wp:post_id>3821</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Despite Photodynamic diagnosis (PDD) having an estimated cost impact of £4.<wbr>95m to the NHS, it would result in the detection of NMIBC in an additional 1,308 patients each year, and the reduction of &gt;2100 bed days.<wbr> Thanks to Audrey Schweitzer and Florence Marteau who forwarded this great news, which should help to build positive messaging on the Health Economics of Hexvix.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Bed Days</STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The analysis used a decision tree approach to determine the potential benefits of adoption of PDD of NMIBC relative to diagnosis using the standard white light cytoscopy (WLC).<wbr> </div><div style="margin-bottom: 10px;">The model follows a cohort of 6,593 patients, based on the estimated number of patients diagnosed with bladder cancer in 2008.<wbr> The model captures tumour recurrences and progression for 5 years after the TURBT.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">to assess the health economic benefits provided by the utilisation of PDD of NMIBC in addition to WLC for patients undergoing TURBT in comparison to WLC alone.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8526_2_ScreenCapture1.jpg"> </div><div>Full report is attached </div><!-- Comment details --><a name="oncology8526attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8526_1_NICE%255fPDD%255fEconomic%255fReport.pdf">NICE_PDD_Economic_Report.pdf</a>&nbsp;&nbsp;(645 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8526_2_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8526_3_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8526">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T13:14:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T13:14:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca to Boost Drug Discovery</title>
	<pubDate>2012-10-15T12:10:01+02:00</pubDate>
	<wp:post_id>3822</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca has entered into a strategic partnership with Beijing-based Pharmaron, a premier R&amp;D service for pharma industry, to speed discovery of new medicines in the fields of cardiovascular, respiratory, GI, cancer, neuroscience, inflammation, as well as diabetes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial: non disclosed.<wbr> </div><div style="margin-bottom: 10px;">Terms: Pharmaron will provide AstraZeneca with discovery services in the areas of chemistry, drug metabolism and pharmacokinetics (DMPK), and efficacy screening.<wbr> </div><div style="margin-bottom: 10px;">Pharmaron will conduct these services with a team consisting of several hundred scientists in dedicated, state-of-the-art research laboratories located in its newly opened drug discovery service center in Beijing.<wbr> </div><div style="margin-bottom: 10px;">The co-location of screening and chemistry services at a single partner is expected to help AstraZeneca scientists drive their drug discovery programs with greater efficiency.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><A href="http://www.pharmaron.com/Pages.aspx/Overview">http:/<wbr>/<wbr>www.<wbr>pharmaron.<wbr>com/<wbr>Pages.<wbr>aspx/<wbr>Overview</A></LI>
<LI>Founded: 2003</LI>
<LI>Services: chemistry, biology, DMPK, pharmacology, toxicology and chemical development</LI>
</UL> </div><div style="margin-bottom: 10px;">
Sept.<wbr> 2011 : strategic partnership with Merck Serono.<wbr> In the framework of this partnership, Pharmaron’s new campus in the Beijing Economic and Technological Development Area (BDA) will serve as home to Merck Serono’s China R&amp;D Laboratory.<wbr> </div><div>Source: Pharmaron; AstraZeneca </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10115">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T12:10:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T12:10:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Fibrocell Strengthens its Aesthetic Platform</title>
	<pubDate>2012-10-15T11:51:24+02:00</pubDate>
	<wp:post_id>3823</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company, which commercializes LAVIV the first and only-FDA approved personalized cell therapy in aesthetic for moderate to severe nasolabial fold wrinkles (smile lines), has announced $45M private placement and a strategic collaboration with Intrexon.<wbr> In the US, LAVIV competes in the aesthetic space with Juvederm (Allergan) and Restylane (Medicis).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Financial</STRONG>: The company raised $45M through the sale of 450 million shares at $0.<wbr>10.<wbr> </div><div style="margin-bottom: 10px;">Third Security, Barclays, MTS and John Carris Investments were placement agents.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG> : to expand the commercial launch of <A href="http://mylaviv.com/">Laviv</A> (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6509" class="defaultlink">Neurology6509: Fibrocell Reports Q2:12 Order Information on its Personalized Filler for Smile Lines</a>), and support its development in additional indications, such as severe restrictive burn scars, vocal cord scarring and acne scars.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Financial</STRONG>: Intrexon to receive upfront technology access fee of $3.<wbr>2938M </div><div style="margin-bottom: 10px;"><STRONG>Terms</STRONG>: The agreement covers the development and commercialization of the next generation of genetically modified and non-genetically modified autologous fibroblasts and autologous dermal celles in the US </div><div style="margin-bottom: 10px;">Intrexon will make available its proprietary platforms and technologies, including <A href="http://www.dna.com/technology">UltraVector</A>(R), DNA and RNA MOD engineering, protein engineering, transcription control chemistry, genome enginering, cell processing and cell system engineering.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG>: Fibrocell's management expects to establish a leadership role in creating additional high-value cellular therapeutics for underserved health needs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>The company will present its business update on Oct.<wbr> 17th, 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6610">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-15T11:51:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-15T11:51:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon Reports Telotristat (LX1032) Ph2 European Data in NETs</title>
	<pubDate>2012-10-12T18:25:20+02:00</pubDate>
	<wp:post_id>3824</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Positive, top-line data from the trial will be presented at the North American Neuroendocrine Tumor Society on Saturday, October 13, 2012 (San Diego, California).<wbr> The results from this recently completed second Phase 2 trial of telotristat etiprate further support its potential utility in the treatment of carcinoid syndrome in a population that is refractory to or cannot tolerate somatostatin analog therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Primary endpoint</U>: reduction of bowel movements from baseline in patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy.<wbr> </div><div style="margin-bottom: 10px;">Patients experienced a 46.<wbr>4% median reduction from baseline at week 12, with the number of daily bowel movements steadily decreasing over time.<wbr> All observed changes from baseline were statistically significant at p &lt; 0.<wbr>001.<wbr> </div><div style="margin-bottom: 10px;">This change corresponded with an increased proportion of patients reporting adequate relief of their carcinoid symptoms, a global assessment which also improved over time, with 75% of the patients with data at week 12 reporting improvement.<wbr> </div><div style="margin-bottom: 10px;">Clinically relevant decreases from baseline were likewise seen for a number of key secondary endpoints, including statistically significant improvements in stool consistency (p &lt; 0.<wbr>001) and trends of reductions in abdominal pain (p=0.<wbr>09) and the number of cutaneous flushing episodes (p=0.<wbr>052).<wbr> The median percentage reductions from baseline of urinary 5-HIAA at weeks 8 and 12 were 68.<wbr>3% (p=0.<wbr>019) and 72.<wbr>7% (p=0.<wbr>031), respectively.<wbr> Urinary 5-HIAA is a biomarker of serotonin synthesis and is of key interest in these patients.<wbr> </div><div style="margin-bottom: 10px;"><U>Safety</U>: There was no evidence of dose–limiting toxicity, and no patient discontinued from the study early due to an adverse event.<wbr> Only 3 patients reported a serious adverse event, none of which was related to study drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Design</U>: open-label, dose-escalation study </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: 15 patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy.<wbr> </div><div style="margin-bottom: 10px;"><U>Protocol</U>: Patients received ascending doses of 150 mg, 250 mg, 350 mg and 500 mg of telotristat etiprate, administered 3 times daily (TID), for 14 days on each dose until reaching a maximal dose, which was then continued until the completion of 12 weeks of therapy.<wbr> Escalation to a higher dose was contingent on tolerability and clinical response.<wbr> </div><div><UL dir="ltr" style="MARGIN-RIGHT: 0px"><LI>
<UL><LI>14 patients (93%) completed the trial, and 12 of these 14 patients were treated with 500 mg TID of study drug during the last four weeks of the treatment period.<wbr> The one patient who discontinued early withdrew from the 350mg TID dose level for reasons not related to drug safety.<wbr> Notably, the 2 patients in the study who were not receiving background somatostatin analog therapy observed reductions in bowel movements of 67% and 48% from baseline to week 12.<wbr></LI>
</UL></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7113">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-12T18:25:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-12T18:25:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 2 - Taking A Deeper Look At Developments in PCa</title>
	<pubDate>2012-10-12T16:32:43+02:00</pubDate>
	<wp:post_id>3825</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This morning <SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; widows: 2; orphans: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr></SPAN> </div><div><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; widows: 2; orphans: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> </SPAN> </div><!-- Comment details --><a name="oncology8524attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8524_2_Post%20ESMO2012%20Webex%20Focus%20on%20PCa%20v2.pdf">Post ESMO2012 Webex Focus on PCa v2.pdf</a>&nbsp;&nbsp;(1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8524">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-12T16:32:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-12T16:32:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Brazil's Health Technology Assessment Body Rejects Botox for OAB</title>
	<pubDate>2012-10-12T10:20:09+02:00</pubDate>
	<wp:post_id>3826</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Claudio Pericles (Ipsen, Brazil) we have learnt that 'the dossier provided by Allergan on OAB was considered by the Regulatory Authorities as "weak, unbalanced and non-comprehensive", regarding the available literature/<wbr>evidence on this field.<wbr> Moreover, the pharmacoeconomic information was not considerd to be realistic'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">CONITEC, Brazil's health technology assessment (HTA) body, rejected the incorporation of the botulinum toxin type A into the SUS for the treatment of overactive bladder (OAB) as the botulinum treatment is considered effective only for patients who have previously failed to react to less complex and aggressive treatments for overactive bladder, such as the use of classic anti-cholergenic therapies.<wbr> </div><div style="margin-bottom: 10px;">Furthermore, CONITEC rejects the introduction of such therapies on the grounds of the fact that more studies should be carried out to find out the exact dosage of botulinum toxin type A to be administered for the specified treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- infliximab, etanercept, adalimumab, Daivobet (calcipotrol + betamethasone dipropionate), and ustekinumab for psoriasis; roflumilast for chronic obstructive pulmonary disease; and botulinum toxin type A for the treatment of overactive bladder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Part of the Ministry of Health (MoH), CONITEC was created in December 2011 via Decree 7.<wbr>646, with the aim of ensuring transparency and speeding up the process of incorporation of drugs into the SUS.<wbr> </div><div style="margin-bottom: 10px;">The agency is increasingly playing a crucial role in ensuring the MoH makes efficient use of its pharmaceutical budget.<wbr> Since President Dilma Rousseff came to power, there has been focus on enhancing funding for the SUS and its overall drug expenditure.<wbr> </div><div>From Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6605">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-12T10:20:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-12T10:20:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from CPhI Madrid (Oct.9th) - Update on GnRH Hybrids</title>
	<pubDate>2012-10-11T16:20:24+02:00</pubDate>
	<wp:post_id>3827</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Except for Peptron which was not present, the event provided this year again the opportunity to validate hybrid competitors' strategies and the latest developments on goserelin, leuprorelin and triptorelin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Strategy</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>In the EU, the business model is to license-out the products.<wbr> On the booth, Business Developmen Manager told us that Acino has "ongoing partnering conversations for the EU".<wbr> </LI>
<LI>Outside the EU, Acino will market its products under its own brand.<wbr> Latin America was cited as being one of the top priorities for the company.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Products</STRONG> </div><div style="margin-bottom: 10px;"><U>Goserelin 1M</U> </div><div style="margin-bottom: 10px;">In the EU, approval is expected late 2012 /<wbr> early 2013.<wbr> No information given on which country first.<wbr> </div><div style="margin-bottom: 10px;"><U>Goserelin 3 M</U> </div><div style="margin-bottom: 10px;">As reported on the booth, this product is 'still behind' the 1M formulation.<wbr> </div><div style="margin-bottom: 10px;">Our interlocutor was overcautious.<wbr> He outlined that Acino was "heavily targeted by AstraZeneca counterintelligence regarding its Goserelin franchise".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Strategy</STRONG> </div><div style="margin-bottom: 10px;">The company is looking at partners for the EU zone (of note, the Korean manufacturer plants are not GMP certified).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Products</STRONG> </div><div style="margin-bottom: 10px;"><U>Triptorelin 1M and 3M</U> </div><div style="margin-bottom: 10px;">Approval in Korea is expected by the end of Q4 2012 (in both prostate cancer and endometriosis indications).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company is Peptron's partner for Luphere Depot.<wbr> We have validated on the booth that Luphere 3M is not yet marketed (timelines not given).<wbr> </div><div style="margin-bottom: 10px;">In addition, we have learnt that DW BTX-A, Daewoong's botulinum toxin, is certainly produced by the company in Korea (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6487" class="defaultlink">Neurology6487: New Trial of Daewoong's Botulinum Toxin for Glabellar Line</a>).<wbr> In the hand-out, the drug is listed in the 'Biologics Pipeline'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Argentinian company expects to launch Leuprolide Depot 1M, 3M in the US in approx.<wbr> 3 years.<wbr> It has no plans for the EU market at the moment.<wbr> </div><div style="margin-bottom: 10px;">The company stated it has a Goserelin Depot in its pipeline, but our contact on the booth was unable to provide any timelines of when it will move into the clinic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="ii" id="oncology8522.014ii">Further information on Octreotide hybrids will be reported in another article.<wbr></DIV> </div><div><DIV class="ii">Source: B.<wbr><WBR> Deschamps and B.<wbr></WBR><WBR> Elliott attended the CPhI event.<wbr></WBR></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=186">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-11T16:20:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-11T16:20:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Medy-Tox Registers Strong First Half Performance</title>
	<pubDate>2012-10-11T16:17:42+02:00</pubDate>
	<wp:post_id>3828</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Medy-Tox Registers Strong First Half Performance</span>&nbsp;<br><span style="font-size: 12px;">Comment: Meyd-Tox posted record-high quarterly earnings in 2Q12 with sales 
(Meditoxin) of W9.<wbr>4bn (up 70.<wbr>1% y-y), operating profit of W5.<wbr>3bn (up 
174.<wbr>5%) and net profit of W4.<wbr>6bn (up 120.<wbr>3% y-y).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6576">...</a><br></div><div>Comment: Thanks to Il-Ok Kim (Korea) we have learnt that as of Sept 24th, Medy-tox was granted approval in Korea for the use of Meditoxin (50, 100 &amp; 200 Units) for adult post stroke upper arm spasticity, strengthening its therapeutic toxin label in this market.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6603">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6576">View thread  Neurology6576: Medy-Tox Registers Strong First Half Performance</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-11T16:17:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-11T16:17:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from CPhI Madrid (Oct.9th) - GP Pharm Update</title>
	<pubDate>2012-10-11T13:32:09+02:00</pubDate>
	<wp:post_id>3829</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On the regulatory side, we have learnt that GP Pharm withdrew the registration of Lutrate 1M in France due to the "costly and time consuming regulatory requirements".<wbr> In the US, the drug could be on the market by end of 2013.<wbr> Business Development Manager on the booth indicated that partnering the whole Lutrate Franchise (1M; 3M; 6M) in the US " is in advanced stage discussions with two US-based companies".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>In the <STRONG>EU</STRONG>, near launch is expected in the UK, and "Holland".<wbr></LI>
<LI>In the <STRONG>US</STRONG>, a pre-IND meeting is taking place on October 22nd.<wbr> Filing is expected by December 2012.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Currently in Ph3.<wbr></LI>
<LI>Simultaneous filings are expected in the <STRONG>EU</STRONG> and <STRONG>US</STRONG> in Q2 2013.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Program "delayed".<wbr></LI>
<LI>The Ph3 is expected to start in Q2 2013.<wbr></LI>
<LI>Simultaneous filings are expected in the <STRONG>EU</STRONG> and <STRONG>US</STRONG> in Q2 2014.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">It is unclear what the clinical status of this program is as there "has been some issues with the registration dossier, which is in the process of being addressed in order to bring it up to EU standards".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">At the booth, hand-out titled "We offer you the latest technology", in the section "Lines of business", one can read the following: </div><div style="margin-bottom: 10px;"><U>Licensing-out</U>: GP Pharm offers the possibility to sell future rights for commercialisation of tis products under dev to those companies willing to collaborate in the pharma and clinical dev/<wbr>registration with us at the current stage of every projects, allowing us to accelerate the dev process or to reach major markets in the world.<wbr> We are open to explore also the possibilities to set other strategic alliance such as JV for dev, licensing and marketing of pharmaceutical products in specific territories.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Information on GP Pharm's Octreotide will be reported in another article.<wbr> </div><div>Source: B.<wbr> Deschamps and B.<wbr> Elliott attended the CPhI event.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8522">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-11T13:32:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-11T13:32:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: World-First Trial to Assess BOTOX Gel for Hay Fever Symptoms</title>
	<pubDate>2012-10-10T23:16:52+02:00</pubDate>
	<wp:post_id>3830</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">World-First Trial to Assess BOTOX Gel for Hay Fever Symptoms</span>&nbsp;<br><span style="font-size: 12px;">Comment: As reported in the Courier-Mail, Southern Health Director of Lung and Sleep Professor Philip Bardin said the Botox in the gel had been re-engineered so it bound to a protein and seeped through the skin and the lining of the nose.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6597">...</a><br></div><div style="margin-bottom: 10px;">The research team plan to expand their asthma results with a larger study planned for next year.<wbr> </div><div style="margin-bottom: 10px;">Additional information and reports on both studies can be found at these links: </div><div style="margin-bottom: 10px;"><A href="http://www.abc.net.au/am/content/2012/s3606460.htm">http:/<wbr>/<wbr>www.<wbr>abc.<wbr>net.<wbr>au/<wbr>am/<wbr>content/<wbr>2012/<wbr>s3606460.<wbr>htm</A> </div><div style="margin-bottom: 10px;"><A href="http://www.theage.com.au/victoria/botox-trial-to-help-fight-hayfever-20121009-27b96.html">http:/<wbr>/<wbr>www.<wbr>theage.<wbr>com.<wbr>au/<wbr>victoria/<wbr>botox-trial-to-help-fight-hayfever-20121009-27b96.<wbr>html</A> </div><div>Andrew Stork, Scientific Manager, Australia </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6601">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6597">View thread  Neurology6597: World-First Trial to Assess BOTOX Gel for Hay Fever Symptoms</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T23:16:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T23:16:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GP Pharm Starts To Commercialise Immediate Release Octreotide Through European Partners</title>
	<pubDate>2012-10-10T18:26:41+02:00</pubDate>
	<wp:post_id>3831</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Barbara Krzystofowicz in Poland, we have learnt that the Polish Authorities have granted a marketing authorisation to CSC Pharmaceuticals Handels GmbH, for three immediate release formulations of octreotide manufactured by Spanish company GP Pharm.<wbr> Intelligence gathering at CPhI, suggests that the company is continuing to progress with the development of a long-acting formulation and that it should be in a position to file in the EU later than first proposed in Q414.<wbr> Development timelines will be evaluated further to help validate this timeliine.<wbr> </div><div style="margin-bottom: 10px;">The three formulation launched in Poland are as follows:- </div><div style="margin-bottom: 10px;">Octreotide CSC solution for injection 50 mcg/<wbr>ml, 100mcg/<wbr>ml and 500mcg/<wbr>ml.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7110_1_ScreenCapture2.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7117c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Generics of the Immediate Release (IRF) Octreotide are already available in most European countries and the US.<wbr> The launch of Generics of IRF Octreotide may lead to a price cut of the existing Octreotide Sandostatin LAR in the country.<wbr> </div><div style="margin-bottom: 10px;">GP Pharm is also developing hybrid of Octreotide LAR and is looking for European partner(s) for this future commercialization: filling in Q4 2014 in EU countries may be an optimistic assumption from GP Pharm (launch timelines to be validated by the Hybrids Task Force) and the global current assumption is that hybrids of Octreotide LAR are not expected before 2016-2017 in the USA and most EU countries (to be validated by the Hybrids Task Force).<wbr> </div><div>Endocrinology Franchise </div></div><a name="endocrinology7110attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7110_1_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(79,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7110">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T18:26:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T18:26:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Trial of Daewoong's Botulinum Toxin for Glabellar Line</title>
	<pubDate>2012-10-10T17:44:19+02:00</pubDate>
	<wp:post_id>3832</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Trial of Daewoong's Botulinum Toxin for Glabellar Line</span>&nbsp;<br><span style="font-size: 12px;">Comment: Just listed in clinicaltrials.<wbr>gov, the Ph3 study which started in March is designed to evaluate the efficacy and safety of Daewoong's DWP450 compared with Botox in patients with moderate to severe glabellar line.<wbr> Whilst highlighted in a recent report dated June 28 by Tongyang Securities as a "2013 catalyst" for the company, there has been no previous published reference to this toxin that may allow its identification.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6487">...</a><br></div><div style="margin-bottom: 10px;">At CPhI (Oct.<wbr> 9th /<wbr> Madrid), we have learnt that the toxin was produced by Daewoong (in Korea).<wbr> DW BTX-A is expected to be registered by the Korean FDA in 2013 for GL.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Indications : </STRONG>Blepharospasm, sweating, CD, upper motor neuron syndrome and chronic migraine are part of the development program of the drug in a near future.<wbr> </div><div>When questionned if the toxin may come from a patnership/<wbr>technology transfer agreement with Medy-Tox, a representative of Daewoong denied, and accentuated that DW BTX-A is a proprietary product from its company.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6600">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6487">View thread  Neurology6487: New Trial of Daewoong's Botulinum Toxin for Glabellar Line</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T17:44:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T17:44:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Comparison Study Between Botox(R) Vs AntiCholinergic in Women with Urinary Incontinence</title>
	<pubDate>2012-10-10T14:25:07+02:00</pubDate>
	<wp:post_id>3833</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Comparison Study Between Botox(R) Vs AntiCholinergic in Women with Urinary Incontinence</span>&nbsp;<br><span style="font-size: 12px;">Comment: This Phase 3 study is a 6-month double-blind randomized trial comparing a single intra-detrusor injection of 100U Botox® and anticholinergic therapy in women without neurologic disease with urge incontinence.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=5103">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">Findings published in the <EM>NEJM</EM> show that o<SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">ral anticholinergic therapy and onabotulinumtoxinA by injection were associated with similar reductions in the frequency of daily episodes of urgency urinary incontinence.<wbr> The group receiving onabotulinumtoxinA was less likely to have dry mouth and more likely to have complete resolution of urgency urinary incontinence but had higher rates of transient urinary retention and urinary tract infections</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="DISPLAY: inline! important; FONT-SIZE: 13px; FLOAT: none; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 17px; FONT-STYLE: normal; FONT-FAMILY: arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; FONT-VARIANT: normal; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">Findings</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">Results of 249 women who underwent randomization, 247 were treated, and 241 had data available for the primary outcome analyses.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">The mean reduction in episodes of urgency urinary incontinence per day over the course of 6 months, from a baseline average of 5.<wbr>0 per day, was 3.<wbr>4 in the anticholinergic group and 3.<wbr>3 in the onabotulinumtoxinA group (P=0.<wbr>81).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">Complete resolution of urgency urinary incontinence was reported by 13% and 27% of the women, respectively (P=0.<wbr>003).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">QoL improved in both groups, without significant between-group differences.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2">The anticholinergic group had a higher rate of dry mouth (46% vs.<wbr> 31%, P=0.<wbr>02) but lower rates of catheter use at 2 months (0% vs.<wbr> 5%, P=0.<wbr>01) and urinary tract infections (13% vs.<wbr> 33%, P&lt;0.<wbr>001).<wbr></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; widows: 2; orphans: 2"><STRONG>Reference</STRONG>: NEJM 2012 Oct.<wbr>4 (Epub ahead of print)</SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6598">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology5103">View thread  Neurology5103: Comparison Study Between Botox(R) Vs AntiCholinergic in Women with Urinary Incontinence</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T14:25:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T14:25:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>World-First Trial to Assess BOTOX Gel for Hay Fever Symptoms</title>
	<pubDate>2012-10-10T14:18:22+02:00</pubDate>
	<wp:post_id>3834</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As reported in the Courier-Mail, Southern Health Director of Lung and Sleep Professor Philip Bardin said the Botox in the gel had been re-engineered so it bound to a protein and seeped through the skin and the lining of the nose.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Victorian Research team will now trial applying the gel to the nasal cavitiy of 70 patients once every 3 months.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: The study would focus on people suffering from allergic rhinitis who were allergic to rye grass.<wbr> If successful, the trial would be extended to people with perennial hay fever.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The researchers have also revealed the results of a trial where Botox was injected into the voicebox to paralyse the muscles of severe asthma sufferers.<wbr> </div><div style="margin-bottom: 10px;">In one group 82% of patients experienced a reduction in symptoms.<wbr> </div><div style="margin-bottom: 10px;">They discovered that the effect lasted for 3 months, giving patients temporary relief and partial muscle paralysis.<wbr> </div><div>Source: <A href="http://www.couriermail.com.au/news/national/botox-might-have-hay-fever-on-run-in-world-first-trial/story-fndo1wyv-1226492333816">http:/<wbr>/<wbr>www.<wbr>couriermail.<wbr>com.<wbr>au/<wbr>news/<wbr>national/<wbr>botox-might-have-hay-fever-on-run-in-world-first-trial/<wbr>story-fndo1wyv-1226492333816</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6601c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The research team plan to expand their asthma results with a larger study planned for next year.<wbr> </div><div style="margin-bottom: 10px;">Additional information and reports on both studies can be found at these links: </div><div style="margin-bottom: 10px;"><A href="http://www.abc.net.au/am/content/2012/s3606460.htm">http:/<wbr>/<wbr>www.<wbr>abc.<wbr>net.<wbr>au/<wbr>am/<wbr>content/<wbr>2012/<wbr>s3606460.<wbr>htm</A> </div><div style="margin-bottom: 10px;"><A href="http://www.theage.com.au/victoria/botox-trial-to-help-fight-hayfever-20121009-27b96.html">http:/<wbr>/<wbr>www.<wbr>theage.<wbr>com.<wbr>au/<wbr>victoria/<wbr>botox-trial-to-help-fight-hayfever-20121009-27b96.<wbr>html</A> </div><div>Andrew Stork, Scientific Manager, Australia </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6597">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T14:18:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T14:18:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on TroVax Development Strategy</title>
	<pubDate>2012-10-10T13:36:12+02:00</pubDate>
	<wp:post_id>3835</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oxford Biomedica plans to close the Ph2 study in the US (8 sites) to assess the activity of TroVax in patients with progressive hormone refractory prostate cancer (HRPC).<wbr> TroVax<SUP>®</SUP> continues to have an active Ph2 development programme in other indications (ovarian cancer; mesothelomia) led by academic collaborators in the UK.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01194960?term=trovax&amp;rank=7&amp;submit_fld_opt="><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><UL><LI>Design: randomised, open-label Ph2 study in patients with metastatic HRPC</LI>
<LI>Start date: September 2010</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- The prostate cancer treatment landscape in the US has changed with new products available and other clinical trials targeting the same indication.<wbr> </div><div style="margin-bottom: 10px;">- Recruitment into the study has been much slower than originally anticipated with 26 patients recruited to date (80 planned).<wbr> </div><div style="margin-bottom: 10px;">- Whilst early data from this study are encouraging, the Board has made a strategic decision to close the US trial in order to focus on investigator-led Ph2 studies, currently in the UK.<wbr> </div><div>Source: Oxford BioMedica </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8517">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T13:36:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T13:36:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Early Initiation of Ferring's Degarelix and Infertility</title>
	<pubDate>2012-10-10T13:20:46+02:00</pubDate>
	<wp:post_id>3836</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Conclusion of the study shows <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG><A href="http://www.controlled-trials.com/ISRCTN69937179/"><STRONG></STRONG></A><STRONG> </STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8516">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T13:20:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T13:20:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Baxter Venture Fund Invests In Novel Peptide</title>
	<pubDate>2012-10-10T10:44:54+02:00</pubDate>
	<wp:post_id>3837</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source.<wbr> <A href="http://www.baxterventures.com/">www.<wbr>baxterventures.<wbr>com</A></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10117c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">A) Time has changed! Baxter's oncology core business was ASTA MEDICA (GE) portfolio made of originators or generics of cytostatic chemotherapy drugs such as cyclophosphamide, ifosphamide and mesna.<wbr> They were even looking (4 years ago)  for buyers.<wbr> </div><div style="margin-bottom: 10px;">B) As mentioned: licensed peptide in development (phase II) is a "cytoprotective peptide to improve peritoneal immune competence and protect peritoneal membrane integrity".<wbr> This peptide might play a role in the therapeutic management of peritoneal carcinomatosis.<wbr> It is remarkable to see that the topic is of interest: As you know it has been decided to submit early next year a new variation for Somatuline PR 30 mg in palliative treatment of clinical symptoms associated with upper intestinal obstruction due to peritoneal carcinomatosis in inoperable patients on top of other symptomatic medication.<wbr>(based on study 156 results) </div><div>Endocrinology Franchise </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10112">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-10T10:44:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-10T10:44:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Therapy Area Landscapes - A New Traction Service</title>
	<pubDate>2012-10-09T22:57:30+02:00</pubDate>
	<wp:post_id>3838</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Therapy Area Landscapes (TALs)</span>&nbsp;<br><span style="font-size: 12px;"><DIV class="i" id="pharmaworld7400.04i">
<DIV class="ii" id="pharmaworld7400.04ii">Comment: We would like to introduce you to a new concept within Traction, the so called "Therapy Area Landscapes" (TAL) This area has been designed to provide you with a distilled overview of the competitive landscape in each of our specialised therapy areas.<wbr> The links, which can be accessed through one of the "Traction Short-Cuts" on the right hand side of the Traction screen, will in time provide access to a presentation on each topic area; a presentation that will be regularly updated with new intelligence as and when it is received.<wbr> The first slide presentation will be on the acromegaly therapy area, however.<wbr> we hope to be in a position to provide a number of other TALs within a matter of weeks.<wbr></DIV>
</DIV></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10099">...</a><br></div><div style="margin-bottom: 10px;">This is wonderful and I think it will be very useful.<wbr>  Thanks.<wbr> </div><div>Prakash Purohit </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10109">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10099">View thread  PharmaWorld10099: Therapy Area Landscapes (TALs)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-09T22:57:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-09T22:57:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Acromegaly Therapy Area Landscape</title>
	<pubDate>2012-10-09T18:55:04+02:00</pubDate>
	<wp:post_id>3839</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As part of our newly launched CI/<wbr>SIS Therapy Area Landscape 
Service, you will find attached an overview of the competitive landscape in the 
acromegaly field.<wbr> We hope you will find this a useful tool and 
one that makes you feel more inclined to contribute to our internal 
knowledge of the therapy area no matter what competitive information you 
may have.<wbr> By keeping us informed of developments in your 
countries, we can build our internal knowledge base and together 
leverage the utility of the tool for everybody's benefit.<wbr> </div><div style="margin-bottom: 10px;">The Acromegaly slide presentation itself builds on 
data included in the 4Yr Brand Plan, providing both an updated 
competitive timeline plus more detail about individual competitive products 
and market trends.<wbr> Highlighted below is a small selection of some 
of the slides from the attached presentation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_5_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_2_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_3_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_4_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Compiled By The CI &amp; SIS Departments </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_1_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="endocrinology7109attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_1_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(902 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_2_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_3_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(179,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_4_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(114,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_5_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(130,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7109_6_Final%20Acromegaly%20Therapeutic%20Landscape%209th%20October%202012.ppt">Final Acromegaly Therapeutic Landscape 9th October 2012.ppt</a>&nbsp;&nbsp;(1,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7109">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-09T18:55:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-09T18:55:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 1 - The Evolving CRPC Landscape</title>
	<pubDate>2012-10-09T18:10:08+02:00</pubDate>
	<wp:post_id>3840</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This year's meeting had a significant prostate cancer focus, with 
new data presented on all of the emerging treatments for CPRC most notably 
sub-group analysis from the AFFIRM trial and QOL data with Alpharadin.<wbr> 
Meanwhile, Sanofi's symposium highlighted the ongoing place for 
chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">Bertrand Tombal's discussion of both the AFFIRM &amp; Alpharadin data 
sets provided some interesting insight.<wbr> </div><div style="margin-bottom: 10px;">From an introductory standpoint , he highlighted what the treatment landscape 
looks like today and how it is likely to rapidly evolve within 2-3 years 
with a number of different drugs adjoining ABI and ENZA in the middle 
ground.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_1_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_2_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_3_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">He then proceeded to review the new Alpharadin data, noting that this is not 
the first radioe-emitter to be used in prostate cancer therapy but an important 
one that whilst demonstrating a modest impact on PSA has shown an impressive 
impact on osteoblasts.<wbr> Tombal classifies it as a bone targeting agent with 
questionable anti-tumour activity that is to be congratulated for having 
demonstrated an improvement in overall survival.<wbr> It is not the first he 
emphasised as strontium has also demonstrated this in a small trial but it is 
the first drug of its kind to have the correct support and be evaluated in an 
appropriately designed and sized trial.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_5_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">He noted that the population studied had extremely advanced prostate cancer 
and in such patients it is questionable how important from a clinicians 
perspective it is to look at OS benefit and delayed SREs in this setting, 
suggesting that what is really important is the benefit a drug has on QOL.<wbr> </div><div style="margin-bottom: 10px;">This is what is important about the data presented by Chris Parker as it 
clearly demonstrates the quicker and more profound deterioration on placebo in 
terms of the FACT-P QOL score.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_6_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">The only criticism Tombal did raise was the lack of pain response data in 
this advanced patient setting, something he claims is critically important.<wbr> </div><div style="margin-bottom: 10px;">The next set of data he reviewed was the important sub-group AFFIRM trial 
data.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_7_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">The results of this sub-set analysis raise some big questions about steroid 
usage in CRPC patients and whether the drugs used at the dosages at which they 
are prescribed have and adverse impact on morbidity.<wbr> </div><div style="margin-bottom: 10px;">Steroids, Tombal claims are the most widely prescribed drugs today in 
the CRPC setting </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_9_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">Patients with baseline steroid use in the AFFRIM trial overall had a worse 
median survival than those with no priior steroid use, a finding that could 
auger well for the results of the enzallutamide pre-chemotherapy 
trial.<wbr> </div><div style="margin-bottom: 10px;">However, what is evident from the data is that there was an imbalance in risk 
factors with the group receiving steroid typically those with more progressive 
disease.<wbr> However, the impact on their survival was greater than that predicted 
by the Halibi nomogram suggesting other factors may be contributing to these 
patients' outcome.<wbr> Hence there is the suggestion that the high dosages used may 
be having an impact on surivival.<wbr> It is an issue that has to be explored further 
and may result in steroid usage being delayed as much as possible in the 
treatment paradigm.<wbr> Something that could be key in terms of usage of drugs that 
require concomitant steroid therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_10_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_11_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_12_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_13_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Sanofi Satellite Symposium</STRONG> </div><div style="margin-bottom: 10px;">Sanofi hosted one of the key satellite events in terms of metastatic castrate 
resistant prostate cancer focusing on the "Reality of Treating Patients".<wbr> 
Speakers included Bertrand Tombal (Brussels), Eleni Efstathiou (Houston), Karim 
Fazazi (Paris) and Zafir Malik (Liverpool) and the event whilst undoubtedly 
biased towards the use of chemotherapy did highlight the continuing rational for 
chemotherapy treatment in some patients and illustrate the type of promotional 
push-back endocrine therapy will receive from the chemotherapy 
manufacturers.<wbr> </div><div style="margin-bottom: 10px;">Bertrand Tombal introduced the symposium highlighting some of the key drugs 
in the new treatment paradigm and previously unseen 2 year survival data from 
the TROPIC (cabazetaxel) and  abiraterone post docetaxel studies.<wbr> He 
also warned that we need to proceed carefully with our eveluation of new drugs 
otherwise the "wall may just end up as a pile of bricks".<wbr> He highlighted a 
number of issues where we need to tread carefully and noted that pricing will 
become ever more of an issue, with reimbursement authorities questioning how 
much more money they are willing to spend to to extend life by a few months.<wbr> As 
an example, he cited <STRONG>NICE which downgraded its "quality adjusted year of 
life" assessment in May from Euro 45,000 to 20,000.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_14_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_15_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_16_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_17_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_18_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_19_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_20_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_21_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;">Eleni Efstathiou re-focused the audience's attention on the complexity of 
androgen signalling in prostate cancer, guiding us as to how therapy may develop 
over time.<wbr> She noted that it is a convoluted field where drugs are moving into 
earlier stages of the treatment paradigm and whilst AR signalling is now 
recognised as an important pathological aspect of CRPC there are other pathways 
that are important that are AR independent.<wbr> As an example, she flagged the 
25-30% of patients with early CRPC demonstrate primary resistance to 
abiraterone.<wbr> However, the key point she made was that there is now some evidence 
leading people to belive a combinatorial strategy may prove advantageous.<wbr> This 
trial is being perfomed and is rapidly accruing.<wbr> </div><div style="margin-bottom: 10px;">The evolution that is occuring is she claimed, leading to deferred 
chemotherapy (current delay is around 10 months).<wbr> However, chemotherapy can be 
beneficial in AR independent cancer so we face a therapeutic challenge whereby 
it is possible that some patients may miss out on the opportunity to receive 
chemotherapy having progressed through a sequence of different treatments.<wbr> 
Moreoever, there is data showing that docetaxel can suppress androgen receptor 
nuclear translocation in PCa tumours.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_22_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_23_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_24_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_25_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;">The symposium then continued in a different vain, with Karim Fizazi and Zafir 
Malik highlighting a number of case studies where there was undsiputable benefit 
seen when the patients received chemotherapy.<wbr> The case studies highlighted some 
key points to consider regarding the positioning of chemotherapy usage, 
namely the benefit of rechallenging with docetaxel and then cabazitaxel when PSA 
rises in patients non-responsive to endocrine therapy </div><div style="margin-bottom: 10px;">Fizazi posed the question as to whether we can predict who may benefit 
from  a rechallenge with docetaxel and concluded the following:- </div><div style="margin-bottom: 10px;">Time from last docetaxel cycle to progression - patients who progress within 
3 months are unlikely to benefit whereas those that progress after 4-8 
months may benefit.<wbr> </div><div style="margin-bottom: 10px;">He also raised the idea of subsequent endocrine manipulation post 
chemotherapy and suggested that a bone marrow biopsy can be helpful in this 
context with intense AR nuclear expression suggestive of a beneficial 
response.<wbr> </div><div style="margin-bottom: 10px;">ADT sensitivity can also be a predictor of patients that may differentially 
benefit from chemo and endocrine therapy with those experiencing &lt;1 yrs 
response likely to be responsive to endocrine therapy.<wbr> </div><div style="margin-bottom: 10px;">Finally, he raised the point about whether ABI and taxanes are cross 
resistant and suggested based on some limited data that they are not.<wbr> He 
also noted that patients with elevated baseline ALK are probably the ones most 
likely to benefit from Alphardin treatment.<wbr> Patients with normal values 
apparently experience only a marginal response.<wbr> </div><div style="margin-bottom: 10px;">His conclusion was that prostate cancer is a chemosensitive malignancy and 
whilst over the last 3-5 years new agents are improving survival, presonalising 
treatment is becoming a priority.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Special Prostate Cancer Symposium</STRONG> </div><div style="margin-bottom: 10px;">One of the other important prostate cancer tracks was a non-industry 
sponsored sympoisum hosted by ESMO.<wbr> This symposium similarly evaluated all 
the different aspects of CRPC treatment including immunological approaches and 
chemotherapy.<wbr> However, the key event was Johanne De Bono's presentation on 
"How to integrate novel therapies".<wbr> </div><div style="margin-bottom: 10px;">Philip Kantoff's presentation on immunotherapeutics was 
interesting highlighting where he sees the vaccine products having the 
most benefit.<wbr>There are a number of unresolved issues with Provenge, nonetheless, 
it does have a place and development of immunotherapeutics is continuing 
with the phIII 1200 patient PROSPECT (PROSTVAC) trial having recently been 
initiated and recruiting rapidly (estimated 2 years to 
completion).<wbr> From a positioning perspective, the focus is very much on 
usage in very early asymptomatic CRPC which is slowly progressing.<wbr> He 
highlighted some hazard ratio data which indicates that those with 
lower PSAs benefit more than those with higher PSAs from vaccine therapy and 
benefit more than is seemingly observed with other forms of 
treatment.<wbr> Kantoff also showed some new data demonstrating that PROVENGe 
may delay the time to onset of pain.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_26_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_27_ScreenCapture28.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_28_ScreenCapture29.jpg"> </div><div style="margin-bottom: 10px;">Oliver Sartori presented an interesting overview of the place for chemo with 
a few key comments mentioned in some of his slides particularly about cross 
resistance between endocrine therapies and the efficacy of docetaxel following 
treamtent with ABI.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_29_ScreenCapture30.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_30_ScreenCapture31.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_31_ScreenCapture32.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_32_ScreenCapture33.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_33_ScreenCapture34.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_34_ScreenCapture35.jpg"> </div><div style="margin-bottom: 10px;">Finally, we arrived at De Bono's presentation on "Integrating Novel Therapies 
- Sequential or Combination Therapy" </div><div style="margin-bottom: 10px;">In his introduction he highlighted the improved survival statistics from 
the Marsden Cohort  but emphasized that the optimal sequence of 
administration of all new drugs now needs to be better defined.<wbr> The problem 
is that all have been developed as single agents and there are now many more 
agents in development.<wbr> He suggested that there is strong evidence that SRC could 
be implicated and is very excited to see what the dasatinib (BMS) data, 
that should emerge shortly, will show.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_35_ScreenCapture36.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_36_ScreenCapture37.jpg"> </div><div style="margin-bottom: 10px;">He suggested that we need to focus on combination therapy and that there are 
lessons to be learnt from breast cancer where combination therapy is widely 
used.<wbr> Cancer, he claimed, is a disease of genomic complexity and complexity 
mandates that combinations will be more successful.<wbr> He also hypothesised that 
there are probably multiple different clones or sub-blones and multiple 
mechanisms of resistance probably operating at the same time in any one patient 
and that in a Darwinian fashion clones may evolve based on therapeutic selective 
pressures.<wbr> They may emerge, regress and re-emerge contingent on the 
therapeutic pressures imposed on them.<wbr> Hence it is possible that a drug that 
worked 2/<wbr>3 years ago could work again when the clone returns.<wbr> Some of the 
questions we need to address in this context are therefore as 
follows:- </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_37_ScreenCapture38.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_38_ScreenCapture39.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_39_ScreenCapture40.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_40_ScreenCapture41.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_41_ScreenCapture42.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_42_ScreenCapture43.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_43_ScreenCapture44.jpg"> </div><div>Source: ESMO 2012 Sept 29th - October 2nd </div><!-- Comment details --><a name="oncology8515attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_1_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(44,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_2_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(51,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(65,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(47,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(43 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(63 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(56,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(81,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(65,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(45 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_14_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(47,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_15_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(49,2 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_16_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(44,2 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_17_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(54,9 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_18_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(57 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_19_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(55,2 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_20_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(45,9 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_21_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(55,6 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_22_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(62,1 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_23_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(71,1 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_24_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(47,8 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_25_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(60,2 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_26_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(86,1 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_27_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(79,5 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_28_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(36,3 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_29_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(75,9 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_30_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(47,2 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_31_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(59,1 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_32_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(39,3 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_33_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(79,1 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_34_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_35_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_36_ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(113,6 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_37_ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(46,1 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_38_ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(52,5 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_39_ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(62,8 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_40_ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(52,9 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_41_ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(50,9 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_42_ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(63,3 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8515_43_ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(67,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8515">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-09T18:10:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-09T18:10:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Therapy Area Landscapes (TALs)</title>
	<pubDate>2012-10-09T14:05:02+02:00</pubDate>
	<wp:post_id>3841</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="i" id="pharmaworld7400.04i">
<DIV class="ii" id="pharmaworld7400.04ii">Comment: We would like to introduce you to a new concept within Traction, the so called "Therapy Area Landscapes" (TAL) This area has been designed to provide you with a distilled overview of the competitive landscape in each of our specialised therapy areas.<wbr> The links, which can be accessed through one of the "Traction Short-Cuts" on the right hand side of the Traction screen, will in time provide access to a presentation on each topic area; a presentation that will be regularly updated with new intelligence as and when it is received.<wbr> The first slide presentation will be on the acromegaly therapy area, however.<wbr> we hope to be in a position to provide a number of other TALs within a matter of weeks.<wbr></DIV>
</DIV> <a name="PharmaWorld10425c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Therapy Area Landscapes - A New Traction Service</span> </div><div style="margin-bottom: 10px;">Very good initiative to gather info per TA, can we envisage one for Short Stature ? </div><div>If yes, can we liaise with our medical colleagues (Bruno Fiorentino &amp; Robin Kingswell) and Brigitte Deschamps to see how we can organize /<wbr> contribute to this possible TAL.<wbr> </div></div></div><div style="margin-bottom: 10px;"><DIV class="i" id="pharmaworld7400.08i">
<DIV class="ii" id="pharmaworld7400.08ii">
<H2><STRONG>ENDOCRINOLOGY</STRONG></H2>
</DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="pharmaworld7400.09i">
<DIV class="ii" id="pharmaworld7400.09ii">
<TABLE border="2" cellpadding="1" cellspacing="1" style="background-color: #f2f2f2; border: #ffffff 2px solid;"><TBODY><TR><TD style="width: 190px; border: #ffffff 1px solid;" valign="top">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20121231&edate=All&cat=%3aEndocrinology%3aTAL%3aAcromegaly&rsin=/link%20%3a%3aEndocrinology%20%3a%3aEndocrinology%3aTAL%3aAcromegaly%20All%20%27Acromegaly%27&title=Acromegaly" class="defaultlink">Acromegaly</a></STRONG></SPAN></P>
</TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20121231&edate=All&cat=%3aEndocrinology%3aTAL%3aCushing&rsin=/link%20%3a%3aEndocrinology%20%3a%3aEndocrinology%3aTAL%3aCushing%20all%20%27Cushing%27&title=Cushing" class="defaultlink">Cushing</a></STRONG></SPAN></P>
</TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20121231&edate=All&cat=%3aEndocrinology%3aTAL%3aNETS&rsin=/link%20%3a%3aEndocrinology%20%3a%3aEndocrinology%3aTAL%3aNETS%20all%20%27NETS%27&title=NETS" class="defaultlink">NETS</a></STRONG></SPAN></P>
</TD>
</TR>
</TBODY>
</TABLE>
</DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="pharmaworld7400.012i">
<DIV class="ii" id="pharmaworld7400.012ii">
<H2><STRONG>NEUROLOGY</STRONG></H2>
</DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="pharmaworld7400.013i">
<DIV class="ii" id="pharmaworld7400.013ii">
<TABLE border="2" cellpadding="1" cellspacing="1" style="background-color: #f2f2f2; border: #ffffff 2px solid;"><TBODY><TR><TD style="width: 190px; border: #ffffff 1px solid;" valign="top">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20121231&edate=All&cat=%3aNeurology%3aTAL%3aAesthetic&rsin=/link%20%3a%3aNeurology%20%3a%3aNeurology%3aTAL%3aAesthetic%20all%20%27Aesthetic%27&title=Aesthetic" class="defaultlink">Aesthetic</a></STRONG></SPAN></P>
</TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top"><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20121231&edate=All&cat=%3aNeurology%3aTAL%3aHuntington&rsin=/link%20%3a%3aNeurology%20%3a%3aNeurology%3aTAL%3aHuntington%20all%20%27Huntington%27&title=Huntington" class="defaultlink">Huntington</a></STRONG></SPAN></TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">&nbsp;</TD>
</TR>
<TR><TD style="width: 190px; border: #ffffff 1px solid;" valign="top"><SPAN style="font-size: medium;"><STRONG><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20121231&edate=All&cat=%3aNeurology%3aTAL%3aTherapeutic&rsin=/link%20%3a%3aNeurology%20%3a%3aNeurology%3aTAL%3aTherapeutic%20all%20%27Therapeutic%27&title=Therapeutic" class="defaultlink">Therapeutic</a></STRONG></STRONG></SPAN></TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top"><SPAN style="font-size: medium;"><STRONG><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20121231&edate=All&cat=%3aNeurology%3aTAL%3aParkinson&rsin=/link%20%3a%3aNeurology%20%3a%3aNeurology%3aTAL%3aParkinson%20all%20%27Parkinson%27&title=Parkinson" class="defaultlink">Parkinson</a></STRONG></STRONG></SPAN></TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">&nbsp;</TD>
</TR>
</TBODY>
</TABLE>
</DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="pharmaworld7400.010i">
<DIV class="ii" id="pharmaworld7400.010ii">
<H2><STRONG>ONCOLOGY</STRONG></H2>
</DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i hovered" id="pharmaworld7400.011i">
<DIV class="ii" id="pharmaworld7400.011ii">
<TABLE border="2" cellpadding="1" cellspacing="1" style="background-color: #f2f2f2; border: #ffffff 2px solid;"><TBODY><TR><TD style="width: 190px; border: #ffffff 1px solid;" valign="top">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20121231&edate=All&cat=%3aOncology%3aTAL%3aADT&rsin=/link%20%3a%3aOncology%20%3a%3aOncology%3aTAL%3aADT%20all%20%27ADT%27&title=ADT" class="defaultlink">ADT</a></STRONG></SPAN></P>
</TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top"><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20121231&edate=All&cat=%3aOncology%3aTAL%3aBladder%20Cancer&rsin=/link%20%3a%3aOncology%20%3a%22%3aOncology%3aTAL%3aBladder%20Cancer%22%20all%20%27Bladder%20Cancer%27&title=Bladder%20Cancer" class="defaultlink">Bladder Cancer</a></STRONG></SPAN></TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top"><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20121231&edate=All&cat=%3aOncology%3aTAL%3aEndometriosis&rsin=/link%20%3a%3aOncology%20%3a%3aOncology%3aTAL%3aEndometriosis%20all%20%27Endometriosis%27&title=Endometriosis" class="defaultlink">Endometriosis</a></STRONG></SPAN></TD>
</TR>
<TR><TD style="width: 190px; border: #ffffff 1px solid;" valign="top"><SPAN style="font-size: medium;"><STRONG style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20121231&edate=All&cat=%3aOncology%3aTAL%3amCRPC&rsin=/link%20%3a%3aOncology%20%3a%3aOncology%3aTAL%3amCRPC%20all%20%27mCRPC%27&title=mCRPC" class="defaultlink">mCRPC</a></STRONG></STRONG></SPAN></TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">&nbsp;</TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">&nbsp;</TD>
</TR>
</TBODY>
</TABLE>
</DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="pharmaworld7400.010i">
<DIV class="ii" id="pharmaworld7400.010ii">
<H2><STRONG>PRIMARY CARE</STRONG></H2>
</DIV>
</DIV> </div><div><DIV class="i hovered" id="pharmaworld7400.011i">
<DIV class="ii" id="pharmaworld7400.011ii">
<TABLE border="2" cellpadding="1" cellspacing="1" style="background-color: #f2f2f2; border: #ffffff 2px solid;"><TBODY><TR><TD style="width: 190px; border: #ffffff 1px solid;" valign="top">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20121231&edate=All&cat=%3aGastroEnterology%3aTAL%3aIBS&rsin=/link%20%3a%3aGastroEnterology%20%3a%3aGastroEnterology%3aTAL%3aIBS%20All%20%27Diarrhea%20and%20IBS%20Symptoms%27&title=Diarrhea%20and%20IBS%20Symptoms" class="defaultlink">Diarrhea and IBS Symptoms</a></STRONG></SPAN></P>
</TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">&nbsp;</TD>
<TD style="width: 190px; border: #ffffff 1px solid;" valign="top">&nbsp;</TD>
</TR>
</TBODY>
</TABLE>
</DIV>
</DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10109c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Therapy Area Landscapes - A New Traction Service</span> </div><div style="margin-bottom: 10px;">This is wonderful and I think it will be very useful.<wbr>  Thanks.<wbr> </div><div>Prakash Purohit </div></div><a name="PharmaWorld10123c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Therapy Area Landscapes - A New Traction Service</span> </div><div>Excellent - thank you, should be really helpful </div></div><a name="PharmaWorld10421c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Therapy Area Landscapes - A New Traction Service</span> </div><div>Thanks a lot for compiling all this  information.<wbr> This will be really useful for the countries during the SP exercice.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10099">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-09T14:05:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-09T14:05:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pioneering Blood Test Is Able To Identify Aggressive Prostate Cancers</title>
	<pubDate>2012-10-09T11:39:09+02:00</pubDate>
	<wp:post_id>3842</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The London Institute of Cancer Research has unveiled the results of a barcode type blood test that can identify the most aggressive form of prostate cancer.<wbr> Its findings are published in the latest edition of Lancet Oncology and are being widely covered by the UK television and press.<wbr> Such a test if fully validated could have important implications for the therapeutic paradigm.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the work, Karina Dalsgaard, Denmark's Aarhus Univeristy Hospital, who was not involved in the study, claimed the findings were welcome and significant.<wbr> </div><div style="margin-bottom: 10px;">In the study undertaken by Johanne De Bono's group, scientists were able to split patients into four groups based on the results of the barcode test.<wbr> For his study De Bono's team scanned all the genes in the blood samples from 100 patients in London &amp; Glasgow with prostate cancer.<wbr> They included some already diagnosed with advanced cancer and some thought to have low-risk disease.<wbr> </div><div style="margin-bottom: 10px;">Using statistical modelling they divided the patients into four groups based on their patterns of gene activity and, after almost two-and-a-half years, they found that patients in one group died significantly earlier than those in the other.<wbr> </div><div style="margin-bottom: 10px;">They pinpointed nine key active genes shared by the patients in that group and then tested their hypotheseis in another 70 American with prostate cancer.<wbr> Similarly, they found that those patients with the activated genes survived for a shorter period of time (9 months compared to 21 months for a group with another gene pattern).<wbr> </div><div style="margin-bottom: 10px;">Importantly, the British team claim that the gene signature includes several genes involved in the immune system - suggesting that the immune system is suprressed in patients whose cancer spread around the body.<wbr> </div><div>source: <A href="http://www.icr.ac.uk/press/press_archive/press_releases_2012/23247.shtml">http:/<wbr>/<wbr>www.<wbr>icr.<wbr>ac.<wbr>uk/<wbr>press/<wbr>press_archive/<wbr>press_releases_2012/<wbr>23247.<wbr>shtml</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8512">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-09T11:39:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-09T11:39:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Regains W/W Rights To Its Topical Toxin</title>
	<pubDate>2012-10-08T16:56:06+02:00</pubDate>
	<wp:post_id>3843</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: Revance Therapeutics has announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corp.<wbr>concerning its topical botuliinum toxin product RT001 and injectable BoNT-A RT002.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Deal Terms</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">As part of the settlement, worldwide rights to develop and commercialize both products across all indications have been returned to Revance.<wbr> The agreement will also resolve the outstanding litigation between the companies.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">As per the agreement, Revance will make an upfront payment to Medicis of $7 million and up to an additional $18 million based on certain events.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">In return, the RT001 Option Agreement and related agreements, and the 2009 RT002 License Agreement will be terminated entirely.<wbr> Medicis will, however retain its current equity ownership in Revance.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Next Steps</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Revance will move forward with the Phase 3 program for RT001 in the lead aesthetic indication and initiate a Phase 1/<wbr>2 program for RT002.<wbr></P> </div><div><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: 13px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #313131; VERTICAL-ALIGN: top; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: <A href="http://www.revance.com/">www.<wbr>revance.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6594">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-08T16:56:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-08T16:56:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring Participates In The Creation Of A New Biotech Company</title>
	<pubDate>2012-10-08T16:16:49+02:00</pubDate>
	<wp:post_id>3844</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ferring has joined forces with Fonds de Soidarite FTQ and CIT Life 
Sciences Fund to create a new biotech firm in Quebec focusing on oncology 
supportive care.<wbr> </div><div style="margin-bottom: 10px;">Together the three partners have invested $12m in the start-up with Feffing 
taking a minority interest.<wbr> </div><div style="margin-bottom: 10px;">The new company will work on developing a new innovative compound based on 
the GLP-2 agonist family, a product under exclusive license from Ferring.<wbr> </div><div style="margin-bottom: 10px;">The first targeted indication will be in the area of supportive oncology care 
and it  is claimed that it could represent a major clinical 
advance.<wbr> </div><div>Source: <A href="http://www.ferring.com">www.<wbr>ferring.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8511">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-08T16:16:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-08T16:16:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: GP Pharm's Lutrate 1M Launched in Spain</title>
	<pubDate>2012-10-08T12:49:36+02:00</pubDate>
	<wp:post_id>3845</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">GP Pharm's Lutrate 1M Launched in Spain</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to E.<wbr> Minguell we have learnt that <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=177">...</a><br></div><div style="margin-bottom: 10px;">comment from<SPAN style="text-decoration: underline;"><STRONG> bruno tissier</STRONG></SPAN> /<wbr> some more info about GP Pharm and the other Lutrate depot formulations (3 &amp; 6 months) </div><div style="margin-bottom: 10px;">from :<A href="http://www.biocat.cat/en/news/gp-pharm-receives-authorization-lutrate-depot%C2%AE-1-month-europe-treatment-advanced-prostate-cancer">http:/<wbr>/<wbr>www.<wbr>biocat.<wbr>cat/<wbr>en/<wbr>news/<wbr>gp-pharm-receives-authorization-lutrate-depot%C2%AE-1-month-europe-treatment-advanced-prostate-cancer</A> </div><div style="margin-bottom: 10px;">Approval of Lutrate Depot &reg; 1 month is the culmination of the <STRONG>first drug developed entirely by GP Pharm</STRONG>, from the initial stages of drug research through to its launch to the pharmaceutical market, making it one of the few Spanish biotechnology firms to launch its own product.<wbr> &ldquo;With this product, we are validating our business model and consolidating our growth potential in a market that represents more than &euro;1,000 millions worldwide,&rdquo; explains Alberto Bueno, CEO of GP Pharm.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE>
<P>This Catalan biotech <STRONG>firm has already initiated Phase III clinical trials on Lutrate Depot &reg; 3 month in the United States.<wbr></STRONG></P>
</BLOCKQUOTE> </div><div style="margin-bottom: 10px;">GP Pharm&rsquo;s new drug<STRONG> is also available in three- and six-month formulas.<wbr></STRONG> Lutrate Depot &reg; 3 month, which allows for a single dose once every three months, is currently undergoing Phase III clinical trials in the United States.<wbr> This is a multicenter study designed to evaluate the efficacy and safety of this new formula, with 160 prostate-cancer patients from 33 specialized care centers in the United States, who will be treated over six months.<wbr> Furthermore, <STRONG>the new Lutrate Depot &reg; 6 month is in the pre-clinical phase and is expected to move into clinical trials in early 2012.<wbr></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2000, this Catalan biopharmaceutical company has a high-tech manufacturing plant in Sant Quint&iacute; de Mediona, 60 kilometers from Barcelona.<wbr> The plant develops and manufactures the company&rsquo;s own products for international consumption.<wbr> It is the only plant for oncological injectables in Spain, and the only one in Europe to produce injectable liposomal forms to treat different types of cancer and that is able to produce microspheres in sterile conditions.<wbr> </div><div style="margin-bottom: 10px;">---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- </div><div style="margin-bottom: 10px;">all reconstitution manipulations could be seen at (in spanish) : </div><div style="margin-bottom: 10px;"><A href="http://eurekasalud.es/prospecto-lutrate+depot+polvo+y+disolv.+para+sol.+iny.3,75+mg-74980">http:/<wbr>/<wbr>eurekasalud.<wbr>es/<wbr>prospecto-lutrate+depot+polvo+y+disolv.<wbr>+para+sol.<wbr>+iny.<wbr>3,75+mg-74980</A> </div><div style="margin-bottom: 10px;">--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- </div><div style="margin-bottom: 10px;">some differences with IPSEN DKP : </div><div style="margin-bottom: 10px;">1) aseptic manufacturing ( =&gt; higher costs of manufacturing) </div><div style="margin-bottom: 10px;">2) use of the Medimop/<wbr>Mixjet device to make extemporaneous suspension .<wbr> This device was appraised by PMT Onco in 2009 and not retained .<wbr> </div><div style="margin-bottom: 10px;">3) storage conditions +2 to +8&deg;C </div><div>4)injection IM with G20 needle ( 0.<wbr>9mm diameter) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=182">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids177">View thread  DKPHybrids177: GP Pharm's Lutrate 1M Launched in Spain</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-08T12:49:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-08T12:49:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis To Pursue Mid-Sized Deals To Counter $2bn Fall In Diovan Sales</title>
	<pubDate>2012-10-08T11:22:16+02:00</pubDate>
	<wp:post_id>3846</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Sunday edition of the newspaper SonntagsZietung features an 
interview with Novartis's CEO Joe Jiminez.<wbr> Reportedly, he highlights the 
significant slump seen in Diovan sales since its patent expiry in September and 
the challenging quarters ahead.<wbr> </div><div style="margin-bottom: 10px;">No new cost initiatives are planned to cover the shortfall but new 
medicines are expected to offset some of the decline.<wbr> 
Nonetheless, generating growth is expected to be tough 
going up until the second half of 2013.<wbr> </div><div style="margin-bottom: 10px;">Jiminez apparently commented on the need to protect the dividend.<wbr> The 
stock's yield last year was 3.<wbr>9% but he also flagged the desire to conduct 
medium-sized acquisitions to boost the company's growth.<wbr> </div><div>Source: <A href="http://www.firstwordpharma.com">www.<wbr>firstwordpharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10097">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-08T11:22:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-08T11:22:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New European Distribution Centre For Janssen</title>
	<pubDate>2012-10-05T18:31:13+02:00</pubDate>
	<wp:post_id>3847</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div><TABLE border="0" cellpadding="0" cellspacing="0" width="100%"><TBODY><TR><TD>
      <TABLE width="100%"><TBODY><TR align="left"><TD valign="top">
            <DIV class="article_body bp">Comment: Janssen Pharmaceuticals 
            has opened a new European distribution center for 
            pharmaceutical drugs in La Louvière, Belgium.<wbr> Janssen has 
            invested €49m in the new center, which will employ 115 
          people.<wbr></DIV></TD>
</TR>
</TBODY>
</TABLE></TD>
</TR>
<TR><TD>
      <TABLE width="100%"><TBODY><TR align="left"><TD valign="top">
            <DIV class="article_body">The European distribution center will 
            centralize the activities of 15 logistics centers, enabling 
            medicines from the different European production sites to be shipped 
            directly to a single, central distribution center.<wbr> From there, the 
            pharmaceutical medicines will be shipped to the Janssen companies in 
            11 European countries and to Johnson &amp; Johnson subsidiaries 
            throughout the world.<wbr> <BR><BR>Tom Heyman, CEO of Janssen, said, “The 
            European distribution center in La Louvière will enable us to more 
            efficiently deliver medicines that respond to the real needs of 
            patients.<wbr> Thanks to the new structure, some of the logistical burden 
            and administrative costs that hospitals are faced with will also 
            disappear.<wbr> In addition, the management team of the three 
            distribution centers in Belgium (Beerse, Courcelles and La Louvière) 
            will be centralized.<wbr> The relative proximity of these three European 
            distribution centers makes it possible to use synergies to the 
            maximum extent, and to exchange best practices and know how.<wbr>” 
            <BR><BR>The inauguration of the new center strengthens Janssen’s 
            integration between Wallonia and Belgium.<wbr> La Louvière’s central 
            position in Europe, at the intersection of a number of major 
            highways and close to the airport of Charleroi, was an important 
            factor in choosing the location for this new hub.<wbr> The well-developed 
            infrastructure also played an important role.<wbr> <BR><BR>Jean-Claude 
            Marcourt, Walloon vice president and minister of economy and foreign 
            trade, said that the group’s new European distribution center – 
            which is dedicated to the distribution of pharmaceutical products – 
            not only confirms that Wallonia is the perfect location when it 
            comes to logistical activities with major added-value, but also the 
            quality and productivity of the local workforce.<wbr> In time, this 
            center will become an important partner for the Walloon 
            'bio-logistics' chain.<wbr> <BR><BR>Janssen's top management confirmed, 
            “We aim to continue our investments in Belgium.<wbr> In recent years, 
            Belgium has made considerable efforts to create an attractive 
            investment climate for the pharmaceutical industry, which is, 
            incidentally, one of the strongholds of the Belgian economy.<wbr> We have 
            therefore quite deliberately continued to invest in Belgium, because 
            we are able to compensate the high payroll costs with sound 
            scientific knowledge and a stimulating tax climate here.<wbr>” 
            <BR><BR>The new distribution center was built on a 70,000m2 site.<wbr> 
            The building itself has a surface area of 21,500m2.<wbr> 385,000 orders 
            will be process annually around 160 million pharmaceutical 
            packs of medicine.<wbr> </DIV>
            
            <DIV class="article_body">The environment was also an important factor 
            in the implementation of the new center.<wbr> This is why local, regional 
            and renewable materials were used during the construction phase, 
            with only wood from sustainable logging being used.<wbr> Moreover, 
            efficient insulation systems have been installed in order to ensure 
            that the buildings are as energy-friendly as possible, and the 
            installation of solar panels is scheduled for 2013, Janssen 
            reported.<wbr></DIV>
            
            <DIV class="article_body">Source: 
      <a href="http://www.janssen.com" class="defaultlink" title="www.janssen.com">janssen.com</a></DIV></TD>
</TR>
</TBODY>
</TABLE>
      <TABLE width="100%"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10096">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-05T18:31:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-05T18:31:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Potential New Therapy For The Treatment Of GIST</title>
	<pubDate>2012-10-05T18:19:23+02:00</pubDate>
	<wp:post_id>3848</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: AB Science has reported that the EMA 
has accepted for review an MAA for masitinib to treat Gleevec-resistant 
gastrointestinal stromal tumors (GIST) based on phase II data.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Key 
Data Supporting The Registration </STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
MAA is based on data from a Phase II trial showing that second-line treatment 
with masitinib significantly improved median overall survival (OS) 
vs.<wbr></SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> sunitinib at a median follow-up of 14 
months in GIST patients whose disease progressed following treatment with Gleevec</SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> (imatinib Novartis).<wbr> Sutent is 
currently considered to be the 2nd line standard of care for GIST 
patients.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">In 
the study 44 patients with inoperable, locally advanced or metastatic GIST and 
showing disease progress while treated with Gleevec 400-800mg/<wbr>day received 
either mastinib (23 pts) at 12mg.<wbr>kg.<wbr>day or sunitinib (21 pts )at 50mg/<wbr>day until 
progression.<wbr> After a medain follow-up of 17 months , the median overall survival 
was not reached masitinib versus 16 months for sunitinib HR0.<wbr>27 implying a 73% 
reduction in mortality.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
OS rate estimates at 6, 12 and 18 months were respectively 95.<wbr>7%, 81.<wbr>9% and 
81.<wbr>9% in masitnib treated patients versus 76.<wbr>2%, 57.<wbr>1% and 42.<wbr>3% in sunitinib 
treated patients.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Masatinib 
was well tolerated with 17% of patients reporting non-hematological Grade 3 AEs 
as compared to 62% in the sunitinib arm.<wbr> No patients receigin masitinib reported 
any related serious advers events compared with 19% in the sunitinib 
arm.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>The 
GIST Market</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">GIST 
is a type of cancer that develops in the cells of the body's connective or 
supportive tissues.<wbr> It arises within the GI Tract.<wbr> Approx 5-6000 patients are 
diagnosed with GIST each year in the US and in 2010 the global GIST market was 
valued at $920m.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Masatinib</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div><P align="left"></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8510">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-05T18:19:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-05T18:19:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GP Pharm's Lutrate 1M Launched in Spain</title>
	<pubDate>2012-10-05T16:07:16+02:00</pubDate>
	<wp:post_id>3849</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to E.<wbr> Minguell we have learnt that <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_177_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The product is registered/<wbr>authorised in the Member States of the EEA under the following names: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_177_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_177_3_ScreenCapture3.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="DKPHybrids182c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">comment from<SPAN style="text-decoration: underline;"><STRONG> bruno tissier</STRONG></SPAN> /<wbr> some more info about GP Pharm and the other Lutrate depot formulations (3 &amp; 6 months) </div><div style="margin-bottom: 10px;">from :<A href="http://www.biocat.cat/en/news/gp-pharm-receives-authorization-lutrate-depot%C2%AE-1-month-europe-treatment-advanced-prostate-cancer">http:/<wbr>/<wbr>www.<wbr>biocat.<wbr>cat/<wbr>en/<wbr>news/<wbr>gp-pharm-receives-authorization-lutrate-depot%C2%AE-1-month-europe-treatment-advanced-prostate-cancer</A> </div><div style="margin-bottom: 10px;">Approval of Lutrate Depot &reg; 1 month is the culmination of the <STRONG>first drug developed entirely by GP Pharm</STRONG>, from the initial stages of drug research through to its launch to the pharmaceutical market, making it one of the few Spanish biotechnology firms to launch its own product.<wbr> &ldquo;With this product, we are validating our business model and consolidating our growth potential in a market that represents more than &euro;1,000 millions worldwide,&rdquo; explains Alberto Bueno, CEO of GP Pharm.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE>
<P>This Catalan biotech <STRONG>firm has already initiated Phase III clinical trials on Lutrate Depot &reg; 3 month in the United States.<wbr></STRONG></P>
</BLOCKQUOTE> </div><div style="margin-bottom: 10px;">GP Pharm&rsquo;s new drug<STRONG> is also available in three- and six-month formulas.<wbr></STRONG> Lutrate Depot &reg; 3 month, which allows for a single dose once every three months, is currently undergoing Phase III clinical trials in the United States.<wbr> This is a multicenter study designed to evaluate the efficacy and safety of this new formula, with 160 prostate-cancer patients from 33 specialized care centers in the United States, who will be treated over six months.<wbr> Furthermore, <STRONG>the new Lutrate Depot &reg; 6 month is in the pre-clinical phase and is expected to move into clinical trials in early 2012.<wbr></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2000, this Catalan biopharmaceutical company has a high-tech manufacturing plant in Sant Quint&iacute; de Mediona, 60 kilometers from Barcelona.<wbr> The plant develops and manufactures the company&rsquo;s own products for international consumption.<wbr> It is the only plant for oncological injectables in Spain, and the only one in Europe to produce injectable liposomal forms to treat different types of cancer and that is able to produce microspheres in sterile conditions.<wbr> </div><div style="margin-bottom: 10px;">---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- </div><div style="margin-bottom: 10px;">all reconstitution manipulations could be seen at (in spanish) : </div><div style="margin-bottom: 10px;"><A href="http://eurekasalud.es/prospecto-lutrate+depot+polvo+y+disolv.+para+sol.+iny.3,75+mg-74980">http:/<wbr>/<wbr>eurekasalud.<wbr>es/<wbr>prospecto-lutrate+depot+polvo+y+disolv.<wbr>+para+sol.<wbr>+iny.<wbr>3,75+mg-74980</A> </div><div style="margin-bottom: 10px;">--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- </div><div style="margin-bottom: 10px;">some differences with IPSEN DKP : </div><div style="margin-bottom: 10px;">1) aseptic manufacturing ( =&gt; higher costs of manufacturing) </div><div style="margin-bottom: 10px;">2) use of the Medimop/<wbr>Mixjet device to make extemporaneous suspension .<wbr> This device was appraised by PMT Onco in 2009 and not retained .<wbr> </div><div style="margin-bottom: 10px;">3) storage conditions +2 to +8&deg;C </div><div>4)injection IM with G20 needle ( 0.<wbr>9mm diameter) </div></div><a name="DKPHybrids193c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Esther Minguell recently reported that the effective launching of the Spanish Lutrate 1M has been delayed due to a double price confusion that is to be clarified by the MoH in the coming days.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In July, Lutrate 1M was given the same price than Procrin Depot 3,75mg in Spain (EFP 107,09€, published in July 2012).<wbr> </div><div style="margin-bottom: 10px;">However, in September the EFP was modified to 85,50€ (a discount of 20%), and published in the September nomenclator.<wbr> </div><div style="margin-bottom: 10px;">Back in October, the price has returned to the initial approved price as of July.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Now the drug is still retained until clarification of an 'official price'.<wbr> </div></div><a name="dkphybrids177attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_177_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_177_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(117,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_177_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(71,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20121231&edate=20120901&rec=177">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-05T16:07:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-05T16:07:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Canadian Provinces Fund Jevtana</title>
	<pubDate>2012-10-05T14:41:46+02:00</pubDate>
	<wp:post_id>3850</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On Oct.<wbr> 4th, Sanofi announced that Alberta, Ontario and Saskatchewan have reached positive reimbursement decisions for Jevtana (cabazitaxel).<wbr> The drug becomes available to patients with second-line castration-resistant metastatic prostate cancer in combination with prednisone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Clearly, as the largest and most influential province, the approval in Ontario represents the most critical outcome here for Sanofi, and it follows Jevtana's initial submission in July 2011.<wbr> </div><div style="margin-bottom: 10px;">The drug will be available on the New Drug Funding Program (NDFP) where costs are split between that programme and hospitals.<wbr> Jevtana has so far had a mixed history on reimbursement, with significant clinical benefit offset by high costs in the eyes of many payors.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8508">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-05T14:41:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-05T14:41:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Findings from the First Head-to-Head Comparison of Allergan's Botox and Anti-cholinergic Drugs</title>
	<pubDate>2012-10-05T14:30:50+02:00</pubDate>
	<wp:post_id>3851</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to research led by a Duke Medicine scientist and funded by the HIH, a one-time Botox injection in the bladder worked as well as daily pills for reducing episodes of urinary incontinence (UI) in women with moderate to severe bladder incontinence.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: 250 women with moderate to severe bladder incontinence, averaging 5 bladder leakage episodes a day.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Locations</STRONG>: 10 medical centers across the US </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG>: One group received Botox injections in the bladder muscle along with 6 months of placebo pills.<wbr> The other group received 6 months of anticholinergic medications and a bladder injection of harmless saline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">At the end of the active treatment phase, 70% of women reported adequate symptom control; women in both groups reporting an average of 3 fewer leakage episodes a day.<wbr> Within 1 month after discontinuation of the oral regimen, significantly fewer women assigned to the pill therapy reported adequate symptom control compared to the injection group – 50% vs.<wbr> 62%.<wbr> </div><div style="margin-bottom: 10px;">At 12 months, 25% of the anticholinergic group and 38% of the Botox group reported continued adequate control.<wbr> </div><div style="margin-bottom: 10px;">Women in the injection group were also twice as likely as those taking daily pills to report complete resolution of the problem - 27% vs.<wbr> 13%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Side effects</STRONG>: The pills caused dry mouth more frequently, and Botox injections resulted in more catheterizations and urinary tract infections.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The findings were published in the Oct.<wbr> 4, 2012, issue of the <EM>New England Journal of Medicine</EM> and presented at the annual meeting of the American Urogynecologic Society.<wbr> </div><div style="margin-bottom: 10px;">Full text is available via an Ipsen subscription at : <A href="http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208872">http:/<wbr>/<wbr>www.<wbr>nejm.<wbr>org/<wbr>doi/<wbr>pdf/<wbr>10.<wbr>1056/<wbr>NEJMoa1208872</A> </div><div>Source: <A href="http://www.dukehealth.org/health_library/news/botox-and-pills-for-overactive-bladder-show-similar-effect">http:/<wbr>/<wbr>www.<wbr>dukehealth.<wbr>org/<wbr>health_library/<wbr>news/<wbr>botox-and-pills-for-overactive-bladder-show-similar-effect</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6592">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-05T14:30:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-05T14:30:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Regulus Raised $45M in IPO</title>
	<pubDate>2012-10-05T11:45:31+02:00</pubDate>
	<wp:post_id>3852</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The $45M were raised through the sale of 11.<wbr>3 million shares at $4.<wbr> The company also raised $25M through the sale of 6.<wbr>3 million shares at the same price to AstraZeneca (development partner of miR-33).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Regulus is currently optimizing anti-miRs in 5 distinct programs, both independently and with AstraZeneca, GlaxoSmithKline and Sanofi (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10011" class="defaultlink">PharmaWorld10011: Leading MicroRNA Company Finalizes Two Deals</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Onco Program</STRONG> </div><div style="margin-bottom: 10px;">Regulus’ lead program in oncology targets microRNA-21 (miR-21).<wbr> Numerous scientific publications suggest that miR-21 plays an important role in the initiation and progression of cancers including liver, kidney, breast, prostate, lung and brain.<wbr> </div><div style="margin-bottom: 10px;">Regulus is developing oncology anti-miRs targeting miR-21 for hepatocellular carcinoma (HCC) because analysis of liver biopsies from HCC patients has shown that miR-21 is up-regulated approximately three-fold in tumors relative to surrounding normal liver tissues.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10094_1_ScreenCapture1.jpg"> </div><div>Source: Biocentury; Regulus </div><!-- Comment details --><a name="pharmaworld10094attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10094_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10094">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-05T11:45:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-05T11:45:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aragon Raise $50M</title>
	<pubDate>2012-10-04T18:49:55+02:00</pubDate>
	<wp:post_id>3853</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has secured $50M of Series D through the venBio Fund to advance its pipeline of therapies targeting hormone-driven cancers, including ARN-509 (in Ph2 for CRPC).<wbr> The financing brings the total capital raised in 2012 to $88M.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ARN-509 is currently in the Phase II portion of a Phase I/<wbr>II clinical trial being conducted at Memorial Sloan-Kettering Cancer Center in New York as well as 15 other institutions across the US.<wbr> </div><div style="margin-bottom: 10px;">The open-label, study will determine the anti-tumor activity, safety and tolerability in patients with advanced castration-resistant prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>venBio is the world's largest independent, strategically oriented, life sciences investment firm.<wbr> It was established with a vision of creating a new model for life sciences investing with the belief that integrating all life sciences stake-holders is critical to success.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8501">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-04T18:49:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-04T18:49:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sarepta Drug Continues To Show Benefit in Duchenne's Muscular Dystrophy</title>
	<pubDate>2012-10-04T09:47:50+02:00</pubDate>
	<wp:post_id>3854</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Comment: Sarepta's updated data from its PhIIb study with eteplirsen in Duchenne muscular dystrophy was well received by the market with the stock increasing $29.<wbr>94 (200%) to $44.<wbr>93.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>The New Data</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Sarepta reported open-label extension data from its Phase IIb trial, demonstrating that high-dose eteplirsen for 48 weeks led to significantly better clinical outcomes at week 48 compared to placebo for 24 weeks followed by low- or high-dose eteplirsen for an additional 24 weeks.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The four patients in the high-dose arm had a 21 m increase in six-minute walk test (6MWT) from baseline to week 48 compared to a 68.<wbr>4 m reduction for the four patients in the placebo/<wbr>delayed eteplirsen group (p=0.<wbr>016).<wbr> The low-dose did not lead to a significant difference in 6MWT.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Both 48-week arms of eteplirsen and the placebo/<wbr>delayed eteplirsen arm also led to significant mean increases in dystrophin-positive muscle fibers from baseline to week 48.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Eteplirsen is a phosphorodiamidate morpholino oligomer (PMO) targeting exon 51.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>Next Steps</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Sarepta plans to request an end-of-Phase IIb meeting with FDA by year end or early 2013 to discuss the design of a confirmatory trial.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>Sarepta's Financial Position</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Sarepta's stock has registered significant gains over the course of the year as the company has reported updated data such thatn now Sarepta's market cap is now $1 billion, up from a valuation of $78.<wbr>3 million on July 23, before the initial data were reported.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>Competitive Positioning</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">There are three drugs currently in phIII development for Duchenne Muscular Dystrophy, GSK,s drispersen, PTC Therapeutics ataluren and Takeda's idebenone.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Genzyme walked away from the PTC Therapeutics programme after spending $100m when atalulren failed a phII trial demonstrating no improvement in walking distance in Duchenne patients.<wbr> Since then PTC has reported more positive data with the drug and has recently initiated a phIII development programme in patients with the nonsense mutation for Duchenne.<wbr> The study which has a US and ex US arm will evaluate lung function in 208 patients with the disease.<wbr> The regional goups should complete in Oct 2012 and May 2013 respectively.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Meanwhile, GSK announced in August that it had completed recruitment in its pivotal phIII trial and expects to complete the trial in July 2013 with results communicated late 2013.<wbr> Takeda's phIII study with idebenone will similarly complete in late 2013.<wbr></SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">source:www.<wbr>saretpa.<wbr>com</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6590">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-04T09:47:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-04T09:47:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Nordisk to Add Staff in Emerging Markets</title>
	<pubDate>2012-10-04T09:18:18+02:00</pubDate>
	<wp:post_id>3855</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jesper Hoiland, head of international operations, has reported to Bloomberg that the company is "rapidly" hiring people in countries where it is targeting expansion, including Colombia, Egypt, Ukraine, Malaysia, Indonesia and Vietnam, which he suggested is "going to be a new mini-China".<wbr> </div><div style="margin-bottom: 10px;">Novo Nordisk plans to hire approx.<wbr> 1000 people over the next 2 years as it looks to maintain growth in emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>To expand its reach in these countries, Novo Nordisk trains doctors to teach their peers locally.<wbr> The company has created mobile clinics that travel to remote areas to screen people for diabetes and help them access treatment.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10093">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-04T09:18:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-04T09:18:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Patent Granted to PROLOR's hGH-CTP</title>
	<pubDate>2012-10-03T15:06:00+02:00</pubDate>
	<wp:post_id>3856</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has received a notice of allowance from the USPTO for a new patent application covering its long-acting CTP-enhanced hGH.<wbr> This new U.<wbr>S.<wbr> patent is expected to issue in the next few months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This new patent is expected to provide additional protection for PROLOR's hGH-CTP compound, in addition to a number of CTP platform patents that have already issued.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Ph3 in adults with growth hormone deficiency (AGHF) and a Ph2 in growth hormone deficient children (PGHD) are planned for 2012.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7108">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-03T15:06:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-03T15:06:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph1 Study of Aeterna Zentaris' AEZS-120 is planned in 4Q 2012</title>
	<pubDate>2012-10-02T14:18:50+02:00</pubDate>
	<wp:post_id>3857</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Preclinical data of the oral prostate cancer vaccine candidate were presented over the weekend at the 32nd Congress of the Société Internationale d'Urologie, which is being held in Fukuoka(Japan).<wbr> The poster presentation underlined the feasibility of an oral therapeutic vaccination approach against prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Safety pharmacology and toxicology data suggest that the profile of AEZS 120 is similar to the approved carrier strain S.<wbr> typhi Ty21a, which has already been safely applied in &gt; 250 million doses.<wbr> </div><div style="margin-bottom: 10px;">Source: <I>"Preclinical Proof of Concept and Characterization of AEZS-120, a Therapeutic Oral Prostate Cancer Vaccine Candidate Based on Live Recombinant Attenuated Salmonella</I>", J.<wbr> Fensterle, B.<wbr> Bergmann, P.<wbr> Schmidt, M.<wbr> Teifel, J.<wbr> Engel, T.<wbr> Rudel, W.<wbr> Goebel, and U.<wbr> Rapp.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8498_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8498attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8498_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(126,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8498">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-02T14:18:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-02T14:18:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Coelho Promoted to VP Commercial Excellence at Merz Inc.</title>
	<pubDate>2012-10-02T13:52:04+02:00</pubDate>
	<wp:post_id>3858</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In her new role, Hyunnah Cohelo will lead the harmonization of several critical functions, such as sales operations, market research, competitive intelligence, forecasting, and operational analytics for the company.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Jan.<wbr> 2010</STRONG> - Joined Merz Aesthetics as Area Business Director, East </div><div style="margin-bottom: 10px;"><STRONG>Nov.<wbr> 2009</STRONG> - Joined Merz as National Sales Director, Aesthetics </div><div style="margin-bottom: 10px;">Prior to joining Merz, she was Eastern Business Unit Director at OraPharma (a division of J&amp;J) for &gt; 8 years.<wbr> </div><div>Coelho obtained her Bachelor of Science from U.<wbr> of South Carolina in Columbia, SC.<wbr> She also earned her Master of Business Administration with a concentration in Pharmaceutical Marketing from St Joseph's U.<wbr> in Philadelphia, PA.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6585">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-02T13:52:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-02T13:52:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanochemia Outlicenses Tolperisone For US Market</title>
	<pubDate>2012-10-02T11:42:52+02:00</pubDate>
	<wp:post_id>3859</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sanochemia has announced today an agreement with US company Katama Pharmaceuticals covering the US &amp; MexICan development and commercialisation of tolperisone for the treatment of painful muscle spasms and spasticity.<wbr> A pivotal registration trial will be paid for by a group of venture investors with a view to commercialisation of the product in 3 to 4 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">San Diego based Katama Pharmaceuticals is a young innovative company specialising in the development of products to treat pain disorders.<wbr> It is headed by Jeff Raser, an entrepeneur who is on the board of a few companies (and is adding Sanochemia to his bow) including OrthoPro (Cystic Fibrosis company).<wbr> He is supposedly the Sr.<wbr> Vice President Sales and Marketing at Somaxon Pharmaceuticals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Tolperisone is registerd and marketed in certain European markets for the treatment of neuromuscular spasms, most notably Germany and Switzerland where it has been marketed by Orion since 2007.<wbr> It is available as an oral immediate and controlled release formulation and is a centrally acting non-sedating muscle relaxant.<wbr> Toleprisone will be regarded as an NCE in terms of the US market and thus if approved will be able to gain market exclusivity through data protection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The license agreement provides for milestone payments tied to development and distribution objectives, as well as revenue-dependent royalities.<wbr> Sanochemia will also own a 9% share of Katama and manufacture the product for the duration of the contract with KATAMA.<wbr> </div><div style="margin-bottom: 10px;">The agreement with KATAMA is viewed as an important milestone for Sanochemia and the first cooperation in the course of the development and marketing of Tolperisone for the US market.<wbr> </div><div>Source:www.<wbr>sanochemia.<wbr>de </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6584">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-02T11:42:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-02T11:42:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Merz Injunction in the US</title>
	<pubDate>2012-10-02T09:07:54+02:00</pubDate>
	<wp:post_id>3860</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a PR published yesterday on its website, Allergan reported that the Court injunction on Xeomin, in facial aesthetics market, remains in place until January 9, 2013.<wbr> </div><div style="margin-bottom: 10px;">U.<wbr>S District Judge A.<wbr> J.<wbr> Guilford also entered an order providing that the terms of the injunction that restrict Merz Aesthetics' ability to sell and solicit purchases of its dermal fillers, as well as the terms that restrict Merz Pharmaceuticals' ability to sell and solicit purchases of Xeomin in the therapeutic market shall remain in place until November 1, 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The order follows the court’s ruling in March 2012 issuing a permanent injunction against Merz, concluding the company misappropriated important trade secrets belonging to Allergan regarding its products BOTOX<SUP>®</SUP> Cosmetic, BOTOX<SUP>®</SUP> and JUVÉDERM<SUP>®</SUP>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6298" class="defaultlink">Neurology6298: Merz Clarifies Its Position In The US Market Post Recent Court Ruling</a> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6283" class="defaultlink">Neurology6283: U.<wbr>S Federal Court Finds in Favor of Allergan vs Merz</a> </div><div>Source: Allergan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6583">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-02T09:07:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-02T09:07:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Ferring to Assess Degarelix in a New Phase 3</title>
	<pubDate>2012-10-02T08:41:21+02:00</pubDate>
	<wp:post_id>3861</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Ferring to Assess Degarelix in a New Phase 3</span>&nbsp;<br><span style="font-size: 12px;">Comment: This study will assess the safety and efficacy of Degarelix given intermittently vs continuous androgen deprivation therapy with Lupron or Degarelix in patients with prostate cancer with prior treatment failure after localized treatment.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=5434">...</a><br></div><div style="margin-bottom: 10px;">This Ph3b completed in September 2012 (18 months later than previously planned).<wbr> Regarding the locations, 59 sites were involved instead of the 65 projected.<wbr> </div><div style="margin-bottom: 10px;">Other endpoints to be assessed is Qol in intermittent and continuous treatment.<wbr> </div><div>Source: TrialTrove </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8497">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology5434">View thread  Oncology5434: Ferring to Assess Degarelix in a New Phase 3</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-02T08:41:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-02T08:41:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study - Negative Results for the IGF-1 Receptor Inhibitor MK-0646 Phase II Study in NETs</title>
	<pubDate>2012-10-01T17:22:56+02:00</pubDate>
	<wp:post_id>3862</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;">Comment : <SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">No partial or complete responses were observed in <SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">15 patients with carcinoid tumors and 10 patients with pancreatic NETs.<wbr></SPAN> The median progression-free survival was 4.<wbr>2 months in the pancreatic NET cohort (range, 0.<wbr>7-6.<wbr>7 months) and 2.<wbr>7 months in the carcinoid cohort (range, 2-3 months).<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Rationale :Preclinical studies suggest that SSA and mTOR inhibitors exhibit antitumor activity against NETs through inhibition of IGF-1-dependent signaling, suggesting that IGF-1R inhibition may be a promising therapeutic approach.<wbr> T</SPAN></SPAN></SPAN><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">he authors of this report evaluated the safety and efficacy of the insulin-like growth factor-1 receptor inhibitor MK-0646, a fully human monoclonal antibody (MoAb) that binds to the IGF-1R <SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;">in patients with metastatic, well-differentiated neuroendocrine tumors.<wbr></SPAN></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Treatment : <SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">25 patients received intravenous MK-0646 10 mg/<wbr>kg once weekly over 1 hour.<wbr></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="font-family: arial,helvetica,sans-serif; color: #000000;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">CONCLUSIONS: Despite a compelling preclinical rationale, MK-0646 was inactive as a single agent in well-differentiated NETs.<wbr> Further studies of MK-0646 as a monotherapy in unselected NETs are unwarranted.<wbr> </SPAN></SPAN></SPAN> </div><div><EM><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Reidy-Lagunes DL</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Vakiani E</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Segal MF</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Hollywood EM</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Tang LH</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Solit DB</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Pietanza MC</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Capanu M</SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> ; </SPAN><SPAN style="line-height: normal; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; font-family: arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Saltz LB</SPAN> A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.<wbr> Cancer 2012: 118(19): 4795-800 </EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7106">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-01T17:22:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-01T17:22:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</title>
	<pubDate>2012-10-01T17:17:43+02:00</pubDate>
	<wp:post_id>3863</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</span>&nbsp;<br><span style="font-size: 12px;">Comment: Methylene Blue MMX<SUP>®</SUP> (for the diagnosis of lesions, polyps and adenomas in the colon) will be presented to approx.<wbr> 500 specialists from around the world during the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano/<wbr>Italy.<wbr> The Methylene blue-MMX<SUP>®</SUP> tablet, currently assessed in Ph2, is an oral colon-release formulation in form of coated tablets, containing methylene blue.<wbr> The company expects market entry end 2013.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1800">...</a><br></div><div style="margin-bottom: 10px;">The company will start a Ph3 this month to evaluate in approx.<wbr> 1000 patients, the safety and efficacy of Methylene Blue MMX&reg; modified release tablets administered to subjects undergoing screening or surveillance colonoscopy.<wbr> Primary endpoint will assess proportion of patients with at least one histologically proven adenoma found during colonoscopy.<wbr> </div><div>Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01694966?no_unk=Y&fund=2&rcv_s=09%2F17%2F2012&rank=72" class="defaultlink">NCT01694966</a> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1859">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1800">View thread  GastroEnterology1800: Cosmo to Present its Methylene Blue MMX® for Colon Diagnosis</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-01T17:17:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-01T17:17:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer and Evotec in Endometriosis Deal</title>
	<pubDate>2012-10-01T14:08:33+02:00</pubDate>
	<wp:post_id>3864</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Evotec, a drug discovery alliance and development partnership company, and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing 3 clinical candidates for endometriosis.<wbr> Both companies will contribute innovative drug targets and high quality technology infrastructures and will share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in endometriosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Bayer will be responsible for any subsequent clinical development and commercialisation.<wbr> </div><div>Evotec will receive €12M as an upfront payment.<wbr> In total Evotec may receive pre-clinical, clinical and sales milestones of potentially up to approximately €580M, plus potential royalties of up to low double digit percent of net sales, depending on which party brought the compound to the collaboration and the successful development and approval of potential drug candidates.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8496">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-01T14:08:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-01T14:08:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aetna Expands Coverage for Provenge in the U.S</title>
	<pubDate>2012-10-01T10:36:36+02:00</pubDate>
	<wp:post_id>3865</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Health insurer Aetna will now provide coverage for patients with metastatic prostate cancer who have failed to respond to hormone therapy, and whose disease has spread to the lungs or the brain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Previously, patients whose cancer spread to the brain or lungs were not covered.<wbr> Patients whose disease has spread to the liver still are not covered.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>The vaccines generated just $213.<wbr>5M in 2011 (roughly half of what Dendreon had originally projected).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8495">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-10-01T10:36:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-10-01T10:36:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Patient In EU Study Begins Sipuleucel-T Infusion</title>
	<pubDate>2012-09-28T11:59:44+02:00</pubDate>
	<wp:post_id>3866</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The open-label study is being conducted in European men with mCRPC to describe product release parameters and report on safety in a EU population.<wbr> Additional details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 45 </div><div style="margin-bottom: 10px;">Locations: 4 sites </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>EU</STRONG> - Dendreon has submitted a MAA for sipuleucel-T which is currently under review by the EMA.<wbr> </div><div><STRONG>US</STRONG> - Sipuleucel-T is approved by the Food and Drug Administration (FDA) in the U.<wbr>S.<wbr> for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8492">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-28T11:59:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-28T11:59:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva Acquires NeuroSearch' Huntexil®</title>
	<pubDate>2012-09-28T11:22:08+02:00</pubDate>
	<wp:post_id>3867</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Under the Asset Transfer Agreement, Teva will pay to NeuroSearch approximately $26M over a period of at least 6 months.<wbr> Regulatory and commercialization milestone payments may result in additional funding for NeuroSearch.<wbr> According to analysts at Jyske Bank, the sales price and the structure of the deal reflects the NeuroSearchs rather weak barging power derived from the lack of financial flexibilit.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Espansion of Teva's CNS development pipeline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Teva intends to design and complete new clinical studies of Huntexil<B>®</B> to assess its potential for symptomatic relief of HD.<wbr> </div><div style="margin-bottom: 10px;">Advanced-stage clinical studies of Huntexil® conducted in the US, EU and Canada in patients with HD demonstrated a significant treatment effect on Total Motor Score [TMS]), but failed to meet the primary endpoint (Modified Total Motor score [mTMS]).<wbr> </div><div style="margin-bottom: 10px;">Data from the clinical studies were presented to the FDA and EMA in the first half of 2011, but were found insufficient to file for marketing approval.<wbr> </div><div>Sources: Teva; Thomson One </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6582">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-28T11:22:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-28T11:22:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PeptiDream and GSK to Discover and Develop Peptide Therapeutics</title>
	<pubDate>2012-09-28T10:20:19+02:00</pubDate>
	<wp:post_id>3868</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK has partnered with the Tokyo-based company to discover and develop peptide therapeutics using PeptiDream's Peptide Discovery Platform System (PDPS).<wbr> <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10089">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-28T10:20:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-28T10:20:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca AKT Inhibitor to Enter Ph1 for mCRPC</title>
	<pubDate>2012-09-27T18:25:13+02:00</pubDate>
	<wp:post_id>3869</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph1b of AZD5363 monotherapy will assess anti-tumour activity (primary endpoints), safety, tolerability and PK.<wbr> Approx.<wbr> 60 participants will be included.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01692262?no_unk=Y&amp;cond=BOTULINUM+OR+PROSTATE+OR+HAEMOPHILIA+OR+SPASTICITY+OR+HEMOPHILIA+OR+NEUROENDDOCRINE&amp;fund=2&amp;rcv_s=09%2F17%2F2012&amp;rank=3"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><DIV class="identifier">cODE/<wbr> NCT01692262</DIV> </div><div style="margin-bottom: 10px;">Start date: Oct.<wbr> 2012 /<wbr> Completion dates: May 2014 /<wbr> August 2014 </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> </div><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">AZD5363 will be investigated in patients who have progressed after chemotherapy (Part A) and in patients who have progressed before receiving chemotherapy (Part B).<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Part A, Group 1 patients (naive to 2nd generation anti-hormonal therapies) will receive AZD5363 480 mg bid intermittently (4 days on/<wbr>3days off).<wbr> Part A, Group 2 patients (progressed after 1 or more 2nd generation anti-hormonal therapies) will receive AZD5363 320 mg bid continuously as monotherapy.<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Part B will only start if there is evidence of anti-tumour activity along with AZD5363 having an acceptable safety profile in Part A.<wbr> Part B will be conducted in pre-chemotherapy patients on a dose and schedule selected from Part A.<wbr></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8491">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-27T18:25:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-27T18:25:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from ESPE (Part4) Considerations for Ending GH Treatment</title>
	<pubDate>2012-09-27T12:24:11+02:00</pubDate>
	<wp:post_id>3870</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novo Nordisk's Symposium was dedicated on factors influencing GH treatment outcome in short children.<wbr> This report will focus on Philippe Backeljauw's presentation, which outlined pathophysiological and management consideration for ending GH treament and in particular 'when not to stop therapy with GH'.<wbr> </div><div style="margin-bottom: 10px;">The decision to stop therapy with GH is jointly taken between patient and doctor, as well aseconomic factors such as insurance coverage.<wbr> However there is no strong consensus about how and when to discontinue GH therapy.<wbr> It generally depends on : </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">However, full maturation continues after completion of longitudinal growth : </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Data from 9 studies show the effect of severe GHD in young adults taken off GH for 8 years after reaching adult height (AH).<wbr> Of note, the increase in fat and LDL and the decrease in muscle mass and bone mineral density (BMD).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Major consequences induce the development of a syndrome of metabolic abnormalities and impaires QoL.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">Philippe Backeljauw highlighted that : </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">In conclusion, he reported that for patients with GHD, somatic development is not finished at adult height achievement.<wbr> During the post-pubertal transition phase, GH-deficient patients deserve re-evaluation of the GH/<wbr>IGF-I axis using evidence based guidelines.<wbr> </div><div style="margin-bottom: 10px;">Consensus statement on the management of the GH treated adolescent in the transition to adult care - <EM>Eur J Endocrinol</EM> 2005; 152:165-170 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_8_ScreenCapture8.jpg"> </div><div>However further research is needed to determine the appropriate timing of this evaluation, and when indicated, the best way to monitor the continuing GH treatment response, to allow for an optimized, individualized treatment approach.<wbr> </div><!-- Comment details --><a name="endocrinology7103attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(31,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(27,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(21,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(14,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(1,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(31,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7103_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(55,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7103">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-27T12:24:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-27T12:24:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MHRA Approves UK Usage of Botox For NDO</title>
	<pubDate>2012-09-27T11:59:18+02:00</pubDate>
	<wp:post_id>3871</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has announced the approval of Botox in the UK for the 
treatment of neurogenic detrusor overactivity due to spinal cord injury or 
multiples sclerosis in patients inadequately managed with anticholinergics.<wbr> </div><div style="margin-bottom: 10px;">In its press release, Allergan notes that approx 140,000 people in the UK are 
living with MS or SCI and that between 75-80% of the MS patientat and 60-80% of 
the SCI sufferers will experience some degree of bladder dysfunction.<wbr> </div><div style="margin-bottom: 10px;">Highlighted alongside the announcement, are the resutls of the PhIII Dignity 
programme which eveluated usage of Botox in nearly 7000 pts.<wbr> The trial found 
that 76% of patients treated with the toxin had statistically significant 
reduction in urinary wetting episodes by week 6, with nearly 40% of the patients 
treated with 200 units dry by week 6 compared to only 9% of placebo 
patients.<wbr> </div><div style="margin-bottom: 10px;">The NDO indication is already approved and commercialised in many countries, 
with the UK one of the few outstanding approvals Allergan has been waiting 
for.<wbr> </div><div>Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6580">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-27T11:59:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-27T11:59:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from ESPE (Part3) - Long-Term Safety of GH Treatment in Children</title>
	<pubDate>2012-09-26T16:22:28+02:00</pubDate>
	<wp:post_id>3872</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Susan Scott's coverage of strategic sessions on the long-term safety of GH treatment, we have an up-to-date overview of the latest presentations and comments on this sensitive topic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> </DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7100_1_ScreenCapture1.jpg"></DIV> </div><!-- Comment details --><a name="endocrinology7100attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7100_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7100">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-26T16:22:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-26T16:22:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence From The 15th ENEA Meeting in Vienna - Key Pasireotide Extension Data</title>
	<pubDate>2012-09-25T16:43:27+02:00</pubDate>
	<wp:post_id>3873</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Dr Dowling's coverage of the ENEA meeting we have an up-to-date account of Novartis's positioning of pasireotide for acromegaly and Cushing's disease and some interesting scientific data on Novartis's experimental approaches to NFPA.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><A href="http://novartis.medicalcongressposters.com/Default.aspx?doc=fb209"></A> </SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><STRONG></STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>OC05</STRONG>: “Long term use of pasireotide results in sustained reductions in UFC and continued improvements in signs and symptoms in patients with Cushing’s disease, presented by R.<wbr> Pivonello, Italy.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l2 level1 lfo1">Methods: 162 patients with persistent/<wbr>recurrent or <I style="mso-bidi-font-style: normal">de novo</I> Cushing’s disease and UFC ≥1.<wbr>5 x ULN received pasireotide 600µg or 900µg sc bid.<wbr> Patients with UFC ≤ ULN or achieving clinical benefit at month 12 were eligible for the extension.<wbr></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l2 level1 lfo1">Results: 58 patients entered the extension study.<wbr> Among patients who completed the 24 month therapy (n=39), mean percentage change in UFC from baseline to month 24 was -62.<wbr>7%.<wbr> At month 24, 20/<wbr>58 (34.<wbr>5%) patients had UFC ≤ ULN.<wbr> Similarly plasma ACTH and serum cortisol decreased from baseline to month 12 and were maintained to month 24.<wbr> No new patients experienced hyperglycemia AEs between 12 and 24 months.<wbr> </LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l2 level1 lfo1">Conclusion: 24-month pasireotide treatment resulted in sustained reductions in UFC, plasma ACTH and serum cortisol and improvements in signs and symptoms and these results further support the long term used of pasireotide for the treatment of Cushing’s disease.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>OC06</STRONG>: “Clinical and Patient reported outcomes associated with Pasireotide in patients with Cushing’s disease, presented by X.<wbr> Badia, Spain.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2">Results: At 6 months, 37% of patients normalised UFC, 80% of patients had a reduction in diastolic BP ≥ 5 mmHg (58%), decrease in weight ≥ 7% (42%) or had improvement ≥ MID on CushingQoL (46%) (mean SD 11.<wbr>1 ± 15.<wbr>2) Improvements in symptoms and HRQoL were maintained at 12 months.<wbr></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2">Conclusion: Pasireotide leads to meaningful improvements in HRQoL in patients with CD.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo3">Treatment for acromaegaly in 2012 and beyond was shared and presented by Annamaria Colao (Italy) and Monica Gadelha (Brazil)</LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo3">A year in Cushing’s disease: New treatment options was shared and presented by Andre Lacroix (Canada) and Antoine Tabarin (France)</LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></P> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></B> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></B> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></P> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></P> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></B> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></B> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></B> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></B> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></P> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></P> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>AMORE Study </STRONG>- (Aggressive Pituitary tumours- a multi center Observational Retrospective study of ENEA) was updated by Annamaria Colao, Italy.<wbr> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>MISSION Study </STRONG>- retrospective observational study in Cushing’s disease was updated and presented by Rosario Pivonello, Italy.<wbr> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></P> </div><div style="margin-bottom: 10px;"><STRONG>S11</STRONG>: Mechanism of Apoptosis Resistance in Pituitary Adenomas, presented by M C Zatelli, Italy </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>S12</STRONG>: Pituitary Stem cells during tissue (re-) modelling, presented by H Vankelecom, Belgium </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l1 level1 lfo2"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><STRONG>S14</STRONG>: Vasopressin receptors in corticotropinomas: Is there a diagnostic/<wbr>therapeutic role? A translational approach, presented by J Castano, Spain</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
<LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level1 lfo1"><SPAN style="FONT-FAMILY: 'Arial Narrow','sans-serif'"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial Narrow','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"></SPAN> </div><div> </div><!-- Comment details --><a name="endocrinology7097attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(42,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(49 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(42 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(23,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(23 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(27,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(29,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(19,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(29,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(24,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(22 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(24,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(34,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(24 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(26,2 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(37,3 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(33,3 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(30,7 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(40,6 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(31,5 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(34,2 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(44,5 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(38,5 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(32,7 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_29_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(35,1 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_30_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(31,6 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7097_31_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(43,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7097">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-25T16:43:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-25T16:43:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from ESPE (Part2) - Cushing Syndrome/Disease in Children</title>
	<pubDate>2012-09-25T15:26:34+02:00</pubDate>
	<wp:post_id>3874</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: An update on the molecular pathogenesis and new avenues in the management were reported in a unique session dedicated to the indication.<wbr> Pediatric Cushing Syndrome is a very rare clinical problem, which is associated with significant morbidity (growth failure; osteopenia; arrested puberty; obesity; fatty liver; depression) and represents diagnosis and therapeutic challenges.<wbr> </div><div style="margin-bottom: 10px;">The session was moderated by <STRONG>Helmuth Dörr</STRONG> (Germany) and <STRONG>George Chrousos</STRONG> (Greece).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Constantine Stratakis</STRONG> introduced the recent advances in the genetics of the various forms of Cushing Syndrome and presented the genetic defects causing the syndrome.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7095_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">When it comes to clinical evaluation of the patients with suspected Cushing Synrome<STRONG>, Helen Storr</STRONG> highlighted that in approx.<wbr> 75-80% of ped.<wbr> cases, the disorder is secondary to an ACTH-secreting pituitary adenoma.<wbr> Most children and adolescents have a typical cushingoid appearance.<wbr> Almost all CD patients have weight gain, evidence of growth failure and short stature.<wbr> </div><div style="margin-bottom: 10px;">She concluded by saying that a diagnostic protocol for investigation is required which broadly follows the model for adults (series of tests, aetiology of CD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ashley Grossman</STRONG> presented the recent therapeutic advances for Cushing Syndrome in children.<wbr> In cases of adrenal adenoma or carcinoma thee need to be surgically removed.<wbr> </div><div style="margin-bottom: 10px;">For Cushing disease, the initial treatment of choice is transsphenoidal surgery (25% failure rate).<wbr> Few data exists with radiosurgery, which does not allow to see the tumour.<wbr> Radiotherapy is often very effective.<wbr> </div><div style="margin-bottom: 10px;">When it comes to medical therapy, Dr Grossman outlined: </div><div style="margin-bottom: 10px;"><UL><LI>1st choice: Metyrapone used for 20 years has a rapid onset of action and is effective in the short-term.<wbr></LI>
<LI>2nde choice: Ketoconazole has a slow onset of action (rare hepatotoxicity)</LI>
<LI>Metyrapone and Ketoconazole may be used in combo.<wbr></LI>
<LI>IV etomidate has an immediate effect as being life saving where parenteral therapy is essential.<wbr></LI>
</UL> </div><div>He added that mifepristone may also have its place.<wbr> Pasireotide has shown to normalise cortisol levels in adult patients, although the induction of hypoglycemia is of some concerns, and is unlikely to be licensed for use in children.<wbr> </div><!-- Comment details --><a name="endocrinology7095attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7095_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(43,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7095">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-25T15:26:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-25T15:26:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck Serono Updated Restructuring Strategy at Bernstein Conference in London</title>
	<pubDate>2012-09-25T12:33:03+02:00</pubDate>
	<wp:post_id>3875</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last week, Dr Stefan Oschmann (Head of Pharmaceuticals) updated on the company's transformation process (2012-2018).<wbr> In the near term (2012-2013), management expects stable revenue, attractive double-digit growth by emerging markets, and solid performance from Endocrinology and Fertility franchises.<wbr> By 2014, €300M net cost savings will come from R&amp;D and commercial operations (€180M).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported that the lack of patent cliff provides resiliency to revenue streams.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_6_ScreenCapture6.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="pharmaworld10084attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(39 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(63,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(51,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(100,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(60,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10084_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(43,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10084">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-25T12:33:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-25T12:33:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mallinckrodt to Acquire CNS Therapeutics for $100M</title>
	<pubDate>2012-09-25T09:26:23+02:00</pubDate>
	<wp:post_id>3876</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: CNS Therapeutics currently markets Gablofen, for severe spastivcity, and has a diverse pipeline of pain and spasticity products in development.<wbr> Mallinckrodt, the pharma business of Covidien, is the largest U.<wbr>S.<wbr> supplier of opioid pain medications and among the top 10 generic pharmaceuticals manufacturers in the U.<wbr>S.<wbr>, based on prescriptions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Covidien said the deal will complement its portfolio of CNS pain and managmeent products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Covidien announced last December that the Company planned to spin off <ORG>Mallinckrodt</ORG> into a stand-alone company, a process that is expected to be completed in mid-2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In November 2010, the FDA approved the drug for severe spasticity, a movement disorder affecting more than 500,000 patients in the U.<wbr>S.<wbr> alone.<wbr> It is often brought on by multiple sclerosis, cerebral palsy, spinal cord injury, brain trauma and stroke.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.gablofen.com/product-info.php">http:/<wbr>/<wbr>www.<wbr>gablofen.<wbr>com/<wbr>product-info.<wbr>php</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6577_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Gablofen is easy to administer with ready-to-use vials and pre-filled syringes offering clear advantages over glass ampules including a reduction in both refill preparation time and the risk of medicine contamination.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>The company is also developing treatments for the management of severe pain, and is collaborating with the U.<wbr> of Helsinki on novel intrathecal therapies for Parkinson's disease.<wbr> This research is in part funded by a grant from the Michael J.<wbr> Fox Foundation.<wbr> </div><!-- Comment details --><a name="neurology6577attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6577_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6577">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-25T09:26:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-25T09:26:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>HDAC Inhibitor Belinostat Meets Primary Endpoint in PTCL Trial</title>
	<pubDate>2012-09-24T15:29:23+02:00</pubDate>
	<wp:post_id>3877</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="article_body">Comment: Topotarget A/<wbr>S has announced top-line data from the pivotal BELIEF trial in patients with relapsed/<wbr>refractory PTCL, highlighting that the primary endpoint has been met.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body">BELIEF is an open-label mulitcentre safety and efficacy study evaluating intravenous belinostat.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body">A special protocol assessment (SPA) agreement with the FDA required the BELIEF trial to reach an objective response rate (ORR) of at least 20% and this objective was met.<wbr> </DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body">The trial was initiated in December 2008 and recruitment was completed with 129 patients in September 2011.<wbr> In total, the study included approximately 100 clinical centers globally</DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body">Data from the trial are being further analyzed and are expected to be communicated during the fourth quarter of 2012.<wbr> <BR><BR></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body">Under the terms of a 2010 license and collaboration agreement, belinostat is currently being developed jointly by Spectrum Pharmaceuticals Inc.<wbr> (Spectrum) and Topotarget.<wbr> Spectrum possesses the commercial rights to market belinostat in North America and India.<wbr> A new drug application (NDA) for belinostat in PTCL is expected to be filed with the FDA by Spectrum in first half of 2013.<wbr> <BR><BR>Should Spectrum receive FDA's acceptance to file the belinostat NDA, Topotarget is entitled to receive one million shares of common stock in Spectrum and a double-digit million dollar cash payment.<wbr> If belinostat is approved by the FDA, Topotarget will further receive a double-digit million USD cash payment.<wbr> <BR><BR>FDA has granted belinostat orphan drug and fast track designation for the treatment of PTCL.<wbr> <BR></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><STRONG>Belinostat's Profile</STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><BR>Belinostat is a new pan-HDAC inhibitor in late-stage clinical development with more than 1,000 patients treated.<wbr> Belinostat has a promising safety profile, which allows combination with traditional chemotherapy.<wbr> Preclinical experiments demonstrated belinostat to be effective against multiple cancers by inhibiting cell proliferation and inducing programed cell death (apoptosis) in tumor cells.<wbr> Belinostat has been tested in a number of Phase I/<wbr>II clinical trials in hematological cancers and solid tumors both in mono- and combination therapy.<wbr> Data from these trials have provided evidence of the anti-tumor effect of belinostat, including as monotherapy in PTCL and cutaneous T-cell lymphoma (CTCL), liver cancer, and thymoma.<wbr></DIV> </div><div><DIV class="article_body">Source: <A href="http://www.topotarget.com/">www.<wbr>topotarget.<wbr>com</A></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8488">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-24T15:29:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-24T15:29:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from ESPE 2012 (Part1) - Developments and New Results of rhGH Drugs</title>
	<pubDate>2012-09-24T13:31:30+02:00</pubDate>
	<wp:post_id>3878</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph1 results of Versartis’ VRS-317, the only once monthly dosing, demonstrate that single doses of VRS-317 sustained IGF-1 responses in the normal range in a dose dependent and tunable manner.<wbr> The PROLOR’s once weekly Ph2 positive results now support Ph3 in adults, expected to be intiated later this year.<wbr> Biopartners, which presented 2 years of Ph3 of LB03002 metabolic profile, expects a launch in 2013 (when asked about the device, a representative from the company highlighted that it is still an ongoing "challenge").<wbr> When it comes to nasal drug delivery, Critical Pharm reported they will partner CP024 to complete development and commercialization (currently the company is actively working on the optimization of its device to ensure full dose delivered).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>VERSARTIS</STRONG> - "Safety and Tolerability of a New Long Acting Human Growth Hormone (VRS-317) in Adult GH Deficiency" </div><div style="margin-bottom: 10px;">The primary objective of the Phase 1 study was to evaluate the safety and tolerability of a single subcutaneous (SC) dose of VRS-317.<wbr> The 60-day, double-blind, randomized, placebo-controlled, single-ascending dose Phase 1 trial enrolled 50 GHD adult patients in the US and EU.<wbr> </div><div style="margin-bottom: 10px;"><U>Results</U> </div><div style="margin-bottom: 10px;">In the <STRONG>Q/<wbr>A session</STRONG>, Dr Bright answered that 5 of 40 patients presented low titer antibody at Day60.<wbr> He highlighted that the ped study is to start in a month.<wbr> </div><div style="margin-bottom: 10px;">Safety: AEs that were considered drug related were primarily mild and transient.<wbr> There were no reported SAEs, no unexpected AEs and no injection site lipoatrophy observed during treatment.<wbr> No significant post-dosing changes were observed for fasting glucose, post-prandial glucose or fasting insulin.<wbr> Substantial reductions in cholesterol, triglycerides and LDL were observed in GHD patients receiving 0.<wbr>80 mg/<wbr>kg VRS-317.<wbr> </div><div style="margin-bottom: 10px;">VRS-317 was rapidly absorbed, achieving a Tmax 2-3 days after a single SC dose.<wbr> The half-life of VRS-317 increased significantly (p=0.<wbr>016) as a linear function of increased dose with a maximum mean terminal half-life of 131 hours at the 0.<wbr>80 mg/<wbr>kg dose of VRS-317.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The PD profile of VRS-317 indicated that IGF-1 was normalized in a dose-dependent manner with the duration of IGF-1 normalization increasing with dose, thus enabling up to once monthly dosing for future clinical trials.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>LG LIFE SCIENCES</STRONG> — “Metabolic effects of LB03002, a sustained release formulation of rhGH, in children with GH deficiency” </div><div style="margin-bottom: 10px;">Two years of Ph3 were presented.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">The effect of the drug on glucose metabolism and lipid parameters were reported in the P1d3293 poster.<wbr> The results show a metabolic profile comparable to conventional daily rhGH products.<wbr> Choloesterol slightly decreased, while fasting glucose, insulin and HbA1c increased overt ime but remained within the normal range.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>PROLOR</STRONG> — “Once-weekly, CTP-modified hGH (MOD-4023) effectively maintains IGF-1 levels within the normal range in AGHD supporting initiation of clinical development in children” </div><div style="margin-bottom: 10px;">In this Ph2 trial, hGH-CTP demonstrated a good safety and tolerability profile.<wbr> In addition, the study showed that only 50-65% of the cumulative weekly dose of conventional human growth hormone was required for the majority of the patients to remain within the normal range of IGF-1, a key biomarker of growth hormone activity.<wbr> </div><div style="margin-bottom: 10px;">The safety profile of hGH-CTP in this trial was further enhanced by the finding that it did not cause excessive IGF-1 levels in patients, nor was any IGF-I accumulation observed.<wbr> An exploratory part of the study also demonstrated the potential for a twice-monthly injection regimen.<wbr> hGH-CTP demonstrated a good safety and tolerability profile in these studies, with no unexpected adverse events.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>CRITICAL PHARM -</STRONG> "Intranasal human growth hormone (CP024) induces IGF-1 in healthy volunteers" </div><div style="margin-bottom: 10px;">In the <STRONG>Q/<wbr>A session</STRONG>, Faron Jordan, PhD answered that antibodies ratio as well as fibrosis have not been assessed yet.<wbr> When questionned on allergy reactions, he answered that mucosa secretion was reported.<wbr> </div><div style="margin-bottom: 10px;">Ph1 Results show that : </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">The drug is the 1st intranasal GH to induce IGF-1 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">In conclusion: </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="endocrinology7094attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(47,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(47,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(43,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(37,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(34,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7094_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(48,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7094">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-24T13:31:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-24T13:31:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Nordisk Invest Further in China</title>
	<pubDate>2012-09-24T12:09:34+02:00</pubDate>
	<wp:post_id>3879</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novo Nordisk announced it has invested an additional $100M to expand its facilities in Beijing.<wbr> With this expansion, the company will ensure the full range of protein research capabilities in China.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The new, expanded facility will enable even stronger contributions from the science team in China across the range of Novo Nordisk’s protein technology, biology and pharmacology research activities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Established in 1997</LI>
<LI>Currently approx.<wbr> 130 scientists (the new site will accomodate a doubling of that number with further expansion potential).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The HQs and R&amp;D Centre are located in Beijing, the production site is in Tianjin, and local offices are located in Shanghai, Guangzhou, Shenyang, Wuhan, Jinan, Hangzhou, Chengdu, Hong Kong and Taiwan.<wbr> </div><div style="margin-bottom: 10px;">Currently, Novo Nordisk employs around 3,000 people in China.<wbr> </div><div>Source: Novo Nordisk </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10080">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-24T12:09:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-24T12:09:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EMA Has Recommended 1st Medicine in EU for IBS-C</title>
	<pubDate>2012-09-24T11:18:08+02:00</pubDate>
	<wp:post_id>3880</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The CMPH reported that linaclotide (guanylate cyclase-C agonist) should be authorised for adults with moderate to severe IBS with constipation.<wbr> Almirall holds exclusive marketing rights for the drug in EU-27, and Mexico.<wbr> Once approved, it will be marketed as Constella®.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Statistics: IBS-C affects &gt;20% of the population in the western world.<wbr> </div><div style="margin-bottom: 10px;">- Current Treatment:  until now no medicines have been authorised in the EU to treat IBS-C specifically.<wbr> Therapies are limited to modifying lifestyle to reduce stress or alter diet, or laxatives.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The positive recommendation is based on the efficacy and safety of linaclotide evaluated in two double‐blind, placebo‐controlled Ph3 clinical studies.<wbr> </div><div style="margin-bottom: 10px;">The clinical trials involved approx.<wbr> 1,600 adult patients (of which more than 800 were treated with linaclotide 290 mcg).<wbr> </div><div style="margin-bottom: 10px;">In both trials, treatment with linaclotide resulted in statistically significant improvements in <STRONG>both</STRONG> abdominal pain/<wbr>discomfort and degree of relief of IBS‐C symptoms (co‐primary endpoints), as well as complete spontaneous bowel movement frequency, stool consistency and severity of straining and bloating (secondary endpoints).<wbr> </div><div>These improvements were maintained over the entire treatment period (12 and 26 weeks).<wbr> The incidence of adverse events was similar in both studies, with diarrhoea being the most common adverse event in linaclotide‐treated patients.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20121231&edate=20120901&rec=1857">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-24T11:18:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-24T11:18:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Backs Approval Of Avastin For Recurrent Ovarian Cancer</title>
	<pubDate>2012-09-24T10:41:32+02:00</pubDate>
	<wp:post_id>3881</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The CHMP has adopted a positive opinion regarding the use of Avastin in combination with chemotherapy (carboplatin and gemcitabine) as a treatment for women with recurrent platinum-sensitive ovarian cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Approval</STRONG> </div><div style="margin-bottom: 10px;">Patients are said to have "platinum-sensitive" disease if their ovarian cancer returns more than six months after completion of the last platinum-based chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">In platinum sensitive disease, Avastin demonstrated in the phIII (OCEANS study) that those women who received the combination Avastin and chemotherapy and then continued with Avastin lived significantly longer without their disease getting worse compared to those who received chemotherapy alone.<wbr> </div><div style="margin-bottom: 10px;">An approval for recurrent disease, would represent another milestone for Avastin following its approval last year for newly diagnosed patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dosage Schedule</STRONG> </div><div style="margin-bottom: 10px;">The recommeneded treatment schedule for the new indication is to give Avastin 15mg/<wbr>kg of body weight once every 3 weeks as an intravenous infusion for 6 - 10 cycles in combination with carboplatin and gemcitabine, followed by continued use as a single agent.<wbr> </div><div>Source: <A href="http://www.roche.com">www.<wbr>roche.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8486">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-24T10:41:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-24T10:41:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Survey Points to Little Growth in Dendreon's Provenge</title>
	<pubDate>2012-09-24T10:38:08+02:00</pubDate>
	<wp:post_id>3882</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Wedbush commissioned a survey of 33 medical onco and 20 uro in the US, who treat advanced CRPC patients (mean patients treated/<wbr>month= 38).<wbr> Results show that a significant portion of physicians still cannot find appropriate patients for Provenge.<wbr> They also cite difficulty of use and reimbursement issues.<wbr> Last July, Dendreon announced Provenge sales 2.<wbr>4% below the previous quarter, the restructuration of one plant, and the loss of approx.<wbr> 600 jobs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Objectives: to gather insight into physician awareness of new treatments for CRPC and their opinions of new therapies recently approved and still under development.<wbr>
</LI>
<LI>Physicians' practice: avrage of 16 years post-residency in their specialty.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">While the majority of physicians (55%) had prescribed it, the majority of the remainder of both oncologists and urologists who had not prescribed stated that a primary reason was &ldquo;no available appropriate patients.<wbr>&rdquo; If, at this stage of the launch of Provenge, a significant portion of physicians still cannot find appropriate patients for Provenge, we believe that our muted expectations for Provenge are justified.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Importantly, physicians foresee little increase in their use over the next 6 months.<wbr> </div><div style="margin-bottom: 10px;">Currently, Provenge-prescribers state they prescribe Provenge to about 18% of their patients (range 10-25% for the bottom and top quartiles), and 6 months from now, they estimated they will prescribe Provenge to about 20% of their patients (range of 5-30% for the bottom and top quartiles).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Availability of appropriate patients was chosen by 61% of physicians as the reason for a change in Provenge use.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">While physicians generally are favorably disposed to Provenge&rsquo;s safety and efficacy, difficulty of use and reimbursement concerns are also top-of-mind for non-prescribers.<wbr> One-half to two-thirds of non-prescribers also cite difficulty of use (51% as a #1 or #2 reason) and reimbursement issues (33% each for #1 and #2 reason).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_1_ScreenCapture1.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="oncology8485attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(36,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8485_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(49,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8485">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-24T10:38:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-24T10:38:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Viropharm Launches New Adrenal Insufficiency Drug The First In 50 Years</title>
	<pubDate>2012-09-21T17:20:45+02:00</pubDate>
	<wp:post_id>3883</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="article_body">Comment: ViroPharma Inc has launched its new modified hydrocortisone formulation in Denmark marking the occasion with a symposium at the recent ENEA meeting.<wbr> Plenadren is a new, oral, once daily hydrocortisone, modified-release tablet that is designed to better mimic the body's normal, cortisol profile, compared with standard treatment.<wbr></DIV> </div><div><TABLE width="100%"><TBODY><TR align="left"><TD>

<DIV class="article_body"><STRONG>Key Clinical Findings</STRONG><BR><BR>The results of a pivotal Phase II/<wbr>III trial showed Plenadren to be effective and well tolerated, compared to standard treatment, demonstrating a delivery of cortisol, which is more in line with the body's own cortisol profile, thus avoiding the afternoon/<wbr>evening peaks.<wbr> These peaks are thought to be associated with an increased risk of morbidity and premature mortality.<wbr> <BR><BR>Dr Anna G Nilsson, principal investigator for all Plenadren studies and consultant in endocrinology at the Sahlgrenska University Hospital, Goteborg, Sweden, said, "There is a clear need in the treatment of AI for an oral hydrocortisone replacement therapy that better resembles the body's natural cortisol production, that can be given once a day and that may improve patients' metabolic status and compliance to treatment.<wbr> A new therapeutic option for the first time in 50 years, that appears to achieve this is exciting news for AI patients.<wbr> The once-daily dosing schedule will help them to manage their condition in a more simple and effective way.<wbr>" <BR></DIV>
<DIV class="article_body"><STRONG>Plenadren's Profile</STRONG></DIV>
<DIV class="article_body"><BR>Plenadren is taken orally as a single dose in the morning and has been designed to provide a dual release pattern of hydrocortisone.<wbr> The outer coating provides a high concentration of cortisol in the morning, meeting the body's requirements.<wbr> The extended-release core provides a smooth cortisol release throughout the day, followed by a cortisol-free interval during the night, avoiding the unphysiological afternoon/<wbr>evening peaks observed with standard treatment.<wbr> <BR><BR>Plenadren is proven to be well tolerated with patients reporting favourable impact on quality of life compared to standard treatment, in terms of psychosocial and cognitive functioning, and psychological general well-being.<wbr> In an 18-month long-term follow-up trial, 98.<wbr>5% of patients rated tolerability as 'very well', 'well' or 'acceptable'.<wbr> <BR></DIV>

<DIV class="article_body"><STRONG>What The Pituitary Foundation Has To Say</STRONG></DIV>
<DIV class="article_body"><BR>Pat McBride, patient support manager of The Pituitary Foundation, UK, said, "For people living with a cortisol deficiency, conventional treatment can have an impact on quality of life, with many patients struggling with peaks and troughs in their replacements as well as managing complicated regimes.<wbr> The availability of Plenadren is an important step forward for patients and may help to improve the management of their condition, helping patients to more actively take part in their work, family and social commitments.<wbr>" </DIV>

<DIV class="article_body"><STRONG>Launch Status<BR></STRONG><BR>In November 2011, the European Commission (EC) granted European marketing authorization for Plenadren, an orphan drug for treatment of adrenal insufficiency in adults.<wbr> Plenadren is not approved in the US; however, it has received orphan drug designation status in the US and has maintained orphan status in Europe.<wbr> <BR><BR>Source: <A href="http://www.viropharm.com">www.<wbr>viropharm.<wbr>com</A></DIV></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7089">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-21T17:20:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-21T17:20:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PhII Localised Prostate Cancer Study Receives Positive Interim Safety Review</title>
	<pubDate>2012-09-21T17:07:31+02:00</pubDate>
	<wp:post_id>3884</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="article_body">
<DIV class="article_body">Comment: Nymox Pharmaceuticals has reported that the Independent Data Monitoring Committee for the company's Phase II study of NX-1207 for low risk localized prostate cancer (NX03-0040) has reported a positive interim safety analysis.<wbr></DIV>
<DIV class="article_body">The safety data represents that collected from the first group of patients to receive either a high or low dose of NX-1207 for treatment of their localized prostate cancer.<wbr> <BR><BR></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body">The NX-1207 dose is administered directly into the area of the prostate where the cancer has been detected.<wbr> The procedure is performed by a urologist in an office setting, does not require anaesthesia, sedation, or catheterization, takes only a few minutes and involves minimal discomfort to the patient.<wbr> <BR><BR>Patients in the study are randomly allocated to either low or high dose NX-1207 or to active surveillance (no treatment).<wbr> Patients undergoing active surveillance in the trial also have the opportunity to receive NX-1207 after their trial active surveillance participation is completed.<wbr> <BR></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><STRONG>Lead Indication Is BPH Which Is Partnered With Recordati</STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="article_body"><BR>NX-1207 is in late stage Phase III development in the US for the treatment of benign prostatic hyperplasia (BPH), a common condition of older men associated with growth in prostate size as men age.<wbr> Phase III trial activities of NX-1207 for BPH have recently begun in Europe sponsored by Recordati S.<wbr>p.<wbr>A.<wbr></DIV> </div><div><DIV class="article_body">In the BPH studies to date, a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs.<wbr></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8483">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-21T17:07:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-21T17:07:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medy-Tox Registers Strong First Half Performance</title>
	<pubDate>2012-09-21T12:05:56+02:00</pubDate>
	<wp:post_id>3885</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Meyd-Tox posted record-high quarterly earnings in 2Q12 with sales 
(Meditoxin) of W9.<wbr>4bn (up 70.<wbr>1% y-y), operating profit of W5.<wbr>3bn (up 
174.<wbr>5%) and net profit of W4.<wbr>6bn (up 120.<wbr>3% y-y).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sales Performance</STRONG> </div><div style="margin-bottom: 10px;">According to Woori Securities domestic sales of Meditoxin reached W4.<wbr>3bn (up 
120.<wbr>5% y-y) led by strong sales of therapeutic Meditoxin (commercialised in 
Q411).<wbr> </div><div style="margin-bottom: 10px;">The company's export sales growth was also robust coming in at 
W5.<wbr>1bn (up 42.<wbr>7% y-y) led by increased exports to Thailand and Hong Kong 
and recovering exports to Brazil and Japan.<wbr> Brazilian growth is expected to be 
even stronger moving forward in the year.<wbr> In detail exports to Asia came in 
at W3.<wbr>9bn (up34.<wbr>8% y-y) to Eastern Europe at W0.<wbr>3bn up 73.<wbr>5% y-y) and to other 
countries including Latin America at W1.<wbr>0bn (up 52.<wbr>7%).<wbr> </div><div style="margin-bottom: 10px;">Based on widening distribution Woori is forecasting 2012 sales of W39.<wbr>3bn (up 
81.<wbr>2% y-y).<wbr> </div><div style="margin-bottom: 10px;">After changes in contract terms with Pacific Pharma Medy-tox started 
distributing Meditoxin for itself in mid-June in its local market a factor 
analysts will drive up domestic sales and profits in the second half of the 
year.<wbr> This year the group has hired 15 employees to sell the product in the 
domestic market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Generation Meditoxin</STRONG> </div><div style="margin-bottom: 10px;">A phII trial is ongoing in Australia and expected to conclude by the year-end 
with plans now underway for phIII to start in 2013.<wbr> The group is still aiming 
for approval in developed countries in 2015 and launch in 2016.<wbr> It will invest 
W40bn in a new manufacturing plant over 2012/<wbr>2013 to support this 
development.<wbr> The analysts claim that Medy-tox's new product is drawing much 
attention from foreign firms increasing its chances of forging a strategic 
partnership with an overseas partner.<wbr> </div><div>Source: Tongyang &amp; Woori Securities Reports </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6603c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Thanks to Il-Ok Kim (Korea) we have learnt that as of Sept 24th, Medy-tox was granted approval in Korea for the use of Meditoxin (50, 100 &amp; 200 Units) for adult post stroke upper arm spasticity, strengthening its therapeutic toxin label in this market.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6576">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-21T12:05:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-21T12:05:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Baxter Acquires EU Rights to Onconova's PI3K inhibitor</title>
	<pubDate>2012-09-20T18:00:17+02:00</pubDate>
	<wp:post_id>3886</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Baxter has acquired European marketing rights to Onconova's PI3K inhibitor rigosertib for the treatment of myelodysplastic syndrome (MDS) and pancreatic cancer in a deal valued at $565m, the former representing a good strategic fit alongside the group's hemophilia franchise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Baxter will make an upfront payment of $50m with further payments of $515m agreed on the basis of development and regulatory milestones.<wbr> </div><div style="margin-bottom: 10px;">Baxter which has an existing $50m investment in Onconov also has the option to participated in the development and commercialisation of rigosertib in other indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rigosertib's Development Status</STRONG> </div><div style="margin-bottom: 10px;">Results from a phIII study of injectable rigosertib in 270 patients with MDS who have failed or relaspsed after receiving existing therapeutic options are expected in the second half of 2013.<wbr> </div><div style="margin-bottom: 10px;">A phII/<wbr>III combination study in patients with previously untreated metastatic pancreatic cancer is also underway, whilst further back in development is an oral formulation of the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Rational</STRONG> </div><div style="margin-bottom: 10px;">Rigosertib's first indication is viewed as complimentary to Baxter's existing treatments for rare hematological conditions, namely its hemophilia business.<wbr> <SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">For Baxter rigosertib provides an ideal training-wheels product.<wbr> MDS represents a good fit with the existing blood business, as it relates to myeloid stem cell disorders, which affect the ability of bone marrow to produce normal, red and white cells as well as platelets.<wbr></SPAN><BR><BR><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The inability of blood stem cells to mature in the disorders mean that these cells, called blasts, either die in the bone marrow or enter the blood.<wbr> MDS is often seen as a precursor to full-blown leukaemia because the more blasts are present in the body the higher likelihood of developing leukaemia.<wbr></SPAN><BR><BR><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">At present the only treatments for MDS are blood transfusions, bone marrow transplants and chemotherapy.<wbr> Rigosertib is being developed for patients who have failed or relapsed on these treatments, and if approved would be the first product on the market.<wbr> An oral version of the drug for first-line use is in phase II trials and it is also being studied in a combination phase II/<wbr>III study for metastatic pancreatic cancer.<wbr></SPAN><BR><BR><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Rigosertib also gives Baxter a way of cashing in on big pharma&rsquo;s increased interest in rare diseases.<wbr> It has been granted orphan drug status on both sides of the Atlantic, meaning that if and when it is approved in Europe it should slot into the existing haematological sales force with little extra cost.<wbr></SPAN> </div><div>Source: <a href="http://www.baxter.com" class="defaultlink" title="http://www.baxter.com">baxter.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8481">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-20T18:00:17+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-20T18:00:17+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GTx To Present Data On Capesaris's MOA At ESMO</title>
	<pubDate>2012-09-20T13:05:49+02:00</pubDate>
	<wp:post_id>3887</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Mitchell S.<wbr> Steiner, MD, Vice-Chairman and CEO of GTx, will 
present data from the company’s Phase II G200707 clinical study of Capesaris 
providing evidence that Capesaris increases SHBG, decreases FT, and reduces 
serum <ORG>PSA</ORG>.<wbr> The data will be presented on September 29th at 1pm.<wbr> </div><div style="margin-bottom: 10px;">In another recent Phase II clinical study conducted by GTx (G200705) in men 
with advanced prostate cancer who were hormone naïve, a significant reduction 
in free testosterone was observed in Capesaris treated subjects in 
comparison to those treated with Lupron®.<wbr> </div><div style="margin-bottom: 10px;">The Phase II clinical studies were stopped early due to an increased risk of 
venous thromboembolic events (VTEs) at the higher Capesaris doses used in these 
previous clinical studies.<wbr> However, clinical data from Phase I and Phase II 
studies suggest that significant increases in serum SHBG, and corresponding 
reductions in free testosterone, can be achieved with lower (125 to 500 mg) 
doses of Capesaris.<wbr> </div><div style="margin-bottom: 10px;">GTx has therefore, initiated a new Phase II clinical trial (G200712) to 
evaluate the safety and effectiveness of lower doses of Capesaris to treat men 
with metastatic castration resistant prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Seventy-five men with metastatic castration resistant prostate cancer will be 
randomized into one of three cohorts to receive a 125 mg, 250 mg or 500 mg daily 
dose of Capesaris.<wbr> Each arm will have 25 subjects and the enrollment will be 
conducted sequentially, with the 125 mg cohort being the first to be enrolled.<wbr> 
The enrollment into the next higher dose of Capesaris will commence if an 
acceptable incidence of VTEs is observed among randomized patients for 30 days 
following enrollment of the last patient in the previous cohort.<wbr> The primary 
endpoint will be to lower serum <ORG>PSA</ORG> by ≥ 50% by day 90.<wbr> Other key 
cancer endpoints include serum <ORG>PSA</ORG> progression, time to progression 
and progression free survival in these study subjects.<wbr> In addition, the study 
will evaluate the ability of Capesaris to treat certain estrogen deficiency side 
effects associated with medical castration such as hot flashes, bone loss, and 
insulin resistance.<wbr> </div><div>Source:  <A href="http://phx.corporate-ir.net/phoenix.zhtml?c=148196&amp;p=irol-newsArticle&amp;ID=1736387&amp;highlight">http:/<wbr>/<wbr>phx.<wbr>corporate-ir.<wbr>net/<wbr>phoenix.<wbr>zhtml?c=148196&amp;p=irol-newsArticle&amp;ID=1736387&amp;highlight</A>= </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8480">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-20T13:05:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-20T13:05:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Ph3 Trial to Compare 177Lu-DOTA0-Tyr3-Octreotate and Octreotide LAR for Midgut Carcinoid Tumours</title>
	<pubDate>2012-09-20T12:42:24+02:00</pubDate>
	<wp:post_id>3888</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Ph3 Trial to Compare 177Lu-DOTA0-Tyr3-Octreotate and Octreotide LAR for Midgut Carcinoid Tumours</span>&nbsp;<br><span style="font-size: 12px;"></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=6907">...</a><br></div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7088">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6907">View thread  Endocrinology6907: New Ph3 Trial to Compare 177Lu-DOTA0-Tyr3-Octreotate and Octreotide LAR for Midgut Carcinoid Tumours</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-20T12:42:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-20T12:42:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Generic Substitution Rates Rise in France</title>
	<pubDate>2012-09-20T12:21:51+02:00</pubDate>
	<wp:post_id>3889</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The French public health insurer CNAM has revealed that generic substitution rates in the country have risen to almost 80%.<wbr> According to Agence France-Presse, CNAM is confident that it is still on course to meet its target substitution rate of 85% by the end of 2012.<wbr> </div><div style="margin-bottom: 10px;">CNAM owes its success to a new policy whereby pharmacists are given financial incentives to implement generic substitution, and patients who refuse must pay the additional costs upfront.<wbr> Patients who refuse substitution must pay the full cost of the brand name product and can then reclaim the reimbursement amount (15%, 30% or 65%, 100%) by sending off a form.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">The rise in generic substitution rates is a continuation of a trend that has been taking place since June, when the substitution rate was just 72%.<wbr> However, although the new reimbursement policy has been successful in driving up sales of generics, there have been a number of teething problems, with some pharmacies wrongly withholding reimbursement from patients whose prescriptions have been marked "NS" (i.<wbr>e.<wbr> non-substitutable) by their doctor.<wbr> A limited number of drugs, such as epilepsy treatments, are also non-substitutable </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10075">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-20T12:21:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-20T12:21:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Expresses Concerns on Drug Prices</title>
	<pubDate>2012-09-20T12:02:06+02:00</pubDate>
	<wp:post_id>3890</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Marijn Dekkers, Bayer's Chief Executive, said that pressure from governments to lower drug prices risk undermining medical innovation.<wbr> He added that "it was easy to attack pharma companies rather than focus on more complex methods of controlling H/<wbr>C costs".<wbr> </div><div style="margin-bottom: 10px;">Speaking a the Boston College yesterday he also indicated that pressure in the US is not as great as in Germany.<wbr> </div><div>He highlighted that Bayer has "a very strong financial foundation" and "good cash flow" but is not angling for an increase in its credit rating (which is currently A-minus).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10074">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-20T12:02:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-20T12:02:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J to Create Regional Innovation Centers to Identify Acquisitions</title>
	<pubDate>2012-09-19T20:17:54+02:00</pubDate>
	<wp:post_id>3891</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 4 centres will be located in California; Boston; London; and China and will be operational in coming months.<wbr> They will comprise science and technology experts and have "local deal-making capabilities, with flexibility to adapt deal structures to match the early-stage opportunity".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Paul Stoffels (Global Pharmaceuticals Head), the company wants to: </div><div style="margin-bottom: 10px;">- strengthen significantly its capabilities to bring on board more products from the biotechnology and academic community.<wbr> </div><div style="margin-bottom: 10px;">- be partners when opportunities emerge in academics, during the venture capital rounds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Areas: Immunology, oncology, and infectious diseases.<wbr> </div><div>Organization: Each will have an initial staff of approx.<wbr> 15 to 20 people, tasked with hunting out partnership and investment opportunities across drugs, medical devices, diagnostics and consumer health.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10069">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-19T20:17:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-19T20:17:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gene Therapy to Enter Ph2 for Relapsed Non-Muscle Invasive Bladder Cancer</title>
	<pubDate>2012-09-18T18:16:38+02:00</pubDate>
	<wp:post_id>3892</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: FKD Therapies Oy, a newly formed company specialising in advanced gene based medicines, will assess the efficacy and safety of intravesical administration of INSTILADRIN (rAd-IFN with Syn 3).<wbr> Primary endpoint will evaluate the incidence of high grade-recurrence free survival following up to 4 instillations of the product.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Interferon alfa 2b protein therapy is a well-established anti-cancer therapy.<wbr> Its efficacy for the treatment of bladder cancer is limited by the fact that after direct administration into the bladder, it is completely cleared within 24hrs.<wbr> </div><div style="margin-bottom: 10px;">Instiladrin™ is an adenoviral (Ad5) vector based gene medicine, containing the interferon alfa 2b transgene with Syn3, an excipient to improve transfection.<wbr> </div><div style="margin-bottom: 10px;">Administered as one dose, the adenovirus carries the interferon gene into the bladder wall cells where it is transported to the nucleus causing the interferon protein to be made intracellularly.<wbr> Evidence suggests that Instiladrin™ may produce a therapeutic concentration of interferon measurable in the bladder for seven days3 killing even cells that are resistant to externally administered interferon protein.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01687244?recr=Open&amp;fund=2&amp;rcv_s=09%2F04%2F2012&amp;rank=44"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 40 </div><div style="margin-bottom: 10px;">Completion date: March 2014 /<wbr>June 2014 </div><div>Location: US (1 site) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8477">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-18T18:16:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-18T18:16:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Strong Support For New Life Science Venture Fund</title>
	<pubDate>2012-09-18T11:13:43+02:00</pubDate>
	<wp:post_id>3893</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: New Life Science Venture Fund Longitude Venture 
Partners announced  in a recent SEC filing that its has raised $331m 
for a second fund and could continue raising up to $375m.<wbr> </div><div style="margin-bottom: 10px;">The company's website suggests that attractive deals for Longitude are with 
companies developing clinically and cost-effective treatments for unmet medical 
needs, and platform technologies that facilitate novel product development.<wbr> </div><div style="margin-bottom: 10px;">It gives preference to early stage medical device and mature biotechnology 
companies, but will invest in companies at any stage with an average investment 
of $10 million to $30 million total.<wbr> </div><div style="margin-bottom: 10px;">Longitude’s portfolio includes 
several publicly traded companies such as Amarin (N, Cadence Pharmaceuticals, 
Corcept Therapeutics and Jazz Pharmaceuticals.<wbr> It also holds stake in a number 
of privately held companies including diagnostic test makers CardioDx and 
Precision Therapeutics, and pain drug developers Collegium and Xanodyne 
Pharmaceuticals.<wbr> </div><div style="margin-bottom: 10px;">Longitude closed its $325 million inaugural fund in 2008.<wbr> It’s exited a few 
companies recently including eyeonics to Bausch &amp; Lomb in 
2008, Ablation Frontiers to Medtronic for $225 million in 2009 and 
Sadra Medical to Boston Scientific for $225 million in 2010.<wbr> </div><div style="margin-bottom: 10px;">The firm, with offices in Menlo Park, California and Greenwich, Connecticut, 
joins the company of numerous others raising or closing $100 million-plus 
venture funds focused on health this year.<wbr> </div><div>Source: <A href="http://www.longitudecapital.com">www.<wbr>longitudecapital.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10066">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-18T11:13:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-18T11:13:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dicerna Presents Positive HCC Preclinical Data At the ILCA Meeting</title>
	<pubDate>2012-09-18T10:58:42+02:00</pubDate>
	<wp:post_id>3894</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div><TABLE border="0" cellpadding="0" cellspacing="0" width="100%"><TBODY><TR><TD>
      <TABLE width="100%"><TBODY><TR align="left"><TD valign="top">
            <DIV class="article_body bp">Comment: Results from the company’s 
            hepatocellular cancer (HCC) program were presented at the 
            International Liver Cancer Association (ILCA) Annual Conference held 
            in Berlin, September 14 – 16, 2012.<wbr> The data were features in three 
            separate poster presentations at the 
      meeting.<wbr></DIV></TD>
</TR>
</TBODY>
</TABLE></TD>
</TR>
<TR><TD>
      <TABLE width="100%"><TBODY><TR align="left"><TD valign="top">
            <DIV class="article_body"><STRONG>Background</STRONG></DIV>
            <DIV class="article_body"><BR>Dicerna has identified the MYC oncogene 
            as a primary target for RNAi intervention and will focus on HCC as 
            its initial indication given the significant need for new treatment 
            options for this disease.<wbr> </DIV>
            
            <DIV class="article_body">MYC is a key regulator of oncogenic pathways 
            and has been identified in multiple types of cancer including, HCC, 
            breast, colorectal, gynecological and prostate, among others.<wbr> 
            However, despite being one of the earliest oncogenes identified, MYC 
            has remained “undruggable” by small molecules and antibodies.<wbr> 
            <BR></DIV>
            <DIV class="article_body"><STRONG>The Poster 
            Data<BR><BR></STRONG>Highlights from the posters presented at the 
            meeting follow below: <BR><BR>The poster “MYC Dicer Substrate siRNA 
            Formulated in EnCore Lipid Nanoparticle Reduces Tumor Burden in the 
            Hep3B Orthotopic Hepatocellular Carcinoma Model,” Darren H Wong et 
            al.<wbr>, demonstrates that EnCore delivered DsiRNA exhibited targeted 
            knockdown of MYC mRNA resulting in tumor growth inhibition in a 
            preclinical model.<wbr> Additionally, MYC DsiRNA co-treatment with 
            sorafenib, the current standard of care for late stage HCC, was 
            well-tolerated and also resulted in significant tumor growth 
            inhibition.<wbr> <BR><BR>This outcome is due to MYC gene target knockdown 
            dependent efficacy, which was demonstrated through a determination 
            of MYC mRNA and MYC protein levels.<wbr> It was further determined that a 
            cellular protein, located downstream of MYC and dependent on MYC 
            expression, was also reduced through the treatment.<wbr> This study 
            provides a rationale for the clinical evaluation of DsiRNA molecules 
            against MYC, a traditionally “undruggable” target, in patients with 
            advanced HCC.<wbr> <BR><BR>In the poster “Dicer Substrate siRNA-Mediated 
            Knockdown of Tumor ß -Catenin Reduces Tumor Burden in The Hep3B 
            Orthotopic Hepatocellular Carcinoma Model,” Hank Dudek et al.<wbr>, 
            DsiRNAs were developed against ß-catenin, a protein with both 
            regulatory and structural functions and a role in human cancer.<wbr> The 
            work presented illustrates that the targeted knockdown of the 
            ß-catenin gene in a mouse model of human HCC results in the 
            reduction of tumor growth.<wbr> <BR><BR>Large-scale screening was used to 
            identify DsiRNAs that are highly potent for ß-catenin knockdown, 
            including those that received extensive secondary modification to 
            their properties, including immunostimulatory properties.<wbr> Delivery 
            of these DsiRNAs in EnCore particles to this orthotopic model of 
            human HCC effectively knocked down tumor ß-catenin expression and 
            inhibited tumor growth.<wbr> The ß-catenin DsiRNAs also inhibited 
            expression of downstream genes dependent on ß-catenin expression in 
            tumors, including MYC, further demonstrating the capability of 
            DsiRNAs to block the oncogenic activities of their molecular 
            targets.<wbr> <BR><BR>The poster “In Vivo Delivery of Multiple 
            Independent Dicer Substrate siRNAs and Gene Silencing Using 
            Encore-DsiRNAs In Multiple Orthotopic Liver Cancer Models And A 
            Liver Fibrosis Model,” Sujit K.<wbr> Basu et al.<wbr>, describes robust and 
            generalizable in vivo delivery of DsiRNA in a series of established 
            mouse models of human HCC and a carbon tetrachloride-induced mouse 
            liver fibrosis model.<wbr> <BR><BR>In the orthotopic Hep3B HCC model, 
            EnCore particle formulations of DsiRNAs targeting either MYC, 
            ß-catenin, or several other challenging gene targets, when 
            administered three times per week for two weeks, resulted in up to 
            70 percent mRNA knockdown as well as approximately 60% tumor growth 
            inhibition.<wbr> These studies form the basis for the clinical evaluation 
            of EnCore-DsiRNAs in liver cancer patients.<wbr> The poster was selected 
            by the ILCA editorial committee as a Top Scored Poster.<wbr> 
            <BR><BR>Douglas Fambrough, chief executive officer of Dicerna, said, 
            "We were very pleased with the positive reception these findings 
            received at the ILCA conference.<wbr> MYC remains a very challenging 
            target for pharmaceutical development when employing small molecules 
            and antibodies.<wbr> Our in vivo success targeting MYC expression with 
            DsiRNA technology delivered via EnCore lipid nanoparticles in models 
            of HCC suggests a significant therapeutic opportunity for this 
            challenging disease.<wbr>”</DIV>
            
            <DIV class="article_body">Source: <A href="http://www.dicerna.com">www.<wbr>dicerna.<wbr>com</A></DIV></TD>
</TR>
</TBODY>
</TABLE>
      <TABLE width="100%"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8476">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-18T10:58:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-18T10:58:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OS Advantage Remains Elusive In Pancreatic Cancer Study But Threshold Blames Trial Design</title>
	<pubDate>2012-09-18T10:40:49+02:00</pubDate>
	<wp:post_id>3895</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: 
Threshold announced yesterday that </SPAN>TH-302<SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> plus gemcitabine non-significantly 
improved median overall survival (OS), a secondary endpoint, vs.<wbr> gemcitabine 
alone in the Phase IIb TH-CR-404 trial to treat advanced pancreatic cancer.<wbr> 
However, with positive previously reported PFS data the company plans with its 
partner to enter phIII development in the 1st line setting by the year 
end.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>The 
New Data</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">TH-302 
plus gemcitabine led to a median OS of 8.<wbr>7 months in patients receiving 240 
mg/<wbr>m2 (p=0.<wbr>827) and 9.<wbr>2 months in patients receiving 340 mg/<wbr>m2 (p=0.<wbr>8) vs.<wbr> 6.<wbr>9 
months in patients receiving gemcitabine alone.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Threshold claims 
the trial was not designed to detect a significant improvement in OS.<wbr> The 
company added that patients who crossed over from the gemcitabine alone arm to 
receive gemcitabine plus TH-302 upon disease progression contributed to an 
increase in survival in the control arm.<wbr> As such, Threshold said it believes the 
lack of significant OS data was partly due to the crossover design of the trial.<wbr> 
</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Previously 
Reported Data</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">In 
February, Threshold reported that pooled data for both doses of TH-302 plus 
gemcitabine met the primary endpoint of median progression-free survival vs.<wbr> 
gemcitabine alone (5.<wbr>6 vs.<wbr> 3.<wbr>6 months, p=0.<wbr>005).<wbr> The forthcoming phIII trial in 
the first-line setting will evaluate higher doses of TH-302.<wbr></SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">TH-302 
is a</SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> 
hypoxia-activated cytotoxic 2-nitroimidazole prodrug of the DNA alkylator 
bromoisophosphoramide mustard (Br-IPM).<wbr> The drug is also  being 
evaluated in a Phase III trial to treat soft tissue sarcoma.<wbr> </SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8475">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-18T10:40:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-18T10:40:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cost Issues with Signifor for Cushing in Germany</title>
	<pubDate>2012-09-18T09:36:00+02:00</pubDate>
	<wp:post_id>3896</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7190c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Germany's Joint Federal Committee (GBA) issued a final assessment on Signifor (Novartis's  pasireotide) last week concluding that it provides only a "marginal degree of additional benefit" for patients with Cushing's disease for whom surgery has failed or is not an option.<wbr> Novartis will now negotiate a price with German's statuatory health insurance funds.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7086">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-18T09:36:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-18T09:36:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Inc Has Initiated Survey for Patients with Blepharospasm</title>
	<pubDate>2012-09-17T17:49:02+02:00</pubDate>
	<wp:post_id>3897</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new observational study to collect information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Information to be collected</U> </div><div style="margin-bottom: 10px;"><UL><LI>how often patients are treated with botulinum toxin, </LI>
<LI>how long their treatment lasts, </LI>
<LI>how satisfied they are with their treatment,</LI>
<LI>any improvement in their symptoms with the treatment</LI>
</UL> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 150 </div><div style="margin-bottom: 10px;">Duration: 3 months </div><div>Location: USA (Florida; Ohio) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6574">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-17T17:49:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-17T17:49:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Inc. Appoints VP Neurology</title>
	<pubDate>2012-09-17T16:03:48+02:00</pubDate>
	<wp:post_id>3898</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cynthia Schwalm will be responsible for the Merz's growing neurology business unit in the U.<wbr>S.<wbr>, which includes the recently acquired product CUVPOSA<SUP>®</SUP>, an oral solution for ped.<wbr> patients with chronic severe drooling associated with neuro conditions.<wbr> Bill Humphries, President &amp; CEO of Merz Inc.<wbr>, reported he will name his entire North American Leadership Team within the next few months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6572_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Prior to joining Merz, Schwalm was the Senior Advisor to the Chief Executive Officer at Chimerix, Inc.<wbr> </div><div style="margin-bottom: 10px;">She has held various international commercial leadership and general management positions with Optimer, Eisai, Amgen, and Johnson &amp; Johnson.<wbr> Schwalm brings with her 30 years of experience in the pharmaceutical and healthcare industry, with commercialization experience in movement disorders and neurology including pain management, Alzheimer's disease, and epilepsy including Lennox Gaustaut syndrome.<wbr> </div><div style="margin-bottom: 10px;"><U>Education</U> </div><div style="margin-bottom: 10px;">Schwalm obtained her Bachelor of Science in Nursing from the University of Delaware in Newark, DE.<wbr> She also earned her Executive Master of Business Administration from the Wharton School of Business from the University in Pennsylvania in Philadelphia, PA.<wbr> Schwalm is a member for Beth Abraham Family Health Services Board and Sarah Cannon Oncology Research Institute Board.<wbr> She will be based out of the office in Greensboro, NC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6529" class="defaultlink">Neurology6529: Merz Strengthens its Neuro Business in the US</a>.<wbr> </div><!-- Comment details --><a name="neurology6572attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6572_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6572">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-17T16:03:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-17T16:03:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Geron Appoints Andrew Grethlein</title>
	<pubDate>2012-09-17T15:53:59+02:00</pubDate>
	<wp:post_id>3899</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Andrew J.<wbr> Grethlein will be appointed as Executive VP of Technical Operations.<wbr> He will be responsible for Geron's manufacturing and quality functions as well as the development of imetelstat, and GRN1005.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>2010-2012 <STRONG>Inspirations</STRONG>' Executive VP and COO</LI>
<LI>2008-2010 <STRONG>Ipsen</STRONG>'s Senior VP of Biotechnology and Portfolio Management Team Leader for Hematology</LI>
<LI>2003-2008 <STRONG>Tercica</STRONG>'s Senior VP of Pharma Operations</LI>
</UL> </div><div style="margin-bottom: 10px;">
Dr.<wbr> Grethlein received his A.<wbr>A.<wbr> degree in liberal arts from Simon's Rock Early College, his B.<wbr>S.<wbr> in biotechnology from Bates College, and his M.<wbr>S.<wbr> and Ph.<wbr>D.<wbr> in chemical engineering from Michigan State University.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10065_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld10065attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10065_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10065">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-17T15:53:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-17T15:53:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>French Government Urges Citizens to Reduce Medicines Consumption</title>
	<pubDate>2012-09-17T13:01:43+02:00</pubDate>
	<wp:post_id>3900</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: French health minister Marisol Touraine has revealed that the government wishes to encourage the population to consume fewer medicines, reports <EM>Reuters</EM>.<wbr> However, in an interview on the Europe 1 radio station, Touraine emphasised the fact that it is not the government's job to evaluate medicines, and that this role must instead be undertaken by the French National Agency for Drug Safety (ANSM), which is the country's recently created independent drug regulatory body.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Touraine made her comments in the context of a discussion over savings that the healthcare service needs to make in order to help reduce public debt.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The French population's heavy consumption of medicines has fallen under the spotlight following the recent publication of a book entitled "<I>Guide des 4,000 médicaments utiles, inutiles ou dangereux</I>" (Guide to 4,000 Useful, Ineffective or Dangerous Medicines), which claims that half of all medicines available in France are ineffective and that 5% are potentially dangerous.<wbr> </div><div style="margin-bottom: 10px;">The book, written by two prominent doctors, has received widespread coverage in the French media.<wbr> The issue of drug safety and efficacy has been particularly sensitive in France since the scandal involving Servier (France)'s diabetes drug Mediator (benfluorex), which was estimated to have caused hundreds of deaths.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10063">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-17T13:01:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-17T13:01:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Resminostat Demonstrates Improvement In Survival in HCC</title>
	<pubDate>2012-09-17T08:40:41+02:00</pubDate>
	<wp:post_id>3901</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Resminostat Demonstrates Improvement In Survival in HCC</span>&nbsp;<br><span style="font-size: 12px;">Comment: 4SC AG has reported additional data from the PhII Shelter trial demonstrating an improvement in overall surivival with its HDAC inhibitor resminostat in the 2nd line HCC setting.<wbr> Median OS was 8 months for the resminostat /<wbr>sorafenib combination is believed to the highest OS value seen in the 2nd line HCC setting.<wbr> 4SC AG is reported as having ongoing partnership discussions with 3 different companies (Bayer seemingly amongst them).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8469">...</a><br></div><div>Interestingly, resminostat appears to dampen the increase in VEGF seen with sorafenib alone.<wbr> This may turn out to be an important feature of its activity, with the potential to show the same with other VEGF pathway inhibitors.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8474">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8469">View thread  Oncology8469: Resminostat Demonstrates Improvement In Survival in HCC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-17T08:40:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-17T08:40:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PhIII Pasireotide Extension Data Presented At The ENEA Meeting In Vienna</title>
	<pubDate>2012-09-14T18:30:46+02:00</pubDate>
	<wp:post_id>3902</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Extension data out to 18 months of treatment demonstrates that 
pasireotide (Signifor) maintains its efficacy profile in those switched from 
octreotide to pasireotide.<wbr> The level of hyperglycaemia and diabetes, 
however, remains high at 23.<wbr>5% and 16% resepctively for pasireotide 
LAR vs.<wbr> 7.<wbr>9% and 7.<wbr>9% for octreotide LAR with even higher nos reporting 
hyperglyceamia-related AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy Data</STRONG> </div><div style="margin-bottom: 10px;">With respect to efficacy 21% of patients inadequately controlled 
by octreotide LAR  during the core 12 months of the 
study acheived biochemical control 6 months after switch to pasireotide 
LAR  compared with 2.<wbr>6% of patients who were inadequately controlled on 
pasireotide LAR who swtiched to octreotide LAR </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7084_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">In the core study tumor volume decrease was fairly comparable.<wbr> At month 6 
after crossover tumor volume had further decreased by a mean of 18.<wbr>1% (CI 
13.<wbr>6,33.<wbr>6) and 12.<wbr>3% (3.<wbr>2%,21.<wbr>4) from extension baseline after patients crossed 
over to pasireotide LAR and octreotide LAR respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety Profile</STRONG> </div><div style="margin-bottom: 10px;">60.<wbr>5% of patients switched to pasireotide LAR reported hyperglycaemia-related 
AEs compared with 18.<wbr>4% of patients switched to octreotide LAR, with 12.<wbr>3% of 
patients who switched to pasireotide LAR discontinuing the study because of 
hyperglycaemia-related AEs compared with 0% who switched to octreotide LAR.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7084_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">The full poster can be accessed through the link below.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://novartis.medicalcongressposters.com/Default.aspx?doc=4713D">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=4713D</A> </div><div>A full report on the meeting will be published on Traction in due 
course.<wbr> </div><!-- Comment details --><a name="endocrinology7084attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7084_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(85,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7084_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(100,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7084">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-14T18:30:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-14T18:30:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Resminostat Demonstrates Improvement In Survival in HCC</title>
	<pubDate>2012-09-14T14:09:36+02:00</pubDate>
	<wp:post_id>3903</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: 4SC AG has reported additional data from the PhII Shelter trial demonstrating an improvement in overall surivival with its HDAC inhibitor resminostat in the 2nd line HCC setting.<wbr> Median OS was 8 months for the resminostat /<wbr>sorafenib combination is believed to the highest OS value seen in the 2nd line HCC setting.<wbr> 4SC AG is reported as having ongoing partnership discussions with 3 different companies (Bayer seemingly amongst them).<wbr> </div><div style="margin-bottom: 10px;">Data from this trial will be presented this weekend at the annual meeting of the International Liver Cancer Association meeting in Berlin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The international, open-label, two-arm SHELTER study enrolled patients with advanced liver cancer who had shown proven radiological tumor progression under first-line therapy with the cancer drug sorafenib (Nexavar(R)).<wbr> The study investigated safety and efficacy of resminostat as a monotherapy and in combination with sorafenib in this patient group with currently no approved treatment option.<wbr> </div><div style="margin-bottom: 10px;">Final median overall survival (OS) of 8.<wbr>0 months was determined in the resminostat/<wbr>sorafenib combination 'intent-to-treat' (ITT) population (n=26), i.<wbr>e.<wbr> all study patients who were treated with the combination of 600 mg resminostat total daily dose (TDD) and 400 mg sorafenib TDD.<wbr> In the resminostat monotherapy group (ITT population, n=19), the final median OS value has been determined as 4.<wbr>1 months.<wbr> All presented data are subject to review upon database lock.<wbr> In both study arms, resminostat has proven to be safe and well tolerated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>High Unmet Need</STRONG> </div><div style="margin-bottom: 10px;">Given the survival expectation of advanced HCC patients after developing progressive tumour disease on this treatment is only 5.<wbr>2 months and there is no approved second-line treatment, there is a particular high medical need for the development of new therapies for advanced HCC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Landscape</STRONG> </div><div>The HCC area has been littered with high-profile failures (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8329" class="defaultlink">Oncology8329: ASCO Intelligence Update - Part V - HCC</a>) but a few promising drugs are now moving towards phIII development including, Arqule 197 (tivatonib) and Exelixis (cabozatinib) (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8459" class="defaultlink">Oncology8459: Exelixis- Update On Pipeline Progress</a>).<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8474c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Interestingly, resminostat appears to dampen the increase in VEGF seen with sorafenib alone.<wbr> This may turn out to be an important feature of its activity, with the potential to show the same with other VEGF pathway inhibitors.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8469">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-14T14:09:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-14T14:09:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's R&D Head Comments on DARPin and TEM</title>
	<pubDate>2012-09-14T11:47:09+02:00</pubDate>
	<wp:post_id>3904</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analysts at Morgan Stanley hosted Scott Whitcup at its Global Conference on September 11th.<wbr> Although Whitcup was not convinced that Allergan has the right dose for Latisse (scalp hair loss), he was bullish on DARPin (wet AMD), and TEM (targeted toxin for PHN).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>DARPin</STRONG> - Whitcup hopes to present data in late 2013 and start Ph3 by early ’2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>TEM</STRONG> - Whitcup likened TEM to the discovery of mAbs.<wbr> He said TEM could open up a whole new platform, much like monoclonal antibodies (mAbs) did over the last few decades.<wbr> Laboratory data suggests that TEM could also be used to target other diseases, including cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6571_1_ScreenCapture1.jpg"> Dr.<wbr> Whitcup has been Executive Vice President, Research and Development since July 2004 and in April 2009 became Chief Scientific Officer.<wbr> Dr.<wbr> Whitcup joined Allergan in 2000 </div><!-- Comment details --><a name="neurology6571attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6571_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(4,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6571">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-14T11:47:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-14T11:47:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Management Change at Valeant</title>
	<pubDate>2012-09-14T10:15:54+02:00</pubDate>
	<wp:post_id>3905</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Rajiv De Silva, Valeant's President and COO of Specialty Pharmaceuticals, will be leaving the company to pursue other interests.<wbr> A number of Medicis executives would accept positions with Valeant after the Medicis acquisition has been completed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6553" class="defaultlink">Neurology6553: Valeant To Acquire Medicis To Become The No 1 Rx Dermatology Company In The US</a>.<wbr> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6559" class="defaultlink">Neurology6559: Medicis Acquisition - Key Takeaways From Conference Call</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10062">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-14T10:15:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-14T10:15:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Final Version of Italian Healthcare Reform Revealed</title>
	<pubDate>2012-09-13T14:08:03+02:00</pubDate>
	<wp:post_id>3906</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The draft decree on healthcare reforms, dubbed a "mini reform", prepared by Italian health minister Renato Balduzzi, has been finalised and made public, and now requires only the signature of the Italian president before it can proceed.<wbr> The decree has been amended, and now comprises 15 articles, rather than the 27 in the first version.<wbr> There are changes to the measures proposed relating to the pharmaceutical sector, although most of these are the same as in the original version.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Revision of National Reimbursement List</B></P> </div><div style="margin-bottom: 10px;">Under the revised decree, by 30 June, the Italian Medicines Agency (AIFA) will carry out a one-off review of the National Reimbursement List, and drugs that are considered therapeutically outdated, or the efficacy of which is considered insufficient in the light of evidence shown since they have been marketed, will be withdrawn from reimbursement and transferred to category "C" of the reimbursement system (non-reimbursed prescription drugs).<wbr> For medicines that do not fulfil cost-effectiveness criteria, price negotiations will be carried out, and in the event of these drugs' prices not being reduced as required, they will be withdrawn from reimbursement by the end of 2013.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Off-Label Medicines</B></P> </div><div style="margin-bottom: 10px;">A medicine can be reimbursed for an off-label indication even if there is a reimbursed medicine available that is registered for that indication, on the condition that that it is judged by AIFA's Technical-Scientific Committee (CTS) to have a safety profile in the indication that is not inferior to the registered medicine, and if treatment with the off-label medicine is at least 50% less expensive than treatment with the registered product.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Innovative Medicines</B></P> </div><div style="margin-bottom: 10px;">Italy's regions and autonomous provinces must reimburse medicines judged by AIFA's CTS to have therapeutic innovation of particular relevance, irrespective of their inclusion in Regional Therapeutic Formularies or Regional Hospital Formularies.<wbr> These regional formularies must be updated every six months, with copies sent to AIFA.<wbr> A permanent monitoring roundtable of regional formularies is to be established by AIFA, in which regions will be included, which will discuss problems and provide guidelines on updating and harmonisation.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Administrative Procedures</B></P> </div><div style="margin-bottom: 10px;">Pharmaceutical companies may only apply for classification for reimbursement for a product within the Italian National Health Service after they have received marketing authorisation for the product.<wbr> In the case of orphan drugs or other drugs considered to have exceptional therapeutic and social importance, subject to the CTS's assessment, these can be reimbursed before they have marketing authorisation; this also applies to medicines that are envisaged for use only within hospitals or similar structures, but does not apply to generics.<wbr> Also, for generics, no classification for the purposes of reimbursement can be made until the exact date of expiry of the originator product, or the exact date of the end of the application for its supplementary protection certificate.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Requirement to Supply Sales Data</B></P> </div><div style="margin-bottom: 10px;">Marketing authorisation holders of reimbursed medicines are required to supply data on the sales of these medicines, according to the method foreseen in the Ministry of Health decree of 15 July 2004.<wbr> In the final version of the decree, however, the measure relating to fines for breaching this regulation has been removed.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Customised Packaging</B></P> </div><div style="margin-bottom: 10px;">It will be possible for hospital pharmacies to prepare individual packaging for medicines, dividing existing packages into smaller units in hospitals, or for patients being treated at home; this also applies to medicines being used off-label.<wbr> The regions will be able to experiment with repackaging in hospitals and for residential treatment, with the aim of eliminating waste and the risk of improper use.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Farmindustria in Talks on INN Prescribing As Branded Drugs' Sales Reportedly Down 10%</B></P> </div><div style="margin-bottom: 10px;">The association of innovative pharmaceutical companies in Italy, Farmindustria, has been in talks with Minister of Economic Development Corrado Passera concerning the recently implemented regulations on prescription by international non-proprietary name (INN), reports Italian news agency ANSA).<wbr> The source reports Farmindustria's president Massimo Scaccabarozzi as saying that, on the basis of data received concerning the 20 days since INN prescription regulations came into force—which he concedes is only partial data—sales of branded drugs were 10% lower than in the equivalent period of 2011.<wbr> Scaccabarozzi is reported as saying that it is necessary to take a step back and reflect on the situation surrounding INN prescribing, adding that he appreciates the government's willingness to discuss the situation.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">Balduzzi's mini reform roused some strong reactions from the pharmaceutical industry, and although a few changes have been made to the pharmaceutical-related measures in the decree, the bulk of them remain unchanged).<wbr> </div><div style="margin-bottom: 10px;">Cost containment dominates the decree's pharma-related measures, as could be expected, in particular those relating to the withdrawal from reimbursement of medicines considered therapeutically outdated, insufficiently efficacious, or lacking cost effectiveness.<wbr> It remains to be seen how transparent the process of selecting which medicines in the national reimbursement list fall into these categories will be; pharmaceutical companies will certainly be interested to know the criteria being applied in each case.<wbr> </div><div style="margin-bottom: 10px;">There are measures that are favourable to the innovative pharmaceutical sector, however: the initiative relating to the reimbursement of innovative medicines in the regions is a continuation of a long series of attempts by successive Italian governments to solve the problem of regional disparities in access to new innovative medicines.<wbr> It remains to be seen how effective it will be, however, and how much co-operation it will receive from the regions, particularly those in the most financial difficulty.<wbr> </div><div style="margin-bottom: 10px;">Additionally, the provision that means companies can only apply for classification for the reimbursement of generics after the originator's patent or supplementary protection certificate has expired means that, in effect, the originator could have several months' extra exclusivity, because the process of classification can take some time.<wbr> </div><div style="margin-bottom: 10px;">Considering the fact that INN prescription came into force less than one month ago, the innovative pharmaceutical sector has several reasons to feel aggrieved with Italy's regulators at the moment; the current talks concerning the new regulation are unlikely to result in its withdrawal, however, and there is not much chance of any significant modifications to INN prescription either.<wbr> For now, it seems like the innovative industry will have to make do with the concessions offered in the new decree, while generics producers are also pegged back a little with restrictions on applying for reimbursement classification.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10060">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-13T14:08:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-13T14:08:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>German Newspaper Reports Novartis is Shifting Clinical Trials to Emerging Markets</title>
	<pubDate>2012-09-13T12:55:14+02:00</pubDate>
	<wp:post_id>3907</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis is shifting more of its clinical trials in Asia-Pacific, the Middle East and Africa, <EM>Handelsblatt</EM> reported, citing the company.<wbr> </div><div>The newspaper reported that the number of trials rose to 44% of all Novartis trials (excepted cancer drugs).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10058">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-13T12:55:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-13T12:55:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Zealand Starts FIM Diabetes and/or Obesity Study with its Glucagon/GLP-1 Dual Agonist</title>
	<pubDate>2012-09-13T12:34:46+02:00</pubDate>
	<wp:post_id>3908</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The clinical development of ZP2929 will start with a randomized, double-blind study to evaluate the safety and tolerability of single ascending daily doses of the drug in healthy subjects.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The study will be conducted in the U.<wbr>S under an IND application with the FDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=6432" class="defaultlink">Endocrinology6432: Zealand and Boehringer Sign Global Agreement for T2DM and Obesity</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7083">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-13T12:34:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-13T12:34:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>European Drug Monitoring Gap Filled by European Parliament Vote</title>
	<pubDate>2012-09-13T11:35:42+02:00</pubDate>
	<wp:post_id>3909</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : The EU's drug monitoring legislation received a further boost on Tuesday September 11th, when the European Parliament voted through the additional pharmacovigilance rules that were proposed last year in the wake of the Mediator affair.<wbr> </div><div style="margin-bottom: 10px;">Those new rules complement the major pharmacovigilance package that was adopted in 2010 and came into effect at the beginning of July : </div><div style="margin-bottom: 10px;"><UL><LI>The most notable innovation is that an urgent consultation at European level is automatically triggered if a company decides not to apply to renew a marketing licence for safety reasons.<wbr> </LI>
<LI>This is accompanied by a new obligation on companies that voluntarily withdraw a drug or do not reapply for a marketing licence.<wbr> They must specifically declare if this is due to a safety concern.<wbr> </LI>
<LI>The new rules also extend the list of medicines subject to additional monitoring - indicated by a "black symbol" on the packaging.<wbr> </LI>
</UL> </div><div>Sources : APM International, September 11, 2012.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10057">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-13T11:35:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-13T11:35:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas' Oncology Strategy</title>
	<pubDate>2012-09-12T16:54:54+02:00</pubDate>
	<wp:post_id>3910</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last week at the Merryll Lynch Investor Conference, management highlighted the company's vision and strategy for development in oncology and urology.<wbr> In the near term the company's plan is 1/<wbr>to leverage expertise in urology to establish a leadership position in UroOncology, 2/<wbr>to ensure successful global launch of enzalutamide (MAA submitted in June, and US launch planned this month for post-chemo setting), and 3/<wbr> to launch next month degarelix 1M (Gonax) in Japan.<wbr> Mid term plan is to develop robust LCM strategies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Sales expansion in Oncology thanks to growth of Eligard and Tarceva revenues, as well as contribution of enzalutamide.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Maximization of OAB global sales to come from the growth of Vesicare and contribution of mirabegron </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="oncology8466attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(81,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(78,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(63,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8466_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(49 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8466">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-12T16:54:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-12T16:54:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Latin American Countries to Create Unified Drug-Pricing Database</title>
	<pubDate>2012-09-12T16:16:01+02:00</pubDate>
	<wp:post_id>3911</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A group of 12 Latin American nations have agreed to create a shared pricing database for drugs.<wbr> According to Dow Jones Global Equity News, the 12 countries, which are all members of the Union of South American Nations, are Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Surinam, Uruguay, and Venezuela, and have a combined population of 400 million people.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">The construction of a unified database for the 12 Latin American countries participating in the project is significant as regional governments can increase savings on purchases and will be able to plan ahead in relation to investment policies.<wbr> </div><div style="margin-bottom: 10px;">The database, which was originally proposed by the Argentine government, is also aimed at helping the countries to work together with pharmaceutical companies to guarantee the safe delivery and storage of drugs.<wbr> The database is a good opportunity for the 12 countries to provide transparent information on drug pricing in the country, in order to avoid manipulation from pharmaceutical companies wishing to invest in the region.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10054">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-12T16:16:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-12T16:16:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Avon's "Revolutionary" Anti-Wrinkle Cream Makes the Buzz in the UK</title>
	<pubDate>2012-09-12T15:42:37+02:00</pubDate>
	<wp:post_id>3912</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to an article published in the Mail Online, the £30 wrinkle cream is reported to have reduced the signs of ageing in 7 days.<wbr> Some women tested said they decided against cosmetic surgery and Botox since using the cream, the firm said.<wbr> A-F33 will go on sale this week.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A-F33 (Amino Fill 33) is a modified protein discovered by scientists in Princeton (US),and licensed to Avon.<wbr> It is reported to boost production of collagen and elastin.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6567_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Shop Online</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6567_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">69 women (between 35 and 59 years old) used the Anew Clinical Pro Line Corrector Treatment cream twice a day for 11 weeks.<wbr> All claimed their wrinkles had been reduced, with some improvements noticeable in a week.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Dermatologists used a 3D imaging camera to look at the skin's response and claimed the cream had thickened the epidermis.<wbr> Another thest on skin cells suggested they expressed more collagen and elastin after being treated with the cream.<wbr> </div><!-- Comment details --><a name="neurology6567attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6567_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6567_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(39,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6567">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-12T15:42:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-12T15:42:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UK Commercial Launch Of Signifor For Cushing's Disease</title>
	<pubDate>2012-09-12T14:10:40+02:00</pubDate>
	<wp:post_id>3913</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Comment: Novartis Pharmaceuticals UK Limited has announced the UK launch of pasireotide (Signifor&reg;) injection for the treatment of adult patients with Cushing&rsquo;s disease for whom surgery is not an option or for whom surgery has failed.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Thanks to Gillian Doodson (UK Product Manager for Somatuline) for highlighting the announcement on the UK's NELM.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>Dosage &amp; Administration</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The recommended initial dose is 0.<wbr>6 mg by subcutaneous injection twice a day.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It is recommended that two months after the start of therapy, patients should be evaluated for clinical benefit and those who experience a significant reduction in urinary free cortisol levels should continue to receive the drug for as long as benefit is derived.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">A dose increase to 0.<wbr>9 mg may be considered based on the response to the treatment, as long as the 0.<wbr>6 mg dose is well tolerated by the patient.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Importantly, patients who do not responded after two months are advised to consider discontinuing treatment.<wbr> It is also suggested that in terms of the management of suspected adverse reactions at any time during treatment a temporary dose reduction should be considered.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: justify; padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 12px/16px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #333333; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG>Pricing</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The basic NHS Price (excluding VAT) for 60 x 1ml ampoules of the following strengths is as follows:</P> </div><div style="margin-bottom: 10px;"><P style="padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">&bull; 0.<wbr>3mg &pound;2800</P> </div><div style="margin-bottom: 10px;"><P style="padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">&bull; 0.<wbr>6mg &pound;3240</P> </div><div style="margin-bottom: 10px;"><P style="padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">&bull; 0.<wbr>9mg &pound;3240</P> </div><div style="margin-bottom: 10px;"><P style="padding-bottom: 3px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; padding-left: 0px; padding-right: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; padding-top: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It is important to note that the dosage of Signifor for Cushing's disease is very different to that under development for acromegaly, where all studies have been undertaken with the monthly LAR formulation.<wbr> As such, we do not anticipate off-label usage for acromegaly.<wbr></P> </div><div><A href="http://www.nelm.nhs.uk//en/NeLM-Area/News/2012---September/03/Pasireotide-Signifor-injection-launched-in-UK-for-treatment-of-Cushings-disease/">http:/<wbr>/<wbr>www.<wbr>nelm.<wbr>nhs.<wbr>uk/<wbr>/<wbr>en/<wbr>NeLM-Area/<wbr>News/<wbr>2012---September/<wbr>03/<wbr>Pasireotide-Signifor-injection-launched-in-UK-for-treatment-of-Cushings-disease/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7079">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-12T14:10:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-12T14:10:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cold Genesys to Start Ph2/Ph3 Study for Non-Muscle Invasive Baldder Cancer</title>
	<pubDate>2012-09-12T13:02:33+02:00</pubDate>
	<wp:post_id>3914</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cold Genesys, a privately held company, acquired the rights to develop CG0070, a adenoviral vector, from Biosante.<wbr> The BOND Ph2/<wbr>Ph3 protocol is designed for non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis) or Cis with Ta and/<wbr>or T1 who have previously failed BCG and refused cystectomy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Primary Outcome Measures: </div><div style="margin-bottom: 10px;"><UL><LI>Complete Response (CR) proportion</LI>
<LI>Durable complete response (CR)</LI>
</UL> </div><div style="margin-bottom: 10px;">
Recruitment: approx.<wbr> 112 participants </div><div style="margin-bottom: 10px;">Completion date: December 2016 /<wbr> March 2017 </div><div style="margin-bottom: 10px;">Principal Investigator: Mxwell V.<wbr> Meng, MD UCSF School of Medicine Department of Urology </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Alex Yeung (President) has outlined that they will 'be searching for the right partners for clinical and manufacturing as soon as possible to ensure that the Ph3 portion of the trial will not be delayed.<wbr>' </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 14px/18px Times-Roman, Times, 'Times New Roman', serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: justify; orphans: 2; widows: 2; -webkit-text-size-adjust: none; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>ASCO GU meeting (Feb 2-4, 2012) #271</LI>
<LI>ASCO Annual meeting (June 1-5, 2012) #4593</LI>
</UL> </div><div style="margin-bottom: 10px;"><A href="http://www.coldgenesys.net/Home.html"><STRONG></STRONG></A><STRONG></STRONG> </div><div><UL><LI>Launched in August 2010</LI>
<LI>Shareholders include BioSante Pharm.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8465">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-12T13:02:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-12T13:02:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Eyes Russia Expansion</title>
	<pubDate>2012-09-12T12:15:17+02:00</pubDate>
	<wp:post_id>3915</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda has announced the completion of its Russian pharmaceutical manufacturing state-of-the-art facility in Yaroslavl (280km from Moscow).<wbr> The company has invested approx.<wbr> €75M ($96M) in the 24,000m² production plant, which is expected to be fully operational by 2014.<wbr> The project was initially started by Nycomed in 2009, but never achieved.<wbr> Russia along with Brazil is Takeda's most important emerging market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Takeda put a big bet on emerging markets when it bought Nycomed last year (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=7407" class="defaultlink">Oncology7407: Takeda Acquires Nycomed To Expand Its European & Emerging Market Presence</a>).<wbr> Emerging markets already account for 13% of Takeda's sales, up from 3% before the Nycomed takeover.<wbr> </div><div style="margin-bottom: 10px;">- to outgrow rivals in the Russian market with the help of a local manufacturing facility (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8436" class="defaultlink">Oncology8436: Takeda's Strategy in Emerging Markets</a>).<wbr> </div><div style="margin-bottom: 10px;">- to meet demand in Russia of Cardiomagnyl, Actovegin, and Calcium tablets.<wbr> </div><div style="margin-bottom: 10px;">- to defend its 7th position in Russia (by sales), and extend it (with a local production base).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>IMS Health expects the Russian drugs market to grow by 11 percent annually between 2012 and 2016.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10051">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-12T12:15:17+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-12T12:15:17+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis's Oncology Strategy</title>
	<pubDate>2012-09-11T10:12:05+02:00</pubDate>
	<wp:post_id>3916</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday at the Morgan Stanley Investor Conference Herve Hoppenot 
President of Novartis Oncology highlighted some of the key products in the 
company's oncology portfolio and the paradigm shift in development that is 
occurring in terms of development of oncology therapeutics.<wbr> </div><div style="margin-bottom: 10px;">Hoppenot emphasised that the case fro investment in the field of oncology 
today  in research is the fact that one can move faster than ever from 
early-stage research to translational medicines and from translational medicine 
into full development.<wbr> </div><div style="margin-bottom: 10px;">He highlighted LDK the group's ALK inhibitor as an example where just a few 
months ago the company didn't even speak about the product and where now as a 
result of phI testing in a well-identified group of patients, the level of 
acitivity seen means that the project can move from early to late-stage far 
faster than has ever happened before.<wbr> This drug is potentially a new targeted 
therapy for NSCLC.<wbr> </div><div style="margin-bottom: 10px;">Hoppenot suggested that after a year of fairly trial and errot type research 
it is now entering a new phase, previously only seen with Glivec and Herceptin 
where products can be designed that are significant driveres of 
disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Interesting Late Stage Assets</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>HDAC Inhibitor LBH.<wbr> PhIII in multiple myeloma now fully accrued</LI>
<LI>PKC that addresses the FLT3 mutation in AML</LI>
<LI>TKI which is an FGF inhibitor in PhIII for kidney cancer</LI>
<LI>PI3K inhibitor BKM which is starting phIII studies in breast 
cancer.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
In terms of the full cycle management of the mTOR PI3 Kinase pathway, 
Hoppenot, noted that it is really the next step moving from a fairly pure mTOR 
inhibitor like Afinitor to a more specfic product targeting PI3 kinase and where 
the hypothesis can be tested that PI3K mutation can be a predictor of activity 
of a product.<wbr> Today this is not established.<wbr> He suggested that it is exactly the 
same logic as described with ALK and that the portfolio of PI3 kinase products - 
because Novartis have so many of them - three in clinical development - is 
likely to be very powerful.<wbr> </div><div style="margin-bottom: 10px;">Afinitor itself is expected to experience rapid adoption in the breast cancer 
setting because of its significant impact on progression of metastatic disease, 
a very valid enpoint where it was able to delay progression by 8-10 months.<wbr> </div><div style="margin-bottom: 10px;">There was no mention of pasireotide throughout the presentation.<wbr> </div><div>Source: <A href="http://www.novartis.com">www.<wbr>novartis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8464">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-11T10:12:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-11T10:12:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Botox 'Booster' to be Launched in the UK</title>
	<pubDate>2012-09-11T09:57:44+02:00</pubDate>
	<wp:post_id>3917</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to an article published in the Mail Online, Zytaze Supplementation, which contains a high dose of zinc combined with phytase, is promising to make the effects of Botox injections last for 30% longer.<wbr> British manufacturer Eden Aesthetics says the pill is unique and can reduce the price of Botox for regular users.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6563_4_ScreenCapture3.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Clinical trial</STRONG> </div><div style="margin-bottom: 10px;">A recent pilot study, utilizing Zytaze demonstrated that increasing zinc levels for 4 days prior to a planned botulinum toxin injection resulted in an increase in both the treatment effect as well as duration.<wbr> The study included blepharospasm, hemifacial spasm and cosmetic patients.<wbr> </div><div style="margin-bottom: 10px;">In a completed formal study (please see attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20121231&edate=20120901&rs=/link%20Neurology6565%403" class="defaultlink">@3</a>) of the pill found that 92% of patients taking Zytaze reported Botox treatments lasted for several weeks longer than normal, and also helped the jab to take effect more quickly.<wbr> The duration of effect increased from 23.<wbr>6% in the pilot study to be 30% in the completed formal study.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6563_2_ScreenCapture2.jpg">Source: Koshly JC, Sharabi SE, Feldman EM, Hollier LH, Patrinely JR, Soparkar CNS.<wbr> - Effect of dietary zinc and phytase supplementation on botulinum toxin treatments - <EM>J Drugs Dermatol</EM> 2012 Apr 1; 11(4):507-12. </div><div style="margin-bottom: 10px;"><STRONG>NHS' view : </STRONG><A href="http://www.nhs.uk/news/2012/09September/Pages/botox-pill-zytaze-claims.aspx">http:/<wbr>/<wbr>www.<wbr>nhs.<wbr>uk/<wbr>news/<wbr>2012/<wbr>09September/<wbr>Pages/<wbr>botox-pill-zytaze-claims.<wbr>aspx</A> </div><div style="margin-bottom: 10px;"><STRONG>Cost</STRONG> </div><div style="margin-bottom: 10px;">£45 for a pack of 10 (in comparison standard zinc supplement costs approx.<wbr> 8£ for a pack of 100 tablets).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Administration</STRONG> </div><div style="margin-bottom: 10px;">5 days, 10 capsules : 25mg pills a day for 4 days prior to having Botox, and on the day they receive the jab.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Prescription</STRONG> </div><div style="margin-bottom: 10px;">Zytaze is classed as a dietary supplement.<wbr> Patient do no need a prescription.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Testimony</STRONG> </div><div style="margin-bottom: 10px;">From Kevin Hancock (plastic surgeon, a member of the British Association of Aesthetic Plastic Surgery Council): " .<wbr>.<wbr>.<wbr> we do know that zinc is crucial in helping injured patients to recover, for example burns victims, so it is fundamental in reparing tissue .<wbr>.<wbr>.<wbr> that may well be influencing the action of the Botox .<wbr>.<wbr>.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=5218" class="defaultlink">Neurology5218: Study: Oral Supplements Enhance Effectiveness of Botulinum Toxin Injections</a> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=5760" class="defaultlink">Neurology5760: USA: Zytaze Now Available For Physician Dispensing</a>.<wbr> </div><!-- Comment details --><a name="neurology6563attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6563_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6563_3_ZYTAZE%255fPilotStudy.pdf">ZYTAZE_PilotStudy.pdf</a>&nbsp;&nbsp;(399,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6563_4_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(5,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6563">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-11T09:57:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-11T09:57:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Investigator-Sponsor Study to Assess Combination of OGX-427 and Zytiga (abiraterone)</title>
	<pubDate>2012-09-10T17:14:19+02:00</pubDate>
	<wp:post_id>3918</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new randomized Ph2 study in approx.<wbr> 74 patients with mCRPC who have PSA progression while receiving abiraterone.<wbr> Primary endpoint will measure PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01681433?fund=2&amp;rcv_s=08%2F27%2F2012&amp;rank=138"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Sponsor: Hoosier Oncology Group </div><div style="margin-bottom: 10px;">PI: Christopher Sweeney, M.<wbr>B.<wbr>, B.<wbr>S.<wbr> (Hoosier Oncology Group).<wbr> </div><div style="margin-bottom: 10px;">According to the company's presentation at the Stifel Nicolaus Annual Healthcare Conference on Sept 5, 2012 interim data might be presented at the beginning of 2014, and estimated primary endpoint results by the end of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8462_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8462_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8462_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="oncology8462attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8462_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8462_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(99,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8462_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(110,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8462_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(94,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8462">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-10T17:14:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-10T17:14:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astex' HSP90 Inhibitor Enters Ph1/Ph2 Trial for CRPC</title>
	<pubDate>2012-09-10T14:39:56+02:00</pubDate>
	<wp:post_id>3919</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AT13387, a potent and selective non-natural product inhibitor of HSP90, is tested in patients with CRPC who are no longer responding to treatment with abiraterone and steroids.<wbr> The primary objective is assessment of safety, tolerability and antitumor activity of the drug + abiraterone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Phase 1 (Part A)</STRONG> </div><div style="margin-bottom: 10px;">Protocol: patients will continue to receive the same doses of abiraterone and steroids received prior to entering the trial, and will be randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with abiraterone acetate.<wbr> </div><div style="margin-bottom: 10px;">Part A will recruit &gt;52 patients, and will establish the safety of the combination, clinical activity, and confirm biological activity by monitoring depletion of androgen receptors in tumor and Circulating Tumor Cells (CTCs) samples following treatment with the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Phase 2 (Part B)</STRONG> </div><div style="margin-bottom: 10px;">The best combination regimen in Part A will then move forward to Phase 2 (Part B) where patients will be randomized to receive either the selected treatment regimen and dose of the drug in combination with abiraterone or the drug alone.<wbr> </div><div style="margin-bottom: 10px;">Part B will recruit &gt; 112 patients </div><div>Source: Astex Pharm.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8461">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-10T14:39:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-10T14:39:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Uncertainties About Costly Cancer Drugs in Norway</title>
	<pubDate>2012-09-10T14:02:36+02:00</pubDate>
	<wp:post_id>3920</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Norwegian Directorate of Health (COM) has announced that it is unable to assess the eligibility of a number of costly cancer drugs for inclusion in the national guidelines for cancer treatments in Norway due to the lack of pricing information.<wbr> The COM will now reach out to the Norwegian Medicines Agency (NMA) to ascertain the cost versus benefit of prostate cancer drug Zytiga (abiraterone; Janssen-Cilag, United States), Jevtana (cabazitaxel; Sanofi, France), and melanoma drug Zelboraf (vemurafenib; Roche; Switzerland).<wbr> </div><div style="margin-bottom: 10px;">The COM did, however, decide to amend the national guidelines for cancer treatment by recommending lung cancer drug Alimta (pemetrexed; Eli Lilly, US) for earlier intervention to improve the overall treatment outcome.<wbr> Eli Lilly's drug was found to be adequately priced in relation to its clinical benefits.<wbr> </div><div style="margin-bottom: 10px;">The Directorate of Health in Norway did not assess Xgeva (denosumab; Amgen, US) as it was "not within the mandate to consider this drug".<wbr> The drug, used for treatment of prostate cancer, was consequently priced too high to even classify for consideration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">With no precise pricing information at hand to make an informed decision about the cost versus benefit of these drugs, the Department of Health is to work closely with the NMA to obtain such information.<wbr> </div><div style="margin-bottom: 10px;">These cancer drugs are found to be highly expensive, with little exception, across the Nordic region and the retail price for Zytiga was found to be at USD5,283 in Finland and USD6,414 in Denmark, and Xgeva's price interestingly was found to be significantly lower, at USD583 in Denmark and USD483 on the Swedish market.<wbr> </div><div style="margin-bottom: 10px;">In addition, the COM drew attention to the fact that the drugs offer limited life extension for serious cancers.<wbr> The tendency to reject innovative medicine at a national level will in extension hinder innovative companies in advancing their research and development capabilities.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8460">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-10T14:02:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-10T14:02:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis- Update On Pipeline Progress</title>
	<pubDate>2012-09-10T10:36:31+02:00</pubDate>
	<wp:post_id>3921</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the BioCentury and Thomson 
Reuters NewsMakers in the BIotech Industry Conference last week, Exelixis 
presented an update on the cabozantinib's development pipeline 
highlighting not only the drug's potential in medullary thyroid cancer 
and prostate cancer but also illustrating its potential efficacy in a number of 
other indications, notably hepatocellular cancer, renal cancer, melanoma and 
NSCLC.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_6_ScreenCapture6.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_7_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="oncology8459attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(70,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(88,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(88,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(87,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(70,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(69,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8459_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(59,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8459">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-10T10:36:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-10T10:36:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK Announces New Business in China</title>
	<pubDate>2012-09-10T10:25:21+02:00</pubDate>
	<wp:post_id>3922</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to <EM>China Daily</EM>, GSK is to open a new research unit in China to look at traditional Chinese medicine (TCM).<wbr> The company's strategy is to integrate the existing TCM knowledge of diseases with modern drug discovery technology and clinical trial methodology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>According to Zang Jingwu (senior VP &amp; Head of R&amp;D China), GKS's new research unit is working with academic TCM experts in China to develop new TCM products for patients in China and the rest of the world.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10045">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-10T10:25:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-10T10:25:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Leading MicroRNA Company Finalizes Two Deals</title>
	<pubDate>2012-09-10T10:17:49+02:00</pubDate>
	<wp:post_id>3923</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Leading MicroRNA Company Finalizes Two Deals</span>&nbsp;<br><span style="font-size: 12px;">Comment: Regulus Therapeutics a company founded by Alnylam 
Therapeutics and ISIS to focus on non-coding microRNAs has announced two 
deals in two days one with Biogen-Idec the other with Astra Zeneca.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10011">...</a><br></div><div style="margin-bottom: 10px;">The company amended its IPO, and now plans to sell 4.<wbr>5 million shares at $10-12 per share.<wbr> An 11$ price would raise $50M, and value the company at $239M.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Regulus said several partners have expressed interest in participating in the offering.<wbr> Sanofi plans to purchase up to $10M, Isis Pharm.<wbr>and GSK plan to purchase up to $2M each.<wbr></SPAN> </div><div><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Source: Biocentury</SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10044">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10011">View thread  PharmaWorld10011: Leading MicroRNA Company Finalizes Two Deals</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-10T10:17:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-10T10:17:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Finalizes Acquisition of Pierre Fabre's Glytone(R) Filler Range</title>
	<pubDate>2012-09-07T10:37:36+02:00</pubDate>
	<wp:post_id>3924</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The companies have signed a partnership agreement on the marketing of Glytone(R) products.<wbr> Merz becomes owner of the global rights to Glytone(R), and the non-US rights to the 'other products of the brand'.<wbr> This move reinforces Merz' strategy in the field of aesthetic dermatology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Merz acquires the Glytone(R) range of products as well as "several accompanying dermo-cosmetic products".<wbr> </div><div style="margin-bottom: 10px;">Financial terms: non disclosed.<wbr> </div><div style="margin-bottom: 10px;">Transaction started on May 14, 2012 (please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6397" class="defaultlink">Neurology6397: Merz Starts Negotiations to Acquier Pierre Fabre's Filler</a>) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Belotero(R) hyaluronic acid filler, Radiesse(R), Bocouture(R).<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6562_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology6562attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6562_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6562">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-07T10:37:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-07T10:37:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's New Targeted Toxin to Enter Safety and Efficacy Trial for PHN</title>
	<pubDate>2012-09-06T17:24:32+02:00</pubDate>
	<wp:post_id>3925</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Currently being evaluated in Ph2 for iOAB (preliminary data to be released soon), AGN-214868 (senrebotase) is planned to enter Ph2 next month for postherpetic neuralgia (PHN).<wbr> Primary outcome measures will assess change from baseline in average pain intensity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01678924?fund=2&amp;rcv_s=08%2F23%2F2012&amp;rank=31"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 342 participants with PHN (with pain present for at least 9 months) </div><div style="margin-bottom: 10px;">Completion date: Nov.<wbr> 2014 /<wbr> Aug.<wbr> 2015 </div><div style="margin-bottom: 10px;">Protocol: 3 arms </div><div style="margin-bottom: 10px;">Locations: USA (1 site); Australia (1 site) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please click &gt; <A href="http://clinicaltrials.gov/ct2/show/NCT01157377?term=AGN-214868&amp;rank=1">NCT01157377</A> OR see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=5055" class="defaultlink">Neurology5055: Allergan's Targeted Toxin to Enter Ph2 in iOAB and PHN</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6560">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-06T17:24:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-06T17:24:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Germany: Health Technology Assessment - Progress</title>
	<pubDate>2012-09-06T16:23:15+02:00</pubDate>
	<wp:post_id>3926</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  Industry representatives have claimed that there is still not enough evidence to suggest that Germany's early benefit assessments for new drugs is a success.<wbr> </div><div style="margin-bottom: 10px;">However, the  GBA, the body in charge of health technology assessments said that the system, introduced under the AMNOG healthcare reform act, is so far working well and there is no need yet for further legislative reform.<wbr> </div><div style="margin-bottom: 10px;">The  BPI, which represents small and medium-sized pharmaceutical companies in Germany claims that they have not seen enough evidence and that the transparency and the legal certainty is still somewhat unclear.<wbr> </div><div style="margin-bottom: 10px;">So far, 25 products have passed through the GBA and IQWiG, and all assessments were completed on time.<wbr> Some 64% of the products were deemed to provide some level of added value compared to the current standard of care.<wbr> </div><div style="margin-bottom: 10px;">The head of the GBA Josef Hecken acknowledged that no drug had yet been deemed to provide "considerable" added benefit, the highest rating a drug can win.<wbr> Four drugs were awarded a rating of "significant" additional benefit and nine drugs a "minor" additional benefit.<wbr> Three drugs were awarded a level of additional benefit that was not quantifiable, while another three drugs were found to provide no additional benefit.<wbr> Two of the products allocated to the "no additional benefit" category were consigned to reference price groups, meaning that the drugs will not attract a premium price.<wbr> </div><div style="margin-bottom: 10px;">In six cases companies failed to give the appropriate evidence which meant that no additional benefit for these products was proven, however companies can submit a new dossier to the GBA.<wbr> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=9761" class="defaultlink">PharmaWorld9761: P&R End-of-Year Review 2011 and Outlook for 2012</a> </div><div>Source: Scrip 5 September 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10040">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-06T16:23:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-06T16:23:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J is Evaluating Abiraterone in Chinese Patients</title>
	<pubDate>2012-09-05T18:02:32+02:00</pubDate>
	<wp:post_id>3927</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of the Ph1 is to evaluate the PK of the drug after oral administration of different doses (250, 500 and 1000 mg).<wbr> According to clinicaltrials.<wbr>gov, the 42-day trial is expected to complete this month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 15 healthy Chinese male participants.<wbr> </div><div style="margin-bottom: 10px;"><U>Protocol</U> </div><div><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">The study consists of 3 phases: screening, open-label treatment, and follow up phases.<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">After screening, randomly assigned participants will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to a randomized schedule under fasted conditions (Sequence 1 = ABC; Sequence 2 = BAC; and Sequence 3 = CBA).<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Each treatment period will be separated by a washout period (period when participant is not receiving any study medication) of at least 7 days.<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">In the follow-up phase, study-related adverse events will be monitored by the investigator.<wbr> Serial blood samples for pharmacokinetic analysis will be collected and safety will be monitored throughout the study.<wbr></P></DIV></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8458">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-05T18:02:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-05T18:02:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First Patient Enters in Ph2 of Oncothyreon's PI-3K for Prostate Cancer</title>
	<pubDate>2012-09-05T17:08:15+02:00</pubDate>
	<wp:post_id>3928</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First Patient Enters in Ph2 of Oncothyreon's PI-3K for Prostate Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: The trial is being conducted by the NCIC Clinical Trials Group (NCIC CTG), Queen's U.<wbr> in Kingston (Canada).<wbr> The primary endpoint of this single-arm screening trial is the proportion of patients with lack of disease progression at 12 weeks from the initiation of therapy with PX-866.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=7742">...</a><br></div><div style="margin-bottom: 10px;">Oncothyreon has announced that the ongoing Ph2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer will be expanded to include an additional group of up to 25 patients whose disease has begun to progress while receiving abiraterone (Zytiga&reg;) and prednisone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Part A</STRONG> - The initial part of this trial (Part A) has enrolled approx.<wbr> 36 of a planned 40 patients with progressive castration-resistant prostate cancer who have received no prior chemotherapy.<wbr> </div><div><STRONG>Part B</STRONG> - Enrollment of Part B of the trial will commence following full enrollment in Part A.<wbr>  Part B will enroll patients who demonstrate disease progression while receiving abiraterone as evidenced by a rising prostate specific antigen (PSA).<wbr> PX-866 will be administered in addition to continuing treatment with abiraterone and prednisone.<wbr> The primary endpoint of each part of this single-arm screening trial is the proportion of patients with lack of disease progression at 12 weeks from the initiation of therapy with PX-866.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8457">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology7742">View thread  Oncology7742: First Patient Enters in Ph2 of Oncothyreon's PI-3K for Prostate Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-05T17:08:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-05T17:08:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Looks to Emerging Markets for Growth</title>
	<pubDate>2012-09-05T16:48:44+02:00</pubDate>
	<wp:post_id>3929</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At its R&amp;D Day on Sept.<wbr> 5th, management reported it would build on its drive into personalised medicine, and keep up spending on R&amp;D.<wbr> As austerity hits EU markets, Roche is targeting growth in emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">With its diagnostics division, Roche has pioneered personalised medicine, or tailoring therapy to the genetic profile of patients.<wbr> </div><div style="margin-bottom: 10px;">CEO S.<wbr> Schwan outlined that ".<wbr>.<wbr>.<wbr> more than 60% of Roche pharma pipeline projects are coupled with the development of companion diagnostics in order to make treatments more effective".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10036_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10036_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10036_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="pharmaworld10036attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10036_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10036_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10036_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(45,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10036">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-05T16:48:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-05T16:48:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Formation Of A New Venture Backed Bioinformatics Company</title>
	<pubDate>2012-09-05T11:51:04+02:00</pubDate>
	<wp:post_id>3930</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As part of its restructuring measures, Merck KgAa is spinning out its bioinformatics department creating a newco Quartz Bio from which it plans to commission work of the order of Euro 2m over the next two to three years.<wbr> </div><div style="margin-bottom: 10px;">The new company will provide biomarker data management and exploratory biomarker analysis services and will be lead by Jerome Wojcik who previously worked in Merck Serono's bioinformatics department.<wbr> The company will employ 4 scientists.<wbr> </div><div style="margin-bottom: 10px;">The company is the second newco created by Merck in a matter of weeks and has been formed as part of Merck's Euro 30m commitment to fund spinouts of non-core activities.<wbr> Prexton Therapeutics was launched in July to develop Merck Serono's Parkinson disease programms targeting mGLuR3 &amp;4 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6518" class="defaultlink">Neurology6518: Merck Serono Creates Newco To Develop Parkinson's Disease Assets</a>).<wbr> </div><div>Source: <A href="http://www.merck.de/">www.<wbr>merck.<wbr>de</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20121231&edate=20120901&rec=10032">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-05T11:51:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-05T11:51:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Telotristat PhII European Data Due Mid Q3</title>
	<pubDate>2012-09-04T17:22:13+02:00</pubDate>
	<wp:post_id>3931</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Telotristat PhII European Data Due Mid Q3</span>&nbsp;<br><span style="font-size: 12px;">Comment: Lexicon is continuing to make good progress across it broad pipeline of product programmes.<wbr> A number of key data points will be reached in Q3 plus two phIII programmes will initiate before the year-end, one of these being for telotristat in carcinoid syndrome (details of which are shown below).<wbr> The emphasis of the group's partnering activities remains focused on its diabetes product LX4211.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7044">...</a><br></div><div style="margin-bottom: 10px;">Design of the Ph3 has just been published in clinicaltrials.<wbr>gov.<wbr> The TELESTAR randomized, placebo-controlled, parallel group, multicenter, double-blind study will enroll approx.<wbr> 105 participants with carcinoid syndrome refractory to SSA therapy.<wbr> Primary outcome measures will assess change from baseline in number of daily bowel movements.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details <a href="http://clinicaltrials.gov/ct2/show/NCT01677910?recr=Open&fund=2&rcv_s=08%2F21%2F2012&rank=11" class="defaultlink">NCT01677910</a></STRONG> </div><div>Timelines: Start date expected this month, with completion date in April 2015 </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7077">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7044">View thread  Endocrinology7044: Telotristat PhII European Data Due Mid Q3</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-04T17:22:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-04T17:22:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Effect of GH Therapy in Children with Anorexia Nervosa</title>
	<pubDate>2012-09-04T16:17:35+02:00</pubDate>
	<wp:post_id>3932</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Juliane Leger, principal investigator at Robert Debré Hospital (France), will be leading this new Ph2/<wbr>Ph3 study to evaluate the effect of Norditropine(R) Simplexx(R) on the growth velocity (primary outcome measures) in prepubertal children (or children in early puberty) with anorexia nervosa and significant reduction of height velocity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01626833?recr=Open&amp;cond=%22growth+hormone%22&amp;fund=2&amp;rank=41"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Sept 2012 - Completion date: Sept 2016 </div><div style="margin-bottom: 10px;">Recruitment: 20 participants (both genders; 8 years to 203 months) </div><div>The primary endpoint will be the linear growth rate 1 year after the start of the trial expressed in cm/<wbr>1 year in the group with hGH compared to the placebo group.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7075">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-04T16:17:35+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-04T16:17:35+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medicis Acquisition - Key Takeaways From Conference Call</title>
	<pubDate>2012-09-04T15:53:16+02:00</pubDate>
	<wp:post_id>3933</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: One of the key reasons Valeant was attracted to Medicis was its excellent reputation in terms of sales and marketing.<wbr> Valeant hopes to navigate the integration so that it retains this capability.<wbr> That said it was keen to emphasise its own success in this area but highlight its hopes that by bringing the two companies together it will bring together the strengths of both resulting in an even more powerful sales and marketing presence in Dermatology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Areas of Complimentarity</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Solodyn and Valeant's anti-acne preparations
</LI>
<LI>Medicisi injectable portfolio of Restylane, Perlane and Dysport and Valeant's Sculptra
</LI>
<LI>Pro-therapy MD offerings
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Impact On Geographic Revenue Mix</STRONG> </div><div style="margin-bottom: 10px;">As a result of the transaction, an increased share of our combined revenues will come from the U.<wbr>S.<wbr> reflecting the fact that Medicis sales are predominantly U.<wbr>S.<wbr> based.<wbr> After the Biovail/<wbr>Valeant merger, U.<wbr>S.<wbr> revenues represented approximately 65% of combined revenues.<wbr> However, within two years the spilt was roughly 50/<wbr>50 and the goal is to continue to have roughly 50% of our revenues generated outside of the United States.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Impact On Product Mix</STRONG> </div><div style="margin-bottom: 10px;">In addition to increasing the percentage of our business in the U.<wbr>S.<wbr>, the transaction will also expand the dermatology segment or dermatology business globally to account for roughly 50% of Valeant's revenues.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>And From A Development Perspective</STRONG> </div><div style="margin-bottom: 10px;">Developing a more robust Late Stage Pipeline wass another key strategic driver of this transaction.<wbr> Medicis strong Late Stage Pipeline which includes both Novel developments and lifecycle management programs in Aesthetics, Anti-Fungals.<wbr> Despite making this statement there was an unwillingness to discuss anything about the pipeline products, their potential or contribution to the value of the deal.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Potential Cost Savings<BR><BR></STRONG>Valeant attaches signficant importance to its ability to quickly integrate Medicis and achieve cost saving of $225m within six months of closing, highlighting its previous success with integrating both Bioavail and Demik and generating cost savings of $110.<wbr>7m by the first quarter of 2012 from those two deals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Comment on Dysport</STRONG> </div><div style="margin-bottom: 10px;">Valeant was quizzed about whether any product might return to its original owner, Dysport being specifically mentioned.<wbr> Michael Pearson Chairman and CEO stated: "No we obviously did a lot of due diligence on that area and we feel quite comfortable.<wbr>" </div><div>Source: <A href="http://www.valeant.com">www.<wbr>valeant.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6559">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-04T15:53:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-04T15:53:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant To Acquire Medicis To Become The No 1 Rx Dermatology Company In The US</title>
	<pubDate>2012-09-04T09:34:51+02:00</pubDate>
	<wp:post_id>3934</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: US based Valeant Pharmaceuticals has agreed to buy Medicis in all cash deal valueing the company at $2.<wbr>6bn.<wbr> This is its 2nd acquisition in under a year aimed at building a leading dermatology business.<wbr> In December 2011 it acquired Sanofi's Demik business for $422m to gain access to W/<wbr>W rights to the injectable filler Sculptra.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms &amp; Analysts Initial Comments</STRONG> </div><div style="margin-bottom: 10px;">Valeant will purchase Medicis outstanding common stock for $44 per share in cash representing a 39% premium to Medicis closing price on Friday.<wbr> </div><div style="margin-bottom: 10px;">The transaction is subject to customary closing conditions, including approval by Medicis stockholders and expiration of any applicable regulatory waiting period.<wbr> Valeant expects the transaction, once completed, to be immediately accretive to Valeant's cash earnings per share.<wbr> The combination is expected to yield cost synergies at an annual run rate of at least$225 millionwithin six months of closing.<wbr> Valeant has secured committed financing for 100% of the transaction value fromJ.<wbr>P.<wbr> Morgan Chase Bank, N.<wbr>A.<wbr> </div><div style="margin-bottom: 10px;">Morgan Stanley's report on the acquisition suggests that it is both "strategically and financially compelling".<wbr> Deutsche Bank suggest that the combined company's US dematology and aesthetic business for 2012 is expected to exceed $1.<wbr>7bn which likely makes it the largest domestic Rx dematology business.<wbr> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Rational For The Purchase</STRONG></P> </div><div style="margin-bottom: 10px;">Valeant's stated rational for the deal is to strengthen "its leadership position in the dermatology field" through the purchase of complimentary products in actinic keratosis, acne aesthetic injectables and antivirals.<wbr> </div><div style="margin-bottom: 10px;">Jonah Schacknai' comments note that the combined portfolio under the Medicis name will be well positioned to capitalize on the meaningful opportunities in the dermatology and aesthetic markets.<wbr> </div><div style="margin-bottom: 10px;">The combined company's commercial dermatology operations will be located inScottsdale, Arizonaand will operate under the name Medicis, a division of Valeant, with its dermatology research and development operations inLaval, QC,Scottsdale, AZandPetaluma, CA, and corporate support functions primarily based in New Jersey.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company &amp; US Dermatology Business Overview</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_4_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_8_ScreenCapture8.jpg"> </div><div>a<img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_9_ScreenCapture9.jpg"> </div><!-- Comment details --><a name="neurology6553attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(165,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(124,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(110,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(116,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(148,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(93,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(141,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6553_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(82,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6553">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-04T09:34:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-04T09:34:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Potential Competitor To Botox For BPH</title>
	<pubDate>2012-09-03T18:14:40+02:00</pubDate>
	<wp:post_id>3935</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sophiris Bio Inc, a urology company developing a targeted treatment for BPH has announced data from its transrectal safety study demonstrating that the drug was well tolerated through three months potentially enabling its administration in future in the urologist's office.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is PRX302</STRONG> </div><div style="margin-bottom: 10px;">PRX302 is designed to be a single treatment for the long-term relief of BPH symtoms.<wbr> The drug is highly targeted to prostate tissue.<wbr> Delivered directly to the prostate tissue via localized injection it is activated by prostate-specific-antigen.<wbr> </div><div style="margin-bottom: 10px;">PRX302 has demonstrated meaningful improvements in IPSS and peak urinary flow rates in a randomised placebo controlled phIIb trial (TRIUMPH study) (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=6467" class="defaultlink">Oncology6467: Protox Data at AUA Meeting</a>)_ </div><div style="margin-bottom: 10px;"><STRONG>Why Transrectal Administration</STRONG> </div><div style="margin-bottom: 10px;">The primary objective of the small study which has just reported was to evaluate the safety and tolerability of delivering PRX302 via the transrectal route using TRUS versus the transperineal route which has been used in previous studies with the drug.<wbr> </div><div style="margin-bottom: 10px;">The decision to move to this route of administration was based on input from advisors and leading urologists treating BPH patients.<wbr> This routr will allow the drug to be administered easily in a urologist office setting in a brief procedure that doesn't require catheterisation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Allergan's BPH Development Programme</STRONG> </div><div style="margin-bottom: 10px;">Allergan reviewed its work in the BPH area with Botox at its R&amp;D meeting in February this year.<wbr> Allergan has completed a phII dose ranging study in BPH patients and expects to move into phIII in 2013.<wbr> Botox is administered transrectally in its development programme.<wbr> (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6332" class="defaultlink">Neurology6332: Allergan's R&D Day Highlights New Therapeutic Opportunities For Botox & Its Novel TEM Programme</a>) </div><div>Source: <A href="http://www.sophiris.com">www.<wbr>sophiris.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20121231&edate=20120901&rec=6546">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-03T18:14:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-03T18:14:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update On The Stampede Trial (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy)</title>
	<pubDate>2012-09-03T15:43:27+02:00</pubDate>
	<wp:post_id>3936</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The STAMPEDE trial, which has been enrolling patients in the UK and 
Switzerland for much of the past 7 years, is rather different to typical trials.<wbr> 
Instead of comparing a standard therapy in one treatment arm to one or two 
investigational therapies in other trial arms, it started out with six trial 
arms.<wbr> </div><div style="margin-bottom: 10px;">STAMPEDE is a randomized, controlled, multi-center, multi-stage, 
multi-arm trial that will enroll a total of about 5,000 patients taking one or 
more of several different therapeutic agents.<wbr> What is more, it is a trial that 
has been able to accept addition of new trial arms over time.<wbr> </div><div style="margin-bottom: 10px;">The STAMPEDE trial was designed to compare outcomes of potential treatments 
for men with high-risk, non-metastatic (M0) or metastatic (M1) prostate cancer 
for whom some form of continuous androgen deprivation therapy (CAD) was now 
considered appropriate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Why Is This Trial Important</STRONG> </div><div style="margin-bottom: 10px;">It is only going to be through trials like this that we will ever have a 
chance to discover “the best” way to manage most men with CRPC.<wbr> and mCRPC </div><div style="margin-bottom: 10px;">The initial, primary goal (endpoint) of the study was to see whether any of 
the investigational treatments could increase overall survival for men with 
high-risk, non-metastatic (M0) or evidently metastatic (M1) prostate cancer 
compared to CAD.<wbr> The secondary endpoints include things like biochemical 
progression-free survival (bPFS), presence of metastases, toxicities of the 
therapies (their side effects), the occurrence of fractures and other 
“skeletal-related events” (SREs), quality of life, and cost effectiveness.<wbr> </div><div style="margin-bottom: 10px;">Eligible patients could be enrolled and randomized to any one of the trial 
arms open to recruitment at a specific point in time.<wbr> The trial arms are listed 
in the table below.<wbr> All patients receive CAD; this is supplemented with standard 
radiotherapy for men with M0 prostate cancer.<wbr> So all trial arms have a common 
therapeutic core and then “add on” therapeutic components are tested: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8455_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">You will see that this trial assesses efficacy and safety of a number of 
interesting potential treatments at the same time.<wbr> It has the potential to allow 
comparison of treatments that look like much more like “real world” therapeutic 
options, </div><div style="margin-bottom: 10px;">As of August 1, 2012, the trial has enrolled a total of 3,300 patients.<wbr> No 
more patients are being enrolled to trial arms D or F and recruitment to 
arm G was only initiated in November 2011.<wbr> A further new research arm, 
radiotherapy to the prostate (arm H) for men with metastatic disease, will be 
initiated late in 2012; scientific approval has recently been granted for 
this.<wbr> </div><div style="margin-bottom: 10px;">The investigators hope to have the original research arms (B, C, and E) fully 
enrolled by early in 2013 and the trial should be able to provide detailed 
outcome data for these comparisons in 2015.<wbr> Survival data for the abiraterone 
comparison should be known in 2017.<wbr> </div><div style="margin-bottom: 10px;">The trial is designed so that recruitment can be stopped early to research 
arms that are not looking sufficiently encouraging in terms of bPFS (because it 
is very unlikely that a benefit in overall survival would be seen at the end of 
the trial if there is no benefit earlier on for bPFS).<wbr> Earlier this year, the 
STAMPEDE investigators published data on arms D and F showing that the 
combination of CAD with celecoxib, dosed at 400 mg b.<wbr>i.<wbr>d.<wbr>, appeared to show no 
clinical benefit compared to CAD alone.<wbr> The trial’s independent data monitoring 
committee therefore recommended no further accrual of patients to trials arm D 
nor any further accrual to arm F (celecoxib plus zoledronic acid); 
administration of celecoxib was terminated in all patients previously assigned 
to these two arms of the study.<wbr> This result is commensurate with data from other 
trials investigating the clinical effectiveness of celecoxib in advanced forms 
of prostate cancer (a form of treatment once thought to look promising).<wbr> </div><div style="margin-bottom: 10px;">Trials like the STAMPEDE study are the likely “gold standard” for comparative 
effectiveness research because they ought to (a) provide quicker answers than a 
series of separate two-arms trials and (b) allow us to do more research with the 
funding available.<wbr> These trials have also been constructed to fit “real world” 
forms of therapy along with investigational forms of therapy.<wbr> We can expect to 
see (and should probably be insisting on) more trials of this type as the range 
of treatments available for the management of advanced forms of prostate cancer 
expands.<wbr> Whether such trials will ever get conducted in America, where 
individual choice is a key factor in how people decide to get treatment, is open 
to greater question.<wbr> We may be relying on data from Europe and elsewhere for 
trials like this for a while.<wbr> </div><div style="margin-bottom: 10px;">However, as an example of the possible, it would be highly informative to see 
data from another STAMPEDE-like trial in which men with metastatic, 
chemotherapy-naive, castration-resistant prostate cancer could be randomized to 
any one of the following seven therapeutic regimens: </div><div style="margin-bottom: 10px;"><UL><LI>Trial arm 1: CAD + sipuleucel-T followed by enzalutamide followed by 
  abiraterone acetate + prednisone (after failure of enzalutamide)</LI>
<LI>Trial arm 2: CAD + sipuleucel-T followed by abiraterone acetate + 
  prednisone followed by enzalutamide (after failure of abiraterone acetate + 
  prednisone)</LI>
<LI>Trial arm 3: CAD + enzalutamide followed by abiraterone acetate + 
  prednisone (after failure of enzalutamide)</LI>
<LI>Trial arm 4: CAD + abiraterone acetate + prednisone followed by 
  enzalutamide (after failure of abiraterone acetate + prednisone)</LI>
<LI>Trial arm 5: CAD + enzalutamide + abiraterone acetate + prednisone (all 
  together)</LI>
<LI>Trial arm 6: CAD + enzalutamide + radium-223 (all together)</LI>
<LI>Trial arm 7: CAD + abiraterone acetate + prednisone + radium-223 (all 
  together)</LI>
</UL> </div><div style="margin-bottom: 10px;">
Following complete failure in any one of these trial arms, participants could 
then (perhaps) be further randomized to one of a couple of chemotherapy 
regimens.<wbr> </div><div style="margin-bottom: 10px;">The same general trial structure might also be appropriate for men with 
non-metastatic, castration-resistant, chemotherapy-naive prostate cancer.<wbr> </div><div><DIV class="narrowcolumnwrapper">
<DIV class="narrowcolumn">
<DIV class="content">
<DIV class="post-16356 post type-post status-publish format-standard hentry category-living-with-prostate-cancer category-management category-treatment-management tag-comparative tag-effectiveness tag-multi-arm tag-stampede tag-trial post">
<DIV id="comment-form-identity" style="DISPLAY: none">
<P class="selected" style="DISPLAY: none"><A href="http://prostatecancerinfolink.net"></A></P></DIV>
 

 </DIV></DIV></DIV></DIV> </div><!-- Comment details --><a name="oncology8455attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8455_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(43,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8455">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-03T15:43:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-03T15:43:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pfizer Initiates Novel Comparison Ph3 Study Between New Mark VII Pen and Genotropin Pen</title>
	<pubDate>2012-09-03T15:34:20+02:00</pubDate>
	<wp:post_id>3937</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pfizer Initiates Novel Comparison Ph3 Study Between New Mark VII Pen and Genotropin Pen</span>&nbsp;<br><span style="font-size: 12px;">Comment: The 'CHOOSE' study will assess the perception of convenience and preference between the two pens.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=5644">...</a><br></div><div style="margin-bottom: 10px;">Results of the study which will be presented at next ESPE (Sept 19-23 in Leipzig) show that both pens were considered easy to use with the majority finding the new pen (Mark VII) as easy or easier to use than the current pen.<wbr> </div><div style="margin-bottom: 10px;">Among those expressing a preference, the majority preferred the new pen.<wbr> </div><div>Adult participants selected the new pen more often than child/<wbr>parent dyads as did participants from the Eastern as opposed to Western parts of Europe.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20121231&edate=20120901&rec=7074">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology5644">View thread  Endocrinology5644: Pfizer Initiates Novel Comparison Ph3 Study Between New Mark VII Pen and Genotropin Pen</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-03T15:34:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-03T15:34:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Enzalutamide (XTANDI) Receives FDA Approval</title>
	<pubDate>2012-09-03T10:07:07+02:00</pubDate>
	<wp:post_id>3938</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a suprise early ruling (PDUFA date was November 29th), the FDA has approved the use of Medivation's (XTANDI) enalutamide for the treatment of patients with metastatic castration-resistant prostate cancer who have previously recieved docetaxel.<wbr> Medivation also confirmed that the European regulators have accepted its MAA for review.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Approved Dose &amp; Key Efficacy Data</STRONG> </div><div style="margin-bottom: 10px;">The approved use is 160mg administered orally once daily with or without food.<wbr> Treatment with XTANDI does not require concomitant steroid use, however, in the phIII AFFIRM trial 48% of patients treated with XTANDI and 46% fo patients on placebo recieved steroids.<wbr> </div><div style="margin-bottom: 10px;">As a recap, the AFFIRM trial demonstrated that XTANDI prolonger survival by 4.<wbr>8 months compared to placebo.<wbr> The median survival in the XTANDI group was 18.<wbr>4 months as compared to 13.<wbr>6 months in the placebo group, and XTANDI reduced the risk of death by 37% as compared to placebo.<wbr> Patients had a median duration of therapy of about 8 months.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Arial','sans-serif'; font-size: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Medivation has agreed with the FDA to conduct an open-label safety study of XTANDI at its approved dose of 160 milligrams per day in 350 patients who are at high risk for seizure, with a commitment to provide study results in 2019.<wbr> In addition to receiving marketing approval in the U.<wbr>S.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Arial','sans-serif'; font-size: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><STRONG>Commercialisation</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Medivation sales team will begin promoting XTANDI shortly after Labor Day and the drug should be available to patients by mid-Sept.<wbr> It will share responsibility for promoting XTANDI in the U.<wbr>S.<wbr> with the Astellas sales team.<wbr> Medivation has a team of 60 sales people whilst Astellas has about 90.<wbr> Medivations' s reps have an average between 10 to 15 years of oncology sales experience, and have come from some of the most prominent companies in oncology.<wbr> </div><div style="margin-bottom: 10px;">The wholesale acquisition cost of XTANDI will be $7,450 for a 30-day supply.<wbr> Astellas has also put programs in place to enable eligible patients to have access to XTANDI regardless of insurance status or ability to pay.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial Implications Of The Approval</STRONG> </div><div style="margin-bottom: 10px;">The FDA&rsquo;s approval of XTANDI and EMA&rsquo;s acceptance of full review of the European marketing application for XTANDI triggered milestone payments to Medivation of $30 million and $5 million, respectively.<wbr> It is required to share 10% of these milestone payments with UCLA under the terms of its license agreement and to pay a low single digit royalty on sales.<wbr> </div><div style="margin-bottom: 10px;">Analysts are projecting sales of around $375m in 2013 based on this approval up from $60m last year.<wbr> </div><div>Source: <a href="http://www.medivation.com" class="defaultlink" title="http://www.medivation.com">medivation.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8449">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-03T10:07:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-03T10:07:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Researchers Are Looking for Funds to Develop an Experimental Drug for Neuroendocrine and Prostate Cancers</title>
	<pubDate>2012-09-03T09:11:07+02:00</pubDate>
	<wp:post_id>3939</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Swedish medical researchers are offering to name an experimental treatment after anyone willing to donate 1 million pounds to fund their work.<wbr> The research group is developing genetically engineered viruses and T cells for cancer therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Focus: prostate adenocarcinoma, neuroendocrine carcinoma and neuroblastoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.klinimm.uu.se/research/clinical_immunology/magnus_essand/?languageId=1">http:/<wbr>/<wbr>www.<wbr>klinimm.<wbr>uu.<wbr>se/<wbr>research/<wbr>clinical_immunology/<wbr>magnus_essand/<wbr>?languageId=1</A> </div><div style="margin-bottom: 10px;"><A href="http://www.scilifelab.uu.se/Research/Infectious_Diseases/Magnus_Essand/">http:/<wbr>/<wbr>www.<wbr>scilifelab.<wbr>uu.<wbr>se/<wbr>Research/<wbr>Infectious_Diseases/<wbr>Magnus_Essand/<wbr></A> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8446_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8446attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8446_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(34,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20121231&edate=20120901&rec=8446">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2012-09-03T09:11:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2012-09-03T09:11:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
